spironolactone has been researched along with eplerenone in 851 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.12) | 18.7374 |
| 1990's | 1 (0.12) | 18.2507 |
| 2000's | 356 (41.83) | 29.6817 |
| 2010's | 439 (51.59) | 24.3611 |
| 2020's | 54 (6.35) | 2.80 |
| Authors | Studies |
|---|---|
| Bell, MG; Belvo, MD; Borromeo, PS; Gernert, DL; Grese, TA; Jadhav, PK; Kelley, SA; Kennedy, JH; Kolis, SP; Lander, PA; Richey, R; Sharp, VS; Steinberg, MI; Stephenson, GA; Williams, JD; Yu, H; Zimmerman, KM | 1 |
| Arhancet, GB; Blinn, JR; Chen, X; Collins, JT; Dietz, JD; Garland, DJ; Heron, MI; Hockerman, SL; Homer, BL; Hu, X; Huang, HC; Long, SA; Mahoney, MW; McGee, KF; Meyers, MJ; Payne, MA; Reitz, DB; Rico, JR; Wendling, JM; Yang, S | 1 |
| Boyd, SA; De Meese, LA; Fukumoto, S; Gauthier, C; Habuka, N; Hasui, T; Igata, Y; Imura, Y; Matsui, H; Matsunaga, N; Motoyaji, T; Nishigaki, N; Ohyabu, N; Ono, M; Ora, T; Siedem, CS; Sogabe, S; Tanaka, T; Tang, TP | 1 |
| Piotrowski, DW | 1 |
| Balsells, J; Bateman, T; Brown, P; Chu, HD; Clemas, J; Contino, L; Cox, JM; Crespo, A; Crook, M; Garcia-Calvo, M; Gibson, J; Lisnock, J; Shen, HC; Sinclair, P; Tong, X; Wiltsie, J; Wu, Z; Xu, L; Yang, C; Zamlynny, B; Zhou, G | 2 |
| Ambler, C; Arhancet, GB; Banker, ME; Banks, T; Boustany-Kari, CM; Cai, C; Casimiro-Garcia, A; Chen, X; Eudy, R; Hepworth, D; Hulford, CA; Jennings, SM; Loria, PM; Meyers, MJ; Petersen, DN; Piotrowski, DW; Raheja, NK; Sammons, M; She, L; Song, K; Vrieze, D; Wei, L | 1 |
| Asano, K; Boyd, SA; De Meese, LA; Endo, S; Fuji, K; Fujimoto, J; Fukumoto, S; Gauthier, C; Habuka, N; Hasui, T; Kusumoto, K; Matsui, H; Mizukami, A; Nishigaki, N; Ohra, T; Ohyabu, N; Ono, M; Oosawa, M; Shiotani, S; Siedem, CS; Sogabe, S; Sugimoto, T; Tang, TP | 1 |
| Balsells, J; Bateman, TJ; Brown, P; Chu, HD; Clemas, J; Contino, L; Cox, JM; Crespo, A; Crook, M; Gao, S; Garcia-Calvo, M; Gibson, J; Lisnock, J; Ma, X; Shen, HC; Sinclair, P; Tong, V; Wiltsie, J; Xu, L; Yang, C; Zamlynny, B; Zhou, G | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bateman, T; Brown, P; Bunte, EV; Clemas, J; Contino, L; Crespo, A; Crook, M; Garcia-Calvo, M; Gibson, J; Jochnowitz, N; Lan, P; Leung, D; Lisnock, J; Liu, K; Ma, X; Mal, R; Ogawa, AK; Pan, Y; Sinclair, P; Sun, Z; Tong, X; Wiltsie, J; Xu, L; Zamlynny, B; Zhou, G | 1 |
| Álvarez de la Rosa, D; Gerona-Navarro, G; González-Muñiz, R; Martín-Martínez, M; Pérez-Gordillo, FL; Rodríguez, Y; Zhou, MM | 1 |
| Akatsuka, H; Iguchi, T; Iijima, T; Ikeda, T; Kato, H; Katoh, M; Kawaguchi, T; Kikkawa, K; Koyama, N; Munakata, H; Nishi, A; Shirata, N; Takakuwa, M; Takedomi, K; Watanabe, Y; Yamamoto, Y | 1 |
| Corvol, P; de Gasparo, M; Jeunemaître, X; Ménard, J; Preiswerk, G; Whitebread, SE | 1 |
| Borkowski, J; Gentsch, C; Mondadori, C | 1 |
| Chadow, HL; Hameedi, A | 1 |
| Adler, GK; Kifor, I; Ochoa-Maya, MR; Rennke, HG; Rocha, R; Stier, CT; Williams, GH | 1 |
| Cook, CS; Fischer, JS; Zhang, L | 1 |
| Lüscher, TF; Quaschning, T; Ruschitzka, F; Shaw, S | 1 |
| Epstein, M | 3 |
| Delyani, JA; Robinson, EL; Rudolph, AE | 1 |
| Bobik, A; Funder, J; Kanellakis, P; Ramsey, D; Ward, MR | 1 |
| Pfeffer, MA | 1 |
| Bittman, R; Burns, D; Hurley, S; Kleiman, J; Lopez-Sendon, J; Martinez, F; Neaton, J; Pitt, B; Remme, W; Roniker, B; Williams, G; Zannad, F | 1 |
| Coats, AJ | 1 |
| Krum, H; Martin, J | 1 |
| Funder, JW | 9 |
| Cook, CS; Delyani, JA; Levin, S; Rocha, R; Roniker, B; Sing, YL; Tobert, DS; Whelihan, B; Workman, DL | 1 |
| McMahon, EG | 2 |
| Adler, GK; Martinez, DV; Matsumura, M; Ochoa-Maya, M; Oestreicher, E; Rocha, R; Roubsanthisuk, W; Williams, GH | 1 |
| Cook, CS; Zhang, L | 2 |
| Deedwania, P; Hurley, S; Jones, P; Mahoney, E; Pitt, B; Poston, C; Spertus, JA; Tooley, J; Weintraub, WS | 1 |
| Duquaine, D; King, S; Patel, P; Pitt, B; Rajagopalan, S | 1 |
| Miller, JM; Williams, ES | 1 |
| Fakouhi, K; He, W; Krause, S; Krum, H; Nolly, H; Roniker, B; Workman, D | 1 |
| Funder, JW; Mardini, M; Mihailidou, AS; Raison, M | 1 |
| Krause, SL; Roniker, B; Weinberger, MH; Weiss, RJ | 1 |
| Carter, BL; Zillich, AJ | 1 |
| Funder, JW; Rocha, R | 1 |
| Blomme, EA; Delyani, JA; Frierdich, GE; Kekec, BK; McMahon, EG; Nachowiak, DA; Rocha, R; Rudolph, AE | 1 |
| Weber, MA | 1 |
| Krum, H; Liew, D | 3 |
| Berry, LM; Burton, EG; Cook, CS; Hribar, JD; Kim, DH; Zhang, L | 1 |
| Delyani, J; Martin-Berger, CL; McMahon, E; Rocha, R; Scherrer, R; Yang, P | 1 |
| Benetos, A; Delcayre, C; Labat, C; Lacolley, P; Pujol, A; Safar, M | 1 |
| Goldstein, S; McMahon, EG; Mishima, T; Morita, H; Rudolph, AE; Sabbah, HN; Sharov, VG; Suzuki, G; Tanhehco, EJ; Todor, A | 1 |
| Pitt, B | 7 |
| Breau, AP; Fast, DM; Zhang, JY | 2 |
| Dilley, R; Funder, JW; Moussa, L; Young, MJ | 1 |
| Auchus, RJ | 1 |
| Brown, R; Kirkpatrick, P; Quirk, J | 1 |
| Folstad, J; Lamb, RE | 1 |
| Ames, GB; Cook, CS; Fischer, J; Levin, S; Zhang, J; Zhang, L | 1 |
| Alzamora, R; Gonzalez, M; Marusic, ET; Michea, L | 1 |
| Badoual, T; Cachin, JC; Castaigne, A; Hittinger, L; Le Corvoisier, P; Lopes, ME; Merlet, P; Su, JB; Tabet, JY | 1 |
| Jessup, M | 1 |
| Bittman, R; Gatlin, M; Hurley, S; Kleiman, J; Martinez, F; Neaton, J; Pitt, B; Remme, W; Roniker, B; Zannad, F | 1 |
| Blasi, ER; Blomme, EA; McMahon, EG; Polly, ML; Rocha, R; Rudolph, AE | 1 |
| Flack, JM; Garthwaite, S; Kleiman, JH; Krause, SL; Oparil, S; Pratt, JH; Roniker, B; Saunders, E; Workman, D; Yang, Y | 1 |
| Ben-Yehuda, O | 1 |
| Duprez, D; Krause, S; Kuse-Hamilton, J; Roniker, B; St Hillaire, R; Weber, MA; White, WB | 1 |
| Pitt, B; Rajagopalan, S | 2 |
| Aaronson, K | 1 |
| Krum, H; Liew, D; Martin, J | 1 |
| Brown, NJ | 1 |
| Conti, CR | 3 |
| Aviram, M; Coleman, R; Hamoud, S; Hayek, T; Kaplan, M; Keidar, S; Pavlotzky, E | 2 |
| Bauersachs, J; Christ, M; Eigenthaler, M; Fraccarollo, D; Hildemann, S; Kobsar, A; Schäfer, A; Walter, U | 1 |
| Blomme, EA; Bond, BR; Funder, JW; Goellner, JJ; McMahon, EG; Qin, W; Rocha, R; Rudolph, AE | 1 |
| Bauersachs, J; Ertl, G; Fraccarollo, D; Hildemann, SK; Schäfer, A; Tas, P | 1 |
| Clark, A; Cleland, JG; Coletta, AP; Louis, A; Nikitin, N | 1 |
| Massie, BM; Teerlink, JR | 1 |
| Aggarwal, A | 1 |
| Carr, AA; Jordan, R; Krause, S; Oigman, W; Roniker, B; White, WB | 1 |
| Buller, GK; Coca, SG | 1 |
| Blaustein, DA; Schwenk, MH | 1 |
| Akhras, KS; Anderson, R; Bittman, RM; Hollenberg, NK; Krause, SL; Williams, GH | 1 |
| Salam, AM | 1 |
| Stier, CT | 2 |
| Akiba, T; Nihei, H; Nitta, K | 1 |
| Doggrell, S | 1 |
| Lakkis, J; Lu, WX; Weir, MR | 1 |
| Hackam, DG | 1 |
| Trifonov, IR | 1 |
| Gay, C; Gunning, K; Magill, MK; Saffel-Shrier, S | 1 |
| Coleman, CI; Perkerson, KA; White, CM | 1 |
| Burns, D; Kleiman, J; Krause, S; Phillips, RA; Pitt, B; Reichek, N; Roniker, B; Willenbrock, R; Williams, GH; Zannad, F | 1 |
| Fakouhi, K; He, W; Krause, SL; Krum, H; Prisant, LM; Roniker, B | 1 |
| SoRelle, R | 1 |
| Berry, LM; Bible, RH; Cook, CS; Hajdu, E; Hribar, JD; Liu, NW | 1 |
| Lee, TH | 1 |
| Burgess, ED; Kleiman, JH; Krause, S; Lacourcière, Y; Maurath, C; Oparil, S; Roniker, B; Ruilope-Urioste, LM | 1 |
| Bauersachs, J; Christ, M; Ertl, G; Fraccarollo, D; Galuppo, P; Hildemann, S | 1 |
| Pfeffer, MA; Solomon, SD | 1 |
| Pitt, B; Rajagopalan, S; Stier, CT | 1 |
| da Silva, AA; de Paula, RB; Hall, JE | 1 |
| Davis, KL; Nappi, JM | 1 |
| Kolloch, R; Offers, E | 1 |
| Avolio, A; Safar, ME | 1 |
| Abe, Y; Kagami, S; Kimura, S; Kiyomoto, H; Kohno, M; Kondo, S; Miyata, K; Nagai, Y; Nishiyama, A; Shokoji, T; Yao, L; Yoshizumi, M | 1 |
| Carretero, OA; Liu, YH; Peterson, E; Rhaleb, NE; Rudolph, AE; Wang, D; Xu, J; Yang, XP | 1 |
| von Haehling, S | 1 |
| MacDonald, TM; Struthers, AD | 1 |
| Taylor, CT | 1 |
| Christ, M; Grimm, W; Maisch, B | 1 |
| Davies, JI; Dawson, A; Struthers, AD | 1 |
| Futterman, LG; Lemberg, L | 1 |
| Funder, JW; Young, M | 1 |
| Riggs, JM | 1 |
| Bittman, R; Garthwaite, S; Gatlin, M; Hiwada, K; Kageyama, S; Ogawa, M; Ogihara, T; Patrick, J; Saruta, T; Tawara, K | 1 |
| Black, HR | 1 |
| Burgess, E; Kipnes, MS; Kolloch, RE; Krause, SL; Niegowska, J; Patrick, JL; Roniker, B; Ruilope, LM; Williams, GH | 1 |
| Endemann, DH; Iglarz, M; Savoia, C; Schiffrin, EL; Touyz, RM | 1 |
| Akino, M; Denhardt, D; Jia, N; Kitabatake, A; Kon, S; Liu, L; Matsui, Y; Morimoto, J; Okamoto, H; Onozuka, H; Rittling, SR; Uede, T | 1 |
| Coghlan, JP; Tait, JF; Tait, SA | 1 |
| Garthwaite, SM; McMahon, EG | 1 |
| Apriletti, JW; Baxter, JD; Funder, JW; Webb, P | 1 |
| McMahon, EG; Rocha, R; Rudolph, AE | 1 |
| Traut, V | 1 |
| Ruilope, LM; Sierra, C | 1 |
| Aforismo, JF | 1 |
| Adams, KF | 1 |
| Nolan, PE | 1 |
| Funder, JW; Levy, DG; Rocha, R | 1 |
| Meier, DJ; Pitt, B; Rajagopalan, S | 1 |
| Khan, NU; Movahed, A | 1 |
| Berry, LM; Burton, E; Cook, CS | 1 |
| Koerner, MM; Thohan, V; Torre-Amione, G | 1 |
| Laustsen, G; Wimett, L | 1 |
| Gumieniak, O; Williams, GH | 1 |
| Gehr, TW; McLaughlin, N; Sica, DA | 1 |
| Jones, P; Krumholz, HM; Soto, GE; Spertus, JA; Weintraub, WS | 1 |
| Omura, T; Yoshikawa, J; Yoshiyama, M | 1 |
| Struthers, AD | 1 |
| Weinberger, MH | 3 |
| Aizawa, Y; Kodama, M; Ma, M; Tachikawa, H; Takahashi, T; Wahed, MI; Watanabe, K; Yamaguchi, K | 1 |
| Annoni, G; Arosio, B; Bai, A; Calabresi, C; Carlo, E; Fiordaliso, F; Latini, R; Martinoli, E; Masson, S; Rudolph, AE; Salio, M; Scanziani, E; Staszewsky, L | 1 |
| Keating, GM; Plosker, GL | 1 |
| Delpiano, AM; Hitschfeld, C; Lavandero, S; Lobos, L; Marusic, ET; Michea, L | 1 |
| Fuller, PJ; Rogerson, FM; Smith, BJ; Yao, Y | 1 |
| Burgess, E | 1 |
| Barnes, BJ; Howard, PA | 1 |
| Croom, KF; Perry, CM | 1 |
| Ostrenga, A; Pitcock, J; Pitcock, M | 1 |
| Colucci, WS; Kotlyar, E; Kuster, GM; Liao, R; Rude, MK; Sam, F; Siwik, DA | 1 |
| Laustsen, G; Wimmett, L | 1 |
| Hara, K; Honda, T; Kobayashi, N; Matsuoka, H; Mita, S; Nakano, S; Onozato, ML; Tojo, A; Tsubokou, Y; Yoshida, K | 1 |
| Caro, J; Goldberg, R; Ishak, J; Kolm, P; Mahoney, EM; Pitt, B; Spertus, JA; Tooley, J; Weintraub, WS; Willke, R; Zhang, Z | 1 |
| Dietz, JD; Du, S; Hu, X; Hultman, ML; Krasnoperova, NV; Lala, DS; Li, S; Welsch, DJ; Xia, C | 1 |
| Iuliano, L; Micheletta, F; Natoli, S | 1 |
| Yamamoto, T; Yano, M | 1 |
| Heinzl, S | 1 |
| Akioka, K; Enomoto, S; Iwao, H; Izumi, Y; Kim, S; Kusuyama, T; Matsumoto, R; Omura, T; Takeuchi, K; Yoshikawa, J; Yoshiyama, M | 1 |
| Asano, K; Takata, Y; Yamashina, A | 1 |
| Takeda, Y | 2 |
| Fügedi, K | 1 |
| Balfagón, G; Cachofeiro, V; Cediel, E; de las Heras, N; Lahera, V; Miana, M; Sanz-Rosa, D | 1 |
| Calhoun, DA; Nishizaka, MK; Pratt-Ubunama, MN | 1 |
| Sica, DA | 4 |
| Bauersachs, J; Ertl, G; Fraccarollo, D; Galuppo, P; Schmidt, I | 1 |
| Ravis, WR; Reid, S; Sica, DA; Tolbert, DS | 1 |
| Iso, Y; Katagiri, T; Sato, T; Suzuki, H; Takeyama, Y; Wakabayashi, K | 1 |
| Aschermann, M; Gheorghiade, M; Krum, H; Martinez, F; Mukherjee, R; Nicolau, J; Pitt, B; van Veldhuisen, DJ; Vincent, J; White, H; Zannad, F | 1 |
| McAnulty, JH; Stecker, EC | 1 |
| Fujita, Y; Ishizawa, K; Ito, H; Izawa, Y; Kanematsu, Y; Miki, C; Miyata, K; Nishiyama, A; Tamaki, T; Tsuchiya, K; Yoshizumi, M | 1 |
| Kitamura, K; Tomita, K | 1 |
| Hu, X; Lala, DS; Li, S; McMahon, EG; Rudolph, AE | 1 |
| Herman, ZS; Krysiak, R; Okopień, B | 1 |
| Davidson, RC; Krause, SL; MacDonald, TM; Patrick, JL; Roniker, B; Ruilope, LM; Weinberger, MH; White, WB | 1 |
| Borgia, MC; Mandolini, C; Vacca, K | 1 |
| Abassi, Z; Gamliel-Lazarovich, A; Hamoud, S; Hayek, T; Kaplan, M; Karry, R; Keidar, S; Pavlotzky, E | 1 |
| Jin, D; Kirimura, K; Miyazaki, M; Muramatsu, M; Sakonjo, H; Takai, S | 1 |
| Ahn, J; Frohlich, ED; Matavelli, LC; Susic, D; Varagic, J | 1 |
| Strawn, WB | 1 |
| Croom, KF; Plosker, GL | 1 |
| Kusano, E; Miyata, Y; Muto, S | 1 |
| Abe, K; Nakao, K; Nakayama, M; Ogawa, H; Saito, Y; Sakamoto, T; Shono, M; Suzuki, S; Yamamuro, M; Yasue, H; Yoshimura, M | 1 |
| Abe, Y; Nishiyama, A | 1 |
| Fottner, C; Weber, MM | 1 |
| Higaki, J; Horiuchi, M; Iwai, M; Mogi, M; Oshita, A; Suzuki, J; Yoshii, T | 1 |
| Chai, W; Danser, AH; de Vries, R; Garrelds, IM | 1 |
| Milan, A; Mulatero, P; Veglio, F; Verhovez, A; Williams, TA | 1 |
| Anderson, JL; Corbalan, R; Gheorghiade, M; Klug, EQ; Mukherjee, R; Parkhomenko, A; Pitt, B; Solomon, H; van Veldhuisen, DJ; Zannad, F | 1 |
| Ichihara, S; Izawa, H; Kato, T; Kimata, H; Murohara, T; Nagata, K; Noda, A; Obata, K; Xu, J; Yokota, M | 1 |
| Honda, T; Kobayashi, N; Matsuoka, H; Nakano, S; Ohno, T; Tsubokou, Y; Yoshida, K | 1 |
| Milan, A; Mulatero, P; Veglio, F; Williams, TA | 1 |
| Bayorh, MA; Eatman, D; Mann, G; Walton, M | 1 |
| Jolobe, OM | 3 |
| Fujita, T; Gotoda, T; Nagase, M; Nagase, T; Shibata, S; Yoshida, S | 1 |
| Burla, AK; Mandarim-de-Lacerda, CA; Neves, MF; Oigman, W | 1 |
| Hach, JT; Havens, JL; Padilla, AG; Pearlman, BA; Pillai, MD | 1 |
| Hoit, BD; Martovitz, NL; Ryu, K; Shroff, SC; Stambler, BS | 1 |
| Ram, R; Van Wagoner, DR | 1 |
| Asano, Y; Fujita, M; Hirata, A; Hori, M; Kitakaze, M; Minamino, T; Okada, K; Sanada, S; Shintani, Y; Takashima, S; Tomoike, H; Tsukamoto, O; Yamasaki, S; Yulin, L | 1 |
| Bauersachs, J; Ertl, G | 1 |
| Akatsu, T; Ishikawa, Y; Minami, Y; Nakamura, M; Satoh, M | 1 |
| Burnier, M; Erne, P; Holm, MV; Schwenkglenks, M; Szucs, TD; Weintraub, WS; Zhang, Z | 1 |
| Mune, T | 1 |
| Funder, JW; Saruta, T; Sato, A | 1 |
| Celik, T; Isik, E; Iyisoy, A; Kursaklioglu, H | 1 |
| Kikkawa, K | 1 |
| Quinkler, M; Reincke, M | 1 |
| Fan, CY; Kawai, Y; Miyamori, I | 1 |
| Matsubara, H; Tatsumi, T | 1 |
| Adler, GK; Guo, C; Kikuchi, T; Lapointe, N; Martinez-Vasquez, D; Mendez, GP; Oestreicher, EM; Pojoga, L; Ricchiuti, V; Toniolo, MF; Williams, GH; Yao, TM | 1 |
| Ahn, J; Frohlich, ED; Matavelli, L; Susic, D; Varagic, J | 1 |
| Gosse, P; Macfadyen, RJ | 1 |
| Chen, YF; Feng, JA; Franco, V; Hasan, E; Li, P; Oparil, S; Perry, GJ; Wang, D | 1 |
| Beltz, T; Felder, RB; Johnson, AK; Johnson, RF; Kang, YM; Weiss, RM; Yu, Y; Zhang, ZH | 1 |
| Armstrong, S; Ding, Q; Feldman, RD; Gros, R; O'Neil, C; Pickering, JG | 1 |
| Athyros, VG; Florentin, M; Kakafika, A; Karagiannis, A; Tziomalos, K | 1 |
| Burnier, M; Pechère, A; Waeber, B | 1 |
| Waeber, B | 1 |
| Hori, M; Mano, T; Masuyama, T; Miwa, T; Nishio, M; Nonaka, Y; Ohta, M; Ohtani, T; Okamoto, M; Sakata, Y; Takeda, Y; Yamamoto, K; Yoshida, J | 1 |
| Mundhenke, M | 1 |
| Griffon, C; Miternique-Grosse, A; Neuville, A; Siegel, L; Stephan, D; Weltin, D | 1 |
| Ferrari, R; Gheorghiade, M; Krum, H; Lopez-Sendon, J; McMurray, J; Pitt, B; van Veldhuisen, DJ | 1 |
| Ando, K; Fujita, T; Gotoda, T; Nagase, M; Nagase, T; Shibata, S; Yoshida, S | 1 |
| Benetos, A; Delcayre, C; Labat, C; Lacolley, P; Mercier, N; Nehme, J; Safar, ME | 1 |
| De Mello, WC | 1 |
| Abe, Y; Izumi, T; Mochizuki, S; Taniguchi, I; Urabe, A | 1 |
| Fujita, T; Kawachi, H; Nagase, M; Shibata, S; Yoshida, S | 1 |
| Hirata, Y; Hirono, Y; Kobayashi, N; Sakurada, M; Shichiri, M; Sugiyama, T; Suzuki, N; Takai, S; Yoshimoto, T | 1 |
| Chu, Y; Felder, RB; Kang, YM; Wei, SG; Weiss, RM; Yu, Y; Zhang, ZH | 1 |
| Inagaki, K; Makino, H; Miyoshi, T; Mukai, T; Ogura, T; Otani, H; Otsuka, F; Suzuki, J; Takeda, M | 1 |
| Altenhenne, C; Büchner, NJ; Dekomien, G; Epplen, JT; Hofebauer, S; Maser-Gluth, C; Rump, LC; Sellin, L; Vonend, O; Weiner, SM | 1 |
| Aragoncillo, P; Cachofeiro, V; de las Heras, N; Egido, J; Lahera, V; Mezzano, S; Miana, M; Ruiz-Ortega, M; Rupérez, M; Sanz-Rosa, D | 1 |
| Hausberg, M; Hillebrand, U; Oberleithner, H; Riethmüller, C; Schillers, H; Stock, C; Wilhelmi, M | 1 |
| van der Horst, IC; van Veldhuisen, DJ; Voors, AA | 1 |
| Fujita, T; Goto, A; Kobayashi, N; Matsuoka, H; Onozato, ML; Tojo, A | 1 |
| Awad, KE; Guglin, M; Polavaram, L; Vankayala, H | 1 |
| MacDonald, TM; Parthasarathy, HK | 1 |
| Hoffmeister, HM; Oikonomopoulos, T; Szabo, S | 1 |
| de Bobadilla, JF; Farreras, V; Pinto-Prades, JL | 1 |
| Gao, XY; Horiuchi, M; Ide, A; Iwai, M; Iwanami, J; Li, JM; Min, LJ; Mogi, M; Okamoto, S; Tsukuda, K | 1 |
| Adler, GK; Feldman, K; Gerhard-Herman, MD; Joffe, HV; Kwong, RY; Rice, C | 1 |
| Abuissa, H; O'Keefe, JH; Pitt, B | 1 |
| Watanabe, J | 1 |
| Hiroe, M; Imanaka-Yoshida, K; Inada, H; Nishioka, T; Onishi, K; Suzuki, M; Takakura, N; Yoshida, T | 1 |
| Yoshimura, M | 1 |
| Yamamoto, T | 1 |
| Francis, GS; Kalidindi, SR; Tang, WH | 1 |
| Fuller, PJ; Funder, JW; Morgan, J; Rickard, AJ; Young, MJ | 1 |
| Burch, AE; Dorrance, AM; Ogbi, S; Pollock, DM; Rigsby, CS | 1 |
| Beckerman, B; Epstein, M; Krause, S; Lewin, A; Mukherjee, R; Patni, R; Weinberger, M; Williams, GH | 1 |
| Kitajima, H; Kusaka, T; Nishiyama, A | 1 |
| Hirata, Y; Nagata, D | 1 |
| Bauersachs, J; Ertl, G; Fraccarollo, D; Galuppo, P; Leutke, M; Sartório, CL; Stefanon, I | 1 |
| Chabielska, E; Gromotowicz, A; Skrzypkowski, P; Stankiewicz, A; Szemraj, J; Wojewódzka-Zelezniakowicz, M | 1 |
| Brandes, RP | 1 |
| Fujita, T; Gotoda, T; Matsui, H; Nagase, M; Shibata, S | 1 |
| Takata, H; Takeda, Y; Usukura, M; Yamagishi, M; Yoneda, T; Zhu, A | 1 |
| Kartalis, G; Mimidis, K; Papadopoulos, V | 1 |
| Alesh, I; Goldstein, S; Gupta, RC; Mishra, S; Rastogi, S; Sabbah, HN; Zacà, V | 1 |
| George, J; Struthers, AD | 1 |
| Hirata, Y; Hirono, Y; Iwashima, F; Minami, I; Sakurada, M; Yoshimoto, T | 1 |
| Connell, JM; McInnes, GT; McManus, F | 1 |
| Abassi, Z; Awaad, H; Hoffman, A; Karram, T; Kawachi, H; Khankin, E; Nakhoul, F; Nakhoul, N; Yaccob, A | 1 |
| Amiri, F; Savoia, C; Schiffrin, EL; Touyz, RM | 1 |
| Solomon, SD; Verma, A | 1 |
| Galve, E | 1 |
| Akasaka, T; Goto, M; Ikejima, H; Imanishi, T; Kobayashi, K; Kuroi, A; Mochizuki, S; Muragaki, Y; Tsujioka, H; Yoshida, K | 1 |
| Bauersachs, J; Ertl, G; Fraccarollo, D; Galuppo, P; Kneitz, S; Schraut, S; van Rooijen, N | 1 |
| Anagnostis, P; Athyros, VG; Kakafika, AI; Karagiannis, A; Mikhailidis, DP; Pagourelias, ED; Papageorgiou, A; Tziomalos, K | 1 |
| Kushibiki, M; Okumura, K; Osanai, T; Tomita, H; Yamada, M | 1 |
| Morton, A | 1 |
| Krum, H; Struthers, A; Williams, GH | 1 |
| Bie, P; Jensen, BL; Marcussen, N; Nielsen, FT; Skøtt, O | 1 |
| Chander, PN; Chaudhary, AN; Ding, G; Gupta, A; Liang, W; Mathew, JT; Patni, H; Singhal, PC | 1 |
| Boomsma, F; Jansen, PM; van den Meiracker, AH | 1 |
| Fujita, T; Kaneko, T; Matsui, H; Ogura, S; Shimosawa, T; Takenaka, K; Uetake, Y; Wang, H; Yatomi, Y | 1 |
| Carey, RM; Fardella, C; Funder, JW; Gomez-Sanchez, CE; Mantero, F; Montori, VM; Stowasser, M; Young, WF | 1 |
| Ahmed, A; Aschermann, M; Cardoso, JS; Corbalán, R; Krum, H; Love, TE; Nicolau, J; Parkhomenko, A; Pitt, B; Shi, H; Solomon, H; Zannad, F | 1 |
| De Mello, WC; Gerena, Y | 1 |
| Ando, K; Fujita, M; Fujita, T; Kawarazaki, H; Matsui, H; Nagae, A; Nagase, M; Shimosawa, T | 1 |
| Abe, K; Nakao, K; Nakayama, M; Ogawa, H; Saito, Y; Sugiyama, S; Sumida, H; Yamamuro, M; Yasue, H; Yoshimura, M | 1 |
| Cowan, BR; Doughty, RN; Edwards, C; Freidlander, D; Kerr, AJ; Occleshaw, C; Richards, AM; Stewart, RA; Whalley, GA; White, HD; Williams, M; Young, AA; Zeng, I | 1 |
| Cha, DR; Han, JY; Han, KH; Han, SY; Kang, YS; Kim, HK; Ko, GJ; Lee, MH; Song, HK | 1 |
| Imagawa, K; Kawata, H; Kishimoto, I; Nakao, K; Naya, N; Saito, Y; Somekawa, S; Takeda, Y; Uemura, S; Zhang, Q | 1 |
| Leopold, JA; Maron, BA | 2 |
| Pollock, DM; Rainey, WE; Sasano, H; Yamashita, T; Ye, P | 1 |
| Bakris, G; DiCarlo, L; Mukherjee, R; Pitt, B; Ruilope, LM | 1 |
| Desai, A | 1 |
| Hamada, Y; Hayashi, T; Nomura, S; Tabira, J | 1 |
| Diah, S; Gang, L; Hamid, MR; Hitomi, H; Kimura, S; Nagai, Y; Nishiyama, A; Tamiya, T; Zhang, GX; Zhang, W | 1 |
| Ramaraj, R | 2 |
| Hlavacova, N; Jezova, D | 1 |
| Aisa, Y; Ikeda, Y; Kato, J; Mori, T; Nakamura, Y; Okamoto, S; Sakurai, M | 1 |
| Beillat, M; de Pouvourville, G; Solesse, A | 1 |
| Kiyomoto, H; Mostofa, M; Nishiyama, A; Rafiq, K | 1 |
| Gabor, A; Leenen, FH | 2 |
| Adamson, GE; Brandish, PE; Chen, H; Flores, OA; Forest, TW; Gatto, NT; Hershey, JC; Ma, BK; Molon-Noblot, S; Szczerba, P; Zwierzynski, I | 1 |
| Chan, PS; Jones, PG; Nallamothu, BK; Soto, G; Spertus, JA; Weintraub, WS; Zhang, Z | 1 |
| Hu, D; Liu, W; Matsumori, A; Shimada, M; Xiao, J | 1 |
| Antonio Costa, J; María Pascual, J; Pérez-Lahiguera, F; Rodilla, E | 1 |
| Marciniak, TA | 1 |
| Chong, KS; Dalzell, JR; Dargie, HJ; Mark, PB; McDonagh, TA; McMurray, JJ; Murphy, CA; Petrie, CJ; Steedman, T; Weir, RA | 1 |
| Athyros, VG; Karagiannis, A; Mikhailidis, DP | 1 |
| Benge, CD; Muldowney, JA; Schoenhard, JA | 1 |
| Allen, TJ; Cooper, ME; Koh, PJ; Koitka, A | 1 |
| De Silva, DS; Garcia, AG; Hutchinson, C; Ip, PC; Ito, M; Lancel, S; Pimentel, DR; Sam, F; Wilson, RM | 1 |
| Aguilar-Llopis, A; Cosín-Aguilar, J; Díez-Gil, JL; Hernándiz-Martínez, A; Portolés-Sanz, M | 1 |
| Angioi, M; Fay, R; Iraqi, W; Ketelslegers, JM; Nuée, J; Pitt, B; Rossignol, P; Vincent, J; Zannad, F | 1 |
| Hoeker, G; Laurita, KR; Martovitz, NL; Shroff, SC; Stambler, BS | 1 |
| Ahmed, A; Pitt, B | 1 |
| Deedwania, P; Stein, PK | 1 |
| Clements, S; Dargie, HJ; Ford, I; Mark, PB; McMurray, JJ; Ng, LL; Petrie, CJ; Squire, IB; Steedman, T; Wagner, GS; Weir, RA | 1 |
| Becker, GJ; Chrysostomou, A; Hewitson, TD | 1 |
| Fujita, K; Funahashi, T; Hibuse, T; Hirata, A; Hiuge, A; Kihara, S; Maeda, N; Okada, T; Shimomura, I | 1 |
| Danser, AH; Imholz, BP; Jansen, PM; van den Meiracker, AH | 1 |
| Demura, M; Karashima, S; Takeda, Y; Usukura, M; Yamagishi, M; Yoneda, T; Zhu, A | 1 |
| Du, J; Fan, YY; Hitomi, H; Kimura, S; Kiyomoto, H; Kohno, M; Kong, CZ; Nakano, D; Nishiyama, A; Noma, T | 1 |
| Homma, I; Iigaya, K; Kobayashi, Y; Minoura, Y; Onimaru, H | 1 |
| Grimm, PR; Holtzclaw, JD; Irsik, DL; Sansom, SC; Settles, DC | 1 |
| Gumułka, W; Makulska-Nowak, HE; Trzaska, E | 1 |
| Kinouchi, T; Kitazato, KT; Nagahiro, S; Satomi, J; Shimada, K; Tada, Y; Tamura, T; Yagi, K | 1 |
| Hosoya, T; Kanzaki, G; Kuriyama, S; Otsuka, Y; Sugano, N; Ueda, H | 1 |
| Delcayre, C; Janel, N; Messaoudi, S; Milliez, P; Noll, C; Samuel, JL | 1 |
| Miller, AB; Shafiq, MM | 1 |
| Balmain, S; Dargie, HJ; Lowe, GD; Ng, LL; Rumley, A; Squire, IB; Steedman, T; Weir, RA | 1 |
| Blair, JE; Gheorghiade, M; Harinstein, ME; Khan, S; Krum, H; Mukherjee, R; Pitt, B | 1 |
| Bauersachs, J | 1 |
| Stowasser, M | 1 |
| Bakris, GL; Kalaitzidis, R; Khosla, N | 1 |
| Grossman, E; Kamari, Y; Koren, F; Peleg, E; Sharabi, Y; Shimoni, N | 1 |
| Ding, L; Gong, B; Leng, Y; Qian, WJ; Wen, AD; Yang, L; Yun, CH | 1 |
| Gutiérrez Solís, E; Gutiérrez, E; Huerta, A; Morales, E; Praga, M; Segura, J | 1 |
| Bakos, J; Hlavacova, N; Jezova, D | 1 |
| Baugh, JA; Dawkins, IR; Ledwidge, MT; Mak, GJ; McDonald, KM; Murphy, NF; Patle, AK; Phelan, DM; Watson, CJ | 1 |
| Fukuda, S; Sato, A | 2 |
| Adamopoulos, C; Ahmed, A; Angioi, M; Fay, R; Filippatos, G; Pitt, B; Vincent, J; Zannad, F | 1 |
| Hamada, M; Hitomi, H; Imanishi, M; Kishida, M; Kobori, H; Konishi, Y; Maeda, I; Morikawa, T; Nagai, Y; Nakagawa, T; Nakano, D; Nishiyama, A; Ohashi, N; Okumura, M | 1 |
| Goto, K; Iida, M; Kagiyama, S; Matsumura, K; Otsubo, T | 1 |
| Drogies, T; Felix, SB; Ghaleh, B; Krieg, T; Schmidt, K; Tissier, R | 1 |
| Dharamsi, JW; Hare, JM; Heidecker, B; Kanashiro-Takeuchi, RM; Lamirault, G | 1 |
| Bokuda, K; Ichihara, A; Itoh, H; Kinouchi, K; Kurauchi-Mito, A; Mizuguchi, Y; Narita, T; Sakoda, M; Seki, Y | 1 |
| Caro, J; Kolm, P; Mahoney, EM; Spertus, J; Weintraub, WS; Willke, R; Zhang, Z | 1 |
| Clements, S; Connell, JM; Dargie, HJ; McInnes, IB; McMurray, JJ; Miller, AM; Murphy, GE; Steedman, T; Weir, RA | 1 |
| Frohlich, ED; Susic, D; Varagic, J | 1 |
| Bauersachs, J; Ertl, G; Flierl, U; Fraccarollo, D; Hildemann, SK; Schafer, A; Vogt, C; Widder, J | 1 |
| Clements, S; Dargie, HJ; Martin, TN; McMurray, JJ; Murphy, CA; Petrie, CJ; Steedman, T; Wagner, GS; Weir, RA | 1 |
| Feldman, AM; Greenberg, B; Konstam, MA; Mukherjee, R; Pitt, B; Solomon, HA; Udelson, JE | 1 |
| Dechend, R; Derer, W; Müller, DN | 1 |
| Hirayama, K; Kitayama, T; Kosaka, H; Kusaka, H; Matsubara, M; Sasaki, K; Yoda, N | 1 |
| Balmain, S; Clements, S; Dargie, HJ; Martin, TN; McMurray, JJ; Murphy, CA; Petrie, CJ; Steedman, T; Wagner, GS; Weir, RA | 1 |
| Adamová, Z; Adler, GK; Khalil, RA; Kumar, A; Pojoga, LH; Romero, JR; Stennett, AK; Williams, GH | 1 |
| Ando, K; Arakawa, Y; Fujita, T; Kubota, K; Nagase, M; Ohtsu, H; Yamada, A; Yamaguchi, T | 1 |
| Dobrev, D; Goette, A; Lendeckel, U | 1 |
| Drexler, H; Krum, H; McMurray, JJ; Pitt, B; Shi, H; Swedberg, K; van Veldhuisen, DJ; Vincent, J; Zannad, F | 1 |
| Davis, I; Flynn, JT; Li, JS; Ogawa, M; Portman, R; Pressler, ML; Shi, H | 1 |
| Alexopoulos, D; Apostolakis, E; Gkizas, SI; Koletsis, E; Mavrilas, D; Pagoulatou, E; Papachristou, DJ; Papadaki, H; Papalois, A | 1 |
| Arhancet, GB; Blinn, JR; Collins, JT; Dietz, JD; Garland, DJ; Hu, X; Huang, HC; Iyanar, K; Numann, RE; Wagner, GM; Woodard, SS | 1 |
| Fujita, T; Nagase, M | 1 |
| Koda, M; Matono, T; Murawaki, Y; Sugihara, T; Tokunaga, S; Ueki, M | 1 |
| Fukuda, N; Fukushima, H; Hirata, H; Ishimitsu, T; Kobayashi, E; Kobayashi, N; Koguchi, W; Machida, Y; Mamada, Y; Suzuki, N; Tabei, K; Takeshima, H; Yokotsuka, F | 1 |
| Boulaksil, M; de Bakker, JM; Engelen, MA; Hauer, RN; Herold, E; Houtman, MJ; Jansen, JA; Joles, JA; Noorman, M; Stein, M; van Rijen, HV; van Veen, TA | 1 |
| Bardon, T; Bernay, F; Elliott, J; Guillot, E; Ovaert, P | 1 |
| Ando, K; Fujita, M; Fujita, T; Kawarazaki, H; Matsui, H; Nagae, A | 1 |
| Fujimoto, S; Fukuda, A; Iwatsubo, S; Kawachi, H; Kitamura, K | 1 |
| Bakhai, A; Burch, J; Fenwick, L; Harden, M; Lorgelly, P; McKenna, C; Palmer, S; Suekarran, S; Walker, S; Witte, K; Woolacott, N; Wright, K | 1 |
| Bunda, S; Hinek, A; Mitts, TF; Wang, Y | 1 |
| Adler, GK; Garg, R; Tirosh, A | 1 |
| Bayorh, MA; Eatman, D; Layas, MF | 1 |
| Kageji, T; Kinouchi, T; Kitazato, KT; Matsushita, N; Nagahiro, S; Nakajima, N; Satomi, J; Shimada, K; Tada, Y; Tamura, T; Yagi, K | 1 |
| Hirooka, Y; Ito, K; Sunagawa, K | 1 |
| Lax, A; Pascual-Figal, DA; Ruipérez, JA; Sánchez-Más, J; Turpín, MC; Valdés Chávarri, M | 1 |
| Hayashi, T; Iguchi, K; Ijiri, Y; Kanada, Y; Kato, R; Murakami, S; Nishihara, M; Suzuki, K; Tamai, H; Tanaka, K; Yamada, T | 1 |
| Ecker, G; Masilamani, SM; West, C; Zhang, Z | 1 |
| Cheva, A; Kallaras, K; Karkavelas, G; Mavrakanas, TA; Mironidou-Tzouveleki, M | 1 |
| Chen, C; Ding, G; Hu, F; Liang, W; Ren, Z; Shi, J; Singhal, PC; van Goor, H | 1 |
| Bentz, K; Eick, C; Kettering, K; Konior, A; Laszlo, R; Schreieck, J; Schreiner, B | 1 |
| Holman, JR; Jamieson, B; Lin, V | 1 |
| Chen, H; Feng, H; Li, Y; Zhang, B | 1 |
| Chen, M; Huang, D; Ni, J; Peng, Y; Wei, J; Yan, S | 1 |
| Simoni, J; Wesson, DE | 1 |
| Abuannadi, M; O'Keefe, JH | 1 |
| Bauersachs, J; Dietrich, B; Ertl, G; Fleissner, F; Hahner, S; Jazbutyte, V; Schmitter, K; Thum, T; Widder, JD; Wiebking, V | 1 |
| Chiba, K; Mori, Y; Ogata, H; Takahashi, H | 1 |
| Chabielska, E; Gromotowicz, A; Mantur, M; Osmólska, U; Szemraj, J; Szoka, P; Zakrzeska, A | 1 |
| Krum, H; McMurray, JJ; Pitt, B; Pocock, SJ; Shi, H; Swedberg, K; van Veldhuisen, DJ; Vincent, J; Zannad, F | 1 |
| Armstrong, PW | 1 |
| Ibuki, C; Kawamata, H; Mizuno, K; Seino, Y | 1 |
| Fujii, M; Horie, M; Kawahara, C; Nishiyama, K; Tsutamoto, T; Yamaji, M; Yamamoto, T | 1 |
| Brownstein, DG; Chapman, K; Deuchar, GA; Hadoke, PWF; Kotelevtsev, YV; McLean, D; Mullins, JJ; Seckl, JR; Webb, DJ | 1 |
| Guglin, M; Kristof-Kuteyeva, O; Novotorova, I; Pratap, P | 1 |
| Inagaki, K; Kumagai, I; Makino, H; Miyoshi, T; Nakamura, E; Ogura, T; Otsuka, F; Suzuki, J; Tanabe, K; Tsukamoto, N | 1 |
| Pignalberi, C; Santini, M | 1 |
| Hitomi, H; Nakano, D; Nishiyama, A; Rafiq, K | 1 |
| Fan, YY; Felder, RA; Fujisawa, Y; Hitomi, H; Kitada, K; Kohno, M; Nakano, D; Nishiyama, A; Noma, T; Ohsaki, H; Rafiq, K; Sherajee, SJ; Yatabe, J; Yatabe, M | 1 |
| Jacob, MS; Tang, WH | 1 |
| Flack, JM; Sica, DA | 1 |
| Fujisawa, Y; Hitomi, H; Ihara, G; Kiyomoto, H; Kobori, H; Kohno, M; Nagai, Y; Nakano, D; Nishiyama, A; Ohashi, N; Rafiq, K | 1 |
| Aizawa, Y; Chinushi, M; Ding, L; Hanawa, H; Hoyano, M; Ito, M; Kimura, S; Kodama, M; Obata, H; Tomita, M | 1 |
| Adiyiah, J; Bayorh, MA; Eatman, D; Lyn, D; Rollins-Hairston, A | 1 |
| Karagiannis, A | 1 |
| Bush, A; Morton, A; Panitz, B | 1 |
| Fujita, K; Hori, S; Katayama, S; Matsui, K; Mori, M; Nariai, T | 1 |
| Aban, IB; Ahmed, A; Ahmed, MI; Deedwania, PC; Feller, MA; Love, TE; Pitt, B | 1 |
| Hoshide, S; Kanemaru, Y; Kario, K; Nagata, M; Sasaki, K; Shimada, K; Tamaki, N; Yano, Y | 1 |
| Karashima, S; Takeda, Y; Yoneda, T | 1 |
| Ertl, G; Merx, MW | 1 |
| Cachofeiro, V; de Las Heras, N; Lahera, V; Martin-Fernandez, B; Martinez-Gonzalez, J; Mezzano, S; Miana, M; Rodriguez, C; Sanz-Rosa, D | 1 |
| Connell, JM; MacDonald, TM; McInnes, GT; Ménard, J; Parthasarathy, HK; Ruilope, LM; White, WB; Williams, B; Williams, GH; Young, WF | 1 |
| Dastidar, AG | 1 |
| März, W; Pilz, S; Tomaschitz, A | 1 |
| Fuchs, FD; Gus, M | 1 |
| Januzzi, JL; Pascual-Figal, DA; Sanchez-Mas, J | 1 |
| Horiuchi, M; Iwanami, J; Jing, F; Min, LJ; Mogi, M; Ohshima, K; Sakata, A; Tsukuda, K | 1 |
| Dong, YF; Fukuda, M; Kataoka, K; Kim-Mitsuyama, S; Nakamura, T; Nako, H; Ogawa, H; Tokutomi, Y; Yamamoto, E; Yasuda, O | 1 |
| Ando, K; Fujita, M; Fujita, T; Kawarasaki, C; Kawarazaki, H; Matsui, H; Muraoka, K; Nagae, A | 1 |
| Almeida, S; Filipe, A; Jiménez, C; Lefebvre, M; Neves, R; Pedroso, P; Pinho, C; Sicard, E | 1 |
| Agostoni, P; Boccanelli, A | 1 |
| Godfrey, V; Lyles, GA; Martin, AL; Struthers, AD | 1 |
| Chen, S; Fang, Z; He, F; Liu, J; Meng, X; Sun, X; Zhang, C; Zhu, Z | 1 |
| Acelajado, MC; Calhoun, DA; Cartmill, FR; Cofield, SS; Dell'Italia, LJ; Dudenbostel, T; Oparil, S; Pisoni, R | 1 |
| Chasiotis, H; Kelly, SP | 1 |
| Hosoya, T; Ishii, T; Kawamura, T; Okonogi, H; Tsuboi, N | 1 |
| Denhardt, DT; Desilva, VR; Enomoto, D; Higaki, J; Irita, J; Jotoku, M; Kurata, M; Matsui, Y; Miyoshi, K; Nagao, T; Okura, T; Rittiling, SR; Uede, T | 1 |
| Fiebeler, A; Kirsch, T; Klinge, U; Kolkhof, P; Lindschau, C; Peters, I | 1 |
| Birocchi, S; Cernuschi, GC | 1 |
| Borden, SA; Kolkhof, P | 1 |
| Briones, AM; Callera, GE; He, Y; Montezano, AC; Nguyen Dinh Cat, A; Touyz, RM; Yogi, A | 1 |
| Bozkurt, B; Deswal, A; Mann, DL; Richardson, P | 1 |
| Chorazyczewski, J; Davis, M; Ding, Q; Feldman, RD; Gros, R; Liu, B; Pickering, JG; Shaikh, R | 1 |
| Krysiak, R; Okopien, B | 1 |
| Ariti, CA; Collier, TJ; Pocock, SJ; Wang, D | 1 |
| Eller, K; Huber, JM; Kirsch, AH; Mayer, G; Rosenkranz, AR; Tagwerker, A; Zitt, E | 1 |
| Connell, JM; Dargie, HJ; Fraser, R; McMurray, JJ; Steedman, T; Tsorlalis, IK; Weir, RA | 1 |
| Crook, MF; Flattery, AM; Forrest, G; Forrest, MJ; Pan, Y; Roy, S; Ruben, Z; Sharif-Rodriguez, W; Szeto, D; Urosevic-Price, O; Wang, L; Zhao, H; Zhou, X; Zhu, Y | 1 |
| Cheng, Y; Demura, M; Karashima, S; Takata, H; Takeda, Y; Yagi, K; Yamagishi, M; Yoneda, T; Zhu, A | 1 |
| Lifschitz, M; Neykin, D; Shavit, L; Slotki, I | 1 |
| Amann, K; Birner, C; Brunner, S; Endemann, DH; Fredersdorf, S; Griese, DP; Kreuzer, P; Luchner, A; Resch, M; Riegger, GA; Schach, C; Schmid, P; Weil, J | 1 |
| Banker, ME; Boustany-Kari, CM; Eudy, RJ; King-Ahmad, A; Loria, P; Near, K; Piotrowski, DW; Sahasrabudhe, V; Sweeney, K; Tugnait, M | 1 |
| Fay, R; Gustafsson, F; Ménard, J; Pitt, B; Rossignol, P; Zannad, F | 1 |
| Emdin, M; Passino, C; Pastormerlo, LE | 1 |
| Chen, J; Huang, J; Ling, Y; Tian, L; Wang, Y; Yin, J | 1 |
| Hamada, K; Horino, T; Inoue, K; Kagawa, T; Ogata, K; Shimamura, Y; Takao, T; Taniguchi, Y; Terada, Y; Ueda, S | 1 |
| Boesby, L; Elung-Jensen, T; Kamper, AL; Klausen, TW; Strandgaard, S | 1 |
| Richards, AM | 1 |
| Funder, J | 1 |
| Deguchi, K; Hitomi, H; Kitada, K; Kobori, H; Lei, B; Masaki, T; Minamino, T; Mori, H; Nakano, D; Nishiyama, A | 1 |
| Bhandari, S; Cleland, JG; Dobre, D; Fay, R; Gustafsson, F; Lamiral, Z; Pitt, B; Rossignol, P; Tala, S; Zannad, F | 1 |
| Bacchi-Modena, A; Berretta, R; Cabassi, A; Regolisti, G; Rocco, R | 1 |
| Fujita, Y; Hara, T; Hitomi, H; Kohno, M; Masaki, T; Mori, H; Nakano, D; Nishiyama, A; Rafiq, K; Sherajee, SJ | 1 |
| Fujimura, K; Hara, Y; Hasegawa, K; Hayashi, K; Homma, K; Hosoya, K; Itoh, H; Minakuchi, H; Tokuyama, H; Wakino, S; Washida, N; Yoshioka, K | 1 |
| Chayama, K; Fujii, Y; Fujimura, N; Hata, T; Hidaka, T; Higashi, Y; Idei, N; Iwamoto, Y; Kato, H; Kihara, Y; Liao, JK; Maruhashi, T; Mikami, S; Noma, K; Soga, J | 1 |
| Arakawa, K; Fujii, M; Inaba, S; Inoki, I; Konoshita, T; Miyamori, I; Morikawa, N; Saga, M; Yoshioka, K | 1 |
| Ito, Y; Maeda, H; Miyata, M; Nakayama, M; Ogawa, K; Oiso, Y; Tsutaya, S; Yoshida, M | 1 |
| Hirooka, Y; Hoka, S; Ito, K; Matsukawa, R; Nakagaki, T; Nakano, M; Nishihara, M; Sunagawa, K | 1 |
| James, RW; Mach, F; Maturana, AD; Pagano, S; Python, M; Rossier, MF; Roux-Lombard, P; Vuilleumier, N | 1 |
| Funahashi, T; Hirata, A; Hiuge-Shimizu, A; Maeda, N; Nakatsuji, H; Okada, T; Shimomura, I | 1 |
| Bertello, C; Fallo, F; Giraudo, G; Monticone, S; Mulatero, P; Urbanet, R; Veglio, F; Vettor, R; Williams, TA | 1 |
| Arlt, W; Attard, G; Carreira, S; de Bono, JS; Goodall, J; Hay, CW; Lim, AC; McEwan, IJ; Nowakowska, K; Pezaro, C; Richards, J; Taylor, AE; Wingate, A | 1 |
| Ayuzawa, N; Fujita, T; Ishizawa, K; Kawarazaki, W; Nagase, M; Takeuchi, M; Ueda, K; Yoshida, S | 1 |
| Ma, TK; Szeto, CC | 1 |
| Albert, NM; Butler, J; Carson, PE; Collins, SP; Colvin-Adams, M; Ezekowitz, JA; Fang, JC; Givertz, MM; Hernandez, AF; Hershberger, RE; Katz, SD; Rogers, JG; Spertus, JA; Starling, RC; Stevenson, WG; Stough, WG; Sweitzer, NK; Tang, WH; Teerlink, JR; Walsh, MN; Westlake Canary, CA | 1 |
| Arai, K; Fujisawa, M; Homma, T; Ikeda, M; Ishii, M; Sada, T | 1 |
| Ashton, AW; Funder, JW; Howell, VM; Loan Le, TY; Mardini, M; Mihailidou, AS | 1 |
| Krum, H; McMurray, JJ; Pitt, B; Shi, H; Swedberg, K; van Veldhuisen, DJ; Vincent, J; Zannad, F | 1 |
| Jurkat-Rott, K; Kauczor, HU; Lehmann-Horn, F; Nagel, AM; Semmler, W; Weber, MA; Wolf, MB | 1 |
| Azibani, F; Benard, L; Carrier, L; Chatziantoniou, C; Delcayre, C; Fazal, L; Launay, JM; Merval, R; Polidano, E; Samuel, JL; Schlossarek, S; Tournoux, F | 1 |
| Adiyiah, J; Bayorh, M; Eatman, D; Lyn, D; Rollins-Hairston, A | 1 |
| Filippatos, G; Gheorghiade, M; Kim, SY; Kober, L; Kolkhof, P; Krum, H; Nowack, C; Pitt, B; Ponikowski, P; Zannad, F | 1 |
| Chen, H; Feng, H; Li, Y; Tang, H; Zhang, B | 1 |
| Krum, H; McMurray, JJ; Pitt, B; Pocock, SJ; Preiss, D; Sattar, N; Shi, H; Swedberg, K; van Veldhuisen, DJ; Vincent, J; Zannad, F | 1 |
| Böhm, M; Dobre, D; Kindermann, I; Lamiral, Z; Mahfoud, F; Pitt, B; Rossignol, P; Tala, S; Turgonyi, E; Ukena, C; Zannad, F | 1 |
| Dąbrowski, R; Szwed, H | 1 |
| Barz, D; Betge, S; Ferrari, M; Figulla, HR; Florvaag, A; Franz, M; Fritzenwanger, M; Goebel, B; Jung, C; Kretschmar, D; Kuethe, F; Oberle, V | 1 |
| Breitenbach, S; Jurkat-Rott, K; Lehmann-Horn, F; Meinck, HM; Nagel, AM; Scharrer, J; Weber, MA | 1 |
| Baker, WL; White, WB | 1 |
| Behar-Cohen, F; Bousquet, E; Célérier, I; Curan, A; Farman, N; Jaisser, F; Jeanny, JC; Jonet, L; Offret, O; Savoldelli, M; Zhao, M | 1 |
| Chalikias, G; Kampourides, N; Konstantinides, S; Maltezos, E; Papazoglou, D; Symeonides, D; Tziakas, D | 1 |
| Clements, S; Dargie, HJ; McInnes, IB; McMurray, JJ; Miller, AM; Ng, LL; Petrie, CJ; Squire, IB; Steedman, T; Weir, RA | 1 |
| Abe, Y; Inokuma, S; Ohara, I; Shuto, C; Shuto, H; Sukigara, M; Suzuki, H | 1 |
| Korz, V; Meyer, K; Wang, H | 1 |
| Taylor, J | 1 |
| Bolorunduro, O; Chatterjee, S; Lichstein, E; Moeller, C; Moskovits, N; Mukherjee, D; Shah, N | 1 |
| Dobre, D; Krum, H; Lamiral, Z; Murin, J; Parkhomenko, A; Pitt, B; Rossignol, P; van Veldhuisen, DJ; Zannad, F | 1 |
| Krum, H; Watanabe, M | 1 |
| Cowie, MR | 1 |
| Chow, SL; Heywood, JT; Talatinian, A | 1 |
| Chamsi-Pasha, M; Nagarajan, V; Tang, WH | 1 |
| Adler, GK; Krug, AW; Lichtman, AH; Rao, AD; Stelzner, L; Williams, GH | 1 |
| Catena, C; Colussi, G; Sechi, LA | 2 |
| Fugh-Berman, AJ; Gupta, S; Scialli, A | 1 |
| Dong, F; Strong, JA; Xie, W; Zhang, JM | 1 |
| Allolio, B; Beuschlein, F; Diederich, S; Endres, S; Fischer, E; Fourkiotis, V; Lang, K; Quinkler, M; Reincke, M; Rump, LC; Vonend, O; Willenberg, HS | 1 |
| Schumacher, MA | 1 |
| Krum, H; McMurray, JJ; Pitt, B; Pocock, SJ; Rogers, JK; Shi, H; Swedberg, K; van Veldhuisen, DJ; Vincent, J; Zannad, F | 1 |
| Bang, CN; Greve, AM; Kober, L; Wachtell, K | 1 |
| Krämer, B | 1 |
| Chen, YQ; Deng, SB; Du, JL; Hu, LJ; She, Q | 1 |
| Hirooka, Y; Ito, K; Matsukawa, R; Nakano, M; Sunagawa, K | 1 |
| Hartmann, RW; Hu, Q; Yin, L | 1 |
| Beuschlein, F; Potthoff, SA; Vonend, O | 1 |
| Sato, A | 1 |
| Coleman, R; Gamliel-Lazarovich, A; Gantman, A; Keidar, S; Raz-Pasteur, A | 1 |
| Coleman, R; Gamliel-Lazarovich, A; Keidar, S; Raz-Pasteur, A | 2 |
| Bednarski, R; Donderski, R; Heleniak, Z; Lizakowski, S; Manitius, J; Przybylska, M; Renke, M; Rutkowski, B; Rutkowski, P; Sulikowska, B; Tylicki, L | 1 |
| Bell, RR; John-Baptiste, A; Levin, S; McMahon, E | 1 |
| Arnoldus, JH; Danser, AH; de Bruijne, EL; Deinum, J; Frenkel, WJ; Jansen, PM; Kerstens, MN; van den Born, BJ; van den Meiracker, AH; Wijbenga, JA; Woittiez, AJ; Zietse, R | 1 |
| Alvarez de la Rosa, D; Clément, K; Delcayre, C; Farman, N; Gravez, B; Jaisser, F; Launay, JM; Messaoudi, S; Ouvrard-Pascaud, A; Pelloux, V; Samuel, J; Sierra-Ramos, C; Tarjus, A | 1 |
| Berger, S; Frieler, RA; Lawrence, DA; Meng, H; Mortensen, RM; Pinsky, DJ; Ramnarayanan, SP; Ray, JJ; Su, EJ; Usher, MG; Wang, MM | 1 |
| Aonuma, K; Igarashi, M; Ito, Y; Kaneshiro, T; Kunugita, F; Kuroki, K; Machino, T; Murakoshi, N; Naruse, Y; Sato, A; Sekiguchi, Y; Tada, H; Xu, D; Yamasaki, H; Yoshida, K | 1 |
| Kumagai, H; Nishida, Y; Oda, T; Onimaru, H; Oshima, N; Takechi, H; Uchida, T; Watanabe, A; Yamamoto, K | 1 |
| Bie, P; Hansen, PB; Jensen, BL; Marcussen, N; Nielsen, FT | 1 |
| Chen, D; Han, H; Huang, Y; Li, W; Li, Z; Ma, C; Peng, Y; Wei, J; Wu, W; Zhan, F | 1 |
| Bral, JM; Hartman, D; Karns, AD; Peppard, T; Schumacher, C | 1 |
| Anegawa, T; Hirooka, Y; Imaizumi, T; Kage, M; Kai, H; Kajimoto, H; Koga, M; Kudo, H; Mifune, H; Miyamoto, T; Takayama, N; Yasuoka, S | 1 |
| Clements, S; Dargie, HJ; McInnes, IB; McMurray, JJ; Miller, AM; Murphy, CA; Ng, LL; Petrie, CJ; Squire, IB; Steedman, T; Weir, RA | 1 |
| Bułdak, Ł; Liber, J; Liber, S; Machnik, G; Okopień, B; Łabuzek, K | 1 |
| Berger, S; Lohmann, C; Lüscher, TF; Matter, CM; Miranda, MX; Nussberger, J; Ruschitzka, F; Schäfer, N; van Tits, LJ; Vergopoulos, A; Verrey, F; Winnik, S | 1 |
| Araki, N; Ishigami, T; Kakizoe, Y; Kitamura, K; Maeda, E; Minegishi, S; Tamura, K; Umemura, M; Umemura, S; Ushio-Yamana, H | 1 |
| Krum, H; McMurray, J; Pitt, B; Pocock, S; Shi, H; Swedberg, K; van Veldhuisen, DJ; Vincent, J; Zannad, F | 1 |
| Cassis, LA; Daugherty, A; Gong, MC; Guo, Z; Liu, S; Pearson, KJ; Xie, Z | 1 |
| Adler, GK; Baudrand, R; Pojoga, LH | 1 |
| Boesby, L; Elung-Jensen, T; Kamper, AL; Strandgaard, S | 1 |
| Christou, DD; English, M; Hwang, MH; Kim, HK; Luttrell, M; Meade, TH; Nichols, WW; Yoo, JK | 1 |
| Higashida, M; Hirata, Y; Kitagawa, T; Kurobe, H; Matsuoka, Y; Maxfield, MW; Nakayama, T; Sata, M; Shimabukuro, M; Sugasawa, N; Yoshida, Y | 1 |
| Dostal, DE; Jewell, C; Song, J; Watson, LE | 1 |
| Christou, DD; English, M; Hwang, MH; Kim, HK; Luttrell, M; Meade, TH; Segal, MS; Yoo, JK | 1 |
| Bart, BA; Nelson, S | 1 |
| Eschalier, R; Krum, H; McMurray, JJ; Pitt, B; Pocock, SJ; Rossignol, P; Shi, H; Swedberg, K; van Veldhuisen, DJ; Vincent, J; Zannad, F | 1 |
| Squara, P | 1 |
| Antunes, TT; Callera, GE; Miquel, P; Montezano, AC; O'Connor, S; Perraud, AL; Schmitz, C; Shrier, A; Touyz, RM; Valinsky, W; Yogi, A | 1 |
| Ahmad, M; Huang, BS; Leenen, FH; White, RA | 1 |
| Collier, TJ; Krum, H; McMurray, JJ; Pitt, B; Pocock, SJ; Shi, H; Swedberg, K; van Veldhuisen, DJ; Vincent, J; Zannad, F | 1 |
| Dhillon, S | 1 |
| Ferluga, D; Kovač, D; Lindič, J; Martinuč Bergoč, M; Pajek, J | 1 |
| Weiner, ID | 1 |
| Casaldàliga, J; Dos, L; Estruch, M; Ferreira-González, I; García-Dorado, D; Marsal, JR; Mas, A; Ordóñez-Llanos, J; Pijuan, A; Pons-Lladó, G; Pujadas, S; Serra, R; Subirana, M | 1 |
| Li, L; Liu, LM; Tan, LL; Zhao, HL | 1 |
| Bartelds, B; Berger, RM; Borgdorff, MA; Dickinson, MG; Steendijk, P | 1 |
| Aragoncillo, P; Caro-Vadillo, A; Casanueva-Eliceiry, S; Egido, J; Fernández-Cruz, A; Gómez-Garre, D; Muñoz-Pacheco, P; Ortega-Hernández, A | 1 |
| Heritier, S; Leung, DY; Leung, M; Mihailidou, AS; Wong, VW | 1 |
| Challande, P; Fay, R; Lacolley, P; Lagrange, J; Pitt, B; Pizard, A; Regnault, V; Rossignol, P; Safar, ME; Zannad, F | 1 |
| Aruga, Y; Ishii, Y; Kanasaki, K; Kitada, M; Koya, D; Miyashita, Y; Nakamura, Y; Sasahara, M; Sasaki, M; Sasaoka, T; Shimano, H; Tsuneki, H; Wada, T | 1 |
| Cheng, SB; Dong, J; Filardo, EJ; Hixon, M; LaRocca, J; Pang, Y; Thomas, P | 1 |
| Overbeck, P | 1 |
| Ares-Carrasco, S; Barbas, C; Caro-Vadillo, A; Egido, J; Ferrarini, A; Klett-Mingo, M; Lorenzo, Ó; Picatoste, B; Ramírez, E; Rupérez, FJ; Tuñón, J | 1 |
| Chen, H; Liu, Y; Shao, Y; Sun, F; Yoshimura, A; Zhong, X | 1 |
| Bakris, G; Dobre, D; Girerd, N; Krum, H; McMurray, JJ; Messig, M; Pitt, B; Rossignol, P; Shi, H; Swedberg, K; van Veldhuisen, DJ; Vincent, J; Zannad, F | 1 |
| Gariani, K; Martin, PY; Mavrakanas, TA | 1 |
| Danjuma, MI; Makaronidis, J; Mukherjee, I; Osula, S | 1 |
| Dohi, Y; Higaki, T; Ikenaga, H; Ishibashi, K; Iwasaki, T; Kihara, Y; Kurisu, S; Mitsuba, N; Shimonaga, T; Watanabe, N | 1 |
| Al-Mohammad, A; Iqbal, J; Newell-Price, J; Parviz, Y; Pitt, B; Zannad, F | 1 |
| Bobrzyk, M; Bułdak, Ł; Krupej-Kędzierska, J; Liber, S; Machnik, G; Okopień, B; Łabuzek, K | 1 |
| Allan, GM; Lindblad, AJ | 1 |
| Ademi, Z; Krum, H; Liew, D; Pasupathi, K | 1 |
| Chi, JF; Guo, HY; Lee, JD; Ueda, T; Uzui, H | 1 |
| Albrecht-Küpper, B; Bärfacker, L; Delbeck, M; Eitner, F; Hartmann, E; Kolkhof, P; Kretschmer, A; Schäfer, S; Steinke, W | 1 |
| Asayama, K; Elnagar, N; Hosaka, M; Imai, Y; Ishikura, K; Mano, N; Obara, T; Ohkubo, T; Satoh, M | 1 |
| Ahmed, A; Angioi, M; Carillo, S; Fay, R; Pitt, B; Sutradhor, SC; Vincent, J; Zannad, F; Zhang, Y | 1 |
| Anzai, T; Fukuda, K; Ito, H; Koide, K; Meguro, T; Nagatomo, Y; Ogawa, S; Yoshikawa, T | 1 |
| Boon, CJ; Breukink, MB; den Hollander, AI; Hoyng, CB; Keunen, JE | 1 |
| Adlam, D; Fay, R; Gunn, J; Iqbal, J; Parviz, Y; Pitt, B; Squire, I; Zannad, F | 1 |
| Berger, S; Fumoto, T; Ikeda, K; Ishii, KA; Ito, M; Schütz, G | 1 |
| Atkinson, AB; Bell, PM; Ennis, C; Hunter, SJ; McMurray, EM; Wallace, IR | 1 |
| Scirica, BM | 1 |
| Flather, M; Hamm, CW; Lopez de Sa, E; Montalescot, G; Orri, M; Pitt, B; Shi, H; Turgonyi, E; Verheugt, F; Vincent, J; Zannad, F | 1 |
| Strong, JA; Xie, W; Ye, L; Zhang, JM | 1 |
| Bolignano, D; Navaneethan, SD; Palmer, SC; Strippoli, GF | 1 |
| Bavry, AA; Cooper-DeHoff, RM; Handberg, EM; Huo, T; Lerman, A; Merz, CN; Pepine, CJ; Quyyumi, AA; Sharaf, B; Shufelt, C; Sopko, G | 1 |
| Anzawa, R; Date, T; Fujisaki, M; Hongo, K; Ito, K; Kashiwagi, Y; Katoh, D; Kayama, Y; Nagoshi, T; Yoshimura, M; Yoshino, T | 1 |
| Isaka, Y; Kawada, N; Kitamura, H; Moriyama, T; Rakugi, H | 1 |
| Carretero, OA; D'Ambrosio, MA; Garvin, JL; Kutskill, K; Leung, P; Peterson, EL; Ren, Y; Wang, H | 1 |
| Akehurst, R; Cowie, MR; Krum, H; Lee, D; McMurray, JJ; Pitt, B; van Veldhuisen, DJ; Vincent, J; Wilson, K; Zannad, F | 1 |
| Allard, J; Azizi, M; Baron, S; Bergerot, D; Blanchard, A; Bridoux, F; Caumont-Prim, A; Desport, E; Dubourg, L; Essig, M; Monge, M; Tack, I; Vallet, M; Vargas-Poussou, R | 1 |
| Baba, HA; Frantz, S; Gaßner, B; Kuhn, M; Nakagawa, H; Nikolaev, VO; Oberwinkler, H; Saito, Y; Umbenhauer, S; Wagner, H | 1 |
| Chabielska, E; Gromotowicz-Popławska, A; Kasacka, I; Kisiel, W; Purta, T; Szemraj, J; Szoka, P; Zakrzeska, A | 1 |
| Leenen, FH; Rafatian, N; Westcott, KV; White, RA | 1 |
| Calomeni, EP; Nadasdy, T; Patel, KA; Zynger, DL | 1 |
| Aidonidis, I; Hatziefthimiou, A; Simopoulos, V; Skoularigis, I; Tagarakis, G; Trantou, V; Triposkiadis, F; Tsilimingas, N | 1 |
| Cwiertnia, B; Dettlaff, K; Dołhań, A; Garbacki, P; Jelińska, A; Kycler, W; Ogrodowczyk, M | 1 |
| Reincke, M; Riester, A | 1 |
| Bilos, A; Deinum, J; Donders, AR; Riksen, NP; Rongen, GA; van den Berg, TN | 1 |
| di Mario, C; Francis, DP; Hayward, C; Krum, H; Lyon, AR; Ozdemir, BA; Patel, HC; Rosen, SD | 1 |
| Ando, K; Arakawa, Y; Fujita, T; Kaname, S; Ohtsu, H; Uchida, S | 1 |
| Gaudio, C; Greco, C; Patti, G; Pelliccia, F; Rosano, G; Volterrani, M | 1 |
| Agra, Y; Moreno-Gómez, AM; Otero, MJ; Santos-Ramos, B | 1 |
| Amâncio, Gde C; de Assis, LV; Faria, Gde O; Hermidorff, MM; Isoldi, MC | 1 |
| Beil, M; Chen, W; Dole, WP; Fu, F; Hu, CW; Jeng, AY; LaSala, D; Leung-Chu, J; Liang, G; Liu, J; Ménard, J; Rebello, S; Rigel, DF; Watson, C; Zhang, Y | 1 |
| Gaudio, C; Greco, C; Patti, G; Pelliccia, F; Rosano, G | 1 |
| Chen, YP; Li, M; Rui, HL; Sun, QL | 1 |
| Amann, K; Brand, S; Mandel, P; Schupp, N; Zimnol, A | 1 |
| Angelini, C | 1 |
| Cripe, LH; Halnon, NJ; He, X; Hor, KN; Jefferies, JL; Kissel, JT; Lowe, J; Mazur, W; McCarthy, B; Rafael-Fortney, JA; Raman, SV; Roble, SL; Smart, S; Taylor, MD; Tran, T | 1 |
| Asai, K; Asakura, M; Hanatani, A; Hirata, K; Hirayakma, A; Kada, A; Kimura, K; Kitakaze, M; Kobayashi, Y; Momomura, S; Nakagawa, Y; Nishi, Y; Saito, Y; Satoh, Y; Uesaka, H; Yamada, T; Yamamoto, H; Yamashina, A; Yasuda, S; Yoshikawa, T | 1 |
| Johannsson, G; Muth, A; Ragnarsson, O; Wängberg, B | 1 |
| Pedersen, EB; Therwani, S | 1 |
| Arab, JP; Arrese, M; Barrera, F; Baudrand, R; Cabrera, D; Fardella, CE; Feldstein, AE; Inzaugarat, E; Moshage, H; Padilla, O; Pizarro, M; Quintero, P; Riquelme, A; Roa, JC; Rojas-de Santiago, P; Solís, N; Wree, A | 1 |
| Anker, SD; Böhm, M; Filippatos, G; Gheorghiade, M; Kim, SY; Kimmeskamp-Kirschbaum, N; Krum, H; Køber, L; Maggioni, AP; Nowack, C; Pieper, A; Pitt, B; Ponikowski, P; Voors, AA; Zannad, F | 1 |
| Chudek, J; Maruniak-Chudek, I; Olszanecka-Glinianowicz, M; Sikora, J; Wyskida, K; Wyskida, M | 1 |
| Dorrance, AM; Jackson, WF; Pires, PW | 1 |
| Fujita, K; Fukuda, N; Hasegawa, F; Hori, S; Iwata, M; Katayama, S; Kato, H; Kawane, K; Matsuda, K; Mori, M; Nakayama, R; Nariai, T; Suzuki, K | 1 |
| Elliott, KS; Fineman, MS; Fischer, DH; Hsu, J; Pitcher, JD; Regillo, CD; Salz, DA; Spirn, MJ; Vander, JF | 1 |
| Kouassi, AC; Lebreton, O; Masse, H; Weber, M | 1 |
| Hayashi, S; Ishizuka, A; Iwashima, Y; Kawano, Y; Kishida, M; Nakamura, S; Ohta, Y; Yoshihara, F | 1 |
| Iellamo, F; Volterrani, M | 1 |
| Chen, W; Fu, C; Lu, Y; Xiao, J; Yan, Z; Ye, Z; Zhang, X; Zhang, Z | 1 |
| Aoki, K; Arai, K; Homma, T; Ishikawa, H; Mizuno, M; Morikawa, Y; Sada, T; Tsuruoka, H; Ubukata, N | 1 |
| Collier, T; Girerd, N; Krum, H; McMurray, JJ; Pitt, B; Pocock, S; Swedberg, K; Van Veldhuisen, DJ; Vincent, J; Zannad, F | 1 |
| Shewan, L; Stewart Coats, AJ | 1 |
| Hasegawa, J; Hongo, K; Mori, C; Murashima, E; Sato, N; Shibata, T; Tsutsumi, J; Yoshimura, M | 1 |
| Bosch, J; Bueti, J; Devereaux, PJ; Gao, P; Garg, AX; Manns, B; Rabbat, C; Smyth, A; Tyrwhitt, J; Wald, R; Walsh, M | 1 |
| Cannon, JA; Collier, TJ; Krum, H; McMurray, JJ; Pitt, B; Pocock, SJ; Shen, L; Swedberg, K; Van Veldhuisen, DJ; Vincent, J; Zannad, F | 1 |
| Adler, GK; Khalil, RA; Opsasnick, LA; Pojoga, LH; Reslan, OM; Siddiqui, WT; Williams, GH; Yao, TM | 1 |
| Deinum, J; Lenders, JW; Riksen, NP | 1 |
| Conte, D; Minas, JN; Nishiyama, A; Ortiz, RM; Thorwald, MA; Vázquez-Medina, JP | 1 |
| Chen, J; Jiang, B; Lou, H; Ruan, Z; Shao, R; Xu, Y | 1 |
| Christou, DD; English, M; Hwang, MH; Luttrell, M; Meade, TH; Yoo, JK | 1 |
| Follath, F | 1 |
| Lalic, N; Milinkovic, I; Pelliccia, F; Ristic, A; Rosano, G; Seferovic, J; Seferovic, PM; Simeunovic, D; Zivkovic, I | 1 |
| Capuano, A; Coats, AJ; Rosano, GM; Rossi, F; Scavone, C; Sportiello, L; Vitale, C | 1 |
| Gaudio, C; Greco, C; Lainscak, M; Pelliccia, F; Rosano, G; Schiariti, M; Speziale, G; Vitale, C | 1 |
| Ghadiali, Q; Jung, JJ; Patel, SN; Yannuzzi, LA; Yu, S | 1 |
| Goto, M; Hasebe, N; Takahashi, F; Wada, Y | 1 |
| Aiba, A; Ayuzawa, N; Fujita, T; Kawarazaki, W; Marumo, T; Nagase, M; Nishimoto, M; Sakurai, T; Shindo, T; Ueda, K | 1 |
| Ernst, ME; Kostis, JB; Roush, GC; Sica, DA; Yeasmin, S | 1 |
| Harpreet Singh, K; Kanchan, V; Pawan, K; Sudhir, V | 1 |
| Osmolovskaya, YF; Tereshchenko, SN; Zhirov, IV | 1 |
| Furukawa, K; Karashima, S; Kometani, M; Mori, S; Ohe, M; Sawamura, T; Seta, T; Takeda, Y; Yamagishi, M; Yoneda, T | 1 |
| Christou, DD; English, M; Hwang, MH; Jaffe, IZ; Kim, HK; Luttrell, M; Meade, TH; Talcott, S; Yoo, JK | 1 |
| Arnold, AC; Biaggioni, I; Black, BK; Elijovich, F; Gamboa, A; Okamoto, LE; Raj, SR; Robertson, D; Shibao, CA | 1 |
| Ahmad, M; Chen, A; Huang, BS; Leenen, FH; Wang, HW; White, RA | 1 |
| Findl, O; Hackl, C; Hirnschall, N; Leisser, C; Plasenzotti, P | 1 |
| Korantzopoulos, P; Letsas, KP; Li, G; Liu, T; Shao, Q; Zhang, Z | 1 |
| Anzai, K; Kawate, H; Matsuda, Y; Matsuzaki, C; Nomura, M; Ohnaka, K; Sakamoto, R; Shibue, K; Takayanagi, R | 1 |
| Bomback, AS | 1 |
| Bian, Z; Chen, P; Gu, H; Guo, L; Hu, C; Pan, Y; Zhang, Y; Zhu, S | 1 |
| Chin, KL; Collier, TJ; Krum, H; McMurray, JJ; Pitt, B; Pocock, SJ; Swedberg, K; Turgonyi, E; van Veldhuisen, DJ; Vincent, J; Zannad, F | 1 |
| Benz, V; Blumrich, A; Brix, S; Foryst-Ludwig, A; Grune, J; Höft, B; Kintscher, U; Klopfleisch, R; Kolkhof, P; Salatzki, J | 1 |
| Yang, J; Young, MJ | 1 |
| Bleich, M; de Bruijn, PI; Jensen, IS; Larsen, CK; Leipziger, J; Praetorius, HA; Sorensen, MV | 1 |
| Kapoor, KG; Wagner, AL | 1 |
| Enseleit, F; Flammer, AJ; Frank, M; Kouroedov, A; Lüscher, TF; Naegele, M; Noll, G; Périat, D; Roas, S; Ruschitzka, F; Sudano, I | 1 |
| Ding, Y; Hou, N; Hu, X; Li, C; Liu, Y; Ma, D; Mao, J; Peng, Y; Shang, H; Sun, X; Wang, C; Wang, J; Xiao, RP; Xiao, Y; Zeng, F; Zhang, J; Zhang, X; Zhang, Y; Zheng, W | 1 |
| Aberer, F; Alesutan, I; Belyavskiy, E; Brussee, H; Dimai, HP; Fahrleitner-Pammer, A; Gaksch, M; Grübler, M; Haas, J; Hartaigh, BÓ; Horina, JH; Lang, F; März, W; Meinitzer, A; Ofner-Ziegenfuss, L; Pieske, B; Pieske-Kraigher, E; Pilz, S; Ritz, E; Rus-Machan, J; Schwetz, V; Stiegler, C; Tomaschitz, A; Verheyen, N; Verheyen, S; Voelkl, J | 1 |
| Ajioka, M; Kato, M; Kim, SY; Kolkhof, P; Myoishi, M; Nowack, C; Sato, N; Shiga, T; Yamada, T | 1 |
| Barbe, C; Bertocchio, JP; Jaisser, F; Lavaud, S; Nazeyrollas, P; Rieu, P; Toupance, O | 1 |
| Bernhardt, R; Brixius-Anderko, S; Hannemann, F; Hobler, A; Müller, AR; Schiffer, L; Zapp, J | 1 |
| Anker, SD; Böhm, M; Filippatos, G; Gheorghiade, M; Kim, SY; Kimmeskamp-Kirschbaum, N; Kolkhof, P; Krum, H; Køber, L; Maggioni, AP; Nowack, C; Palombo, G; Pieper, A; Pitt, B; Ponikowski, P; Voors, AA; Zannad, F | 1 |
| Agostini, H; Böhringer, D; Bühler, A; Cakir, B; Ehlken, C; Fischer, F; Lange, C; Schlunck, G; Stahl, A | 1 |
| Deinum, J; Morshuis, WJ; Riksen, NP; Rongen, GA; van den Berg, TN; van Swieten, HA; Verweij, V; Vos, JC; Wouterse, AC | 1 |
| Ademi, Z; Liew, D; Pasupathi, K | 1 |
| Chapman, KE; Hadoke, PW; MacRae, VE; Rashdan, NA; Zhu, D | 1 |
| Chen, HJ; Jia, K; Li, R; Lin, JZ; Peng, LX; Wang, P; Zhao, G; Zou, L | 1 |
| Cofta, S; Krasińska, B; Krasiński, Z; Miazga, A; Pawlaczyk-Gabriel, K; Szczepaniak-Chicheł, L; Trafas, T; Tykarski, A | 1 |
| Denis, D; Gascon, P; Ho Wang Yin, G; Hoffart, L; Matonti, F; Sampo, M; Soler, V | 1 |
| Chen, J; Du, M; Hang, T; Pan, C; Song, M; Zhu, T | 1 |
| Baigent, C; Bueti, J; Garg, AX; Hawley, C; Haynes, R; Lvtvyn, L; Manns, B; Perkovic, V; Quach, K; Rabbat, CG; Wald, R; Walsh, M | 1 |
| Eguchi, K; Hoshide, S; Ishikawa, S; Kabutoya, T; Kario, K | 1 |
| Ezekowitz, JA; Kaul, P; Thanh, NX; Tran, DT | 1 |
| Jokinen, V; Kalso, E; Kambur, O; Laitila, J; Lilius, T; Niemi, M; Rauhala, P | 1 |
| Herpin, D; Lefebvre, H; Pechère-Bertschi, A | 1 |
| Chen, X; Du, L; Duan, S; Liu, X; Liu, Y; Wang, Q; Yi, Y; Zhang, W | 1 |
| Belyavskiy, E; Brandenburg, VM; Brussee, H; Catena, C; Fahrleitner-Pammer, A; Gaksch, M; Grübler, MR; März, W; Meinitzer, A; Perl, S; Pieske, B; Pilz, S; Scharnagl, H; Sechi, LA; Tomaschitz, A; Van Ballegooijen, AJ; Verheyen, N; Wetzel, J | 1 |
| Kaplan, NM | 1 |
| Asensio-López, MC; Caballero, L; Fernández-Del Palacio, MJ; Gimeno-Blanes, JR; Lax, A; Navarro-Peñalver, M; Pascual-Figal, DA; Pérez-Martínez, MT; Sánchez-Más, J | 1 |
| Brown, MC; Flatt, DM; King, BJ; Mizeracki, AM; Weber, KT | 1 |
| Jolly, A; Miquel, P; Shrier, A; Touyz, RM; Valinsky, WC | 1 |
| Chaudhari, PD; Kendre, PN | 1 |
| An, Y; Guo, A; Li, Y; Liu, T; Wang, M; Wang, Y; Zhang, G; Zhang, Y; Zhou, K | 1 |
| Bornstein, SR; Brown, NF; Brunssen, C; Deussen, A; Eisenhofer, G; Engelmann, F; Hofmann, A; Huber, J; Jannasch, A; Martin, M; Mittag, J; Morawietz, H; Peitzsch, M; Streicher, R; Weldon, SM | 1 |
| Aoun, P; Roelfsema, F; Veldhuis, JD | 1 |
| Carey, RM | 1 |
| Asbach, E; Bidlingmaier, M; Fourkiotis, V; Gerum, S; Lichtenauer, UD; Manolopoulou, J; Quinkler, M; Reincke, M | 1 |
| Bartunek, J; Dierckx, R; Goethals, M; Heggermont, WA; Vanderheyden, M; Verstreken, S | 1 |
| Ecsedy, M; Gergely, R; Kovács, I; Nagy, ZZ; Papp, A; Récsán, Z; Resch, M; Schneider, M | 1 |
| Agrinier, N; Camenzind, E; Fay, R; Girerd, N; Pitt, B; Popovic, B; Rossignol, P; Zannad, F | 1 |
| Adler, GK; Baudrand, R; Ferri, C; Garza, AE; Gupta, N; Hopkins, PN; Jeunemaitre, X; Leopold, JA; Loscalzo, J; Pojoga, LH; Romero, JR; Vaidya, A; Williams, GH; Williams, J | 1 |
| Dhople, VM; Felix, SB; Gross, S; Hammer, E; Könemann, S; Samal, R; Völker, U; Wenzel, K | 1 |
| Behar-Cohen, F; Carrai, P; Ciardella, A; Nucci, P; Pichi, F | 1 |
| Chadwick, JA; Floyd, KT; Gomez-Sanchez, CE; Gomez-Sanchez, EP; Janssen, PM; Kadakia, FK; Lowe, J; Rafael-Fortney, JA; Raman, SV; Rastogi, N; Schultz, EJ; Smart, S; Swager, SA; Zins, JG | 1 |
| Filippatos, G; Jaisser, F; Kim, SY; Kolkhof, P; Nowack, C; Pitt, B | 1 |
| Bakris, G; Claggett, B; Fay, R; Girerd, N; Krum, H; Lamiral, Z; McMurray, JJV; Pitt, B; Rossignol, P; Shi, H; Solomon, SD; Spanyers, S; Swedberg, K; van Veldhuisen, DJ; Vardeny, O; Vincent, J; Zannad, F | 1 |
| Eliott, D; Yang, D | 1 |
| Oishi, M; Sweeney, K; Tomono, Y; Zhao, Q | 1 |
| Channar, PA; El-Seedi, H; Faisal, M; Larik, FA; Mehfooz, H; Saeed, A; Shahzad, D | 1 |
| Kalizki, T; Karg, MV; Reinold, A; Schmidt, BM; Schmieder, RE; Schneider, A; Schneider, MP; Schwab, J | 1 |
| Agarwal, N; Alex, A; Bailey, E; Batten, J; Boucher, K; Gaston, D; Gill, D; Gupta, S; Hahn, A; Stenehjem, D | 1 |
| Eleftheriadis, T; Georgianos, PI; Liakopoulos, V; Vaios, V; Zebekakis, P | 1 |
| Kalizki, T; Raff, U; Reinold, A; Schmidt, BMW; Schmieder, RE; Schneider, A; Schneider, MP; Schwarz, TK | 1 |
| Cripe, LH; He, X; Hor, KN; Kissel, JT; Mazur, W; McCarthy, B; Raman, SV; Roble, SL; Smart, S | 1 |
| Kinkade, A; Masson, SC; Stabler, SN; Tam, TS; Tejani, AM; Tsang, MP; Tung, A; Wu, MH | 1 |
| Laurie, J; Morton, A | 1 |
| Bramlage, P; Fay, R; Girerd, N; Ketelslegers, JM; Michel, JB; Olivier, A; Pitt, B; Rossignol, P; Vincent, J; Zannad, F | 1 |
| Collier, TJ; Girerd, N; Lamiral, Z; Machu, JL; McMurray, JJV; Olivier, A; Pitt, B; Pizard, A; Pocock, SJ; Rossignol, P; Swedberg, K; van Veldhuisen, DJ; Zannad, F | 1 |
| Breitenbach, S; Jurkat-Rott, K; Lehmann-Horn, F | 1 |
| He, JQ; Liang, LJ; Liu, BB; Ma, XL; Shimosawa, T; Wang, CH; Wang, XT; Wang, Z; Xu, QY | 1 |
| Adam, MK; Chiang, A; Fineman, MS; Hsu, J; Kaiser, RS; Pitcher, JD; Rahimy, E; Samara, WA; Shahlaee, A; Spirn, MJ; Vander, JF | 1 |
| Chadwick, JA; Gomez-Sanchez, CE; Gomez-Sanchez, EP; Hauck, JS; Rafael-Fortney, JA | 1 |
| Ahmed, A; Anker, SD; Blackman, MR; White, M | 1 |
| Cohen, S; Goldenberg, D; Goldstein, M; Guzner-Gur, H; Habot-Wilner, Z; Loewenstein, A; Martinez, MR; Nutman, A; Schwartz, R; Shulman, S | 1 |
| Glemser, PA; Jaeger, H; Jurkat-Rott, K; Lehmann-Horn, F; Nagel, AM; Schlemmer, HP; Simons, D; Weber, MA; Ziegler, AE | 1 |
| Bakris, G; Dojki, FK | 1 |
| Fukunami, M; Furukawa, Y; Iwasaki, Y; Kawasaki, M; Kikuchi, A; Morita, T; Okuyama, Y; Sakata, Y; Tamaki, S; Yamada, T | 1 |
| Dohi, K; Fujimoto, N; Ichikawa, T; Isaka, N; Ito, M; Kitamura, T; Koyabu, S; Makino, K; Nakamura, M; Nishikawa, M; Ogura, T; Okamoto, S; Okubo, S; Sawai, T; Tamaru, S; Yamada, T | 1 |
| de Sa, EL; Duarte, K; Ferreira, JP; Flather, M; Hamm, CW; Montalescot, G; Orri, M; Pitt, B; Rossignol, P; Shi, H; Turgonyi, E; Verheugt, F; Vincent, J; Zannad, F | 1 |
| Alesutan, I; Amrein, K; Brussee, H; Catena, C; Dimai, HP; Fahrleitner-Pammer, A; Grübler, MR; März, W; Meinitzer, A; Pilz, S; Schwetz, V; Tomaschitz, A; Trummer, C; Verheyen, N; Voelkl, J; von Lewinski, D | 1 |
| Hori, Y; Hoshi, F; Itoh, N; Kanai, K; Saitoh, R; Touei, D; Yamagishi, M | 1 |
| Awad, KS; Biancotto, A; Cai, R; Chen, LY; Danner, RL; Dougherty, EJ; Elinoff, JM; Preston, IR; Siddiqui, AH; Solomon, MA; Sun, J; Wang, S; Weir, NA | 1 |
| de Faria, AP; Modolo, R; Moreno, H; Yugar-Toledo, JC | 1 |
| Behar-Cohen, F; Daruich, A; Matet, A | 1 |
| Gong, H; Li, H; Lu, Y; Ma, X; Wang, B; Wang, C; Wu, Z; Yan, Y; Zhang, X | 1 |
| Berenfeld, O; Ennis, SR; Guerrero-Serna, G; Jalife, J; Kaur, K; Ponce-Balbuena, D; Ramirez, RJ; Ramos-Mondragón, R; Salvador-Montañés, O; Takemoto, Y | 1 |
| Elliott, AD; Linz, D; Sanders, P | 1 |
| Baldin, G; Bandello, F; Cicinelli, MV; Marchese, A; Montorio, D; Querques, G; Querques, L; Rabiolo, A; Sacconi, R; Zucchiatti, I | 1 |
| Baker, WL; de Denus, S; Korol, S; Mottet, F; Perreault, S; White, M | 1 |
| Chen, YP; Cheng, H; Dong, HR; Dong, J; Liu, BL; Rui, HL; Yang, M; Zhu, JJ | 1 |
| Agrawal, YO; Chandrayan, G; Goyal, SN; Mahajan, UB; Ojha, S; Patil, CR; Patil, PD | 1 |
| Aagaard, A; Bamberg, K; Björnson Granqvist, A; Edman, K; Geschwindner, S; Granberg, KL; Gunnarsson, A; Hartleib-Geschwindner, J; Huang, Y; Jaisser, F; Jansson-Löfmark, R; Johansson, U; Myhre, S; William-Olsson, L | 1 |
| Abe, T; Harada, M; Kanematsu, Y; Kinouchi, T; Kitazato, KT; Korai, M; Kuwayama, K; Matsushita, N; Miyamoto, T; Mure, H; Nagahiro, S; Nakajima, K; Okayama, Y; Satomi, J; Shimada, K; Tada, Y; Yagi, K; Yamaguchi, T | 1 |
| Ben-Gal, T; Hasin, T; Kornowski, R; Leshem-Lev, D; Lev, EI; Levi, A; Mats, I; Murninkas, D; Weissler-Snir, A | 1 |
| Bus-Kwasnik, K; Filist, M; Rudzki, PJ | 1 |
| Ando, Y; Baba, A; Imamura, Y; Ishida, M; Ogawa, J; Suzuki, A; Takano, Y | 1 |
| Beygui, F; Ecollan, P; Flather, M; Hamm, CW; Lopez De Sa, E; Machecourt, J; Montalescot, G; Pitt, B; Van Belle, E; Verheugt, FWA; Vicaut, E; Zannad, F | 1 |
| Bouchi, R; Fujii, Y; Fukuda, T; Hashimoto, K; Kihara, K; Minami, I; Murakami, M; Nakano, Y; Ogawa, Y; Yoshimoto, T | 1 |
| Filemonowicz-Skoczek, A; Karska-Basta, I; Kubicka-Trzaska, A; Ozog-Baran, J; Pociej-Marciak, W; Romanowska-Dixon, B | 1 |
| Aberer, F; Alesutan, I; Bachmann, A; Catena, C; Grübler, MR; März, W; Meinitzer, A; Obermayer-Pietsch, B; Pandis, M; Pilz, S; Schwetz, V; Sechi, LA; Tomaschitz, A; Trummer, C; Verheyen, N; Voelkl, J | 1 |
| Carrero, JJ; Jernberg, T; Löfman, I; Lund, LH; Olsson, H; Szummer, K | 1 |
| Angel, A; Chernichovski, T; Grupper, A; Hod, T; Kazan, S; Kliuk-Ben Bassat, O; Naveh, S; Schwartz, IF; Shashar, M; Weinstein, T | 1 |
| Bernier, M; Chaar, D; de Denus, S; Ducharme, A; Guertin, MC; Jutras, M; Korol, S; Lavoie, J; Leclair, G; Liszkowski, M; Mansour, A; Neagoe, PE; O'Meara, E; Racine, N; Rouleau, JL; Sirois, MG; Tournoux, F; White, M | 1 |
| Aonuma, K; Baba, M; Hamada-Harimura, Y; Higuchi, H; Ishizu, T; Machino-Ohtsuka, T; Nakatsukasa, T; Nishi, I; Obara, K; Sai, S; Seo, Y; Sugano, A; Yamamoto, M | 1 |
| Abreu, P; Beckerman, B; Burgess, E; Fernet, M; Lins, K; Vincent, J | 1 |
| Bousquet, E; Dhundass, M; Gaudric, A; Krivosic, V; Lejoyeux, R; Mrejen, S; Shinojima, A; Tadayoni, R | 1 |
| Balogh, DB; Fekete, A; Genovese, F; Hodrea, J; Hosszu, A; Koszegi, S; Lakat, T; Lenart, L; Molnar, A; Sparding, N; Szabo, AJ; Szkibinszkij, E; Vannay, A; Wagner, L | 1 |
| de Borst, MH; Laverman, GD; Navis, G | 1 |
| Badmus, OO; Kim, I; Olatunji, LA; Usman, TO | 1 |
| Manolis, AA; Manolis, AS; Manolis, TA; Melita, H | 1 |
| Arroyo, JG; Seto, BK; Sun, P; Tandias, RM; Wang, SK | 1 |
| Chen, X; Shen, W; Wu, Q; Wu, T; Xu, G; Xu, X; Yang, P; Zhu, D | 1 |
| Atar, D; Clark, AL; Frankenstein, L; Fröhlich, H; Jensen, K; Katus, HA; Naci, H; Nee, P; Seide, S; Seiz, M; Täger, T; Uhlmann, L | 1 |
| Battaglia, G; Fiorini, F; Granata, A; La Rosa, S; Maccarrone, R; Ocello, A; Randone, S | 1 |
| Behar-Cohen, F; Bousquet, E; Daruich, A; Zhao, M | 1 |
| Bíró, T; Farman, N; Funk, W; Hundt, JE; Langan, EA; Paus, R; Sass, S | 1 |
| Fusi-Rubiano, W; Patel, V; Saedon, H; Yang, YC | 1 |
| Auerbach, SR; Cardona, A; Cripe, LH; Halnon, N; He, X; Hor, KN; Kissel, JT; Markham, L; Mazur, W; McCarthy, B; Puchalski, MD; Raman, SV; Saeed, IM; Smart, S; Soslow, JH; Statland, JM; Truong, U | 1 |
| Eschalier, R; Ferreira, JP; Girerd, N; McMurray, JJV; Pitt, B; Pocock, S; Rossello, X; Rossignol, P; Zannad, F | 1 |
| Andrade, MHG; de Assis, LVM; Hermidorff, MM; Isoldi, MC; Natali, AJ; Rodrigues, JA; Soares, LL | 1 |
| Campo, G; Dewan, P; Ferreira, JP; Jackson, A; Jhund, PS; McMurray, JJV; Petrie, MC; Pitt, B; Rossignol, P; Serenelli, M; Zannad, F | 1 |
| Bandello, F; Rabiolo, A | 1 |
| Aoki, K; Asoh, Y; Hanzawa, H; Hayashi, N; Homma, T; Honzumi, M; Saito, K; Takahashi, M; Tsuruoka, H; Ubukata, O | 1 |
| Sadda, SR | 1 |
| Sehgal, R; Singh, H; Singh, IP | 1 |
| Ferreira, JP; Girerd, N; Lam, CSP; McMurray, JJV; Pitt, B; Pocock, SJ; Rossello, X; Rossignol, P; Solomon, SD; Zannad, F | 1 |
| Sueta, D; Tsujita, K; Yamamoto, E | 1 |
| Adler, GK; Baudrand, R; Brooks, D; Garza, AE; Katayama Rangel, IA; Moize, B; Pojoga, LH; Ranjit, S; Romero, JR; Treesaranuwattana, T; Trefts, E; Williams, GH; Yao, TM | 1 |
| Cleland, JG; Ferreira, JP; Girerd, N; Pellicori, P; Pitt, B; Rossignol, P; Stienen, S; Zannad, F | 1 |
| Agarwal, A; Cheung, AK | 1 |
| Balogh, DB; Fekete, A; Hodrea, J; Hosszu, A; Lakat, T; Lenart, L; Molnar, A; Szabo, AJ | 1 |
| Abdin, AD; Fraenkel, D; Langenbucher, A; Seitz, B; Suffo, S | 1 |
| Besheer, J; Fortino, B; Irukulapati, P; Makhijani, VH; Van Voorhies, K | 1 |
| Claggett, BL; Docherty, KF; Ferreira, JP; Gregson, J; Jhund, PS; McMurray, JJV; Petrie, MC; Pocock, SJ; Solomon, SD; Stienen, S; Zannad, F | 1 |
| Bolignano, D; Chung, EY; Natale, P; Navaneethan, SD; Palmer, SC; Ruospo, M; Strippoli, GF | 1 |
| Abe, Y; Asai, K; Asakura, M; Hanatani, A; Higashino, Y; Higuchi, Y; Hirata, KI; Hirayama, A; Ito, S; Iwahashi, N; Kada, A; Kawai, H; Kawata, H; Kimura, K; Kitakaze, M; Kobayashi, M; Kobayashi, Y; Koitabashi, T; Maejima, Y; Momomura, SI; Niinuma, H; Nomura, A; Okuhara, Y; Saito, Y; Satoh, Y; Shibata, Y; Sugino, H; Tamaki, S; Tamaki, Y; Tanaka, J; Tsujimoto, M; Yamada, T; Yamamoto, H; Yamashina, A; Yasuda, S; Yokoi, Y; Yoshikawa, T | 1 |
| Borrelli, E; Querques, G; Sacconi, R | 1 |
| Bodaghi, B; LeHoang, P; Stanescu-Segall, D; Touhami, S | 1 |
| Harris, RA; Lotery, A; O'Connell, A; Reeves, BC; Sivaprasad, S | 1 |
| Edwards, C | 1 |
| Hasegawa, T; Levack, WM; Nishiwaki, H; Noma, H; Ota, E | 1 |
| Khani, A; Nabati, M; Tabiban, S; Vafainezhad, H; Yazdani, J | 1 |
| Allen, S; Davis, H; Jacobs, D; Lipscomb, J; Moote, R; Moreno, V; Oliver, A; Rubio, A | 1 |
| Lotery, A; O'Connell, A; Reeves, B; Sivaprasad, S | 1 |
| Ferreira, JP; Lamiral, Z; McMurray, JJV; Pitt, B; Pocock, SJ; Rossignol, P; Swedberg, K; van Veldhuisen, DJ; Vincent, J; Zannad, F | 1 |
| An, J; Niu, F; Sim, JJ | 1 |
| Hryhoryshyn, RS; Kulynych, HB; Nesterak, RV; Savchuk, NV; Vakaliuk, IP | 1 |
| Baker, ME; Hyodo, S; Katsu, Y; Lin, X; Oana, S | 1 |
| Abba, ML; Abumayyaleh, M; Akin, I; Behnes, M; Bertsch, T; Mashayekhi, K; Reiser, L; Schupp, T; von Zworowsky, M; Weidner, K | 1 |
| Clements, S; Dargie, HJ; McMurray, JJV; Steedman, T; Weir, RAP | 1 |
| Abdelhakeem, E; El-Nabarawi, M; Shamma, R | 1 |
| Asadipooya, K; Bakhtiari, M | 1 |
| Almenar-Bonet, L; Barge-Caballero, E; Barge-Caballero, G; Bouzas-Mosquera, A; Couto-Mallón, D; Crespo-Leiro, MG; Muñiz, J; Paniagua-Martín, MJ; Pardo-Martínez, P; Prada-Delgado, Ó; Sagastagoitia-Fornie, M; Vázquez-Rodríguez, JM | 1 |
| Pitt, B; Rossignol, P | 1 |
| Hartinger, J; Holaj, R; Krátká, Z; Kurcová, I; Marešová, V; Nikrýnová Nguyen, TMP; Petrák, O; Pilková, A; Štrauch, B; Waldauf, P; Widimský, J; Zelinka, T | 1 |
| Forestiero, V; Monticone, S; Mulatero, P; Sconfienza, E | 1 |
| Lerma, EV; Wilson, DJ | 1 |
| Bedrouni, W; Claggett, B; Ferreira, JP; Giannetti, N; Girerd, N; Huynh, T; Lam, CSP; McMurray, J; Ni, J; Pitt, B; Pocock, S; Rossignol, P; Sharma, A; Solomon, SD; Zannad, F | 1 |
| Armani, A; Caprio, M; Infante, M; Marzolla, V; Rizzo, M | 1 |
| Misra, A; Singh, A; Singh, AK; Singh, R | 1 |
| Dragomiretskaya, NA; Kucherova, JS; Podzolkov, VI; Tarzimanova, AI | 1 |
| Chhablani, J; Goté, JT; Singh, SR | 1 |
| Abo Zaid, MH; Belal, F; El-Enany, N; Hadad, GM; Mostafa, AE | 1 |
| Málek, F | 1 |
| Adler, GK; Baak, S; Burdo, TH; deFilippi, CR; DiCarli, M; Dunderdale, CN; Feldpausch, M; Grinspoon, SK; Huck, DM; Islam, S; Iyengar, S; Jerosch-Herold, M; Kwong, R; Lee, H; Lu, MT; Robbins, GK; Shen, G; Srinivasa, S; Thomas, TS; Torriani, M; Walpert, AR | 1 |
| Durak-Nalbantic, A; Karic, A; Naser, N; Sabanovic-Bajramovic, N | 1 |
| Akdur, A; Baskin, E; Çolak, MY; Gülleroğlu, K; Haberal, M; Moray, G; Özdemir, BH; Siddiqui, MA; Soy, EA; Yılmaz, AÇ | 1 |
| Denholt, CS; Fosbøl, E; Gustafsson, F; Kristensen, SL; Køber, L; Larsson, JE; Nielsen, OW; Raja, AA; Schou, M; Thune, JJ | 1 |
| Duarte, K; Ferreira, JP; Girerd, N; McMurray, JJV; Monzo, L; Pitt, B; Pocock, SJ; Swedberg, K; van Veldhuisen, DJ; Zannad, F | 1 |
194 review(s) available for spironolactone and eplerenone
| Article | Year |
|---|---|
Mineralocorticoid receptor antagonists for the treatment of hypertension and diabetic nephropathy.
Topics: Animals; Diabetic Nephropathies; Drug Design; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Receptors, Mineralocorticoid | 2012 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
The promise of selective aldosterone receptor antagonists for the treatment of hypertension and congestive heart failure.
Topics: Aldosterone; Animals; Antihypertensive Agents; Eplerenone; Heart Failure; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Spironolactone | 2000 |
Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Eplerenone; Humans; Hypertension; Kidney Failure, Chronic; Mineralocorticoid Receptor Antagonists; Rats; Rats, Inbred SHR; Spironolactone | 2001 |
Eplerenone (GD Searle & Co).
Topics: Animals; Antihypertensive Agents; Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Hypertension; Kidney Diseases; Mineralocorticoid Receptor Antagonists; Spironolactone | 2001 |
Eplerenone: a selective aldosterone receptor antagonist (SARA).
Topics: Animals; Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Spironolactone | 2001 |
Recent studies with eplerenone, a novel selective aldosterone receptor antagonist.
Topics: Aldosterone; Animals; Cardiovascular System; Clinical Trials as Topic; Endothelium, Vascular; Eplerenone; Heart Failure; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Protective Agents; Receptors, Mineralocorticoid; Renin-Angiotensin System; Spironolactone; Tissue Survival | 2001 |
Eplerenone--a novel selective aldosterone blocker.
Topics: Animals; Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Spironolactone | 2002 |
The pathophysiology of aldosterone in the cardiovascular system.
Topics: Aldosterone; Animals; Brain; Cardiovascular Diseases; Eplerenone; Heart; Humans; Kidney; Mineralocorticoid Receptor Antagonists; Myocardium; Randomized Controlled Trials as Topic; Salts; Spironolactone | 2002 |
New biology of aldosterone, and experimental studies on the selective aldosterone blocker eplerenone.
Topics: Aldosterone; Animals; Cardiomegaly; Clinical Trials as Topic; Desoxycorticosterone; Eplerenone; Fibrosis; Heart; Heart Failure; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Myocardium; Rats; Rats, Inbred SHR; Receptors, Mineralocorticoid; Spironolactone | 2002 |
Clinical implications of aldosterone blockade.
Topics: Aldosterone; Antihypertensive Agents; Black People; Blood Pressure; Cardiovascular Diseases; Clinical Trials as Topic; Eplerenone; Humans; Hypertension; Kidney Diseases; Losartan; Mineralocorticoid Receptor Antagonists; Potassium; Renin-Angiotensin System; Spironolactone | 2002 |
The role of aldosterone receptor blockade in the management of cardiovascular disease.
Topics: Aldosterone; Animals; Cardiovascular Diseases; Eplerenone; Heart Failure; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Spironolactone | 2002 |
Do diuretics and aldosterone receptor antagonists improve ventricular remodeling?
Topics: Diuretics; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Spironolactone; Ventricular Dysfunction, Left; Ventricular Remodeling | 2002 |
Aldo is back: recent advances and unresolved controversies in hyperaldosteronism.
Topics: Eplerenone; Female; Follow-Up Studies; Humans; Hyperaldosteronism; Hypertension; Incidence; Male; Renin-Angiotensin System; Risk Assessment; Severity of Illness Index; Spironolactone; Treatment Outcome | 2003 |
Eplerenone.
Topics: Aldosterone; Antihypertensive Agents; Clinical Trials as Topic; Drug Approval; Eplerenone; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Spironolactone; United States; United States Food and Drug Administration | 2003 |
Aldosterone receptor antagonists: focus on eplerenone.
Topics: Antihypertensive Agents; Blood Pressure; Cardiac Output; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Receptors, Mineralocorticoid; Renin-Angiotensin System; Spironolactone; United States; Vascular Resistance | 2003 |
[Aldosterone and its antagonists in heart failure].
Topics: Adrenergic beta-Antagonists; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Diuretics; Eplerenone; Heart Failure; Homeostasis; Humans; Mineralocorticoid Receptor Antagonists; Multicenter Studies as Topic; Placebos; Randomized Controlled Trials as Topic; Receptors, Mineralocorticoid; Spironolactone; Time Factors | 2003 |
Eplerenone, a new selective aldosterone blocker.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiovascular System; Disease Models, Animal; Dogs; Eplerenone; Heart Injuries; Humans; Kidney Diseases; Mineralocorticoid Receptor Antagonists; Rats; Renin-Angiotensin System; Spironolactone | 2003 |
Aldosterone as a target in congestive heart failure.
Topics: Aldosterone; Cardiovascular Agents; Endothelium, Vascular; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Muscle, Smooth, Vascular; Myocardium; Plasminogen Activator Inhibitor 1; Progesterone; Randomized Controlled Trials as Topic; Spironolactone; Treatment Outcome | 2003 |
Eplerenone. Pharmacia.
Topics: Animals; Clinical Trials as Topic; Eplerenone; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Spironolactone | 2003 |
Eplerenone: cardiovascular protection.
Topics: Aldosterone; Animals; Cardiovascular Diseases; Cardiovascular System; Disease Models, Animal; Eplerenone; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Renin-Angiotensin System; Spironolactone; Treatment Outcome | 2003 |
Aldosterone resurgens--letter from EPHESUS.
Topics: Aldosterone; Animals; Cardiac Output, Low; Cardiovascular Diseases; Eplerenone; Humans; Inflammation; Metaphor; Mineralocorticoid Receptor Antagonists; Randomized Controlled Trials as Topic; Spironolactone | 2003 |
Update of clinical trials from the American College of Cardiology 2003. EPHESUS, SPORTIF-III, ASCOT, COMPANION, UK-PACE and T-wave alternans.
Topics: Anticoagulants; Cardiac Pacing, Artificial; Defibrillators, Implantable; Electrocardiography; Eplerenone; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mineralocorticoid Receptor Antagonists; Pacemaker, Artificial; Spironolactone; Ventricular Dysfunction, Left; Warfarin | 2003 |
Selective aldosterone blockade with eplerenone in patients with congestive heart failure.
Topics: Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Renin-Angiotensin System; Spironolactone; Ventricular Function, Left | 2003 |
Eplerenone: a selective aldosterone blocker.
Topics: Animals; Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Hypertension; Hypertrophy, Left Ventricular; Mineralocorticoid Receptor Antagonists; Spironolactone | 2003 |
Should the aldosterone-receptor antagonist - eplerenone - be used after acute myocardial infarction with left ventricular dysfunction?
Topics: Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Randomized Controlled Trials as Topic; Spironolactone; Treatment Outcome; Ventricular Dysfunction, Left | 2003 |
RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease.
Topics: Aldosterone; Cardiovascular Diseases; Eplerenone; Humans; Kidney Diseases; Mineralocorticoid Receptor Antagonists; Renin-Angiotensin System; Spironolactone | 2003 |
Aldosterone receptor antagonists for hypertension: what do they offer?
Topics: Aldosterone; Clinical Trials as Topic; Diuretics; Eplerenone; Heart Failure; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Mineralocorticoids; Renin-Angiotensin System; Spironolactone | 2003 |
New developments in the management of hypertension.
Topics: Aged; Antihypertensive Agents; Eplerenone; Humans; Hypertension; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Spironolactone | 2003 |
Aldosterone receptor blockade and the role of eplerenone: evolving perspectives.
Topics: Aldosterone; Cardiovascular Diseases; Controlled Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Eplerenone; Female; Humans; Male; Mineralocorticoid Receptor Antagonists; Prognosis; Receptors, Mineralocorticoid; Renal Insufficiency; Risk Assessment; Spironolactone; Survival Analysis; Treatment Outcome | 2003 |
Aldosterone receptor antagonists in the treatment of heart failure.
Topics: Aged; Cardiac Output, Low; Clinical Trials as Topic; Eplerenone; Humans; Male; Mineralocorticoid Receptor Antagonists; Spironolactone | 2003 |
Aldosterone blockade in patients with systolic left ventricular dysfunction.
Topics: Aldosterone; Eplerenone; Forecasting; Heart Failure; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Patient Selection; Randomized Controlled Trials as Topic; Spironolactone; Systole; Ventricular Dysfunction, Left | 2003 |
Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease.
Topics: Animals; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Receptors, Mineralocorticoid; Spironolactone; Ventricular Dysfunction, Left | 2003 |
The role of mineralocorticoid receptor antagonists in the treatment of cardiac failure.
Topics: 11-beta-Hydroxysteroid Dehydrogenases; Animals; Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Hydrocortisone; Hypertension; Mineralocorticoid Receptor Antagonists; Receptors, Mineralocorticoid; Spironolactone | 2003 |
The cardiovascular effects of eplerenone, a selective aldosterone-receptor antagonist.
Topics: Area Under Curve; Clinical Trials as Topic; Drug Interactions; Eplerenone; Humans; Hyperkalemia; Hypertension; Hypertrophy, Left Ventricular; Mineralocorticoid Receptor Antagonists; Proteinuria; Spironolactone; Ventricular Dysfunction, Left | 2003 |
Review of aldosterone- and angiotensin II-induced target organ damage and prevention.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 2 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiovascular Diseases; Endothelium, Vascular; Eplerenone; Humans; Kidney; Mineralocorticoid Receptor Antagonists; Myocardium; Spironolactone | 2004 |
[Significance of aldosterone antagonist therapy].
Topics: Aldosterone; Cardiovascular Diseases; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Eplerenone; Heart Failure; Hemodynamics; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Receptors, Mineralocorticoid; Spironolactone; Water-Electrolyte Balance | 2004 |
The role of aldosterone in heart failure and the clinical benefits of aldosterone blockade.
Topics: Aldosterone; Autonomic Nervous System Diseases; Endomyocardial Fibrosis; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Vascular Diseases; Water-Electrolyte Imbalance | 2004 |
New therapies for heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Agents; Diuretics; Drug Therapy, Combination; Eplerenone; Heart Failure; Humans; Hydrazones; Natriuretic Agents; Natriuretic Peptide, Brain; Neurotransmitter Agents; Pyridazines; Simendan; Spironolactone; Treatment Outcome; United States | 2004 |
Evolving role of aldosterone blockers alone and in combination with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in hypertension management: a review of mechanistic and clinical data.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Drug Therapy, Combination; Eplerenone; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Renin-Angiotensin System; Spironolactone | 2004 |
Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Digoxin; Enzyme Inhibitors; Eplerenone; Female; Humans; Male; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Randomized Controlled Trials as Topic; Spironolactone; Systole; Ventricular Dysfunction, Left | 2004 |
Towards selectively modulating mineralocorticoid receptor function: lessons from other systems.
Topics: Aldosterone; Anti-Inflammatory Agents; Crystallography, X-Ray; Epithelium; Eplerenone; Hydrocortisone; Mineralocorticoid Receptor Antagonists; Myocytes, Cardiac; Protein Binding; Protein Structure, Tertiary; Receptors, Glucocorticoid; Receptors, Mineralocorticoid; Receptors, Thyroid Hormone; Signal Transduction; Spironolactone; Structure-Activity Relationship | 2004 |
Aldosterone target organ protection by eplerenone.
Topics: Aldosterone; Blood Vessels; Brain; Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Myocardium; Receptors, Mineralocorticoid; Spironolactone; Vasculitis, Central Nervous System; Ventricular Remodeling | 2004 |
Role of the selective aldosterone receptor blockers in arterial hypertension.
Topics: Animals; Eplerenone; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Spironolactone; Ventricular Dysfunction, Left | 2004 |
Eplerenone in the treatment of chronic heart failure.
Topics: Aldosterone; Chronic Disease; Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Spironolactone; Treatment Outcome | 2004 |
Pathophysiologic role of the renin-angiotensin-aldosterone and sympathetic nervous systems in heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Renin-Angiotensin System; Spironolactone; Sympathetic Nervous System | 2004 |
Integrating traditional and emerging treatment options in heart failure.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Biological Availability; Eplerenone; Half-Life; Humans; Male; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Randomized Controlled Trials as Topic; Spironolactone | 2004 |
Eplerenone: will it have a role in the treatment of acute coronary syndromes?
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Collagen; Coronary Restenosis; Eplerenone; Humans; Inflammation; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Spironolactone; Syndrome; Thrombosis | 2004 |
The role of aldosterone and aldosterone-receptor antagonists in heart failure.
Topics: Aldosterone; Eplerenone; Fibrosis; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardium; Spironolactone | 2004 |
Aldosterone antagonism and congestive heart failure: a new look at an old therapy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Combination; Enalapril; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Randomized Controlled Trials as Topic; Spironolactone; Treatment Outcome; Ventricular Function, Left; Ventricular Remodeling | 2004 |
Inspra improves survival for CHF patients.
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Eplerenone; Heart Failure; Humans; Hyperkalemia; Mineralocorticoid Receptor Antagonists; Spironolactone; Survival Analysis; Treatment Outcome | 2004 |
Mineralocorticoid receptor antagonists and hypertension: is there a rationale?
Topics: Albuminuria; Aldosterone; Animals; Drug Therapy, Combination; Eplerenone; Humans; Hyperkalemia; Hypertension; Hypertrophy, Left Ventricular; Mineralocorticoid Receptor Antagonists; Renin-Angiotensin System; Spironolactone; Vasodilation | 2004 |
Additive improvement of left ventricular remodeling by aldosterone receptor blockade with eplerenone and angiotensin II type 1 receptor antagonist in rats with myocardial infarction.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Eplerenone; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Rats; Spironolactone; Tetrazoles; Ventricular Dysfunction, Left; Ventricular Remodeling | 2004 |
The clinical implications of aldosterone escape in congestive heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Death, Sudden, Cardiac; Endothelium, Vascular; Eplerenone; Fibrosis; Heart Failure; Humans; Myocardium; Spironolactone; Ventricular Remodeling | 2004 |
The use of selective aldosterone antagonists.
Topics: Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Eplerenone; Female; Heart Failure; Humans; Hypertension; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Prognosis; Randomized Controlled Trials as Topic; Severity of Illness Index; Spironolactone; Survival Analysis; Treatment Outcome | 2004 |
Eplerenone: a new selective aldosterone receptor antagonist.
Topics: Aldosterone; Animals; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Receptors, Mineralocorticoid; Spironolactone | 2004 |
Eplerenone : a review of its use in left ventricular systolic dysfunction and heart failure after acute myocardial infarction.
Topics: Animals; Area Under Curve; Economics, Pharmaceutical; Eplerenone; Half-Life; Heart Failure; Humans; Middle Aged; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Randomized Controlled Trials as Topic; Rats; Spironolactone; Ventricular Dysfunction, Left | 2004 |
The use of aldosterone receptor blockers in the treatment of hypertension.
Topics: Eplerenone; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Spironolactone | 2004 |
Eplerenone in hypertension.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Enalapril; Eplerenone; Humans; Hypertension; Spironolactone | 2004 |
Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure.
Topics: Animals; Cardiovascular Agents; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Molecular Structure; Randomized Controlled Trials as Topic; Spironolactone | 2005 |
Eplerenone: a review of its use in essential hypertension.
Topics: Antihypertensive Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Eplerenone; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Randomized Controlled Trials as Topic; Spironolactone | 2005 |
A new selective aldosterone antagonist. Inspra's role in hypertension and post-MI heart failure.
Topics: Arrhythmias, Cardiac; Drug Interactions; Eplerenone; Evidence-Based Medicine; Heart Failure; Humans; Hypertension; Myocardial Infarction; Patient Selection; Quality of Life; Risk Factors; Spironolactone; United States | 2005 |
2004 drug approval highlights: FDA update.
Topics: Administration, Cutaneous; Amlodipine; Anti-Bacterial Agents; Antidepressive Agents; Bronchodilator Agents; Cardiovascular Agents; Drug Approval; Drug Combinations; Duloxetine Hydrochloride; Eplerenone; Estradiol; Excitatory Amino Acid Antagonists; Female; Gastrointestinal Agents; Heptanoic Acids; Humans; Ketolides; Male; Memantine; Osteoporosis, Postmenopausal; Pyrroles; Rifamycins; Rifaximin; Scopolamine Derivatives; Spironolactone; Thiophenes; Tiotropium Bromide; United States | 2005 |
[Aldosterone antagonist therapy for chronic heart failure].
Topics: Aldosterone; Chronic Disease; Death, Sudden, Cardiac; Diuretics; Eplerenone; Fibrosis; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardium; Randomized Controlled Trials as Topic; Spironolactone; Sulfonamides; Torsemide; Ventricular Remodeling | 2005 |
Pleiotropic actions of aldosterone and the effects of eplerenone, a selective mineralocorticoid receptor antagonist.
Topics: Aldosterone; Animals; Drug Interactions; Eplerenone; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Spironolactone | 2004 |
[The role of aldosterone-antagonists in the treatment of congestive heart failure].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Severity of Illness Index; Spironolactone; Stroke Volume | 2005 |
Aldosterone antagonism: an emerging strategy for effective blood pressure lowering.
Topics: Eplerenone; Humans; Hyperaldosteronism; Hypertension; Mineralocorticoid Receptor Antagonists; Spironolactone | 2005 |
Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis.
Topics: Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Mineralocorticoids; Potassium; Spironolactone | 2005 |
The role of aldosterone blockade in patients with heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Diuretics; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Randomized Controlled Trials as Topic; Spironolactone | 2005 |
The risks and benefits of aldosterone antagonists.
Topics: Eplerenone; Heart Failure; Humans; Hyperkalemia; Mineralocorticoid Receptor Antagonists; Spironolactone | 2005 |
[Roll of aldosterone in pathogenesis of kidney disorders].
Topics: Aldosterone; Animals; Body Water; Disease Models, Animal; Eplerenone; Humans; Hypertension; Kidney Diseases; Mineralocorticoid Receptor Antagonists; Potassium; Proteinuria; Receptors, Mineralocorticoid; Sodium; Spironolactone | 2005 |
Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone.
Topics: Aldosterone; Animals; Eplerenone; Heart Failure; Hypertension; Ligands; Mineralocorticoid Receptor Antagonists; Receptors, Mineralocorticoid; Spironolactone; Transcription, Genetic | 2005 |
[Recent insights into the role of aldosterone in physiology, pathology and therapy].
Topics: Aldosterone; Cardiovascular Diseases; Eplerenone; Humans; Spironolactone | 2005 |
New aldosteron receptor inhibitors in heart failure.
Topics: Decision Trees; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone | 2005 |
Eplerenone : a pharmacoeconomic review of its use in patients with post-myocardial infarction heart failure.
Topics: Aged; Cost-Benefit Analysis; Economics, Pharmaceutical; Eplerenone; Female; Heart Failure; Heart Rupture, Post-Infarction; Humans; Male; Middle Aged; Multicenter Studies as Topic; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Spironolactone | 2005 |
Molecular mechanisms and therapeutic strategies of chronic renal injury: renoprotective effects of aldosterone blockade.
Topics: Aldosterone; Animals; Cell Proliferation; Cell Shape; Cells, Cultured; Collagen; Eplerenone; Fibroblasts; Fibrosis; Humans; Kidney; Kidney Diseases; Mesangial Cells; Mineralocorticoid Receptor Antagonists; Mitogen-Activated Protein Kinases; Rats; Reactive Oxygen Species; Receptors, Mineralocorticoid; Spironolactone | 2006 |
[The latest developments in endocrinology 2004/2005].
Topics: Adrenal Gland Neoplasms; Adult; Bone Density Conservation Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Clinical Trials as Topic; Endocrinology; Eplerenone; Female; Humans; Hyperaldosteronism; Hyperparathyroidism; Hyperparathyroidism, Primary; Hyperparathyroidism, Secondary; Hypogonadism; Hypothyroidism; Male; Naphthalenes; Neuroendocrine Tumors; Organometallic Compounds; Osteoporosis, Postmenopausal; Pheochromocytoma; Positron-Emission Tomography; Pregnancy; Radiography, Abdominal; Spironolactone; Teriparatide; Testosterone; Testosterone Congeners; Thiophenes; Time Factors; Tomography, X-Ray Computed | 2006 |
Mineralocorticoid receptor blockade in the protection of target organ damage.
Topics: Aldosterone; Animals; Brain; Brain Diseases; Cardiovascular Diseases; Eplerenone; Heart; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Spironolactone | 2006 |
Aldosterone receptor antagonists for heart failure: current status, future indications.
Topics: Angiotensin-Converting Enzyme Inhibitors; Eplerenone; Forecasting; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Risk Factors; Spironolactone | 2006 |
[Aldosterone receptor blockade after acute myocardial infarction with heart failure].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Diuretics; Drug Approval; Drug Therapy, Combination; Eplerenone; Heart Failure; Humans; Hyperkalemia; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Practice Guidelines as Topic; Spironolactone; Treatment Outcome; Ventricular Dysfunction, Left | 2006 |
[Deficiency of 11beta-hydroxysteroid dehydrogenase type 2 (syndrome of apparent mineralocorticoid excess)].
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Diagnosis, Differential; Eplerenone; Mineralocorticoid Excess Syndrome, Apparent; Mineralocorticoid Receptor Antagonists; Mutation; Prognosis; Spironolactone | 2006 |
Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Combination; Eplerenone; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Renin-Angiotensin System; Spironolactone | 2006 |
[Antihypertensive drugs in clinical development].
Topics: Amides; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Eplerenone; Fumarates; Heterocyclic Compounds, 3-Ring; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone | 2006 |
[Modern pharmacological aspects of hyperaldosteronism therapy].
Topics: Adrenal Hyperplasia, Congenital; Adrenalectomy; Adrenocortical Adenoma; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Diagnosis, Differential; Eplerenone; Humans; Hyperaldosteronism; Hypertension; Risk Factors; Spironolactone | 2006 |
[Cardiovascular action of aldosterone].
Topics: Aldosterone; Animals; Cardiovascular Diseases; Endothelium, Vascular; Epithelial Sodium Channels; Eplerenone; Fibrosis; Humans; Mineralocorticoid Receptor Antagonists; Muscle, Smooth, Vascular; Myocardium; Oxidative Stress; Receptors, Mineralocorticoid; Sodium Channels; Sodium-Potassium-Exchanging ATPase; Sodium, Dietary; Spironolactone | 2006 |
[Cardioprotective effect of aldosterone antagonists for ventricular remodeling].
Topics: Aldosterone; Animals; Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Reactive Oxygen Species; Receptors, Mineralocorticoid; Spironolactone; Ventricular Remodeling | 2006 |
Does eplerenone have a future in the management of hypertension in Europe?
Topics: Clinical Trials as Topic; Drug Costs; Eplerenone; Europe; Heart Failure; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Spironolactone; United Kingdom | 2006 |
[The revived interest in aldosterone antagonists].
Topics: Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Eplerenone; Heart Failure; Humans; Hypertension; Hypokalemia; Mineralocorticoid Receptor Antagonists; Spironolactone; Treatment Outcome | 2006 |
Aldosterone blockade in post-acute myocardial infarction heart failure.
Topics: Algorithms; Cardiac Output, Low; Eplerenone; Humans; Hyperkalemia; Hypotension; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Risk Factors; Spironolactone; Systole; Ventricular Dysfunction, Left | 2006 |
Aldosterone blockade: an emerging strategy for abrogating progressive renal disease.
Topics: Aldosterone; Algorithms; Disease Progression; Disease Susceptibility; Drug Labeling; Eplerenone; Fibrosis; Heart Failure; Humans; Hyperkalemia; Kidney; Mineralocorticoid Receptor Antagonists; Renal Agents; Renal Insufficiency; Spironolactone | 2006 |
Mineralocorticoid receptor antagonists.
Topics: Animals; Canrenoic Acid; Cardiovascular Diseases; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Renin-Angiotensin System; Spironolactone | 2007 |
[Eplerenone for treatment of heart failure].
Topics: Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Hydrocortisone; Hypertension; Mineralocorticoid Receptor Antagonists; Receptors, Mineralocorticoid; Spironolactone | 2007 |
[Aldosterone antagonists: characteristics, mechanisms of action, pharmacokinetics, indication, contraindication, clinical data, and side effects].
Topics: Aldosterone; Chronic Disease; Contraindications; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Prognosis; Randomized Controlled Trials as Topic; Spironolactone; Survival Rate | 2007 |
Drug insight: aldosterone-receptor antagonists in heart failure--the journey continues.
Topics: Aldosterone; Contraindications; Drug Therapy, Combination; Eplerenone; Heart Failure; Humans; Hypertension; Kaplan-Meier Estimate; Mineralocorticoid Receptor Antagonists; Practice Guidelines as Topic; Spironolactone | 2007 |
[Role of aldosterone in oxidative stress and renal injury].
Topics: Aldosterone; Animals; Cardiovascular Diseases; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; NADPH Oxidases; Oxidative Stress; Rats; Reactive Oxygen Species; Receptors, Mineralocorticoid; Renal Insufficiency; Spironolactone | 2007 |
[Molecular mechanism of cardiovascular damage induced by aldosterone].
Topics: Aldosterone; Animals; Biopterins; Cardiovascular Diseases; Cells, Cultured; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; NADPH Oxidases; Nitric Oxide; Nitric Oxide Synthase Type III; Phosphoprotein Phosphatases; Reactive Oxygen Species; Receptors, Mineralocorticoid; Spironolactone | 2007 |
Evaluation of the aldosterone-blocking agent eplerenone in hypertension and heart failure.
Topics: Animals; Antihypertensive Agents; Cardiovascular Agents; Drug and Narcotic Control; Eplerenone; Heart Failure; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Renin-Angiotensin System; Spironolactone; Treatment Outcome | 2007 |
Drug Insight: eplerenone, a mineralocorticoid-receptor antagonist.
Topics: Animals; Cardiovascular Diseases; Disease Models, Animal; Eplerenone; Heart Failure; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Spironolactone | 2008 |
Eplerenone after myocardial infarction?
Topics: Contraindications; Drug Costs; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Spironolactone | 2008 |
Optimizing care of heart failure after acute MI with an aldosterone receptor antagonist.
Topics: Eplerenone; Evidence-Based Medicine; Heart Failure; Humans; Hyperkalemia; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Receptors, Mineralocorticoid; Risk Factors; Spironolactone; Ventricular Dysfunction, Left | 2007 |
[Antialdosteronic agents: their role in heart failure].
Topics: Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone | 2008 |
A comparison of the aldosterone-blocking agents eplerenone and spironolactone.
Topics: Eplerenone; Heart Failure; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Spironolactone | 2008 |
Mineralocorticoid receptor antagonists and endothelial function.
Topics: Aldosterone; Animals; Endocrine System Diseases; Endothelium, Vascular; Eplerenone; Humans; Hyperaldosteronism; Mineralocorticoid Receptor Antagonists; Spironolactone | 2008 |
[Pharmacology profile and clinical findings of Selara Tablets (eplerenone)].
Topics: Animals; Eplerenone; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Rats; Receptors, Steroid; Spironolactone | 2008 |
Possible underlying mechanisms responsible for aldosterone and mineralocorticoid receptor-dependent renal injury.
Topics: Aldosterone; Animals; Eplerenone; Humans; Kidney; Kidney Diseases; Mitogen-Activated Protein Kinases; Reactive Oxygen Species; Receptors, Mineralocorticoid; rho-Associated Kinases; Spironolactone | 2008 |
Effects of eplerenone, a selective mineralocorticoid receptor antagonist, on clinical and experimental salt-sensitive hypertension.
Topics: Aldosterone; Animals; Disease Models, Animal; Eplerenone; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Rats; Rats, Inbred Dahl; Sodium Chloride; Spironolactone | 2009 |
The clinical pharmacology of eplerenone.
Topics: Animals; Controlled Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Hyperkalemia; Mineralocorticoid Receptor Antagonists; Spironolactone | 2009 |
Aldosterone-receptor antagonism in hypertension.
Topics: Albuminuria; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Arrhythmias, Cardiac; Drug Therapy, Combination; Electrocardiography; Eplerenone; Fibrosis; Glomerular Filtration Rate; Humans; Hypertension; Hypertrophy, Left Ventricular; Mineralocorticoid Receptor Antagonists; Myocardium; Spironolactone | 2009 |
[The use of aldosterone antagonists in the cardiovascular diseases].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Cardiomegaly; Cardiovascular Diseases; Eplerenone; Heart Failure; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Peptidyl-Dipeptidase A; Spironolactone | 2009 |
Blocking aldosterone in heart failure.
Topics: Aldosterone; Cardiovascular Agents; Drug Therapy, Combination; Eplerenone; Fibrosis; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardium; Spironolactone; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Remodeling | 2009 |
[Mineralocorticoid receptor antagonists: inhibition of the renin angiotensin system].
Topics: Albuminuria; Diabetes Mellitus, Type 2; Eplerenone; Female; Heart Failure; Humans; Hyperaldosteronism; Hypertension; Mineralocorticoid Receptor Antagonists; Practice Guidelines as Topic; Prospective Studies; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Spironolactone; Treatment Outcome | 2010 |
[Chronic kidney disease and the aldosterone/mineralocorticoid receptor system].
Topics: Aldosterone; Animals; Chronic Disease; Eplerenone; Humans; Kidney Diseases; Metabolic Syndrome; Mineralocorticoid Receptor Antagonists; Podocytes; Proteinuria; Receptors, Mineralocorticoid; Risk Factors; Spironolactone | 2010 |
Aldosterone receptor antagonists--how cardiovascular actions may explain their beneficial effects in heart failure.
Topics: Animals; Autonomic Nervous System; Cardiovascular System; Dog Diseases; Dogs; Eplerenone; Heart Failure; Mineralocorticoid Receptor Antagonists; Spironolactone | 2010 |
A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
Topics: Bayes Theorem; Clinical Trials as Topic; Cost-Benefit Analysis; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Quality-Adjusted Life Years; Spironolactone; State Medicine; United Kingdom | 2010 |
Mineralocorticoid receptor antagonists and the metabolic syndrome.
Topics: Aldosterone; Antihypertensive Agents; Eplerenone; Humans; Hypertension; Inflammation; Insulin Resistance; Lipid Metabolism; Lipids; Metabolic Syndrome; Mineralocorticoid Receptor Antagonists; Obesity; Signal Transduction; Spironolactone | 2010 |
Clinical Inquiries: Which drugs should post-MI patients routinely receive?
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atorvastatin; Clopidogrel; Eplerenone; Heptanoic Acids; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyrroles; Spironolactone; Ticlopidine | 2010 |
The effect of aldosterone antagonists for ventricular arrhythmia: a meta-analysis.
Topics: Confidence Intervals; Death, Sudden, Cardiac; Diuretics; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Risk; Spironolactone | 2010 |
Review article: eplerenone: an underused medication?
Topics: Cardiovascular Diseases; Eplerenone; Heart Failure; Humans; Hyperkalemia; Hypertension; Hypertrophy, Left Ventricular; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Prognosis; Renin-Angiotensin System; Risk; Spironolactone; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Remodeling | 2010 |
[Prothrombotic aldosterone action--a new side of the hormone].
Topics: Aldosterone; Animals; Eplerenone; Hemostasis; Platelet Adhesiveness; Rats; Spironolactone; Thrombosis | 2010 |
Aldosterone antagonists in heart failure.
Topics: Aldosterone; Animals; Eplerenone; Heart Failure; Humans; Hyperkalemia; Mineralocorticoid Receptor Antagonists; Patient Selection; Severity of Illness Index; Spironolactone | 2011 |
Pathophysiological roles of aldosterone and mineralocorticoid receptor in the kidney.
Topics: Aldosterone; Animals; Blood Pressure; Electrolytes; Eplerenone; Homeostasis; Humans; Kidney; Kidney Diseases; Mineralocorticoid Receptor Antagonists; Oxidative Stress; Rats; Receptors, Mineralocorticoid; Renal Circulation; Spironolactone | 2011 |
Treatment of primary aldosteronism: Where are we now?
Topics: Adrenalectomy; Eplerenone; Humans; Hyperaldosteronism; Spironolactone | 2011 |
Primary aldosteronism, diagnosis and treatment in Japan.
Topics: Eplerenone; Humans; Hyperaldosteronism; Japan; Spironolactone | 2011 |
[Heart failure].
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Benzazepines; Cardiac Resynchronization Therapy; Combined Modality Therapy; Cyclic Nucleotide-Gated Cation Channels; Eplerenone; Heart Failure; Heart Rate; Hemodynamics; Humans; Ivabradine; Mineralocorticoid Receptor Antagonists; Spironolactone; Stroke Volume; Survival Rate | 2011 |
Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics.
Topics: Androstenes; Animals; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Models, Biological; Models, Molecular; Molecular Targeted Therapy; Receptors, Mineralocorticoid; Spironolactone | 2012 |
Aldosterone stimulates nuclear factor-kappa B activity and transcription of intercellular adhesion molecule-1 and connective tissue growth factor in rat mesangial cells via serum- and glucocorticoid-inducible protein kinase-1.
Topics: Aldosterone; Animals; Connective Tissue Growth Factor; Eplerenone; Glomerulonephritis; I-kappa B Proteins; Immediate-Early Proteins; Intercellular Adhesion Molecule-1; Kidney; MAP Kinase Kinase 1; Mesangial Cells; Mineralocorticoid Receptor Antagonists; NF-kappa B; Phosphatidylinositol 3-Kinases; Protein Serine-Threonine Kinases; Rats; Spironolactone | 2012 |
Mineralocorticoid receptor antagonists for heart failure.
Topics: Aldosterone; Animals; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Randomized Controlled Trials as Topic; Spironolactone; Treatment Outcome | 2011 |
Mineralocorticoid receptor antagonist for renal protection.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Eplerenone; Humans; Kidney Diseases; Mineralocorticoid Receptor Antagonists; Renin-Angiotensin System; Spironolactone | 2012 |
Antiarrhythmic potential of aldosterone antagonists in atrial fibrillation.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Renin-Angiotensin System; Spironolactone | 2012 |
Safety of mineralocorticoid receptor antagonists in patients receiving hemodialysis.
Topics: Eplerenone; Humans; Kidney Failure, Chronic; Mineralocorticoid Receptor Antagonists; Potassium; Renal Dialysis; Spironolactone | 2012 |
Eplerenone is not superior to older and less expensive aldosterone antagonists.
Topics: Canrenone; Cause of Death; Cost-Benefit Analysis; Drug Costs; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Survival Rate; Treatment Outcome | 2012 |
Eplerenone for the treatment of cardiovascular disorders.
Topics: Aldosterone; Animals; Cardiovascular Agents; Cardiovascular Diseases; Eplerenone; Humans; Hydrocortisone; Mineralocorticoid Receptor Antagonists; Receptors, Mineralocorticoid; Spironolactone | 2012 |
Expanding role of mineralocorticoid receptor antagonists in the treatment of heart failure.
Topics: Death, Sudden, Cardiac; Eplerenone; Heart Failure; Humans; Hyperkalemia; Mineralocorticoid Receptor Antagonists; Practice Guidelines as Topic; Risk Factors; Spironolactone; Ventricular Remodeling | 2012 |
The role of aldosterone receptor antagonists in the management of heart failure: an update.
Topics: Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone | 2012 |
Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension.
Topics: Blood Pressure; Eplerenone; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Spironolactone; Treatment Outcome | 2013 |
Additional use of an aldosterone antagonist in patients with mild to moderate chronic heart failure: a systematic review and meta-analysis.
Topics: Canrenone; Chronic Disease; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Randomized Controlled Trials as Topic; Severity of Illness Index; Spironolactone; Ventricular Remodeling | 2013 |
[Primay hyperaldosteronism--diagnostic and treatment].
Topics: Adrenal Cortex Neoplasms; Adrenal Glands; Adrenal Hyperplasia, Congenital; Adrenocortical Adenoma; Aldosterone; Antihypertensive Agents; Diagnosis, Differential; Eplerenone; Hyperaldosteronism; Hypertension; Hypokalemia; Magnetic Resonance Imaging; Mass Screening; Renin; Spironolactone; Tomography, X-Ray Computed | 2012 |
Mineralocorticoid receptor antagonists: their use and differentiation in Japan.
Topics: Comorbidity; Contraindications; Dose-Response Relationship, Drug; Drug Therapy, Combination; Eplerenone; Humans; Hypertension; Japan; Mineralocorticoid Receptor Antagonists; Spironolactone; Treatment Outcome | 2013 |
Eplerenone: a review of its use in patients with chronic systolic heart failure and mild symptoms.
Topics: Adult; Device Approval; Drug Interactions; Eplerenone; European Union; Heart Failure, Systolic; Humans; Hyperkalemia; Mineralocorticoid Receptor Antagonists; Randomized Controlled Trials as Topic; Severity of Illness Index; Spironolactone | 2013 |
Successful treatment of severe hantavirus nephritis with corticosteroids: a case report and literature review.
Topics: Adult; Dose-Response Relationship, Drug; Eplerenone; Follow-Up Studies; Glucocorticoids; Hantavirus Infections; Humans; Kidney Failure, Chronic; Male; Methylprednisolone; Mineralocorticoid Receptor Antagonists; Renal Dialysis; Severity of Illness Index; Spironolactone; Treatment Outcome | 2013 |
Endocrine and hypertensive disorders of potassium regulation: primary aldosteronism.
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Adenoma; Aldosterone; Eplerenone; Humans; Hyperaldosteronism; Hypertension; Hypokalemia; Mineralocorticoid Receptor Antagonists; Renin; Spironolactone | 2013 |
Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diabetic Nephropathies; Drug Therapy, Combination; Eplerenone; Glomerular Filtration Rate; Humans; Hyperkalemia; Mineralocorticoid Receptor Antagonists; Renal Insufficiency, Chronic; Spironolactone; Treatment Outcome | 2014 |
Converging indications of aldosterone antagonists (spironolactone and eplerenone): a narrative review of safety profiles.
Topics: Animals; Eplerenone; Humans; Hyperkalemia; Hypertension; Mineralocorticoid Receptor Antagonists; Spironolactone | 2014 |
Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure.
Topics: Eplerenone; Heart Failure; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Spironolactone; Ventricular Dysfunction, Left | 2014 |
Aldosterone antagonists for preventing the progression of chronic kidney disease.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Disease Progression; Eplerenone; Humans; Hyperkalemia; Kidney Failure, Chronic; Mineralocorticoid Receptor Antagonists; Proteinuria; Randomized Controlled Trials as Topic; Spironolactone | 2014 |
Heart failure: the role for mineralocorticoid receptor antagonists.
Topics: Eplerenone; Heart Failure; Humans; Hyperkalemia; Mineralocorticoid Receptor Antagonists; Spironolactone; Stroke Volume; Ventricular Dysfunction, Left | 2014 |
Aldosterone and volume management in hypertensive heart disease.
Topics: Aldosterone; Area Under Curve; Diuretics; Eplerenone; Heart Failure; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Renal Insufficiency, Chronic; Spironolactone | 2014 |
Progress in primary aldosteronism: mineralocorticoid receptor antagonists and management of primary aldosteronism in pregnancy.
Topics: Animals; Disease Management; Eplerenone; Female; Humans; Hyperaldosteronism; Mineralocorticoid Receptor Antagonists; Pregnancy; Pregnancy Complications; Spironolactone | 2015 |
Magnitude of blood pressure reduction in the placebo arms of modern hypertension trials: implications for trials of renal denervation.
Topics: Amides; Antihypertensive Agents; Benzimidazoles; Benzopyrans; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Control Groups; Double-Blind Method; Drug Resistance; Eplerenone; Ethanolamines; Fumarates; Humans; Hypertension; Imidazoles; Kidney; Nebivolol; Oxadiazoles; Placebo Effect; Placebos; Randomized Controlled Trials as Topic; Regression Analysis; Research Design; Spironolactone; Sympathectomy; Tetrazoles; Treatment Outcome | 2015 |
Efficacy and safety of mineralocorticoid receptors in mild to moderate arterial hypertension.
Topics: Eplerenone; Humans; Hyperaldosteronism; Hypertension; Mineralocorticoid Receptor Antagonists; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Spironolactone | 2015 |
Efficacy and safety of eplerenone in the management of mild to moderate arterial hypertension: systematic review and meta-analysis.
Topics: Blood Pressure; Eplerenone; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Severity of Illness Index; Spironolactone; Treatment Outcome | 2014 |
Systematic review of surgery and outcomes in patients with primary aldosteronism.
Topics: Adrenalectomy; Epidemiologic Methods; Eplerenone; Humans; Hyperaldosteronism; Mineralocorticoid Receptor Antagonists; Spironolactone; Treatment Outcome | 2015 |
[Hypertension in the course of primary aldosteronism during pregnancy].
Topics: Acid Sensing Ion Channel Blockers; Aldosterone; Amiloride; Antihypertensive Agents; Eplerenone; Female; Humans; Hyperaldosteronism; Hypertension; Poland; Pregnancy; Pregnancy Complications; Progesterone; Spironolactone | 2015 |
Eplerenone in chronic heart failure with depressed systolic function.
Topics: Chronic Disease; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Spironolactone | 2015 |
Eplerenone's role in the management of complex cardiovascular disorders.
Topics: Cardiovascular Diseases; Eplerenone; Humans; Kidney Diseases; Mineralocorticoid Receptor Antagonists; Spironolactone; Treatment Outcome | 2015 |
Pharmacological treatment of aldosterone excess.
Topics: Aldosterone; Cytochrome P-450 CYP11B2; Dihydropyridines; Drug Interactions; Epithelial Sodium Channel Blockers; Eplerenone; Glucocorticoids; Heart Failure; Hyperaldosteronism; Hypertension; Mineralocorticoid Receptor Antagonists; Spironolactone | 2015 |
Mineralocorticoid receptor antagonists, a class beyond spironolactone--Focus on the special pharmacologic properties of eplerenone.
Topics: Drug Interactions; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Renin-Angiotensin System; Spironolactone | 2015 |
Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).
Topics: Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Randomized Controlled Trials as Topic; Spironolactone; Stroke Volume | 2015 |
Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone.
Topics: Aldosterone; Drug Interactions; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Randomized Controlled Trials as Topic; Spironolactone | 2015 |
Dose doubling, relative potency, and dose equivalence of potassium-sparing diuretics affecting blood pressure and serum potassium: systematic review and meta-analyses.
Topics: Amiloride; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Eplerenone; Humans; Hyperkalemia; Potassium; Sodium Chloride Symporter Inhibitors; Spironolactone; Therapeutic Equivalency; Triamterene | 2016 |
[Mineralocorticoid receptor antagonists in the treatment of patients with chronic heart failure. Positions in 2015].
Topics: Eplerenone; Heart Failure, Systolic; Humans; Mineralocorticoid Receptor Antagonists; Prognosis; Randomized Controlled Trials as Topic; Spironolactone; Treatment Outcome; Ventricular Function, Left | 2015 |
Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis.
Topics: Aldosterone; Atrial Fibrillation; Cardiac Surgical Procedures; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Randomized Controlled Trials as Topic; Spironolactone | 2016 |
Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease: Efficacy and Safety.
Topics: Aldosterone; Blood Pressure; Disease Progression; Eplerenone; Heart Failure; Humans; Kidney Failure, Chronic; Mineralocorticoid Receptor Antagonists; Patient Safety; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Spironolactone; Stroke Volume; Survival Analysis; Treatment Outcome; Ventricular Remodeling | 2016 |
Mineralocorticoid receptor antagonists-pharmacodynamics and pharmacokinetic differences.
Topics: Aldosterone; Animals; Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone | 2016 |
The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis.
Topics: Cardiovascular Diseases; Cause of Death; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Randomized Controlled Trials as Topic; Renal Dialysis; Spironolactone | 2016 |
Mineralocorticoid Receptor Antagonists in the Management of Heart Failure and Resistant Hypertension: A Review.
Topics: Eplerenone; Heart Failure; Humans; Hyperkalemia; Hypertension; Mineralocorticoid Receptor Antagonists; Spironolactone; Ventricular Dysfunction, Left | 2016 |
Diagnosing and Managing Primary Aldosteronism in Hypertensive Patients: a Case-Based Approach.
Topics: Adrenalectomy; Eplerenone; Humans; Hyperaldosteronism; Hypertension; Hypokalemia; Laparoscopy; Mass Screening; Mineralocorticoid Receptor Antagonists; Practice Guidelines as Topic; Prevalence; Spironolactone | 2016 |
Should MRAs be at the front row in heart failure? A plea for the early use of mineralocorticoid receptor antagonists in medical therapy for heart failure based on clinical experience.
Topics: Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Practice Guidelines as Topic; Spironolactone; Stroke Volume | 2016 |
Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside.
Topics: Animals; Cardio-Renal Syndrome; Diabetic Nephropathies; Endothelial Cells; Eplerenone; Fibroblasts; Heart Failure; Humans; Macrophages; Mineralocorticoid Receptor Antagonists; Muscle, Smooth, Vascular; Myocytes, Cardiac; Myocytes, Smooth Muscle; Naphthyridines; Receptors, Mineralocorticoid; Spironolactone; Stroke Volume | 2017 |
Systemic Mineralocorticoid Antagonists in the Treatment of Central Serous Chorioretinopathy.
Topics: Central Serous Chorioretinopathy; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone | 2017 |
Synthetic approaches towards the multi target drug spironolactone and its potent analogues/derivatives.
Topics: Aldosterone; Androstadienes; Androstenes; Animals; Canrenone; Chloranil; Dehydroepiandrosterone; Eplerenone; Humans; Molecular Structure; Receptors, Mineralocorticoid; Spironolactone | 2017 |
Mineralocorticoid Antagonists in ESRD: An Overview of Clinical Trial Evidence.
Topics: Eplerenone; Humans; Kidney Failure, Chronic; Mineralocorticoid Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Spironolactone | 2017 |
Eplerenone for hypertension.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Eplerenone; Essential Hypertension; Female; Humans; Hypertension; Male; Middle Aged; Patient Dropouts; Randomized Controlled Trials as Topic; Spironolactone | 2017 |
Nonsteroidal mineralocorticoid antagonists in diabetic kidney disease.
Topics: Albuminuria; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Renin-Angiotensin System; Spironolactone | 2017 |
Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Drug Resistance; Eplerenone; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Renin-Angiotensin System; Spironolactone; Treatment Outcome | 2017 |
A systematic review and meta-analysis of the impact of mineralocorticoid receptor antagonists on glucose homeostasis.
Topics: Blood Glucose; Canrenone; Eplerenone; Glycated Hemoglobin; Homeostasis; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone | 2017 |
Individual participant data analysis of two trials on aldosterone blockade in myocardial infarction.
Topics: Aged; Canrenoic Acid; Eplerenone; Equivalence Trials as Topic; Female; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Multicenter Studies as Topic; Risk Factors; Spironolactone; ST Elevation Myocardial Infarction; Time Factors; Treatment Outcome | 2018 |
Eplerenone Versus Spironolactone in Resistant Hypertension: an Efficacy and/or Cost or Just a Men's Issue?
Topics: Aldosterone; Antihypertensive Agents; Eplerenone; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Spironolactone | 2019 |
Mineralocorticoid Receptor Antagonists in Central Serous Chorioretinopathy: A Meta-Analysis of Randomized Controlled Trials.
Topics: Central Serous Chorioretinopathy; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Randomized Controlled Trials as Topic; Spironolactone; Visual Acuity; Watchful Waiting | 2019 |
Comparative efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a network meta-analysis of randomized controlled trials.
Topics: Eplerenone; Heart Failure; Hospitalization; Humans; Hyperkalemia; Mineralocorticoid Receptor Antagonists; Naphthyridines; Natriuretic Peptide, Brain; Network Meta-Analysis; Peptide Fragments; Randomized Controlled Trials as Topic; Renal Insufficiency; Spironolactone; Treatment Outcome | 2019 |
Relative Efficacy of Spironolactone, Eplerenone, and cAnRenone in patients with Chronic Heart failure (RESEARCH): a systematic review and network meta-analysis of randomized controlled trials.
Topics: Canrenone; Diuretics; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Network Meta-Analysis; Randomized Controlled Trials as Topic; Spironolactone; Treatment Outcome | 2020 |
[Antifibrotic renal role of mineralcorticoid receptor antagonists].
Topics: Aldosterone; Body Fluids; Cardiovascular Diseases; Clinical Trials as Topic; Cytokines; Diabetic Nephropathies; Eplerenone; Fibrosis; Heart; Heart Diseases; Homeostasis; Humans; Kidney; Mineralocorticoid Receptor Antagonists; Naphthyridines; Receptors, Mineralocorticoid; Renal Insufficiency, Chronic; Spironolactone | 2019 |
Mineralocorticoid antagonists in the treatment of central serous chorioetinopathy: Review of the pre-clinical and clinical evidence.
Topics: Central Serous Chorioretinopathy; Drug Evaluation, Preclinical; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Treatment Outcome | 2019 |
Oral medications for central serous chorioretinopathy: a literature review.
Topics: Central Serous Chorioretinopathy; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Photochemotherapy; Spironolactone | 2020 |
Sex differences in mineralocorticoid receptor antagonist trials: a pooled analysis of three large clinical trials.
Topics: Eplerenone; Female; Heart Failure; Humans; Male; Mineralocorticoid Receptor Antagonists; Randomized Controlled Trials as Topic; Sex Characteristics; Spironolactone; Stroke Volume | 2020 |
Mineralocorticoid Receptor Blockers: Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonists.
Topics: Eplerenone; Heart Failure; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Receptors, Mineralocorticoid; Spironolactone | 2020 |
Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bias; Calcium Channel Blockers; Canrenone; Disease Progression; Eplerenone; Humans; Hyperkalemia; Kidney Failure, Chronic; Mineralocorticoid Receptor Antagonists; Naphthyridines; Proteinuria; Randomized Controlled Trials as Topic; Spironolactone | 2020 |
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Topics: Bias; Cardiovascular Diseases; Cause of Death; Cerebrovascular Disorders; Eplerenone; Gynecomastia; Humans; Hyperkalemia; Mineralocorticoid Receptor Antagonists; Placebos; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Spironolactone | 2021 |
Eplerenone repurposing in management of chorioretinopathy: Mechanism, nanomedicine-based delivery applications and future trends.
Topics: Central Serous Chorioretinopathy; Chronic Disease; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Nanomedicine; Spironolactone | 2022 |
Primary aldosteronism in pregnancy.
Topics: Eplerenone; Female; Humans; Hyperaldosteronism; Hypertension; Mineralocorticoid Receptor Antagonists; Pregnancy; Spironolactone | 2023 |
Finerenone: a mineralocorticoid receptor antagonist for the treatment of chronic kidney disease associated with type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Naphthyridines; Potassium; Renal Insufficiency, Chronic; Spironolactone | 2022 |
Efficacy and safety of finerenone for treatment of diabetic kidney disease: current knowledge and future perspective.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Eplerenone; Heart Failure; Humans; Hyperkalemia; Mineralocorticoid Receptor Antagonists; Naphthyridines; Receptors, Mineralocorticoid; Renal Insufficiency, Chronic; Spironolactone; Stroke Volume | 2022 |
Finerenone in diabetic kidney disease: A systematic review and critical appraisal.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Eplerenone; Glycated Hemoglobin; Heart Failure; Humans; Hyperkalemia; Male; Mineralocorticoid Receptor Antagonists; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Spironolactone | 2022 |
Randomized controlled trials in central serous chorioretinopathy: A review.
Topics: Central Serous Chorioretinopathy; Eplerenone; Humans; Randomized Controlled Trials as Topic; Spironolactone; Tomography, Optical Coherence; Visual Acuity | 2023 |
148 trial(s) available for spironolactone and eplerenone
| Article | Year |
|---|---|
Expanding the outcomes in clinical trials of heart failure: the quality of life and economic components of EPHESUS (EPlerenone's neuroHormonal Efficacy and SUrvival Study).
Topics: Antihypertensive Agents; Cost-Benefit Analysis; Disease Progression; Eplerenone; Health Status Indicators; Heart Failure; Hospital Costs; Hospitalization; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Quality of Life; Research Design; Severity of Illness Index; Spironolactone; Treatment Outcome | 2002 |
Results from late-breaking clinical trial sessions at the American College of Cardiology 51st Annual Scientific Session.
Topics: Adenosine; Angioplasty, Balloon, Coronary; Anti-Arrhythmia Agents; Antihypertensive Agents; Atherectomy, Coronary; Atrial Fibrillation; Azithromycin; Chlamydophila Infections; Coronary Disease; Defibrillators, Implantable; Double-Blind Method; Eplerenone; Heart Failure; Heart Transplantation; Heart-Assist Devices; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertrophy, Left Ventricular; Myocardial Reperfusion; Pyridines; Radiology, Interventional; Spironolactone; Stents; Thiazepines; Thrombolytic Therapy | 2002 |
Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients.
Topics: Abdominal Pain; Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Eplerenone; Female; Headache; Heart Rate; Humans; Hypertension; Irbesartan; Losartan; Male; Middle Aged; Patient Dropouts; Renin-Angiotensin System; Spironolactone; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2002 |
Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Blood Pressure; Double-Blind Method; Eplerenone; Female; Humans; Hypertension; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Placebo Effect; Spironolactone; Statistics, Nonparametric | 2002 |
A validated SPE-LC-MS/MS assay for Eplerenone and its hydrolyzed metabolite in human urine.
Topics: Calibration; Chromatography, High Pressure Liquid; Chromatography, Liquid; Eplerenone; Freezing; Humans; Hydrolysis; Indicators and Reagents; Mass Spectrometry; Mineralocorticoid Receptor Antagonists; Quality Control; Reference Standards; Reproducibility of Results; Spironolactone | 2003 |
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Topics: Aged; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Potassium; Spironolactone; Survival Analysis; Ventricular Dysfunction, Left | 2003 |
Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients.
Topics: Adult; Aldosterone; Analysis of Variance; Angiotensin Receptor Antagonists; Antihypertensive Agents; Black People; Blood Pressure; Double-Blind Method; Eplerenone; Female; Humans; Hypertension; Losartan; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Renin; Renin-Angiotensin System; Spironolactone; Treatment Outcome; White People | 2003 |
Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension.
Topics: Aged; Albuminuria; Amlodipine; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Creatinine; Diarrhea; Double-Blind Method; Eplerenone; Female; Headache; Heart Rate; Humans; Hypertension; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Nausea; Pulsatile Flow; Spironolactone; Systole; Treatment Outcome | 2003 |
Update of clinical trials from the American College of Cardiology 2003. EPHESUS, SPORTIF-III, ASCOT, COMPANION, UK-PACE and T-wave alternans.
Topics: Anticoagulants; Cardiac Pacing, Artificial; Defibrillators, Implantable; Electrocardiography; Eplerenone; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mineralocorticoid Receptor Antagonists; Pacemaker, Artificial; Spironolactone; Ventricular Dysfunction, Left; Warfarin | 2003 |
Late breaking heart failure trials from the 2003 ACC meeting: EPHESUS and COMPANION.
Topics: Aged; Defibrillators, Implantable; Eplerenone; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Pacemaker, Artificial; Spironolactone; Ventricular Dysfunction, Left | 2003 |
Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension.
Topics: Aldosterone; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Eplerenone; Female; Heart Rate; Humans; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Potassium; Renin; Spironolactone | 2003 |
Symptoms and the distress they cause: comparison of an aldosterone antagonist and a calcium channel blocking agent in patients with systolic hypertension.
Topics: Aged; Amlodipine; Analysis of Variance; Calcium Channel Blockers; Eplerenone; Female; Humans; Hypertension; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Quality of Life; Renin-Angiotensin System; Spironolactone; Statistics, Nonparametric; Treatment Outcome | 2003 |
[Efficacy of an aldosterone receptor blocker eplerenone in high risk survivors of acute myocardial infarction with signs of heart failure: results of EPHESUS].
Topics: Acute Disease; Diabetes Complications; Drug Administration Schedule; Drug Therapy, Combination; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Spironolactone; Treatment Outcome | 2003 |
Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study.
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Enalapril; Eplerenone; Female; Humans; Hydrochlorothiazide; Hypertension; Hypertrophy, Left Ventricular; Magnetic Resonance Imaging; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Myocardium; Potassium; Renin-Angiotensin System; Spironolactone; Treatment Outcome | 2003 |
Can renin status predict the antihypertensive efficacy of eplerenone add-on therapy?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antihypertensive Agents; Double-Blind Method; Drug Therapy, Combination; Eplerenone; Female; Humans; Hypertension; Male; Middle Aged; Predictive Value of Tests; Renin; Single-Blind Method; Spironolactone | 2003 |
Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Eplerenone; Female; Humans; Hypertension; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Spironolactone | 2003 |
Efficacy and safety of the selective aldosterone blocker eplerenone in Japanese patients with hypertension: a randomized, double-blind, placebo-controlled, dose-ranging study.
Topics: Adult; Aged; Diuretics; Eplerenone; Female; Humans; Hypertension; Japan; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Placebos; Safety; Spironolactone; Treatment Outcome | 2004 |
Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Blood Pressure; Cough; Drug Tolerance; Enalapril; Eplerenone; Female; Humans; Hypertension; Male; Middle Aged; Potassium; Renin-Angiotensin System; Spironolactone | 2004 |
Distinguishing the antihypertensive and electrolyte effects of eplerenone.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Electrolytes; Eplerenone; Female; Humans; Hypertension; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Potassium; Spironolactone | 2004 |
Prognostic value of health status in patients with heart failure after acute myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Americas; Cardiovascular Diseases; Cohort Studies; Comorbidity; Disease-Free Survival; Eplerenone; Europe; Female; Health Status Indicators; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Prognosis; Prospective Studies; Risk Factors; Severity of Illness Index; Spironolactone | 2004 |
Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure.
Topics: Aged; Cause of Death; Comorbidity; Cost-Benefit Analysis; Double-Blind Method; Drug Costs; Eplerenone; Female; Health Care Costs; Heart Failure; Humans; Life Expectancy; Male; Middle Aged; Mortality; Myocardial Infarction; Quality-Adjusted Life Years; Spironolactone; Ventricular Dysfunction, Left | 2005 |
[Eplerenone Post-AMI Heart Failure Efficacy and survival study (EPHESUS)].
Topics: Double-Blind Method; Eplerenone; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Spironolactone | 2005 |
Pharmacokinetics of eplerenone after single and multiple dosing in subjects with and without renal impairment.
Topics: Administration, Oral; Adult; Aged; Area Under Curve; Creatinine; Eplerenone; Female; Humans; Hyperkalemia; Kidney Diseases; Male; Metabolic Clearance Rate; Middle Aged; Mineralocorticoid Receptor Antagonists; Renal Dialysis; Spironolactone | 2005 |
Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure.
Topics: Aged; Coronary Angiography; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Eplerenone; Female; Follow-Up Studies; Heart Failure; Heart Function Tests; Humans; Male; Middle Aged; Myocardial Infarction; Probability; Proportional Hazards Models; Reference Values; Severity of Illness Index; Spironolactone; Treatment Outcome; Ventricular Dysfunction, Left | 2005 |
Effects of eplerenone versus losartan in patients with low-renin hypertension.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Double-Blind Method; Eplerenone; Female; Humans; Hypertension; Losartan; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Renin; Spironolactone | 2005 |
Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction
Topics: Adult; Aged; Eplerenone; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Spironolactone; Stroke Volume; Ventricular Function, Left | 2006 |
Cost-effectiveness of eplerenone in patients with left ventricular dysfunction after myocardial infarction--an analysis of the EPHESUS study from a Swiss perspective.
Topics: Adult; Aged; Cost-Benefit Analysis; Eplerenone; Female; Health Care Costs; Humans; Male; Middle Aged; Myocardial Infarction; Spironolactone; Ventricular Dysfunction, Left | 2006 |
Aldosterone antagonists: the most underutilized class of heart failure medications.
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Combination; Drug Utilization; Eplerenone; Female; Heart Failure; Humans; Inpatients; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Patient Discharge; Spironolactone; Surveys and Questionnaires | 2007 |
Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus.
Topics: Adult; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Blood Pressure; Brachial Artery; Coronary Circulation; Cross-Over Studies; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diuretics; Drug Therapy, Combination; Eplerenone; Female; Humans; Hydrochlorothiazide; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Pilot Projects; Potassium; Renal Circulation; Spironolactone | 2007 |
Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.
Topics: Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Creatinine; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Enalapril; Eplerenone; Female; Glomerular Filtration Rate; Humans; Hyperkalemia; Incidence; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Potassium; Spironolactone; Treatment Outcome; United States | 2006 |
Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients.
Topics: Adrenergic beta-Antagonists; Adult; Arteries; Atenolol; Blood Pressure; Buttocks; Collagen; Diastole; Double-Blind Method; Elasticity; Elastin; Eplerenone; Female; Humans; Hypertension; Inflammation Mediators; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Myography; Spironolactone; Subcutaneous Tissue; Systole; Vascular Resistance | 2008 |
Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Drug Administration Schedule; Eplerenone; Female; Gynecomastia; Humans; Hyperaldosteronism; Hyperkalemia; Hypertension; Hypokalemia; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Potassium; Prospective Studies; Spironolactone; Time Factors; Treatment Outcome | 2008 |
History of hypertension and eplerenone in patients with acute myocardial infarction complicated by heart failure.
Topics: Aged; Cause of Death; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Eplerenone; Female; Heart Failure; Humans; Hypertension; Logistic Models; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Multivariate Analysis; Myocardial Infarction; Probability; Prognosis; Risk Assessment; Spironolactone; Survival Analysis; Treatment Outcome | 2008 |
A randomized trial of the aldosterone-receptor antagonist eplerenone in asymptomatic moderate-severe aortic stenosis.
Topics: Aged; Aortic Valve Stenosis; Blood Flow Velocity; Echocardiography, Doppler; Eplerenone; Female; Humans; Hypertrophy, Left Ventricular; Magnetic Resonance Imaging; Male; Mineralocorticoid Receptor Antagonists; Spironolactone; Statistics, Nonparametric; Ventricular Dysfunction, Left | 2008 |
Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS).
Topics: Aged; Eplerenone; Female; Heart Failure; Humans; Hyperkalemia; Incidence; Logistic Models; Male; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Potassium; Predictive Value of Tests; Risk Factors; Spironolactone; Treatment Outcome; Ventricular Dysfunction, Left | 2008 |
Cost-effectiveness analysis of aldosterone blockade with eplerenone in patients with heart failure after acute myocardial infarction in the French context: the EPHESUS study.
Topics: Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Eplerenone; Health Care Costs; Heart Failure; Hospitalization; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Proportional Hazards Models; Risk Assessment; Secondary Prevention; Spironolactone; Stochastic Processes; Time Factors; Treatment Outcome | 2008 |
Patient health status and costs in heart failure: insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS).
Topics: Acute Disease; Aged; Cohort Studies; Eplerenone; Female; Follow-Up Studies; Health Care Costs; Health Status; Heart Failure; Humans; Internationality; Male; Middle Aged; Myocardial Infarction; Spironolactone; Survival Rate; Ventricular Dysfunction, Left | 2009 |
Plasma apelin concentration is depressed following acute myocardial infarction in man.
Topics: Apelin; Biomarkers; Chromatography, High Pressure Liquid; Double-Blind Method; Echocardiography; Eplerenone; Female; Follow-Up Studies; Heart Ventricles; Humans; Intercellular Signaling Peptides and Proteins; Ligands; Magnetic Resonance Imaging; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Prognosis; Spironolactone; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Remodeling | 2009 |
Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EP
Topics: Aged; Biomarkers; Collagen Type I; Collagen Type III; Death, Sudden, Cardiac; Eplerenone; Extracellular Matrix; Female; Heart Failure; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Placebos; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Spironolactone; Ventricular Dysfunction, Left | 2009 |
A history of systemic hypertension and incident heart failure hospitalization in patients with acute myocardial infarction and left ventricular systolic dysfunction.
Topics: Aged; Double-Blind Method; Eplerenone; Female; Heart Failure; Hospitalization; Humans; Hypertension; Incidence; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Probability; Prognosis; Proportional Hazards Models; Risk Assessment; Risk Factors; Spironolactone; Survival Analysis | 2009 |
Usefulness of abnormal heart rate turbulence to predict cardiovascular mortality in high-risk patients with acute myocardial infarction and left ventricular dysfunction (from the EPHESUS study).
Topics: Aged; Electrocardiography, Ambulatory; Eplerenone; Female; Heart Failure; Heart Rate; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Risk Assessment; Spironolactone; Ventricular Dysfunction, Left | 2009 |
Left ventricular remodeling after acute myocardial infarction: does eplerenone have an effect?
Topics: Aged; Biomarkers; Double-Blind Method; Eplerenone; Female; Humans; Magnetic Resonance Imaging; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Middle Aged; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Spironolactone; Treatment Outcome; Ventricular Remodeling | 2009 |
Tissue plasminogen activator antigen predicts medium-term left ventricular end-systolic volume after acute myocardial infarction.
Topics: Aged; Biomarkers; Double-Blind Method; Eplerenone; Female; Humans; Male; Matrix Metalloproteinases; Middle Aged; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Natriuretic Peptide, Brain; Predictive Value of Tests; Spironolactone; Stroke Volume; Tissue Plasminogen Activator; Ventricular Remodeling; von Willebrand Factor | 2010 |
The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction.
Topics: Aged; Double-Blind Method; Eplerenone; Female; Heart Failure; Hospitalization; Humans; Length of Stay; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Spironolactone; Ventricular Dysfunction, Left | 2009 |
Predictors of hyperkalemia risk following hypertension control with aldosterone blockade.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Drug Therapy, Combination; Eplerenone; Female; Humans; Hyperkalemia; Hypertension, Renal; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Potassium; Predictive Value of Tests; Proteinuria; Risk Factors; Spironolactone | 2009 |
[The antiproteinuric effect of the blockage of the renin-angiotensin-aldosterone system (RAAS) in obese patients. Which treatment option is the most effective? ].
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Eplerenone; Female; Humans; Lisinopril; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Obesity; Prospective Studies; Proteinuria; Spironolactone; Tetrazoles | 2009 |
Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone.
Topics: Aged; Aged, 80 and over; Biomarkers; Collagen Type I; Collagen Type III; Echocardiography, Doppler; Eplerenone; Female; Follow-Up Studies; Heart Failure, Diastolic; Heart Ventricles; Humans; Male; Mineralocorticoid Receptor Antagonists; Procollagen; Prospective Studies; Radioimmunoassay; Spironolactone; Treatment Outcome | 2009 |
Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial.
Topics: Death, Sudden, Cardiac; Double-Blind Method; Eplerenone; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Proportional Hazards Models; Risk Factors; Spironolactone; Survival Rate; Time Factors; Treatment Outcome; Ventricular Dysfunction, Left | 2009 |
Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction.
Topics: Aged; Biomarkers; Cohort Studies; Double-Blind Method; Eplerenone; Female; Humans; Interleukin-1 Receptor-Like 1 Protein; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Predictive Value of Tests; Receptors, Cell Surface; Spironolactone; Stroke Volume; Treatment Outcome; Ventricular Remodeling | 2010 |
Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction.
Topics: Aged; Cohort Studies; Double-Blind Method; Eplerenone; Female; Gated Blood-Pool Imaging; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Natriuretic Peptide, Brain; Procollagen; Quality of Life; Spironolactone; Stroke Volume; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Remodeling | 2010 |
Microvascular obstruction remains a portent of adverse remodeling in optimally treated patients with left ventricular systolic dysfunction after acute myocardial infarction.
Topics: Chi-Square Distribution; Contrast Media; Double-Blind Method; Eplerenone; Female; Gadolinium DTPA; Humans; Image Processing, Computer-Assisted; Linear Models; Magnetic Resonance Angiography; Male; Microcirculation; Middle Aged; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Placebos; Predictive Value of Tests; Spironolactone; Statistics, Nonparametric; Systole; Ventricular Dysfunction, Left; Ventricular Remodeling | 2010 |
Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effect
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Chronic Disease; Creatine; Drug Therapy, Combination; Eplerenone; Female; Humans; Hypertension; Kidney; Kidney Diseases; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Sodium Chloride, Dietary; Spironolactone; Young Adult | 2010 |
Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF).
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Double-Blind Method; Eplerenone; Heart Failure, Systolic; Hospitalization; Humans; Mineralocorticoid Receptor Antagonists; Research Design; Spironolactone; Survival Analysis | 2010 |
The efficacy and safety of the novel aldosterone antagonist eplerenone in children with hypertension: a randomized, double-blind, dose-response study.
Topics: Adolescent; Blood Pressure; Child; Child, Preschool; Dose-Response Relationship, Drug; Double-Blind Method; Eplerenone; Female; Humans; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Placebos; Safety; Spironolactone; Treatment Outcome | 2010 |
A population approach to eplerenone pharmacokinetics and saturable protein binding.
Topics: Area Under Curve; Asian People; Clinical Trials, Phase I as Topic; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Models, Biological; Protein Binding; Spironolactone; White People | 2010 |
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Implantable; Double-Blind Method; Eplerenone; Female; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Proportional Hazards Models; Spironolactone | 2011 |
Effect of eplerenone versus spironolactone on cortisol and hemoglobin A₁(c) levels in patients with chronic heart failure.
Topics: Aged; Biomarkers; Dose-Response Relationship, Drug; Eplerenone; Female; Glycated Hemoglobin; Heart Failure; Humans; Hydrocortisone; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Spironolactone; Treatment Outcome | 2010 |
A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism.
Topics: Adult; Antihypertensive Agents; Double-Blind Method; Eplerenone; Female; Humans; Hyperaldosteronism; Male; Middle Aged; Placebos; Quality of Life; Spironolactone | 2011 |
Study on the bioequivalence of two formulations of eplerenone in healthy volunteers under fasting conditions: data from a single-center, randomized, single-dose, open-label, 2-way crossover bioequivalence study.
Topics: Adolescent; Adult; Area Under Curve; Biological Availability; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Cross-Over Studies; Eplerenone; Fasting; Female; Half-Life; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Spironolactone; Tandem Mass Spectrometry; Therapeutic Equivalency; Young Adult | 2011 |
Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF).
Topics: Aged; Aged, 80 and over; Biomarkers; Collagen; Double-Blind Method; Eplerenone; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Spironolactone; Stroke Volume | 2011 |
Aldosterone and cortisol predict medium-term left ventricular remodelling following myocardial infarction.
Topics: Aldosterone; Biomarkers; Double-Blind Method; Echocardiography; Electrocardiography; Eplerenone; Female; Follow-Up Studies; Heart Ventricles; Humans; Hydrocortisone; Magnetic Resonance Imaging, Cine; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Prospective Studies; Spironolactone; Time Factors; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Remodeling | 2011 |
The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism.
Topics: Adult; Aldosterone; Animals; Area Under Curve; Biomarkers; Cell Line, Tumor; Eplerenone; Humans; Male; Mineralocorticoid Receptor Antagonists; Potassium; Rats; Rats, Sprague-Dawley; Receptors, Mineralocorticoid; Sodium; Spironolactone; Time Factors; Translational Research, Biomedical; Young Adult | 2011 |
Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study.
Topics: Adult; Aged; Cross-Over Studies; Eplerenone; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Proteinuria; Spironolactone | 2011 |
Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study.
Topics: Aged; Eplerenone; Glomerular Filtration Rate; Heart Failure; Heart Failure, Systolic; Humans; Kidney; Middle Aged; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Prognosis; Spironolactone; Treatment Outcome; Ventricular Dysfunction, Left | 2012 |
Mineralocorticoid receptor blocker eplerenone improves endothelial function and inhibits Rho-associated kinase activity in patients with hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Cell Movement; Endothelium, Vascular; Eplerenone; Female; Humans; Hypertension; Leukocytes; Losartan; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Nifedipine; Nitroglycerin; rho-Associated Kinases; Spironolactone; Stem Cells; Vascular Endothelial Growth Factor A; Vasodilation | 2012 |
Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study.
Topics: Aged; Atrial Fibrillation; Disease Progression; Dose-Response Relationship, Drug; Electrocardiography; Eplerenone; Female; Heart Failure, Systolic; Heart Rate; Hospitalization; Humans; Incidence; Male; Mineralocorticoid Receptor Antagonists; Prognosis; Spironolactone; Survival Rate; United States | 2012 |
Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease.
Topics: Aldosterone; Confidence Intervals; Double-Blind Method; Eplerenone; Female; Health Status Indicators; Heart Failure; Humans; Kidney Failure, Chronic; Male; Mineralocorticoid Receptor Antagonists; Receptors, Mineralocorticoid; Research Design; Severity of Illness Index; Spironolactone | 2012 |
Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).
Topics: Aged; Diabetes Mellitus; Eplerenone; Female; Heart Failure; Hospitalization; Humans; Male; Mineralocorticoid Receptor Antagonists; Prognosis; Proportional Hazards Models; Risk Factors; Severity of Illness Index; Spironolactone | 2012 |
Hypo- and hyperglycemia predict outcome in patients with left ventricular dysfunction after acute myocardial infarction: data from EPHESUS.
Topics: Aged; Blood Glucose; Diabetes Complications; Double-Blind Method; Eplerenone; Female; Humans; Hyperglycemia; Hypoglycemia; Incidence; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Prognosis; Proportional Hazards Models; Risk Factors; Spironolactone; Treatment Outcome; Ventricular Dysfunction, Left | 2012 |
Interleukin-21--a biomarker of importance in predicting myocardial function following acute infarction?
Topics: Aged; Biomarkers; Double-Blind Method; Eplerenone; Female; Humans; Interleukins; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 3; Matrix Metalloproteinase 9; Middle Aged; Mineralocorticoid Receptor Antagonists; Multivariate Analysis; Myocardial Infarction; Predictive Value of Tests; Spironolactone; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2; Tissue Inhibitor of Metalloproteinase-4; Tissue Inhibitor of Metalloproteinases; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Remodeling | 2012 |
Statin therapy and clinical outcomes in myocardial infarction patients complicated by acute heart failure: insights from the EPHESUS trial.
Topics: Acute Disease; Aged; Double-Blind Method; Drug Therapy, Combination; Eplerenone; Female; Heart Failure, Systolic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Propensity Score; Spironolactone; Stroke Volume; Survival Analysis; Treatment Outcome; United States | 2013 |
Effectiveness of eplerenone or spironolactone treatment in preserving renal function in primary aldosteronism.
Topics: Adrenalectomy; Adult; Aged; Aged, 80 and over; Albuminuria; Blood Pressure; Creatinine; Eplerenone; Female; Glomerular Filtration Rate; Humans; Hyperaldosteronism; Kidney; Kidney Function Tests; Male; Middle Aged; Prospective Studies; Spironolactone | 2013 |
The enhanced renin-angiotensin-aldosteron system pharmacological blockade--which is the best?.
Topics: Adult; Albuminuria; Amides; Angiotensin Receptor Antagonists; Benzimidazoles; Benzoates; Comorbidity; Cross-Over Studies; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Eplerenone; Female; Fumarates; Humans; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Prospective Studies; Proteinuria; Renal Insufficiency, Chronic; Renin; Renin-Angiotensin System; Severity of Illness Index; Spironolactone; Telmisartan; Treatment Outcome | 2012 |
Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Blood Pressure; Cytochrome P-450 CYP11B2; Double-Blind Method; Eplerenone; Female; Humans; Hypertension; Iceland; Imidazoles; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Prospective Studies; Pyridines; Spironolactone; Treatment Outcome; United States; Young Adult | 2013 |
Galectin-3 and cardiac function in survivors of acute myocardial infarction.
Topics: Aged; Eplerenone; Extracellular Matrix; Female; Galectin 3; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Spironolactone; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Remodeling | 2013 |
Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study.
Topics: Adrenergic Antagonists; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Benchmarking; Drug Therapy, Combination; Eplerenone; Female; Heart Failure; Humans; Male; Mineralocorticoid Receptor Antagonists; Spironolactone | 2013 |
Eplerenone attenuates pulse wave reflection in chronic kidney disease stage 3-4--a randomized controlled study.
Topics: Blood Pressure; Demography; Eplerenone; Female; Heart Rate; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Pulse Wave Analysis; Renal Insufficiency, Chronic; Spironolactone; Vascular Stiffness | 2013 |
Role of mineralocorticoid receptors in arterial stiffness in human aging.
Topics: Aged; Aging; Blood Pressure; Cross-Over Studies; Double-Blind Method; Eplerenone; Female; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Oxidative Stress; Receptors, Mineralocorticoid; Spironolactone; Vascular Stiffness | 2013 |
Mineralocorticoid receptors modulate vascular endothelial function in human obesity.
Topics: Abdominal Fat; Aged; Body Composition; Body Mass Index; Brachial Artery; Cross-Over Studies; Double-Blind Method; Endothelial Cells; Eplerenone; F2-Isoprostanes; Female; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; NADPH Oxidases; Obesity; Oxidative Stress; Receptors, Mineralocorticoid; Spironolactone; Tyrosine; Ultrasonography | 2013 |
Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
Topics: Aged; Aged, 80 and over; Eplerenone; Female; Heart Failure; Hospitalization; Humans; Hyperkalemia; Kidney Function Tests; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Renal Insufficiency, Chronic; Risk Factors; Spironolactone; Survival Rate; Treatment Outcome | 2013 |
Effect of aldosterone breakthrough on albuminuria during treatment with a direct renin inhibitor and combined effect with a mineralocorticoid receptor antagonist.
Topics: Aged; Albuminuria; Aldosterone; Amides; Blood Pressure; Dose-Response Relationship, Drug; Drug Therapy, Combination; Eplerenone; Female; Fumarates; Humans; Hypertension; Incidence; Longitudinal Studies; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Renin; Renin-Angiotensin System; Spironolactone; Time Factors | 2013 |
The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial.
Topics: Adult; Aged; Death, Sudden, Cardiac; Eplerenone; Female; Heart Failure, Systolic; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Prognosis; Proportional Hazards Models; Risk Assessment; Spironolactone | 2013 |
Eplerenone in systemic right ventricle: double blind randomized clinical trial. The evedes study.
Topics: Adult; Aldosterone; Cardiac Imaging Techniques; Collagen; Double-Blind Method; Eplerenone; Female; Fibrosis; Follow-Up Studies; Heart Failure; Humans; Magnetic Resonance Imaging; Male; Mineralocorticoid Receptor Antagonists; Myocardium; Spironolactone; Transposition of Great Vessels; Treatment Outcome; Ventricular Dysfunction, Right; Young Adult | 2013 |
Rationale and design of a randomized trial on the impact of aldosterone antagonism on cardiac structure and function in diabetic cardiomyopathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Agents; Clinical Protocols; Collagen; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Diastole; Double-Blind Method; Drug Therapy, Combination; Echocardiography, Doppler; Eplerenone; Fibrosis; Humans; Mineralocorticoid Receptor Antagonists; Myocardium; New South Wales; Prospective Studies; Recovery of Function; Research Design; Spironolactone; Systole; Time Factors; Treatment Outcome; Ventricular Function, Left | 2013 |
Opposite predictive value of pulse pressure and aortic pulse wave velocity on heart failure with reduced left ventricular ejection fraction: insights from an Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) s
Topics: Aged; Arterial Pressure; Eplerenone; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Predictive Value of Tests; Prognosis; Pulse Wave Analysis; Spironolactone; Stroke Volume; Ventricular Dysfunction, Left | 2014 |
Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Eplerenone; Female; Follow-Up Studies; Glomerular Filtration Rate; Heart Failure; Hospitalization; Humans; Hyperkalemia; Incidence; Longitudinal Studies; Male; Mineralocorticoid Receptor Antagonists; Multivariate Analysis; Potassium; Prognosis; Risk Factors; Spironolactone; Survival Rate | 2014 |
Effect of eplerenone in percutaneous coronary intervention-treated post-myocardial infarction patients with left ventricular systolic dysfunction: a subanalysis of the EPHESUS trial.
Topics: Aged; Aged, 80 and over; Comorbidity; Double-Blind Method; Eplerenone; Female; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Percutaneous Coronary Intervention; Spironolactone; Treatment Outcome; Ventricular Dysfunction, Left | 2014 |
Effect of eplerenone on insulin action in essential hypertension: a randomised, controlled, crossover study.
Topics: Blood Glucose; Cross-Over Studies; Double-Blind Method; Eplerenone; Essential Hypertension; Female; Humans; Hypertension; Insulin; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Spironolactone | 2014 |
Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study.
Topics: Double-Blind Method; Eplerenone; Female; Heart Failure; Humans; Length of Stay; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Patient Readmission; Spironolactone; Treatment Outcome | 2014 |
Aldosterone inhibition and coronary endothelial function in women without obstructive coronary artery disease: an ancillary study of the national heart, lung, and blood institute-sponsored women's ischemia syndrome evaluation.
Topics: Acetylcholine; Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiac Catheterization; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Double-Blind Method; Drug Therapy, Combination; Endothelium, Vascular; Eplerenone; Female; Humans; Middle Aged; Mineralocorticoid Receptor Antagonists; National Heart, Lung, and Blood Institute (U.S.); Spironolactone; Treatment Outcome; United States; Vasodilation; Vasodilator Agents | 2014 |
A pilot study of the effects of eplerenone add-on therapy in patients taking renin-angiotensin system blockers.
Topics: Adult; Aged; Albuminuria; Aldosterone; Blood Pressure; Diastole; Eplerenone; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Pilot Projects; Renin-Angiotensin System; Spironolactone; Systole | 2015 |
Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cost-Benefit Analysis; Drug Costs; Eplerenone; Health Expenditures; Heart Failure, Systolic; Humans; Mineralocorticoid Receptor Antagonists; Patient Simulation; Quality of Life; Severity of Illness Index; Spain; Spironolactone; United Kingdom; Ventricular Function, Left | 2014 |
Indomethacin, amiloride, or eplerenone for treating hypokalemia in Gitelman syndrome.
Topics: Adolescent; Adult; Amiloride; Blood Pressure; Body Weight; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Eplerenone; Female; Gitelman Syndrome; Glomerular Filtration Rate; Heart Rate; Humans; Hypokalemia; Indomethacin; Male; Middle Aged; Potassium; Renin; Spironolactone; Treatment Outcome; Young Adult | 2015 |
The effect of eplerenone on adenosine formation in humans in vivo: a double-blinded randomised controlled study.
Topics: Adenosine; Caffeine; Dipyridamole; Double-Blind Method; Eplerenone; Forearm; Hemodynamics; Humans; Hyperemia; Male; Nitroprusside; Regional Blood Flow; Spironolactone; Treatment Outcome; Young Adult | 2014 |
Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial.
Topics: Adult; Aged; Albuminuria; Antihypertensive Agents; Creatinine; Double-Blind Method; Eplerenone; Female; Humans; Hypertension; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Protective Agents; Renal Insufficiency, Chronic; Spironolactone | 2014 |
Aldosterone synthase inhibition: cardiorenal protection in animal disease models and translation of hormonal effects to human subjects.
Topics: Angiotensinogen; Animals; Cytochrome P-450 CYP11B2; Disease Models, Animal; Double-Blind Method; Eplerenone; Haplorhini; Heart; Humans; Imidazoles; Kidney; Male; Placebos; Pyridines; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Renin; Spironolactone; Translational Research, Biomedical | 2014 |
Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Cardiomyopathies; Child; Cohort Studies; Double-Blind Method; Early Diagnosis; Eplerenone; Follow-Up Studies; Humans; Male; Mineralocorticoid Receptor Antagonists; Muscular Dystrophy, Duchenne; Spironolactone; Young Adult | 2015 |
Rationale and Design of the Double-Blind, Randomized, Placebo-Controlled Multicenter Trial on Efficacy of Early Initiation of Eplerenone Treatment in Patients with Acute Heart Failure (EARLIER).
Topics: Acute Disease; Adult; Clinical Protocols; Double-Blind Method; Early Medical Intervention; Eplerenone; Female; Heart Failure; Humans; Male; Mineralocorticoid Receptor Antagonists; Spironolactone; Young Adult | 2015 |
Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease.
Topics: Comorbidity; Diabetes Mellitus, Type 2; Double-Blind Method; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Naphthyridines; Natriuretic Agents; Natriuretic Peptide, Brain; Peptide Fragments; Renal Insufficiency, Chronic; Spironolactone | 2015 |
Effects of a selective aldosterone blocker and thiazide-type diuretic on blood pressure and organ damage in hypertensive patients.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aged; Blood Pressure; Blood Pressure Determination; Calcium Channel Blockers; Deoxyguanosine; Diuretics; Eplerenone; Female; Glomerular Filtration Rate; Humans; Hypertension; Indapamide; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Potassium; Pulse Wave Analysis; Spironolactone; Treatment Outcome; Uric Acid | 2015 |
Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial.
Topics: Acute Coronary Syndrome; Aged; Eplerenone; Female; Follow-Up Studies; Heart Failure, Systolic; Hospitalization; Humans; Hyperkalemia; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Patient Readmission; Secondary Prevention; Spironolactone; Treatment Outcome | 2015 |
The Safety of Eplerenone in Hemodialysis Patients: A Noninferiority Randomized Controlled Trial.
Topics: Aged; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Eplerenone; Female; Humans; Hyperkalemia; Hypotension; Kidney Failure, Chronic; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Pilot Projects; Potassium; Renal Dialysis; Spironolactone; Withholding Treatment | 2015 |
Clinical outcomes according to QRS duration and morphology in the Eplerenone in Mild Patients: Hospitalization and SurvIval Study in Heart Failure (EMPHASIS-HF).
Topics: Aged; Double-Blind Method; Electrocardiography; Eplerenone; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Random Allocation; Spironolactone; Stroke Volume; Survival Rate; Treatment Outcome | 2015 |
Dose Proportionality and Pharmacokinetics of Eplerenone in Healthy Chinese Subjects.
Topics: Administration, Oral; Adolescent; Adult; Area Under Curve; Asian People; Cross-Over Studies; Dose-Response Relationship, Drug; Eplerenone; Female; Healthy Volunteers; Humans; Male; Middle Aged; Spironolactone; Young Adult | 2016 |
Effect of Selective Mineralocorticoid Receptor Blockade on Flow-Mediated Dilation and Insulin Resistance in Older Adults with Metabolic Syndrome.
Topics: Aged; Brachial Artery; Cross-Over Studies; Double-Blind Method; Endothelium, Vascular; Eplerenone; Humans; Insulin Resistance; Metabolic Syndrome; Middle Aged; Mineralocorticoid Receptor Antagonists; Oxidative Stress; Placebos; Regional Blood Flow; Spironolactone; Ultrasonography; Vasodilation | 2015 |
Effect of low-dose mineralocorticoid receptor antagonists on metabolic profile and endothelial dysfunction in metabolic syndrome.
Topics: Adult; Aged, 80 and over; Biomarkers; Eplerenone; Female; Humans; Lipids; Male; Metabolic Syndrome; Middle Aged; Mineralocorticoid Receptor Antagonists; Spironolactone; Vasodilation | 2016 |
Comparison of eplerenone and spironolactone for the treatment of primary aldosteronism.
Topics: Adult; Aged; Blood Pressure; Eplerenone; Female; Humans; Hyperaldosteronism; Kidney Function Tests; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Potassium; Spironolactone | 2016 |
Acute effect of mineralocorticoid receptor antagonism on vascular function in healthy older adults.
Topics: Aged; Aging; Biomarkers; Blood Proteins; Brachial Artery; Cross-Over Studies; Double-Blind Method; Endothelium, Vascular; Eplerenone; Female; Hemodynamics; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Muscle, Smooth, Vascular; Receptors, Mineralocorticoid; Spironolactone; Vasodilation | 2016 |
Mineralocorticoid Receptor Activation Contributes to the Supine Hypertension of Autonomic Failure.
Topics: Administration, Oral; Aged; Autonomic Nervous System; Blood Pressure; Blood Pressure Determination; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Eplerenone; Female; Follow-Up Studies; Humans; Hypertension; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Pure Autonomic Failure; Spironolactone; Supine Position; Treatment Outcome | 2016 |
Vascular Effects of Eplerenone in Coronary Artery Disease With Preserved Ejection Fraction: A Double-Blind, Randomized, Placebo-Controlled Trial.
Topics: Aged; Blood Pressure; Brachial Artery; Coronary Artery Disease; Double-Blind Method; Endothelial Progenitor Cells; Eplerenone; Female; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Platelet Adhesiveness; Spironolactone; Stroke Volume; Switzerland; Time Factors; Treatment Outcome; Vasodilation; Ventricular Function, Left | 2016 |
Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: results from the EPATH randomized, placebo-controlled trial.
Topics: Aged; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Diastole; Double-Blind Method; Echocardiography; Eplerenone; Female; Humans; Hyperparathyroidism, Primary; Hypertension; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Parathyroid Hormone; Spironolactone; Systole; Vitamin D | 2016 |
A Randomized Controlled Study of Finerenone vs. Eplerenone in Japanese Patients With Worsening Chronic Heart Failure and Diabetes and/or Chronic Kidney Disease.
Topics: Adult; Chronic Disease; Diabetes Mellitus; Double-Blind Method; Eplerenone; Heart Failure; Humans; Hyperkalemia; Japan; Naphthyridines; Natriuretic Peptide, Brain; Patient Safety; Peptide Fragments; Renal Insufficiency, Chronic; Spironolactone | 2016 |
Safety of Eplerenone for Kidney-Transplant Recipients with Impaired Renal Function and Receiving Cyclosporine A.
Topics: Adult; Aged; Cyclosporine; Drug Therapy, Combination; Eplerenone; Female; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Prospective Studies; Renal Insufficiency; ROC Curve; Safety; Spironolactone; Transplant Recipients | 2016 |
A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease.
Topics: Aged; Chronic Disease; Diabetes Mellitus; Double-Blind Method; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Natriuretic Peptide, Brain; Peptide Fragments; Renal Insufficiency, Chronic; Spironolactone | 2016 |
Eplerenone does not limit ischemia-reperfusion injury in human myocardial tissue.
Topics: Aged; Cardiovascular Diseases; Elective Surgical Procedures; Eplerenone; Female; Heart; Heart Atria; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Models, Biological; Random Allocation; Reperfusion Injury; Spironolactone | 2016 |
Effect of eplerenone on the severity of obstructive sleep apnea and arterial stiffness in patients with resistant arterial hypertension.
Topics: Aged; Eplerenone; Female; Humans; Hypertension; Male; Middle Aged; Severity of Illness Index; Sleep Apnea, Obstructive; Spironolactone; Vascular Stiffness | 2016 |
Add-On Use of Eplerenone Is Effective for Lowering Home and Ambulatory Blood Pressure in Drug-Resistant Hypertension.
Topics: Aged; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Drug Resistance; Drug Therapy, Combination; Eplerenone; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Pulse Wave Analysis; Spironolactone | 2016 |
Pulsatile Cortisol Feedback on ACTH Secretion Is Mediated by the Glucocorticoid Receptor and Modulated by Gender.
Topics: Adrenocorticotropic Hormone; Adult; Double-Blind Method; Eplerenone; Female; Hormone Antagonists; Humans; Hydrocortisone; Male; Middle Aged; Mifepristone; Mineralocorticoid Receptor Antagonists; Prospective Studies; Receptors, Glucocorticoid; Sex Factors; Spironolactone | 2016 |
MINERALOCORTICOID RECEPTOR ANTAGONIST TREATMENT IN BILATERAL CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: A COMPARATIVE STUDY OF EXUDATIVE AND NONEXUDATIVE FELLOW EYES.
Topics: Administration, Oral; Adult; Aged; Central Serous Chorioretinopathy; Choroid; Chronic Disease; Eplerenone; Exudates and Transudates; Female; Fluorescein Angiography; Follow-Up Studies; Fundus Oculi; Humans; Macula Lutea; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Prospective Studies; Spironolactone; Tomography, Optical Coherence; Treatment Outcome; Visual Acuity | 2017 |
Prognostic Value of the Thrombolysis in Myocardial Infarction Risk Score in ST-Elevation Myocardial Infarction Patients With Left Ventricular Dysfunction (from the EPHESUS Trial).
Topics: Aged; Cause of Death; Double-Blind Method; Electrocardiography; Eplerenone; Female; Follow-Up Studies; France; Humans; Male; Mineralocorticoid Receptor Antagonists; Myocardial Revascularization; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Spironolactone; ST Elevation Myocardial Infarction; Stroke Volume; Survival Rate; Thrombolytic Therapy; Time Factors; Ventricular Dysfunction, Left | 2016 |
Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy.
Topics: Adult; Aged; Aged, 80 and over; Central Serous Chorioretinopathy; Dose-Response Relationship, Drug; Drug Administration Schedule; Eplerenone; Female; Fluorescein Angiography; Follow-Up Studies; Fundus Oculi; Humans; Intravitreal Injections; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Prospective Studies; Spironolactone; Tomography, Optical Coherence; Treatment Outcome; Visual Acuity | 2017 |
Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia.
Topics: Dose-Response Relationship, Drug; Eplerenone; Europe; Female; Follow-Up Studies; Heart Failure, Systolic; Humans; Hypokalemia; Male; Mineralocorticoid Receptor Antagonists; Prognosis; Spironolactone; Survival Rate; Time Factors; Treatment Outcome | 2017 |
Population Pharmacokinetics of Eplerenone in Japanese Patients With Chronic Heart Failure.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Chronic Disease; Double-Blind Method; Eplerenone; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Models, Biological; Spironolactone | 2017 |
Low-dose eplerenone decreases left ventricular mass in treatment-resistant hypertension.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Coronary Vasospasm; Double-Blind Method; Drug Therapy, Combination; Eplerenone; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Magnetic Resonance Imaging; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Spironolactone | 2017 |
Low dose-eplerenone treatment decreases aortic stiffness in patients with resistant hypertension.
Topics: Aged; Blood Pressure Determination; Carotid Intima-Media Thickness; Coronary Vasospasm; Double-Blind Method; Eplerenone; Female; Humans; Hypertension; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Prospective Studies; Pulse Wave Analysis; Serum Albumin, Human; Spironolactone; Vascular Stiffness | 2017 |
Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: results of a two-year open-label extension trial.
Topics: Adolescent; Adult; Cardiomyopathies; Child; Double-Blind Method; Eplerenone; Humans; Male; Mineralocorticoid Receptor Antagonists; Muscular Dystrophy, Duchenne; Potassium; Spironolactone; Young Adult | 2017 |
Combined baseline and one-month changes in big endothelin-1 and brain natriuretic peptide plasma concentrations predict clinical outcomes in patients with left ventricular dysfunction after acute myocardial infarction: Insights from the Eplerenone Post-Ac
Topics: Aged; Biomarkers; Endothelin-1; Eplerenone; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Natriuretic Peptide, Brain; Predictive Value of Tests; Spironolactone; Survival Rate; Time Factors; Treatment Outcome; Ventricular Dysfunction, Left | 2017 |
Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trial.
Topics: Aged; Aldosterone; Drug Monitoring; Eplerenone; Female; Heart Failure, Systolic; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Obesity, Abdominal; Spironolactone; Stroke Volume; Treatment Outcome; Ventricular Dysfunction, Left | 2017 |
A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROL PILOT STUDY OF EPLERENONE FOR THE TREATMENT OF CENTRAL SEROUS CHORIORETINOPATHY (ECSELSIOR).
Topics: Administration, Oral; Adult; Aged; Central Serous Chorioretinopathy; Chronic Disease; Double-Blind Method; Eplerenone; Female; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Pilot Projects; Prospective Studies; Retina; Spironolactone; Subretinal Fluid; Visual Acuity | 2018 |
Eplerenone might affect atrial fibrosis in patients with hypertension.
Topics: Aged; Atrial Fibrillation; Electrocardiography; Eplerenone; Female; Fibrosis; Heart Atria; Humans; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Spironolactone | 2017 |
Antialbuminuric effect of eplerenone in comparison to thiazide diuretics in patients with hypertension.
Topics: Aged; Aged, 80 and over; Albuminuria; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Creatinine; Eplerenone; Female; Humans; Hypertension; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Prospective Studies; Serum Albumin, Human; Sodium Chloride Symporter Inhibitors; Spironolactone | 2017 |
Effect of eplerenone on extracellular cardiac matrix biomarkers in patients with acute ST-elevation myocardial infarction without heart failure: insights from the randomized double-blind REMINDER Study.
Topics: Aged; Biomarkers; Double-Blind Method; Eplerenone; Female; Humans; Linear Models; Logistic Models; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Natriuretic Peptide, Brain; Peptide Fragments; Principal Component Analysis; Procollagen; Proportional Hazards Models; Spironolactone; ST Elevation Myocardial Infarction; Time Factors; Treatment Outcome; Troponin I; Troponin T | 2018 |
Effect of eplerenone on markers of bone turnover in patients with primary hyperparathyroidism - The randomized, placebo-controlled EPATH trial.
Topics: Aged; Biomarkers; Bone Remodeling; Cohort Studies; Eplerenone; Female; Follow-Up Studies; Humans; Hyperparathyroidism, Primary; Male; Placebos; Renin-Angiotensin System; Spironolactone; Treatment Outcome | 2017 |
Treatment of Unruptured Cerebral Aneurysms with the Mineralocorticoid Receptor Blocker Eplerenone-Pilot Study.
Topics: Aged; Aneurysm, Ruptured; Brain; Disease Progression; Eplerenone; Female; Follow-Up Studies; Humans; Intracranial Aneurysm; Male; Mineralocorticoid Receptor Antagonists; Neuroprotective Agents; Pilot Projects; Spironolactone; Treatment Outcome | 2018 |
The Effect of Mineralocorticoid Receptor Antagonists on Recruitment and Function of Endothelial Progenitor Cells in Patients with Congestive Heart Failure.
Topics: AC133 Antigen; Aged; Antigens, CD34; Cell Survival; Cohort Studies; Endothelial Progenitor Cells; Eplerenone; Female; Flow Cytometry; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Prospective Studies; Spironolactone; Vascular Endothelial Growth Factor Receptor-2 | 2018 |
Mineralocorticoid Receptor Blockers and Aldosterone to Renin Ratio: A Randomized Controlled Trial and Observational Data.
Topics: Aged; Aldosterone; Double-Blind Method; Eplerenone; Female; Humans; Hyperaldosteronism; Hyperparathyroidism; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Renin; Spironolactone; Time Factors | 2018 |
A comparison of the effects of selective and non-selective mineralocorticoid antagonism on glucose homeostasis of heart failure patients with glucose intolerance or type II diabetes: A randomized controlled double-blind trial.
Topics: Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Eplerenone; Female; Glucose Intolerance; Glycated Hemoglobin; Heart Failure; Homeostasis; Humans; Insulin; Insulin Resistance; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Prospective Studies; Spironolactone; Stroke Volume | 2018 |
Predictive Factors of Response to Mineralocorticoid Receptor Antagonists in Nonresolving Central Serous Chorioretinopathy.
Topics: Administration, Oral; Adult; Aged; Central Serous Chorioretinopathy; Choroid; Eplerenone; Female; Fluorescein Angiography; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Multimodal Imaging; Retina; Retrospective Studies; Spironolactone; Tomography, Optical Coherence; Treatment Outcome; Visual Acuity | 2019 |
Stabilization of Early Duchenne Cardiomyopathy With Aldosterone Inhibition: Results of the Multicenter AIDMD Trial.
Topics: Adolescent; Cardiomyopathies; Child; Double-Blind Method; Eplerenone; Humans; Magnetic Resonance Imaging, Cine; Male; Mineralocorticoid Receptor Antagonists; Muscular Dystrophy, Duchenne; Myocardial Contraction; Spironolactone; Stroke Volume; Time Factors; Treatment Outcome; United States; Ventricular Function, Left; Young Adult | 2019 |
MRAs in Elderly HF Patients: Individual Patient-Data Meta-Analysis of RALES, EMPHASIS-HF, and TOPCAT.
Topics: Age Factors; Aged; Aged, 80 and over; Eplerenone; Female; Heart Failure; Humans; Male; Meta-Analysis as Topic; Middle Aged; Mineralocorticoid Receptor Antagonists; Spironolactone; Stroke Volume | 2019 |
Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction.
Topics: Aged; Blood Pressure; Eplerenone; Female; Heart Failure; Humans; Male; Mineralocorticoid Receptor Antagonists; Spironolactone; Stroke Volume; Treatment Outcome | 2020 |
Comparative study of spironolactone and eplerenone in management of ascites in patients of cirrhosis of liver.
Topics: Adult; Aged; Ascites; Diet, Sodium-Restricted; Eplerenone; Female; Humans; Liver Cirrhosis; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Spironolactone; Treatment Outcome | 2020 |
Efficacy and Safety of Early Initiation of Eplerenone Treatment in Patients with Acute Heart Failure (EARLIER trial): a multicentre, randomized, double-blind, placebo-controlled trial.
Topics: Aged; Eplerenone; Female; Heart Failure; Humans; Male; Spironolactone; Stroke Volume; Ventricular Function, Left | 2022 |
The Effects of Spironolactone and Eplerenone on Left Ventricular Function Using Echocardiography in Symptomatic Patients With New-Onset Systolic Heart Failure: A Comparative Randomised Controlled Trial.
Topics: Echocardiography; Eplerenone; Heart Failure; Heart Failure, Systolic; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Ventricular Function, Left | 2021 |
Randomized Placebo-Controlled Trial to Evaluate Effects of Eplerenone on Myocardial Perfusion and Function Among Persons With Human Immunodeficiency Virus (HIV)-Results From the MIRACLE HIV Study.
Topics: Eplerenone; HIV; HIV Infections; Humans; Mineralocorticoid Receptor Antagonists; Perfusion; Spironolactone | 2023 |
The Effectiveness of Eplerenone vs Spironolactone on Left Ventricular Systolic Function, Hospitalization and Cardiovascular Death in Patients With Chronic Heart Failure-HFrEF.
Topics: Chronic Disease; Eplerenone; Heart Failure; Hospitalization; Humans; Mineralocorticoid Receptor Antagonists; Prospective Studies; Single-Blind Method; Spironolactone; Stroke Volume; Treatment Outcome; Ventricular Function, Left | 2023 |
Long-term effect of eplerenone treatment in children with chronic allograft nephropathy.
Topics: Allografts; Child; Creatinine; Eplerenone; Glomerular Filtration Rate; Humans; Hyperkalemia; Mineralocorticoid Receptor Antagonists; Spironolactone | 2023 |
Time to clinical benefit of eplerenone among patients with heart failure and reduced ejection fraction: A subgroups analysis from the EMPHASIS-HF trial.
Topics: Aged; Eplerenone; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Spironolactone; Stroke Volume; Ventricular Function, Left | 2023 |
510 other study(ies) available for spironolactone and eplerenone
| Article | Year |
|---|---|
(S)-N-{3-[1-cyclopropyl-1-(2,4-difluoro-phenyl)-ethyl]-1H-indol-7-yl}-methanesulfonamide: a potent, nonsteroidal, functional antagonist of the mineralocorticoid receptor.
Topics: Animals; Antihypertensive Agents; Crystallography, X-Ray; Indoles; Mineralocorticoid Receptor Antagonists; Models, Molecular; Rats; Rats, Sprague-Dawley; Stereoisomerism; Structure-Activity Relationship; Sulfonamides | 2007 |
Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Cell Line, Tumor; Chlorobenzenes; Crystallography, X-Ray; Humans; Hypertension; Indazoles; Indenes; Kidney Diseases; Male; Mineralocorticoid Receptor Antagonists; Models, Molecular; Molecular Conformation; Nitriles; Radioligand Assay; Rats; Rats, Inbred Dahl; Rats, Sprague-Dawley; Stereoisomerism; Structure-Activity Relationship | 2010 |
Identification of benzoxazin-3-one derivatives as novel, potent, and selective nonsteroidal mineralocorticoid receptor antagonists.
Topics: Animals; Antihypertensive Agents; Benzoxazines; Binding, Competitive; Crystallography, X-Ray; Microsomes, Liver; Mineralocorticoid Receptor Antagonists; Models, Molecular; Protein Conformation; Pyrazoles; Rats; Rats, Wistar; Structure-Activity Relationship | 2011 |
Discovery of novel oxazolidinedione derivatives as potent and selective mineralocorticoid receptor antagonists.
Topics: Animals; Binding Sites; Drug Evaluation, Preclinical; Half-Life; Humans; Microsomes; Mineralocorticoid Receptor Antagonists; Molecular Docking Simulation; Oxazoles; Protein Structure, Tertiary; Rats; Receptors, Mineralocorticoid; Structure-Activity Relationship | 2013 |
Mineralocorticoid receptor antagonists: identification of heterocyclic amide replacements in the oxazolidinedione series.
Topics: Amides; Animals; Dose-Response Relationship, Drug; Heterocyclic Compounds; Humans; Microsomes, Liver; Mineralocorticoid Receptor Antagonists; Molecular Structure; Oxazoles; Rats; Receptors, Mineralocorticoid; Structure-Activity Relationship | 2014 |
Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist.
Topics: Animals; Drug Discovery; Male; Mineralocorticoid Receptor Antagonists; Molecular Docking Simulation; Nicotinic Acids; Potassium; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptors, Mineralocorticoid; Sodium; Structure-Activity Relationship | 2014 |
Discovery of 6-[5-(4-fluorophenyl)-3-methyl-pyrazol-4-yl]-benzoxazin-3-one derivatives as novel selective nonsteroidal mineralocorticoid receptor antagonists.
Topics: Androgen Antagonists; Animals; Antihypertensive Agents; Chlorocebus aethiops; COS Cells; Crystallography, X-Ray; Desoxycorticosterone Acetate; Dose-Response Relationship, Drug; Drug Discovery; Humans; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Models, Molecular; Molecular Structure; Oxazines; Pyrazoles; Rats; Rats, Wistar; Receptors, Mineralocorticoid; Structure-Activity Relationship | 2014 |
Discovery of benzimidazole oxazolidinediones as novel and selective nonsteroidal mineralocorticoid receptor antagonists.
Topics: | 2015 |
Discovery of novel non-steroidal reverse indole mineralocorticoid receptor antagonists.
Topics: Dose-Response Relationship, Drug; Drug Discovery; Humans; Indoles; Mineralocorticoid Receptor Antagonists; Molecular Structure; Receptors, Mineralocorticoid; Structure-Activity Relationship | 2016 |
Modulating Mineralocorticoid Receptor with Non-steroidal Antagonists. New Opportunities for the Development of Potent and Selective Ligands without Off-Target Side Effects.
Topics: Amino Acid Sequence; Animals; Benzoxazines; Dihydropyridines; Drug Discovery; Humans; Ligands; Macrolides; Mineralocorticoid Receptor Antagonists; Models, Molecular; Oxazolidinones; Peptides; Pyrazoles; Pyrroles; Receptors, Mineralocorticoid; Structure-Activity Relationship; Sulfonamides | 2017 |
Discovery of Apararenone (MT-3995) as a Highly Selective, Potent, and Novel Nonsteroidal Mineralocorticoid Receptor Antagonist.
Topics: Animals; Antihypertensive Agents; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Oxazines; Rats; Receptors, Mineralocorticoid; Sulfonamides | 2022 |
Antialdosterones: incidence and prevention of sexual side effects.
Topics: Blood Pressure; Female; Fludrocortisone; Gynecomastia; Humans; Hypertension; Male; Menstruation Disturbances; Potassium; Sodium; Spironolactone | 1989 |
The memory-facilitating effects of the competitive NMDA-receptor antagonist CGP 37849 are steroid-sensitive, whereas its memory-impairing effects are not.
Topics: 2-Amino-5-phosphonovalerate; Aldosterone; Aminoglutethimide; Animals; Corticosterone; Dose-Response Relationship, Drug; Drug Interactions; Excitatory Amino Acid Antagonists; Male; Memory; Mice; Mineralocorticoid Receptor Antagonists; Spironolactone | 1996 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibitors; Eplerenone; Hormone Antagonists; Kidney; Male; Myocardium; Necrosis; NG-Nitroarginine Methyl Ester; Rats; Rats, Wistar; Renal Artery; Renin; Sodium Chloride; Spironolactone; Vascular Diseases | 2000 |
Absorption and disposition of a selective aldosterone receptor antagonist, eplerenone, in the dog.
Topics: Administration, Oral; Administration, Rectal; Animals; Body Fluid Compartments; Dogs; Eplerenone; Feces; Female; Gastric Mucosa; Injections, Intravenous; Intestinal Absorption; Intestinal Mucosa; Male; Mineralocorticoid Receptor Antagonists; Mouth Mucosa; Spironolactone; Stomach | 2000 |
Aldosterone receptor antagonism normalizes vascular function in liquorice-induced hypertension.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Animals; Aorta; Blood Pressure; Body Weight; Endothelin-1; Endothelium, Vascular; Enzyme Inhibitors; Eplerenone; Glycyrrhiza; Glycyrrhizic Acid; Heart Rate; Hydroxysteroid Dehydrogenases; Hypertension; In Vitro Techniques; Male; Mineralocorticoid Receptor Antagonists; Molecular Structure; Nitrates; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Plants, Medicinal; Rats; Rats, Inbred WKY; Spironolactone; Vasodilation | 2001 |
Effect of a selective aldosterone receptor antagonist in myocardial infarction.
Topics: Animals; Eplerenone; Fibrosis; Male; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Rats; Rats, Sprague-Dawley; Receptors, Mineralocorticoid; Spironolactone; Ventricular Remodeling | 2001 |
Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries.
Topics: Aldosterone; Angioplasty, Balloon; Animals; Collagen; Constriction, Pathologic; Coronary Disease; Coronary Vessels; Elastin; Eplerenone; Iliac Artery; Male; Mineralocorticoid Receptor Antagonists; Spironolactone; Swine; Swine, Miniature; Tunica Intima | 2001 |
New treasures from old? EPHESUS. Eplerenome Post-AHI Heart Failure Efficacy and Survival Study.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Renin-Angiotensin System; Spironolactone | 2001 |
The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study.
Topics: Aldosterone; Double-Blind Method; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Multicenter Studies as Topic; Myocardial Infarction; Randomized Controlled Trials as Topic; Research Design; Sample Size; Spironolactone; Survival Analysis; Systole | 2001 |
Exciting new drugs on the horizon - eplerenone, a selective aldosterone receptor antagonist (SARA).
Topics: Eplerenone; Heart Failure; Humans; Hypertrophy, Left Ventricular; Mineralocorticoid Receptor Antagonists; Spironolactone | 2001 |
Aldosterone 2001.
Topics: Aldosterone; Alternative Splicing; Body Composition; Calcium Channels; Epithelial Sodium Channels; Eplerenone; Glycyrrhiza; Humans; Phosphatidylinositol 3-Kinases; Plasminogen Activator Inhibitor 1; Receptors, Cytoplasmic and Nuclear; Receptors, Mineralocorticoid; Sodium Channels; Spironolactone; Transcription Factors; Vasopressins | 2001 |
Cardiac damage prevention by eplerenone: comparison with low sodium diet or potassium loading.
Topics: Aldosterone; Angiotensin II; Animals; Diet, Sodium-Restricted; Disease Models, Animal; Eplerenone; Heart Diseases; Male; Mineralocorticoid Receptor Antagonists; NG-Nitroarginine Methyl Ester; Potassium; Rats; Rats, Wistar; Spironolactone | 2002 |
Atypical dose-route-dependent food effects of eplerenone in the dog: presence of food effects following intravenous dosing and lack of food effects of following oral dosing.
Topics: Administration, Oral; Animals; Area Under Curve; Dogs; Eplerenone; Food-Drug Interactions; Infusions, Intravenous; Liver; Mass Spectrometry; Mineralocorticoid Receptor Antagonists; Portal Vein; Spironolactone | 2002 |
Mineralocorticoid receptor antagonism in experimental atherosclerosis.
Topics: Animals; Aorta; Arteriosclerosis; Dose-Response Relationship, Drug; Endothelium, Vascular; Eplerenone; Male; Mineralocorticoid Receptor Antagonists; Multienzyme Complexes; NADH, NADPH Oxidoreductases; NADPH Oxidases; Organ Culture Techniques; Rabbits; Receptors, Mineralocorticoid; RNA, Messenger; Signal Transduction; Spironolactone; Superoxides; Vasomotor System | 2002 |
Interconversion pharmacokinetics of eplerenone, a selective aldosterone blocker, and its lactone-ring open form.
Topics: Aldosterone; Animals; Dogs; Eplerenone; Female; Injections, Intravenous; Lactones; Models, Animal; Spironolactone | 2002 |
Mineralocorticoid and angiotensin receptor antagonism during hyperaldosteronemia.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Animals; Blood Pressure; Eplerenone; Heart Ventricles; Hyperaldosteronism; Losartan; Magnesium; Male; Membrane Potentials; Mineralocorticoid Receptor Antagonists; Patch-Clamp Techniques; Potassium; Rabbits; Sodium; Sodium-Potassium-Exchanging ATPase; Spironolactone; Ventricular Function | 2002 |
Aldosterone induces a vascular inflammatory phenotype in the rat heart.
Topics: Aldosterone; Animals; Blood Pressure; Chemokine CCL2; Coronary Vessels; Cyclooxygenase 2; Endomyocardial Fibrosis; Eplerenone; Gene Expression; Hypertension; Immunohistochemistry; In Situ Hybridization; Intercellular Adhesion Molecule-1; Isoenzymes; Male; Myocardium; Osteopontin; Phenotype; Prostaglandin-Endoperoxide Synthases; Rats; Rats, Sprague-Dawley; Sialoglycoproteins; Spironolactone; Vascular Cell Adhesion Molecule-1; Vasculitis | 2002 |
[Selective aldosterone blocker for hypertension and heart failure. Better tolerance than previous drugs].
Topics: Aldosterone; Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Hypertension; Spironolactone | 2002 |
Involvement of CYP3A in the metabolism of eplerenone in humans and dogs: differential metabolism by CYP3A4 and CYP3A5.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dogs; Eplerenone; Humans; Microsomes, Liver; Oxidoreductases, N-Demethylating; Species Specificity; Spironolactone | 2002 |
Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Body Weight; Coronary Disease; Coronary Vessels; Corticosterone; Cyclooxygenase 2; Diuresis; Drinking; Eating; Eplerenone; Heart; Hypertension; Isoenzymes; Macrophages; Male; Mineralocorticoid Receptor Antagonists; Myocardium; Necrosis; Organ Size; Osteopontin; Potassium; Prostaglandin-Endoperoxide Synthases; Rats; Rats, Wistar; Renin; Sialoglycoproteins; Sodium; Sodium Chloride; Spironolactone; Vasculitis | 2002 |
Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats: effects of eplerenone.
Topics: Aldosterone; Animals; Blood Pressure; Blotting, Northern; Carotid Arteries; Collagen; Collagen Type I; Collagen Type III; Disease Models, Animal; Dose-Response Relationship, Drug; Elasticity; Elastin; Eplerenone; Fibronectins; Hyperaldosteronism; Immunohistochemistry; Injections, Subcutaneous; Male; Mineralocorticoid Receptor Antagonists; Nephrectomy; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sodium, Dietary; Spironolactone; Ultrasonography; Vascular Patency | 2002 |
Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure.
Topics: Administration, Oral; Animals; Chronic Disease; Disease Models, Animal; Disease Progression; Dogs; Echocardiography; Enzyme Activation; Eplerenone; Fibroblast Growth Factor 2; Heart; Heart Failure; Hemodynamics; Mineralocorticoid Receptor Antagonists; Myocardium; RNA, Messenger; Spironolactone; Stroke Volume; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Remodeling | 2002 |
Early inflammatory responses in experimental cardiac hypertrophy and fibrosis: effects of 11 beta-hydroxysteroid dehydrogenase inactivation.
Topics: 11-beta-Hydroxysteroid Dehydrogenases; Animals; Blood Pressure; Carbenoxolone; Cardiomegaly; Coronary Disease; Desoxycorticosterone; Enzyme Inhibitors; Eplerenone; Fibrosis; Heart; Hydroxysteroid Dehydrogenases; Kidney; Male; Mineralocorticoid Receptor Antagonists; Muscle, Smooth, Vascular; Myocardium; Nephrectomy; Organ Size; Rats; Rats, Sprague-Dawley; Sodium Chloride; Solutions; Spironolactone; Vasculitis | 2003 |
Single- and repeated-dose pharmacokinetics of eplerenone, a selective aldosterone receptor blocker, in rats.
Topics: Administration, Oral; Animals; Biotransformation; Cytochrome P-450 CYP4A; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Eplerenone; Feces; Female; Half-Life; In Vitro Techniques; Injections, Intravenous; Male; Microsomes, Liver; Mineralocorticoid Receptor Antagonists; Mixed Function Oxygenases; Rats; Rats, Sprague-Dawley; Sex Factors; Spironolactone; Subcellular Fractions | 2003 |
Nongenomic effect of aldosterone on Na+,K+-adenosine triphosphatase in arterial vessels.
Topics: Aldosterone; Animals; Aorta, Thoracic; Catalytic Domain; Cycloheximide; Dactinomycin; Enzyme Inhibitors; Eplerenone; Indoles; Ionophores; Male; Maleimides; Mineralocorticoid Receptor Antagonists; Monensin; Protein Biosynthesis; Protein Kinase C; Protein Synthesis Inhibitors; Rats; Rats, Sprague-Dawley; Sodium; Sodium-Potassium-Exchanging ATPase; Spironolactone; Transcription, Genetic | 2003 |
Development and validation of a liquid chromatography-tandem mass spectrometric assay for Eplerenone and its hydrolyzed metabolite in human plasma.
Topics: Chromatography, High Pressure Liquid; Eplerenone; Hemolysis; Humans; Hydrolysis; Mass Spectrometry; Reference Standards; Reproducibility of Results; Spironolactone | 2003 |
Aldosterone blockade and heart failure.
Topics: Aldosterone; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Spironolactone; Ventricular Dysfunction, Left | 2003 |
Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats.
Topics: Aldosterone; Animals; Blood Pressure; Cytokines; Eplerenone; Fibrosis; Hypertension, Renal; Immunohistochemistry; In Situ Hybridization; Kidney; Macrophages; Male; Nephritis; Rats; Rats, Sprague-Dawley; Sodium Chloride; Spironolactone | 2003 |
New antihypertensive drug class.
Topics: Antihypertensive Agents; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone | 2003 |
Hypertension, angiotensin II, aldosterone, and race.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Antihypertensive Agents; Black People; Eplerenone; Humans; Hypertension; Losartan; Mineralocorticoid Receptor Antagonists; Renin; Renin-Angiotensin System; Spironolactone; Treatment Outcome; White People | 2003 |
Eplerenone (Inspra).
Topics: Diuresis; Dose-Response Relationship, Drug; Drug Interactions; Eplerenone; Fees, Pharmaceutical; Half-Life; Heart Failure; Humans; Hyperkalemia; Hypertension; Randomized Controlled Trials as Topic; Spironolactone | 2003 |
More hope for heart failure. Findings suggest expanded use of aldosterone-blockers.
Topics: Angiotensin-Converting Enzyme Inhibitors; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Randomized Controlled Trials as Topic; Spironolactone; Ventricular Remodeling | 2003 |
Aldosterone antagonism and hypertension.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Physiological Phenomena; Cardiovascular System; Drug Therapy, Combination; Eplerenone; Humans; Hypertension; Peptidyl-Dipeptidase A; Renin-Angiotensin System; Spironolactone; Treatment Outcome | 2003 |
Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice.
Topics: Aldosterone; Animals; Apolipoproteins E; Arteriosclerosis; Aryldialkylphosphatase; Blood Pressure; Eplerenone; Free Radical Scavengers; Lipid Peroxidation; Lipids; Macrophages, Peritoneal; Mice; Mineralocorticoid Receptor Antagonists; Oxidative Stress; Spironolactone; Superoxides; Time Factors | 2003 |
Aldosterone blockade in patients with acute myocardial infarction.
Topics: Acute Disease; Catecholamines; Collagen; Eplerenone; Heart Rate; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Randomized Controlled Trials as Topic; Spironolactone; Treatment Outcome; Ventricular Dysfunction; Ventricular Remodeling | 2003 |
Inhibition of platelet activation in congestive heart failure by aldosterone receptor antagonism and ACE inhibition.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cell Adhesion Molecules; Drug Therapy, Combination; Eplerenone; Fibrinogen; Heart Failure; Indoles; Male; Microfilament Proteins; Mineralocorticoid Receptor Antagonists; Nitric Oxide; P-Selectin; Phosphoproteins; Platelet Activation; Rats; Rats, Wistar; Renin-Angiotensin System; Spironolactone | 2003 |
Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Aldosterone; Animals; Blood Pressure; Cardiomegaly; Disease Models, Animal; Echocardiography; Eplerenone; Female; Fibrosis; Gene Expression Regulation; Gene Expression Regulation, Enzymologic; Heart Failure; Hydroxysteroid Dehydrogenases; Kidney; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mineralocorticoid Receptor Antagonists; Myocardium; Myocytes, Cardiac; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spironolactone; Up-Regulation; Ventricular Dysfunction, Left | 2003 |
Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial dysfunction.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta; Blotting, Western; Drug Therapy, Combination; Endothelium, Vascular; Eplerenone; Heart Failure; In Vitro Techniques; Indoles; Male; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Nitroprusside; Rats; Rats, Wistar; Spironolactone; Vasodilator Agents | 2003 |
Eplerenone in patients with left ventricular dysfunction.
Topics: Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Research Design; Spironolactone; Ventricular Dysfunction, Left | 2003 |
Eplerenone in patients with left ventricular dysfunction.
Topics: Death, Sudden, Cardiac; Eplerenone; Humans; Hypokalemia; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Spironolactone; Ventricular Dysfunction, Left | 2003 |
Eplerenone in patients with left ventricular dysfunction.
Topics: Contraindications; Creatinine; Eplerenone; Humans; Hyperkalemia; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Spironolactone; Ventricular Dysfunction, Left | 2003 |
Aldosterone blockade and vascular calcification in hemodialysis patients.
Topics: Administration, Oral; Animals; Calcinosis; Eplerenone; Humans; Kidney Failure, Chronic; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Osteopontin; Rats; Renal Dialysis; Sialoglycoproteins; Spironolactone; Vascular Diseases | 2003 |
Aldosterone blockade after myocardial infarction.
Topics: Double-Blind Method; Eplerenone; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Randomized Controlled Trials as Topic; Spironolactone; Treatment Outcome | 2003 |
Two better than one.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Animals; Class Ib Phosphatidylinositol 3-Kinase; Cognition Disorders; Contraindications; Drug Therapy, Combination; Enalapril; Eplerenone; Fibrinolytic Agents; Heart Failure; Humans; Hypertension; Hypertrophy, Left Ventricular; Isoenzymes; Mice; Mice, Knockout; Middle Aged; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Myocardial Reperfusion; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Receptors, Adrenergic, beta; Spironolactone | 2003 |
Pharmacokinetics and metabolism of [14C]eplerenone after oral administration to humans.
Topics: Administration, Oral; Adult; Carbon Radioisotopes; Eplerenone; Humans; Male; Middle Aged; Spironolactone | 2003 |
Ask the doctor. I am a 50-year-old man with congestive heart failure. My doctor has me on all the usual drugs, and a couple of years ago added spironolactone. I did okay with it for a while, but then began to notice that my breasts were getting bigger and
Topics: Diuretics; Eplerenone; Gynecomastia; Heart Failure; Humans; Male; Middle Aged; Spironolactone | 2003 |
[Which patient needs an aldosterone antagonist?].
Topics: Cardiovascular Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone | 2003 |
Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blotting, Western; Drug Synergism; Drug Therapy, Combination; Endothelium, Vascular; Eplerenone; Hemodynamics; Indoles; Male; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Nitric Oxide Synthase; Rats; Spironolactone; Ventricular Dysfunction, Left; Ventricular Remodeling | 2003 |
Aldosterone antagonism and myocardial infarction: from animals to man and back.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Drug Synergism; Drug Therapy, Combination; Eplerenone; Humans; Indoles; Mineralocorticoid Receptor Antagonists; Spironolactone; Ventricular Remodeling | 2003 |
Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration.
Topics: Animals; Dogs; Eplerenone; Glomerular Filtration Rate; Hemodynamics; Hormones; Hypertension; Mineralocorticoid Receptor Antagonists; Obesity; Sodium; Spironolactone | 2004 |
[Selective aldosterone blocking in heart failure. Eplerenone reduces the risk after infarction].
Topics: Controlled Clinical Trials as Topic; Death, Sudden, Cardiac; Diuretics; Double-Blind Method; Eplerenone; Female; Follow-Up Studies; Heart Failure; Humans; Male; Mineralocorticoid Receptor Antagonists; Multicenter Studies as Topic; Myocardial Infarction; Placebos; Prospective Studies; Retrospective Studies; Risk Factors; Spironolactone; Time Factors; Ventricular Dysfunction, Left | 2003 |
[Aldosterone receptor antagonists in heart failure. Rightly brought back from retirement].
Topics: Aldosterone; Clinical Trials as Topic; Eplerenone; Germany; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Survival Rate; Treatment Outcome; Ventricular Dysfunction, Left | 2003 |
Aldosterone antagonism and arterial stiffness.
Topics: Animals; Antihypertensive Agents; Arteries; Compliance; Eplerenone; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Pulsatile Flow; Rats; Spironolactone | 2004 |
Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats.
Topics: Aldosterone; Animals; Cyclic N-Oxides; Eplerenone; Hypertension; JNK Mitogen-Activated Protein Kinases; Kidney Cortex; Male; MAP Kinase Signaling System; Membrane Transport Proteins; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinase 7; Mitogen-Activated Protein Kinases; NADPH Dehydrogenase; NADPH Oxidase 4; NADPH Oxidases; Oxidative Stress; Phosphoproteins; Proteinuria; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Sodium Chloride; Spin Labels; Spironolactone | 2004 |
Role of a selective aldosterone blocker in mice with chronic heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiac Output; Collagen; Disease Models, Animal; Drug Therapy, Combination; Echocardiography; Eplerenone; Heart Failure; Mice; Mice, Inbred C57BL; Mineralocorticoid Receptor Antagonists; Muscle Cells; Myocardial Infarction; Spironolactone; Stroke Volume; Treatment Outcome; Ventricular Remodeling | 2004 |
The European Society of Cardiology working group on heart failure: Heart Failure Update 2003.
Topics: Carbazoles; Cardiac Pacing, Artificial; Carvedilol; Eplerenone; Europe; Heart Failure; Humans; Metoprolol; Myocardial Infarction; Prognosis; Propanolamines; Spironolactone; Tumor Necrosis Factor-alpha; Uric Acid | 2003 |
Eplerenone (Inspra) for hypertension.
Topics: Diuretics; Eplerenone; Humans; Hypertension; Spironolactone | 2004 |
The resurrection of spironolactone on its golden anniversary.
Topics: Aged; Eplerenone; Female; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Water-Electrolyte Balance | 2004 |
Eplerenone, but not steroid withdrawal, reverses cardiac fibrosis in deoxycorticosterone/salt-treated rats.
Topics: Animals; Biomarkers; Coronary Vessels; Desoxycorticosterone; Eplerenone; Fibrosis; Male; Mineralocorticoid Receptor Antagonists; Myocardium; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Sodium Chloride, Dietary; Spironolactone; Vasculitis | 2004 |
Avoid the risks of mixed medications. How to minimize dangerous interactions with cardiovascular drugs.
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Agents; Drug Interactions; Eplerenone; Ezetimibe; Fluorobenzenes; Humans; Polypharmacy; Pyrimidines; Rosuvastatin Calcium; Spironolactone; Sulfonamides | 2003 |
Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats.
Topics: Acetylcholine; Aldosterone; Animals; Antihypertensive Agents; Antioxidants; Blood Pressure; Collagen; Dose-Response Relationship, Drug; Endothelium, Vascular; Eplerenone; Fibrosis; Heart; Hydralazine; Hypertension; Male; Mesenteric Arteries; Mineralocorticoid Receptor Antagonists; Myocardium; Natriuresis; Organ Size; Rats; Rats, Inbred SHR; Receptors, Mineralocorticoid; Sodium Chloride, Dietary; Spironolactone; Thiobarbituric Acid Reactive Substances; Tunica Media; Vasodilation | 2004 |
Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Aortic Diseases; Apolipoproteins E; Arteriosclerosis; Cell Line; Enzyme Induction; Eplerenone; Hormone Antagonists; Humans; Lipid Peroxidation; Lipoproteins, LDL; Losartan; Macrophages, Peritoneal; Membrane Proteins; Mice; Mice, Knockout; Mineralocorticoid Receptor Antagonists; NADPH Oxidases; Oxidative Stress; Peptidyl-Dipeptidase A; Phosphoproteins; Protein Transport; Ramipril; Receptor, Angiotensin, Type 1; Receptors, Mineralocorticoid; RNA, Messenger; Spironolactone; Superoxides | 2004 |
Role of osteopontin in cardiac fibrosis and remodeling in angiotensin II-induced cardiac hypertrophy.
Topics: Aldosterone; Angiotensin II; Animals; Apoptosis; Blood Pressure; Cardiomegaly; Cell Size; Eplerenone; Fibrosis; Heart Rate; Hypertrophy, Left Ventricular; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardium; Myocytes, Cardiac; Osteopontin; Reverse Transcriptase Polymerase Chain Reaction; Sialoglycoproteins; Spironolactone; Ultrasonography; Ventricular Remodeling | 2004 |
The discovery, isolation and identification of aldosterone: reflections on emerging regulation and function.
Topics: Aldosterone; Angiotensins; Biological Assay; Clinical Trials as Topic; Eplerenone; History, 20th Century; Humans; Proteins; Spironolactone; Technology, Pharmaceutical | 2004 |
The evolution of aldosterone antagonists.
Topics: Aldosterone; Animals; Cardiovascular Diseases; Clinical Trials as Topic; Eplerenone; Gynecomastia; History, 20th Century; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone | 2004 |
[Primary prevention of sudden cardiac death].
Topics: Clinical Trials as Topic; Death, Sudden, Cardiac; Eplerenone; Humans; Placebos; Primary Prevention; Spironolactone; Time Factors | 2004 |
Role of aldosterone blockade in managing heart failure: new and emerging treatment options. Introduction.
Topics: Aged; Eplerenone; Female; Heart Failure; Humans; Incidence; Male; Mineralocorticoid Receptor Antagonists; Spironolactone; United States | 2004 |
Ask the doctors. I read about a new drug for heart failure called eplerenone. How does it work? Is it safe?
Topics: Contraindications; Diuretics; Drug Interactions; Eplerenone; Heart Failure; Humans; Spironolactone | 2004 |
Prediction of in vivo drug interactions with eplerenone in man from in vitro metabolic inhibition data.
Topics: Drug Antagonism; Eplerenone; Humans; Hydroxylation; In Vitro Techniques; Microsomes, Liver; Pharmaceutical Preparations; Pharmacokinetics; Spironolactone | 2004 |
Aldosterone-receptor antagonism and end-stage renal disease.
Topics: Eplerenone; Heart; Homeostasis; Humans; Kidney; Kidney Failure, Chronic; Mineralocorticoid Receptor Antagonists; Peritoneal Dialysis; Renal Dialysis; Spironolactone | 2004 |
Effects of eplerenone, a selective aldosterone blocker, on the progression of left ventricular dysfunction and remodeling in rats with dilated cardiomyopathy.
Topics: Animals; Autoimmune Diseases; Cardiomyopathy, Dilated; Collagen Type III; Dose-Response Relationship, Drug; Electrocardiography; Eplerenone; Fibrosis; Hemodynamics; Male; Mineralocorticoid Receptor Antagonists; Myocarditis; Myocardium; Rats; Rats, Inbred Lew; RNA, Messenger; Spironolactone; Transforming Growth Factor beta; Ventricular Dysfunction, Left; Ventricular Remodeling | 2005 |
Eplerenone, a selective aldosterone blocker, improves diastolic function in aged rats with small-to-moderate myocardial infarction.
Topics: Analysis of Variance; Animals; Aorta; Diastole; Echocardiography; Eplerenone; Hemodynamics; Kidney; Male; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Myocardium; Rats; Rats, Wistar; Spironolactone; Treatment Outcome; Ventricular Function, Left | 2004 |
Eplerenone blocks nongenomic effects of aldosterone on the Na+/H+ exchanger, intracellular Ca2+ levels, and vasoconstriction in mesenteric resistance vessels.
Topics: Aldosterone; Androstadienes; Animals; Blotting, Western; Calcium; Chromones; Enzyme Inhibitors; Eplerenone; Flavonoids; Hydrogen-Ion Concentration; Indoles; Male; Maleimides; Mesenteric Arteries; Mineralocorticoid Receptor Antagonists; Morpholines; p38 Mitogen-Activated Protein Kinases; Phenylephrine; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase C; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Sodium-Hydrogen Exchanger 1; Sodium-Hydrogen Exchangers; Spironolactone; Time Factors; Vasoconstriction; Wortmannin | 2005 |
Differences in the determinants of eplerenone, spironolactone and aldosterone binding to the mineralocorticoid receptor.
Topics: Aldosterone; Animals; Chlorocebus aethiops; COS Cells; Crystallization; Eplerenone; Kinetics; Ligands; Mineralocorticoid Receptor Antagonists; Models, Molecular; Receptors, Glucocorticoid; Receptors, Mineralocorticoid; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; Spironolactone | 2004 |
[Therapy of heart failure after myocardial infarction. With eplerenone a new course].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diuretics; Drug Therapy, Combination; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Placebos; Prognosis; Randomized Controlled Trials as Topic; Spironolactone; Time Factors | 2004 |
[More benefit in hypertension and high-grade reduction of the pump performance. Earlier beginning of therapy maximizes the benefit].
Topics: Controlled Clinical Trials as Topic; Diuretics; Eplerenone; Heart Failure; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Placebos; Spironolactone; Stroke Volume; Time Factors | 2004 |
Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload.
Topics: Animals; Aorta; Apoptosis; Blood Pressure; Cell Size; Chronic Disease; Constriction, Pathologic; Drug Evaluation, Preclinical; Eplerenone; Fibrosis; Heart Failure; Hypertrophy, Left Ventricular; Intercellular Adhesion Molecule-1; Ligation; Male; Matrix Metalloproteinases; Mice; Mineralocorticoid Receptor Antagonists; Myocarditis; Myocardium; Myocytes, Cardiac; Oxidative Stress; Pressure; Random Allocation; Receptors, Mineralocorticoid; Spironolactone; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2; Tyrosine | 2005 |
Management of heart failure and left ventricular systolic dysfunction following acute myocardial infarction.
Topics: Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Spironolactone; Ventricular Dysfunction, Left | 2005 |
Eplerenone shows renoprotective effect by reducing LOX-1-mediated adhesion molecule, PKCepsilon-MAPK-p90RSK, and Rho-kinase pathway.
Topics: Animals; Cell Adhesion Molecules; Cytoprotection; Eplerenone; Glomerulosclerosis, Focal Segmental; Hypertension; Intracellular Signaling Peptides and Proteins; Kidney; Male; Mineralocorticoid Receptor Antagonists; Mitogen-Activated Protein Kinases; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Protein Kinase C; Protein Kinase C-epsilon; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteinuria; Rats; Rats, Inbred Dahl; Receptors, LDL; Receptors, Oxidized LDL; rho-Associated Kinases; Ribosomal Protein S6 Kinases, 90-kDa; RNA, Messenger; Scavenger Receptors, Class E; Spironolactone | 2005 |
The ligand-dependent interaction of mineralocorticoid receptor with coactivator and corepressor peptides suggests multiple activation mechanisms.
Topics: Aldosterone; Amino Acid Motifs; Amino Acid Sequence; Cell Line; Cells, Cultured; Dose-Response Relationship, Drug; Eplerenone; Fluorescence Resonance Energy Transfer; Gene Expression Regulation; Glucocorticoids; Humans; Hydrocortisone; Ligands; Models, Biological; Molecular Sequence Data; Mutation; Peptides; Protein Binding; Protein Conformation; Protein Structure, Tertiary; Receptors, Mineralocorticoid; Sequence Homology, Amino Acid; Spironolactone; Transcription, Genetic; Transfection | 2005 |
Implantable cardioverter-defibrillator therapy after myocardial infarction.
Topics: Arrhythmias, Cardiac; Defibrillators, Implantable; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Spironolactone; Stroke Volume | 2005 |
[Aldosterone and aldosterone antagonists. Eplerenone in cardiac insufficiency after myocardial infarction].
Topics: Aldosterone; Cardiac Output, Low; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Spironolactone | 2005 |
Effects of eplerenone on transcriptional factors and mRNA expression related to cardiac remodelling after myocardial infarction.
Topics: Animals; Blood Pressure; Blotting, Northern; Body Weight; Coronary Vessels; Echocardiography, Doppler; Eplerenone; Heart; Heart Ventricles; Ligation; Male; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Organ Size; Random Allocation; Rats; Rats, Wistar; RNA, Messenger; Spironolactone; Transcription Factors; Ventricular Remodeling | 2005 |
Participation of aldosterone in the vascular inflammatory response of spontaneously hypertensive rats: role of the NFkappaB/IkappaB system.
Topics: Aldosterone; Animals; Antihypertensive Agents; Drug Therapy, Combination; Eplerenone; Hypertension; I-kappa B Proteins; Interleukin-1; Interleukin-6; Male; Mineralocorticoid Receptor Antagonists; NF-kappa B; Rats; Rats, Inbred SHR; Rats, Inbred WKY; RNA, Messenger; Spironolactone; Tumor Necrosis Factor-alpha; Vasculitis | 2005 |
Additive amelioration of left ventricular remodeling and molecular alterations by combined aldosterone and angiotensin receptor blockade after myocardial infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Blotting, Western; Collagen Type I; Eplerenone; Heart Failure; Hemodynamics; Irbesartan; Male; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Myocardium; Rats; Rats, Wistar; Spironolactone; Tetrazoles; Ventricular Remodeling | 2005 |
Eplerenone suppresses neointimal formation after coronary stent implantation in swine.
Topics: Actins; Administration, Oral; Animals; Blood Vessel Prosthesis Implantation; Collagen Type I; Collagen Type III; Coronary Restenosis; Coronary Vessels; Disease Models, Animal; Eplerenone; Fibrosis; Hyperplasia; Immunohistochemistry; Macrophages; Male; Mineralocorticoid Receptor Antagonists; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spironolactone; Stents; Swine; Time Factors; Transforming Growth Factor beta; Tunica Intima | 2006 |
[Heart failure after acute myocardial infarct. Early aldosterone blockade increases survival rate].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Prognosis; Spironolactone; Ventricular Dysfunction, Left | 2005 |
[Neurohumoral systems escape control. Heart failure symptoms even once--long-term high risk prognosis].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Eplerenone; Heart Failure; Humans; Myocardial Infarction; Neurotransmitter Agents; Prognosis; Spironolactone; Stroke Volume; Ventricular Dysfunction, Left | 2005 |
Letter regarding article by Weintraub et al, "Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure".
Topics: Cost-Benefit Analysis; Drug Costs; Eplerenone; Health Care Costs; Humans; Myocardial Infarction; Placebos; Spironolactone; Ventricular Dysfunction, Left | 2005 |
Aldosterone stimulates vascular smooth muscle cell proliferation via big mitogen-activated protein kinase 1 activation.
Topics: 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt; Aldosterone; Animals; Calcium-Calmodulin-Dependent Protein Kinases; Cell Proliferation; Cells, Cultured; Cycloheximide; Enzyme Activation; Eplerenone; Flavonoids; Genes, Dominant; MAP Kinase Kinase 5; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinase 7; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Protein Synthesis Inhibitors; Rats; Receptors, Mineralocorticoid; Spironolactone; Transfection | 2005 |
Heart failure after acute ST-segment elevation myocardial infarction: what should we do about it?
Topics: Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Patient Selection; Prognosis; Risk Assessment; Spironolactone | 2005 |
Sudden death in patients with myocardial infarction.
Topics: Death, Sudden, Cardiac; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Risk; Spironolactone; Stroke Volume; Time Factors; Ventricular Dysfunction, Left | 2005 |
Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients.
Topics: Adult; Aged; Aldosterone; Angiotensin-Converting Enzyme 2; Animals; Carboxypeptidases; Eplerenone; Heart Failure; Humans; Macrophages; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Middle Aged; Mineralocorticoid Receptor Antagonists; NADPH Oxidases; Oxidative Stress; Peptidyl-Dipeptidase A; Renin-Angiotensin System; Spironolactone | 2005 |
Eplerenone inhibits atherosclerosis in nonhuman primates.
Topics: Acetylcholine; Animals; Aorta; Atherosclerosis; Carotid Arteries; Chemokine CCL2; Cholesterol, Dietary; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Eplerenone; Lipid Metabolism; Lipoproteins, LDL; Macaca fascicularis; Male; Malondialdehyde; Peptidyl-Dipeptidase A; Renin; Spironolactone; Tunica Intima; Ultrasonography; Vasodilation | 2005 |
Beneficial cardiovascular actions of eplerenone in the spontaneously hypertensive rat.
Topics: Animals; Blood Pressure; Coronary Circulation; Eplerenone; Hypertension; Lisinopril; Male; Rats; Rats, Inbred SHR; Spironolactone; Vascular Resistance | 2005 |
Eplerenone antagonizes atherosclerosis, but what is the agonist?
Topics: Aldosterone; Animals; Atherosclerosis; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Receptors, Mineralocorticoid; Spironolactone | 2005 |
Mechanisms for nongenomic and genomic effects of aldosterone on Na+/H+ exchange in vascular smooth muscle cells.
Topics: Aldosterone; Amiloride; Animals; Cells, Cultured; Eplerenone; Fluorescent Dyes; Genome; Hydrogen-Ion Concentration; Ion Transport; Kinetics; Mineralocorticoid Receptor Antagonists; Muscle, Smooth, Vascular; Rats; Sodium-Hydrogen Exchangers; Spironolactone | 2005 |
Direct effects of aldosterone on cardiomyocytes in the presence of normal and elevated extracellular sodium.
Topics: Aldosterone; Amides; Animals; Benzofurans; Cells, Cultured; Eplerenone; Hemodynamics; Hypertrophy; Indoles; Leucine; Mineralocorticoid Receptor Antagonists; Myocytes, Cardiac; Phthalic Acids; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; Sodium; Sodium-Hydrogen Exchangers; Spironolactone; Time Factors | 2006 |
[Heart failure after myocardial infarction. Increased risk, poorer treatment].
Topics: Clinical Trials as Topic; Drug Therapy, Combination; Eplerenone; Heart Failure; Hospital Mortality; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Spironolactone; Survival Rate | 2005 |
[Efficient improvement of prognosis after myocardial infarct? Additional aldosterone inhibition is required].
Topics: Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Drug Therapy, Combination; Eplerenone; Germany; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Prognosis; Spironolactone; Survival Rate | 2005 |
Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation.
Topics: Aldosterone; Animals; Aorta; Atherosclerosis; Blood Pressure; Cells, Cultured; Chemokine CCL2; Cholesterol, Dietary; Diet, Atherogenic; Enzyme Activation; Eplerenone; Inflammation; Male; Mice; Muscle, Smooth, Vascular; NADPH Oxidases; Oxidative Stress; Spironolactone; Superoxides; Tetrazoles; Tumor Necrosis Factor-alpha; Valine; Valsartan | 2006 |
Cardioprotective effects of eplerenone in the rat heart: interaction with locally synthesized or blood-derived aldosterone?
Topics: Aldosterone; Animals; Cardiotonic Agents; Drug Interactions; Eplerenone; Heart; Hemodynamics; In Vitro Techniques; Kinetics; Male; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Myocardial Ischemia; Myocardium; Rats; Rats, Wistar; Spironolactone | 2006 |
Protective effect of spironolactone on endothelial cell apoptosis.
Topics: Aldosterone; Apoptosis; Blotting, Western; Caspase 3; Caspases; Cell Nucleus; Cell Survival; Cells, Cultured; Cytochromes c; Cytosol; Dexamethasone; Dihydrotestosterone; Endothelial Cells; Enzyme Activation; Eplerenone; Humans; Hydrocortisone; Mineralocorticoid Receptor Antagonists; Mitochondria; Nitric Oxide; Nitric Oxide Synthase; Poly(ADP-ribose) Polymerases; Receptors, Progesterone; Spironolactone; Time Factors; Umbilical Veins | 2006 |
Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats.
Topics: Aldosterone; Animals; Cardiac Output, Low; Cardiomegaly; Cardiotonic Agents; Coronary Vessels; Corticosterone; Echocardiography; Eplerenone; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Myocardium; Osmolar Concentration; Oxidative Stress; Peptidyl-Dipeptidase A; Rats; Rats, Inbred Dahl; Receptor, Angiotensin, Type 1; Receptors, Mineralocorticoid; Renin; RNA, Messenger; Spironolactone; Vasculitis; Ventricular Function; Ventricular Remodeling | 2006 |
Mineralocorticoid receptors and cardiovascular damage: it's not just aldosterone.
Topics: Aldosterone; Animals; Cardiac Output, Low; Cardiomegaly; Cardiotonic Agents; Corticosterone; Eplerenone; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Receptors, Mineralocorticoid; Renin; Spironolactone; Ultrasonography | 2006 |
Cardioprotective mechanisms of eplerenone on cardiac performance and remodeling in failing rat hearts.
Topics: Animals; Cardiac Output, Low; Cardiotonic Agents; Drug Interactions; Echocardiography; Elasticity; Eplerenone; Heart; Male; Mineralocorticoid Receptor Antagonists; Mitogen-Activated Protein Kinases; Myocardial Contraction; Myocardium; NADPH Oxidases; NF-kappa B; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Oxidative Stress; Proto-Oncogene Proteins c-akt; Rats; Rats, Inbred Dahl; Scavenger Receptors, Class E; Spironolactone; Superoxides; Systole; Ventricular Remodeling | 2006 |
Effects of enalapril, tempol, and eplerenone on salt-induced hypertension in dahl salt-sensitive rats.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antioxidants; Blood Pressure; Cyclic N-Oxides; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Enalapril; Eplerenone; Epoprostenol; Hypertension; Male; Nitric Oxide; Oxidative Stress; Rats; Rats, Inbred Dahl; Sodium Chloride; Spin Labels; Spironolactone; Treatment Outcome | 2006 |
Hypertension and ethnic group: eplerenone may have role in hypertension related atrial fibrillation.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Atrial Fibrillation; Black People; Eplerenone; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Spironolactone | 2006 |
Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker.
Topics: Animals; Apoptosis; Biomarkers; Blood Pressure; Eplerenone; Fibrosis; Glomerulosclerosis, Focal Segmental; Hydralazine; Hypertension; Kidney; Male; Microscopy, Electron; Mineralocorticoid Receptor Antagonists; Nephritis; Oxidative Stress; Podocytes; Proteinuria; Rats; Rats, Inbred Dahl; Spironolactone; Time Factors | 2006 |
Eplerenone offsets cardiac and aortic adverse remodeling in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Aorta; Enalapril; Eplerenone; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Rats; Rats, Inbred SHR; Rats, Wistar; Spironolactone; Ventricular Remodeling | 2007 |
A new approach to the furan degradation problem involving ozonolysis of the trans-enedione and its use in a cost-effective synthesis of eplerenone.
Topics: Catalysis; Eplerenone; Furans; Molecular Structure; Ozone; Spironolactone; Stereoisomerism | 2006 |
Selective aldosterone blockade suppresses atrial tachyarrhythmias in heart failure.
Topics: Administration, Oral; Animals; Dogs; Eplerenone; Heart Atria; Heart Conduction System; Heart Failure; Mineralocorticoid Receptor Antagonists; Random Allocation; Spironolactone; Tachycardia; Treatment Outcome; Ventricular Dysfunction, Left | 2006 |
Aldosterone antagonism as an antiarrhythmic approach for atrial arrhythmias in heart failure.
Topics: Administration, Oral; Animals; Dogs; Eplerenone; Heart Atria; Heart Conduction System; Heart Failure; Mineralocorticoid Receptor Antagonists; Random Allocation; Spironolactone; Tachycardia; Treatment Outcome; Ventricular Dysfunction, Left | 2006 |
The antagonism of aldosterone receptor prevents the development of hypertensive heart failure induced by chronic inhibition of nitric oxide synthesis in rats.
Topics: Actins; Aldosterone; Animals; Blotting, Western; Cytochrome P-450 CYP11B2; Drug Therapy, Combination; Eplerenone; Fibrosis; Heart Failure; Heart Ventricles; Hypertension; Immunohistochemistry; Male; Mineralocorticoid Receptor Antagonists; NF-kappa B; NG-Nitroarginine Methyl Ester; Nitric Oxide; Peptide Fragments; Proliferating Cell Nuclear Antigen; Protein Precursors; Random Allocation; Rats; Rats, Inbred WKY; Receptors, Mineralocorticoid; RNA, Messenger; Spironolactone; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2006 |
Eplerenone inhibits tumour necrosis factor alpha shedding process by tumour necrosis factor alpha converting enzyme in monocytes from patients with congestive heart failure.
Topics: ADAM Proteins; ADAM17 Protein; Dose-Response Relationship, Drug; Eplerenone; Heart Failure; Humans; Monocytes; Spironolactone; Tumor Necrosis Factor-alpha | 2006 |
Eplerenone suppresses neointima after coronary stenting in pigs: could it be extrapolated to stent restenosis in humans?
Topics: Angioplasty, Balloon, Coronary; Animals; Collagen; Coronary Restenosis; Disease Models, Animal; Eplerenone; Humans; Hyperplasia; Mineralocorticoid Receptor Antagonists; Spironolactone; Stents; Swine; Tunica Intima | 2007 |
[Combination drug therapy after myocardial infarction. Early aldosterone blocking protects risk patients].
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Drug Therapy, Combination; Eplerenone; Humans; Hypolipidemic Agents; Myocardial Infarction; Placebos; Randomized Controlled Trials as Topic; Risk Factors; Spironolactone; Time Factors | 2006 |
Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus.
Topics: Albuminuria; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Eplerenone; Hypertrophy; Kidney; Male; Mice; Mice, Inbred C57BL; Mineralocorticoid Receptor Antagonists; Osteopontin; Rats; Rats, Wistar; Receptors, Mineralocorticoid; RNA, Messenger; Spironolactone; Streptozocin; Systole | 2006 |
Long-term mineralocorticoid receptor blockade reduces fibrosis and improves cardiac performance and coronary hemodynamics in elderly SHR.
Topics: Animals; Blood Pressure; Coronary Circulation; Eplerenone; Fibrosis; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Myocardium; Rats; Rats, Inbred SHR; Spironolactone; Time Factors; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left | 2007 |
Eplerenone prevents adverse cardiac remodelling induced by pressure overload in atrial natriuretic peptide-null mice.
Topics: Aldosterone; Animals; Atrial Natriuretic Factor; Blood Pressure; Cardiomegaly; Eplerenone; Heart; Hypertrophy; Male; Mice; Mice, Knockout; Myocardium; Spironolactone; Ventricular Remodeling | 2006 |
Mineralocorticoid-receptor blockade, hypertension and heart failure.
Topics: Aldosterone; Clinical Trials as Topic; Eplerenone; Heart Failure; Hormone Antagonists; Humans; Hyperkalemia; Hypertension; Mineralocorticoid Receptor Antagonists; Spironolactone | 2005 |
Novel effect of mineralocorticoid receptor antagonism to reduce proinflammatory cytokines and hypothalamic activation in rats with ischemia-induced heart failure.
Topics: Animals; Cytokines; Drug Synergism; Echocardiography; Eplerenone; Etanercept; Heart Failure; Hypothalamus; Immunoglobulin G; Inflammation Mediators; Male; Mineralocorticoid Receptor Antagonists; Myocardial Ischemia; Pertussis Toxin; Rats; Rats, Sprague-Dawley; Receptors, Tumor Necrosis Factor; Spironolactone | 2006 |
Rapid effects of aldosterone on clonal human vascular smooth muscle cells.
Topics: Aldosterone; Aorta, Thoracic; Cell Line; Clone Cells; Eplerenone; Estradiol; Humans; Hydrocortisone; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Myosin Light Chains; Phosphatidylinositol 3-Kinases; Phosphorylation; Signal Transduction; Spironolactone; Vasoconstriction; Vasoconstrictor Agents | 2007 |
Eplerenone relieves spironolactone-induced painful gynaecomastia in a patient with primary aldosteronism.
Topics: Administration, Oral; Aldosterone; Clinical Trials as Topic; Eplerenone; Gynecomastia; Humans; Hyperaldosteronism; Hypertension; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Renin; Sex Factors; Spironolactone | 2007 |
[Antihypertensive agents used as first line agents: beta-blockers under pressure].
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Dihydropyridines; Diuretics; Drug Therapy, Combination; Eplerenone; Humans; Hypertension; Spironolactone; Treatment Outcome | 2006 |
Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: Beneficial effects of mineralocorticoid receptor blocker.
Topics: Aldosterone; Angiotensin II; Animals; Blotting, Western; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP11B2; Diastole; Eplerenone; Heart Failure; Heart Ventricles; Male; Mass Spectrometry; Mineralocorticoid Receptor Antagonists; Myocardial Contraction; Myocardium; Rats; Rats, Inbred Dahl; Receptors, Mineralocorticoid; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spironolactone; Steroids; Stroke Volume; Ventricular Function, Left | 2007 |
[Cardioverter-defibrillator (ICD) and resynchronization in every patient with cardiac failure].
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Death, Sudden, Cardiac; Defibrillators, Implantable; Drug Therapy, Combination; Eplerenone; Evidence-Based Medicine; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Prospective Studies; Randomized Controlled Trials as Topic; Risk Factors; Spironolactone; Stem Cell Transplantation; Time Factors; Treatment Outcome | 2006 |
Antiangiogenic effects of spironolactone and other potassium-sparing diuretics in human umbilical vein endothelial cells and in fibrin gel chambers implanted in rats.
Topics: Amiloride; Angiogenesis Inhibitors; Animals; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Endothelial Cells; Eplerenone; Fibrin; Humans; Male; Neovascularization, Physiologic; Rats; Rats, Wistar; Sodium Channel Blockers; Spironolactone; Umbilical Veins | 2006 |
Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors.
Topics: Adipocytes; Adrenal Glands; Aldosterone; Animals; Cyclic N-Oxides; Disease Models, Animal; Eplerenone; Immediate-Early Proteins; Kidney Failure, Chronic; Male; Metabolic Syndrome; Mineralocorticoid Receptor Antagonists; Obesity; Podocytes; Protein Serine-Threonine Kinases; Protein Synthesis Inhibitors; Proteinuria; Rats; Rats, Inbred SHR; Receptors, Mineralocorticoid; RNA, Messenger; Spin Labels; Spironolactone | 2006 |
Differences between cardiac and arterial fibrosis and stiffness in aldosterone-salt rats: effect of eplerenone.
Topics: Animals; Aorta; Blood Pressure; Blotting, Northern; Carotid Artery Diseases; Collagen; Eplerenone; Fibrosis; Heart Diseases; Hypertension; Immunohistochemistry; Male; Mineralocorticoid Receptor Antagonists; Myocardium; Rats; Rats, Sprague-Dawley; RNA, Messenger; Spironolactone; Structure-Activity Relationship; Vascular Diseases | 2006 |
Beneficial effect of eplerenone on cardiac remodelling and electrical properties of the failing heart.
Topics: Animals; Cell Separation; Cricetinae; Electrocardiography; Electrophysiology; Eplerenone; Heart Conduction System; Heart Failure; Membrane Potentials; Myocardium; Sodium-Potassium-Exchanging ATPase; Spironolactone; Ventricular Remodeling | 2006 |
Effects of eplerenone and salt intake on left ventricular remodeling after myocardial infarction in rats.
Topics: Aldosterone; Animals; Cardiomegaly; Diet, Sodium-Restricted; Echocardiography; Eplerenone; Fibrosis; Food-Drug Interactions; Heart; Male; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Rats; Rats, Wistar; Sodium Chloride; Spironolactone; Ventricular Remodeling | 2006 |
Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1.
Topics: Aldosterone; Animals; Antihypertensive Agents; Antioxidants; Blood Pressure; Cells, Cultured; Cyclic N-Oxides; Enzyme Activation; Eplerenone; Hydralazine; Immediate-Early Proteins; Infusion Pumps; Kidney; Mineralocorticoid Receptor Antagonists; NADPH Oxidases; Nephrectomy; Oxidative Stress; Podocytes; Protein Serine-Threonine Kinases; Proteinuria; Rats; Rats, Sprague-Dawley; Receptors, Mineralocorticoid; Spin Labels; Spironolactone; Time Factors; Up-Regulation | 2007 |
Angiotensin II receptor type 1-mediated vascular oxidative stress and proinflammatory gene expression in aldosterone-induced hypertension: the possible role of local renin-angiotensin system.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; Blood Vessels; Cyclic N-Oxides; Eplerenone; Gene Expression Regulation; Hypertension; Inflammation Mediators; Male; Models, Biological; Oxidative Stress; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Spin Labels; Spironolactone; Tetrazoles | 2007 |
Increased cyclooxygenase-2 expression in hypothalamic paraventricular nucleus in rats with heart failure: role of nuclear factor kappaB.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Cyclooxygenase 2; Cytokines; Disease Models, Animal; Eplerenone; Heart Failure; Male; NF-kappa B; Paraventricular Hypothalamic Nucleus; Pyrrolidines; Rats; Rats, Sprague-Dawley; Spironolactone; Thiocarbamates | 2007 |
Antagonistic effects of bone morphogenetic protein-4 and -7 on renal mesangial cell proliferation induced by aldosterone through MAPK activation.
Topics: Aldosterone; Animals; Bone Morphogenetic Protein 4; Bone Morphogenetic Protein 7; Bone Morphogenetic Protein Receptors, Type I; Bone Morphogenetic Proteins; Cell Line; Cell Proliferation; Enzyme Activation; Eplerenone; Extracellular Signal-Regulated MAP Kinases; JNK Mitogen-Activated Protein Kinases; Mesangial Cells; Mice; Mineralocorticoid Receptor Antagonists; Mitogen-Activated Protein Kinases; Mitosis; Phosphorylation; Signal Transduction; Smad6 Protein; Spironolactone; Transforming Growth Factor beta | 2007 |
A German family with glucocorticoid-remediable aldosteronism.
Topics: Adolescent; Aldosterone; Algorithms; Blood Pressure; Dexamethasone; Eplerenone; Female; Germany; Glucocorticoids; Humans; Hydrocortisone; Hyperaldosteronism; Male; Middle Aged; Molecular Sequence Data; Pedigree; Sodium; Spironolactone; Steroid 11-beta-Hydroxylase | 2007 |
Interactions between aldosterone and connective tissue growth factor in vascular and renal damage in spontaneously hypertensive rats.
Topics: Aldosterone; Animals; Aorta; Blood Pressure; Blood Pressure Determination; Cells, Cultured; Connective Tissue Growth Factor; Eplerenone; Hypertension; Immediate-Early Proteins; Immunohistochemistry; Intercellular Signaling Peptides and Proteins; Kidney Glomerulus; Kidney Tubules; Male; Mineralocorticoid Receptor Antagonists; Muscle, Smooth, Vascular; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Spironolactone; Up-Regulation | 2007 |
Dose-dependent endothelial cell growth and stiffening by aldosterone: endothelial protection by eplerenone.
Topics: Aldosterone; Cell Enlargement; Cell Line; Cells, Cultured; Coronary Vessels; Dose-Response Relationship, Drug; Elasticity; Endothelial Cells; Eplerenone; Humans; In Vitro Techniques; Microscopy, Atomic Force; Mineralocorticoid Receptor Antagonists; Spironolactone | 2007 |
Treatment of heart failure with ACE inhibitors and beta-blockers: what is next? Aldosterone receptor antagonists?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiac Output, Low; Chronic Disease; Death, Sudden, Cardiac; Drug Therapy, Combination; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Renin-Angiotensin System; Spironolactone; Treatment Outcome | 2007 |
Dual blockade of aldosterone and angiotensin II additively suppresses TGF-beta and NADPH oxidase in the hypertensive kidney.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiac Output, Low; Drug Synergism; Eplerenone; Hypertension; Indoles; Kidney; Male; Mineralocorticoid Receptor Antagonists; NADPH Oxidases; Oxidative Stress; Rats; Rats, Inbred Dahl; Reactive Oxygen Species; Sodium-Potassium-Exchanging ATPase; Spironolactone; Superoxide Dismutase; Transforming Growth Factor beta | 2007 |
Primary percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Platelet Aggregation Inhibitors; Spironolactone; Ticlopidine | 2007 |
Willingness to pay for a reduction in mortality risk after a myocardial infarction: an application of the contingent valuation method to the case of eplerenone.
Topics: Attitude to Health; Cost-Benefit Analysis; Eplerenone; Female; Financing, Personal; Focus Groups; Health Care Surveys; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Risk Reduction Behavior; Spain; Spironolactone | 2008 |
Pretreatment with eplerenone reduces stroke volume in mouse middle cerebral artery occlusion model.
Topics: Animals; Blood Pressure; Brain Ischemia; Disease Models, Animal; Eplerenone; Infarction, Middle Cerebral Artery; Male; Mice; Mice, Inbred C57BL; Mineralocorticoid Receptor Antagonists; Spironolactone; Stroke Volume; Superoxides | 2007 |
Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS.
Topics: Aged; Clinical Trials as Topic; Diabetes Complications; Eplerenone; Female; Heart Failure; Humans; Hyperkalemia; Hyperuricemia; Hypokalemia; Male; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Prognosis; Retrospective Studies; Risk Factors; Spironolactone; Treatment Outcome; Ventricular Dysfunction, Left | 2008 |
[Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study].
Topics: Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Spironolactone | 2007 |
Eplerenone attenuates myocardial fibrosis in the angiotensin II-induced hypertensive mouse: involvement of tenascin-C induced by aldosterone-mediated inflammation.
Topics: Aldosterone; Analysis of Variance; Angiotensin II; Animals; Blood Pressure; Body Weight; Cytokines; Disease Models, Animal; Eplerenone; Female; Fibroblasts; Fibrosis; Hypertension; Immunohistochemistry; In Situ Hybridization; Inflammation Mediators; Intercellular Signaling Peptides and Proteins; Macrophages; Mice; Mice, Inbred BALB C; Mineralocorticoid Receptor Antagonists; Myocardium; Reverse Transcriptase Polymerase Chain Reaction; Spironolactone; Tenascin; Up-Regulation; Vasoconstrictor Agents | 2007 |
Does glucocorticoid receptor blockade exacerbate tissue damage after mineralocorticoid/salt administration?
Topics: Animals; Biomarkers; Blood Pressure; Cardiomegaly; Cardiomyopathies; Coronary Vessels; Desoxycorticosterone; Drug Administration Schedule; Eplerenone; Fibrosis; Hormone Antagonists; Male; Mifepristone; Myocardium; Organ Size; Oxidative Stress; Rats; Rats, Sprague-Dawley; Receptors, Glucocorticoid; Signal Transduction; Sodium Chloride; Spironolactone; Vasculitis | 2007 |
Intact female stroke-prone hypertensive rats lack responsiveness to mineralocorticoid receptor antagonists.
Topics: Animals; Brain Ischemia; Cerebral Arteries; Eplerenone; Female; Male; Mineralocorticoid Receptor Antagonists; Ovariectomy; Rats; Rats, Inbred SHR; Receptors, Mineralocorticoid; Sex Characteristics; Spironolactone; Stroke | 2007 |
Mineralocorticoid receptor blockade improves vasomotor dysfunction and vascular oxidative stress early after myocardial infarction.
Topics: Animals; Aorta, Thoracic; Disease Models, Animal; Dose-Response Relationship, Drug; Eplerenone; Male; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; NADPH Oxidases; Organ Culture Techniques; Oxidative Stress; Rats; Rats, Wistar; Reactive Oxygen Species; Spironolactone; Time Factors; Vasodilation; Vasodilator Agents; Vasomotor System | 2007 |
Acute aldosterone infusion enhances thrombosis development in normotensive rats.
Topics: Aldosterone; Animals; Blood Coagulation; Blood Pressure; Carboxypeptidase B2; Disease Models, Animal; Eplerenone; Infusions, Intravenous; Male; Mineralocorticoid Receptor Antagonists; Plasminogen Activator Inhibitor 1; Rats; Rats, Wistar; Receptors, Mineralocorticoid; Spironolactone; Thromboplastin; Thrombosis; Tissue Plasminogen Activator | 2007 |
Avoiding vicious circles: mineralocorticoid receptor antagonism prevents vascular oxidative stress early after myocardial infarction.
Topics: Aldosterone; Angiotensin II; Animals; Endothelium, Vascular; Eplerenone; Humans; Mice; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Oxidative Stress; Rats; Signal Transduction; Spironolactone | 2007 |
Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress.
Topics: Aldosterone; Animals; Antioxidants; Cyclic N-Oxides; Disease Models, Animal; Eplerenone; Hypertension; Kidney Diseases; Male; Metabolic Syndrome; Obesity; Oxidative Stress; Rats; Rats, Inbred SHR; Rats, Mutant Strains; Receptors, Cell Surface; Receptors, Leptin; Receptors, Mineralocorticoid; Renin; Sodium Chloride, Dietary; Spin Labels; Spironolactone | 2007 |
Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Angiotensinogen; Animals; Benzimidazoles; Biphenyl Compounds; Cardiomegaly; Endothelium, Vascular; Eplerenone; Fibrosis; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Myocardium; Peptidyl-Dipeptidase A; Rats; Rats, Inbred Dahl; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; RNA, Messenger; Spironolactone; Tetrazoles | 2007 |
Eplerenone relieves spironolactone-induced painful gynaecomastia in patients with decompensated hepatitis B-related cirrhosis.
Topics: Ascites; Eplerenone; Gynecomastia; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Mineralocorticoid Receptor Antagonists; Spironolactone | 2007 |
Effect of long-term monotherapy with the aldosterone receptor blocker eplerenone on cytoskeletal proteins and matrix metalloproteinases in dogs with heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cytoskeletal Proteins; Dogs; Eplerenone; Heart Failure; Matrix Metalloproteinases; Mineralocorticoid Receptor Antagonists; RNA, Messenger; Spironolactone; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2 | 2007 |
Aldosterone induces superoxide generation via Rac1 activation in endothelial cells.
Topics: Acetophenones; Aldosterone; Animals; Aorta, Thoracic; Cells, Cultured; Dose-Response Relationship, Drug; Endothelium, Vascular; Enzyme Inhibitors; Eplerenone; Male; Mineralocorticoid Receptor Antagonists; NADPH Oxidases; rac1 GTP-Binding Protein; Rats; Rats, Sprague-Dawley; Receptors, Mineralocorticoid; Spironolactone; Superoxides | 2008 |
Eplerenone potentiates the antiproteinuric effects of enalapril in experimental nephrotic syndrome.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Blood Urea Nitrogen; Drug Synergism; Electrolytes; Enalapril; Eplerenone; Immunohistochemistry; Lipids; Male; Mineralocorticoid Receptor Antagonists; Nephrotic Syndrome; Proteinuria; Rats; Rats, Sprague-Dawley; Spironolactone | 2008 |
Addition of eplerenone to an angiotensin-converting enzyme inhibitor effectively improves nitric oxide bioavailability.
Topics: Acetylcholine; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta, Thoracic; Atherosclerosis; Biological Availability; Blood Pressure; Cholesterol; Enalapril; Eplerenone; Mineralocorticoid Receptor Antagonists; Nitric Oxide; Peptidyl-Dipeptidase A; Peroxynitrous Acid; Rabbits; Reactive Oxygen Species; Spironolactone | 2008 |
Immediate mineralocorticoid receptor blockade improves myocardial infarct healing by modulation of the inflammatory response.
Topics: Aldosterone; Animals; Clodronic Acid; Collagen; Cytokines; Eplerenone; Factor XIIIa; Heart Failure; Humans; Male; Mineralocorticoid Receptor Antagonists; Monocytes; Myocardial Infarction; Myocarditis; Myocardium; Neovascularization, Physiologic; Rats; Rats, Wistar; RNA, Messenger; Spironolactone; Ventricular Function, Left; Wound Healing | 2008 |
Translational research goes both ways: lessons from clinical studies.
Topics: Aldosterone; Amino Acid Sequence; Antihypertensive Agents; Biomedical Research; Clinical Trials as Topic; Corticosterone; Dose-Response Relationship, Drug; Eplerenone; Genetic Predisposition to Disease; Heart Failure; Humans; Hypertension; Receptors, Mineralocorticoid; Spironolactone | 2008 |
Vasoconstrictor effect of aldosterone via angiotensin II type 1 (AT1) receptor: possible role of AT1 receptor dimerization.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Arterioles; Benzimidazoles; Biphenyl Compounds; Dimerization; Eplerenone; Male; Mesentery; Mice; Mice, Inbred C57BL; Mice, Knockout; Mineralocorticoid Receptor Antagonists; Receptor, Angiotensin, Type 1; Spironolactone; Tetrazoles; Transglutaminases; Valine; Valsartan; Vasoconstriction; Vasodilation | 2008 |
Eplerenone in the treatment of Gitelman's syndrome.
Topics: Adult; Eplerenone; Female; Gitelman Syndrome; Humans; Spironolactone; Treatment Outcome | 2008 |
Inhibition of mineralocorticoid receptors with eplerenone alleviates short-term cyclosporin A nephrotoxicity in conscious rats.
Topics: Animals; Blood Pressure; Cyclosporine; Disease Models, Animal; Eplerenone; Glomerular Filtration Rate; Kidney; Kidney Function Tests; Male; Mineralocorticoid Receptor Antagonists; Rats; Rats, Sprague-Dawley; Receptors, Mineralocorticoid; Regional Blood Flow; Spironolactone | 2008 |
Aldosterone induces mesangial cell apoptosis both in vivo and in vitro.
Topics: Aldosterone; Animals; Antioxidants; Apoptosis; bcl-Associated Death Protein; Blood Pressure; Creatinine; Cytochromes c; Eplerenone; Free Radical Scavengers; Humans; In Situ Nick-End Labeling; Kidney Glomerulus; Male; Mesangial Cells; Mineralocorticoid Receptor Antagonists; Oxidative Stress; Proliferating Cell Nuclear Antigen; Rats; Rats, Sprague-Dawley; Spironolactone | 2008 |
Aldosterone-to-renin ratio as a screening test for primary aldosteronism--the Dutch ARRAT Study.
Topics: Antihypertensive Agents; Clinical Trials as Topic; Drug Resistance; Eplerenone; Humans; Hyperaldosteronism; Hypertension; Mass Screening; Mineralocorticoid Receptor Antagonists; Netherlands; Prevalence; Renin-Angiotensin System; Risk Factors; Spironolactone | 2008 |
Paradoxical mineralocorticoid receptor activation and left ventricular diastolic dysfunction under high oxidative stress conditions.
Topics: Angiotensin II; Animals; Antioxidants; Cyclic N-Oxides; Diastole; Disease Models, Animal; Eplerenone; Male; Mineralocorticoid Receptor Antagonists; Oxidative Stress; Rats; Rats, Sprague-Dawley; Receptors, Mineralocorticoid; Sodium Chloride, Dietary; Spin Labels; Spironolactone; Vasoconstrictor Agents; Ventricular Dysfunction, Left | 2008 |
Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline.
Topics: Algorithms; Catheterization; Combined Modality Therapy; Cosyntropin; Diagnostic Techniques, Endocrine; Eplerenone; Hormone Replacement Therapy; Humans; Hyperaldosteronism; Mineralocorticoid Receptor Antagonists; Reproducibility of Results; Spironolactone | 2008 |
Eplerenone inhibits the intracrine and extracellular actions of angiotensin II on the inward calcium current in the failing heart. On the presence of an intracrine renin angiotensin aldosterone system.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Calcium Signaling; Cardiomyopathies; Cricetinae; Eplerenone; Heart Failure; Mineralocorticoid Receptor Antagonists; Models, Cardiovascular; Receptor, Angiotensin, Type 1; Receptors, Mineralocorticoid; Renin-Angiotensin System; Spironolactone | 2008 |
Salt excess causes left ventricular diastolic dysfunction in rats with metabolic disorder.
Topics: Aldosterone; Animals; Blood Pressure Determination; Disease Models, Animal; Echocardiography, Doppler; Eplerenone; Heart Failure, Diastolic; Heart Function Tests; Male; Metabolic Syndrome; Random Allocation; Rats; Rats, Inbred SHR; Reactive Oxygen Species; Reference Values; Sensitivity and Specificity; Sodium Chloride; Spironolactone; Urinalysis; Ventricular Dysfunction, Left | 2008 |
Aldosterone, but not angiotensin II, reduces angiotensin converting enzyme 2 gene expression levels in cultured neonatal rat cardiomyocytes.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; Animals, Newborn; Cells, Cultured; Down-Regulation; Eplerenone; Mineralocorticoid Receptor Antagonists; Myocytes, Cardiac; Peptidyl-Dipeptidase A; Rats; Rats, Wistar; Receptors, Mineralocorticoid; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spironolactone; Time Factors | 2008 |
Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Base Sequence; Collagen Type IV; Diabetes Mellitus, Type 2; Diabetic Nephropathies; DNA Primers; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enalapril; Eplerenone; Extracellular Matrix Proteins; Gene Expression; Glomerular Filtration Rate; In Vitro Techniques; Male; Mesangial Cells; Mineralocorticoid Receptor Antagonists; Plasminogen Activator Inhibitor 1; Rats; Rats, Inbred OLETF; Renin-Angiotensin System; Spironolactone; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2009 |
[Misdiagnosed emergency: heart failure symptoms after infarct. Rapid aldosterone block can safe the tired heart].
Topics: Drug Administration Schedule; Emergencies; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Prognosis; Spironolactone; Ventricular Remodeling | 2008 |
The specific mineralocorticoid receptor blocker eplerenone attenuates left ventricular remodeling in mice lacking the gene encoding guanylyl cyclase-A.
Topics: Animals; Atrial Natriuretic Factor; Eplerenone; Guanylate Cyclase; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mineralocorticoid Receptor Antagonists; Spironolactone; Systole; Ventricular Remodeling | 2008 |
Contrasting effects of eplerenone and spironolactone on adrenal cell steroidogenesis.
Topics: Adrenal Glands; Dose-Response Relationship, Drug; Eplerenone; Humans; Hydrocortisone; Mineralocorticoid Receptor Antagonists; Mineralocorticoids; Receptors, Mineralocorticoid; Spironolactone; Steroids; Transcriptional Activation; Tumor Cells, Cultured | 2009 |
Hyperkalemia associated with inhibitors of the renin-angiotensin-aldosterone system: balancing risk and benefit.
Topics: Eplerenone; Heart Diseases; Humans; Hyperkalemia; Mineralocorticoid Receptor Antagonists; Renin-Angiotensin System; Risk Assessment; Risk Factors; Spironolactone | 2008 |
Aldosterone induces myofibroblastic transdifferentiation and collagen gene expression through the Rho-kinase dependent signaling pathway in rat mesangial cells.
Topics: Aldosterone; Amides; Animals; Cell Transdifferentiation; Collagen; Eplerenone; Gene Expression Regulation; Hypertrophy; Mesangial Cells; Mineralocorticoid Receptor Antagonists; Muscle Development; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Mineralocorticoid; rho-Associated Kinases; Signal Transduction; Spironolactone | 2008 |
Eplerenone in patients with acute myocardial infarction complicated by heart failure.
Topics: Eplerenone; Heart Failure; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Spironolactone | 2008 |
Effect of single treatment with the antihypertensive drug eplerenone on hormone levels and anxiety-like behaviour in rats.
Topics: Adrenocorticotropic Hormone; Aldosterone; Animals; Antihypertensive Agents; Anxiety; Behavior, Animal; Corticosterone; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Eplerenone; Hormones; Male; Maze Learning; Rats; Rats, Wistar; Renin; Spironolactone | 2008 |
Hypotension due to the drug interaction of voriconazole with eplerenone and nifedipine.
Topics: Antifungal Agents; Antihypertensive Agents; Drug Interactions; Drug Therapy, Combination; Eplerenone; Humans; Hypotension; Male; Middle Aged; Nifedipine; Pyrimidines; Spironolactone; Triazoles; Voriconazole | 2009 |
Mechanisms in the PVN mediating local and central sodium-induced hypertension in Wistar rats.
Topics: Aldosterone; Amiloride; Angiotensins; Animals; Antihypertensive Agents; Blood Pressure; Cardiotonic Agents; Cerebrospinal Fluid; Diuretics; Dose-Response Relationship, Drug; Eplerenone; Heart Rate; Hypertension; Injections, Intraventricular; Losartan; Ouabain; Paraventricular Hypothalamic Nucleus; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptors, Mineralocorticoid; Sodium; Spironolactone | 2009 |
Eplerenone decreases inflammatory foci in spontaneously hypertensive rat hearts with minimal effects on blood pressure.
Topics: Animals; Blood Pressure; Eplerenone; Heart; Hypertension; Losartan; Male; Rats; Rats, Inbred SHR; Sodium Chloride, Dietary; Spironolactone | 2009 |
Anti-inflammatory effects of eplerenone on viral myocarditis.
Topics: Animals; Cardiovirus Infections; Disease Models, Animal; DNA, Viral; Encephalomyocarditis virus; Eplerenone; Male; Mice; Mice, Inbred DBA; Mineralocorticoid Receptor Antagonists; Myocarditis; Myocardium; Polymerase Chain Reaction; Spironolactone; Treatment Outcome | 2009 |
[Eplerenone in resistant hypertension with previous spironolactone intolerance].
Topics: Drug Resistance; Eplerenone; Female; Humans; Hypertension; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Retrospective Studies; Spironolactone | 2009 |
Role of aldosterone receptor antagonist eplerenone in aortic stenosis.
Topics: Aortic Valve Stenosis; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Potassium; Spironolactone; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2009 |
Eplerenone treatment of aortic stenosis. [letter].
Topics: Aortic Valve Stenosis; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Potassium; Spironolactone | 2009 |
A comparison of the aldosterone-blocking agents eplerenone and spironolactone.
Topics: Eplerenone; Heart Failure; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Randomized Controlled Trials as Topic; Spironolactone | 2009 |
Eplerenone does not attenuate diabetes-associated atherosclerosis.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Blood Pressure; Diabetes Mellitus, Experimental; Enzyme-Linked Immunosorbent Assay; Eplerenone; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mineralocorticoid Receptor Antagonists; Oxidative Stress; Polymerase Chain Reaction; Renin-Angiotensin System; Spironolactone; Superoxides | 2009 |
Fenofibrate inhibits aldosterone-induced apoptosis in adult rat ventricular myocytes via stress-activated kinase-dependent mechanisms.
Topics: Aldosterone; Animals; Apoptosis; bcl-2-Associated X Protein; Cell Survival; Cells, Cultured; Drug Interactions; Eplerenone; Fenofibrate; Hypolipidemic Agents; JNK Mitogen-Activated Protein Kinases; Male; MAP Kinase Signaling System; Mice; Mice, Inbred Strains; Mineralocorticoid Receptor Antagonists; Mitochondria; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Myocytes, Cardiac; p38 Mitogen-Activated Protein Kinases; PPAR alpha; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Sprague-Dawley; Spironolactone | 2009 |
Prevention of myocardial dysfunction by Eplerenon in experimental tachycardiomyopathy.
Topics: Animals; Cardiomyopathies; Eplerenone; Female; Male; Mineralocorticoid Receptor Antagonists; Spironolactone; Swine; Tachycardia | 2009 |
Aldosterone blockade attenuates development of an electrophysiological substrate associated with ventricular tachyarrhythmias in heart failure.
Topics: Animals; Disease Models, Animal; Dogs; Electrocardiography; Eplerenone; Heart Failure; Mineralocorticoid Receptor Antagonists; Spironolactone; Tachycardia, Ventricular; Ventricular Remodeling | 2009 |
Aldosterone in clinical nephrology--old hormone, new questions.
Topics: Aldosterone; Eplerenone; Humans; Hypertension; Kidney Diseases; Mineralocorticoid Receptor Antagonists; Nephrology; Spironolactone | 2009 |
Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice.
Topics: 3T3-L1 Cells; Adipocytes; Adipose Tissue; Animals; Eplerenone; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Mineralocorticoid Receptor Antagonists; NADPH Oxidases; Obesity; Reactive Oxygen Species; Receptors, Mineralocorticoid; RNA, Messenger; RNA, Small Interfering; Spironolactone | 2009 |
Effect of mineralocorticoid receptor blockade on the renal renin-angiotensin system in Dahl salt-sensitive hypertensive rats.
Topics: Animals; Eplerenone; Hypertension; Kidney; Kidney Glomerulus; Male; Mineralocorticoid Receptor Antagonists; Prorenin Receptor; Rats; Rats, Inbred Dahl; Receptor, Angiotensin, Type 1; Receptors, Cell Surface; Renin-Angiotensin System; Sclerosis; Sodium, Dietary; Spironolactone | 2009 |
Mineralocorticoid receptor blockade and calcium channel blockade have different renoprotective effects on glomerular and interstitial injury in rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cell Hypoxia; Creatinine; Drug Therapy, Combination; Endothelial Cells; Eplerenone; Fibrosis; Hypertension; Immediate-Early Proteins; Kidney Diseases; Kidney Glomerulus; Kidney Tubules; Male; Mineralocorticoid Receptor Antagonists; Podocytes; Protein Serine-Threonine Kinases; Proteinuria; Rats; Rats, Inbred Dahl; Receptors, Mineralocorticoid; Sodium Chloride, Dietary; Spironolactone; Time Factors; Vascular Endothelial Growth Factor A | 2009 |
Electrophysiological responses of sympathetic preganglionic neurons to ANG II and aldosterone.
Topics: Aldosterone; Anesthetics, Local; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Autonomic Fibers, Preganglionic; Benzimidazoles; Biphenyl Compounds; Eplerenone; Excitatory Postsynaptic Potentials; Female; In Vitro Techniques; Male; Mineralocorticoid Receptor Antagonists; Patch-Clamp Techniques; Presynaptic Terminals; Rats; Rats, Wistar; Spironolactone; Synaptic Transmission; Tetrazoles; Tetrodotoxin; Time Factors | 2009 |
Hypertension of Kcnmb1-/- is linked to deficient K secretion and aldosteronism.
Topics: Analysis of Variance; Animals; Eplerenone; Hyperaldosteronism; Hyperkalemia; Hypertension; Kidney Tubules, Collecting; Large-Conductance Calcium-Activated Potassium Channel beta Subunits; Mice; Mice, Knockout; Potassium; Spironolactone | 2009 |
Role of mineralocorticoid receptor on experimental cerebral aneurysms in rats.
Topics: Aldosterone; Angiotensin II; Animals; Blood Pressure; Cerebral Arteries; Chemokine CCL2; Eplerenone; Female; Gene Expression; Hypertension, Renal; Immunohistochemistry; Intracranial Aneurysm; Mineralocorticoid Receptor Antagonists; NADPH Oxidases; Ovariectomy; Oxidative Stress; Peptidyl-Dipeptidase A; Rats; Rats, Sprague-Dawley; Receptors, Mineralocorticoid; Renin-Angiotensin System; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spironolactone; Tyrosine | 2009 |
Successful effect of triple blockade of renin-angiotensin-aldosterone system on massive proteinuria in a patient with chronic kidney disease.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Eplerenone; Glomerulonephritis, Membranous; Humans; Kidney Failure, Chronic; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Proteinuria; Renin-Angiotensin System; Spironolactone | 2009 |
Eplerenone administration has beneficial effect on hepatic paraoxonase 1 activity in diabetic mice.
Topics: Animals; Aryldialkylphosphatase; Diabetes Mellitus, Experimental; Eplerenone; Mice; Spironolactone | 2010 |
[Aldosterone antagonists for all patients with heart failure?].
Topics: Angiotensin-Converting Enzyme Inhibitors; Death, Sudden, Cardiac; Drug Therapy, Combination; Eplerenone; Evidence-Based Medicine; Heart Failure; Humans; Kidney Function Tests; Mineralocorticoid Receptor Antagonists; Potassium; Spironolactone; Survival Analysis | 2009 |
Update in primary aldosteronism.
Topics: Adrenalectomy; Adrenocorticotropic Hormone; Aldosterone; Amiloride; Antihypertensive Agents; Chromosomes, Human, Pair 7; Cytochrome P-450 CYP11B2; Diagnosis, Differential; Drug Administration Schedule; Eplerenone; Genetic Linkage; Glucocorticoids; Humans; Hyperaldosteronism; Hypertension; Lod Score; Mineralocorticoid Receptor Antagonists; Spironolactone | 2009 |
High-salt diet increases plasma adiponectin levels independent of blood pressure in hypertensive rats: the role of the renin-angiotensin-aldosterone system.
Topics: Adiponectin; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Clonidine; Eplerenone; Hydralazine; Hypertension; Male; Rats; Rats, Sprague-Dawley; Renin-Angiotensin System; Sodium Chloride, Dietary; Spironolactone; Telmisartan | 2010 |
Establishment of HPLC-ESI-MS method for the determination of eplerenone in human plasma and its pharmacokinetics.
Topics: Chromatography, High Pressure Liquid; Eplerenone; Humans; Spectrometry, Mass, Electrospray Ionization; Spironolactone | 2009 |
Eplerenone, a selective mineralocorticoid receptor blocker, exerts anxiolytic effects accompanied by changes in stress hormone release.
Topics: Adrenal Cortex; Aldosterone; Animals; Anti-Anxiety Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Corticosterone; Eplerenone; Exploratory Behavior; Hippocampus; Male; Mineralocorticoid Receptor Antagonists; Neuronal Plasticity; Oxytocin; Pituitary Gland, Posterior; Random Allocation; Rats; Rats, Wistar; Spironolactone; Stress, Psychological; Vasopressins | 2010 |
Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertension.
Topics: Aged; Albuminuria; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Asian People; Calcium Channel Blockers; Drug Therapy, Combination; Eplerenone; Female; Humans; Hypertension; Japan; Male; Metabolic Syndrome; Middle Aged; Mineralocorticoid Receptor Antagonists; Renin; Spironolactone; Treatment Outcome; Triglycerides | 2010 |
Mineralocorticoid receptor blockade enhances the antiproteinuric effect of an angiotensin II blocker through inhibiting podocyte injury in type 2 diabetic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Diabetes Mellitus, Type 2; Drug Synergism; Eplerenone; Intracellular Signaling Peptides and Proteins; Kidney Glomerulus; Male; Membrane Proteins; Mineralocorticoid Receptor Antagonists; Podocytes; Proteinuria; Rats; Rats, Inbred OLETF; Spironolactone; Telmisartan | 2010 |
Role of Rho kinase and oxidative stress in cardiac fibrosis induced by aldosterone and salt in angiotensin type 1a receptor knockout mice.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aldosterone; Animals; Blood Pressure; Eplerenone; Fibrosis; Heart; Immunohistochemistry; Mice; Mice, Knockout; Mineralocorticoid Receptor Antagonists; Myocardium; Oxidative Stress; Receptor, Angiotensin, Type 1; Reverse Transcriptase Polymerase Chain Reaction; rho-Associated Kinases; Sodium Chloride; Spironolactone | 2010 |
Cardioprotective effects of mineralocorticoid receptor antagonists at reperfusion.
Topics: Animals; Canrenoic Acid; Eplerenone; Ischemic Preconditioning, Myocardial; Mice; Mice, Knockout; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Myocardial Reperfusion Injury; Phosphorylation; Phosphotransferases; Rabbits; Rats; Rats, Wistar; Spironolactone | 2010 |
Sex-specific impact of aldosterone receptor antagonism on ventricular remodeling and gene expression after myocardial infarction.
Topics: Animals; Cluster Analysis; Eplerenone; Female; Fibrosis; Gene Expression Profiling; Gene Expression Regulation; Male; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Placebos; Rats; Rats, Wistar; Sex Characteristics; Spironolactone; Ventricular Remodeling | 2009 |
Renoprotective effects of mineralocorticoid receptor blockade in heminephrectomized (pro)renin receptor transgenic rats.
Topics: Aldosterone; Animals; Eplerenone; Humans; Kidney Diseases; Mineralocorticoid Receptor Antagonists; Nephrectomy; Prorenin Receptor; Rats; Rats, Transgenic; Receptors, Cell Surface; Sodium Chloride, Dietary; Spironolactone | 2010 |
Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Therapy, Combination; Eplerenone; Female; Follow-Up Studies; Health Care Costs; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Regression Analysis; Spironolactone | 2010 |
Cardiovascular effects of inhibition of renin-angiotensin-aldosterone system components in hypertensive rats given salt excess.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cardiomyopathies; Cardiovascular System; Eplerenone; Hypertension; Hypertrophy; Kidney; Male; Mineralocorticoid Receptor Antagonists; Quinapril; Rats; Rats, Inbred SHR; Receptors, Mineralocorticoid; Regional Blood Flow; Renin-Angiotensin System; Sodium Chloride, Dietary; Spironolactone; Tetrahydroisoquinolines; Tetrazoles; Ventricular Dysfunction, Left | 2010 |
Agents with antialdosterone properties should be the preferred diuretics for reducing hypertension related atrial fibrillation.
Topics: Antihypertensive Agents; Atrial Fibrillation; Diuretics; Eplerenone; Humans; Hypertension; Spironolactone; Sulfonamides; Torsemide | 2010 |
Aldosterone receptor antagonists: effective but often forgotten.
Topics: Eplerenone; Female; Follow-Up Studies; Humans; Hypertension; Middle Aged; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Renal Insufficiency, Chronic; Spironolactone; Treatment Outcome | 2010 |
Eplerenone improves vascular function and reduces platelet activation in diabetic rats.
Topics: Animals; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Endothelium, Vascular; Eplerenone; Male; Platelet Aggregation Inhibitors; Rats; Rats, Wistar; Spironolactone; Vasodilation | 2010 |
Monocyte chemoattractant protein-1: a dichotomous role in cardiac remodeling following acute myocardial infarction in man?
Topics: Biomarkers; Chemokine CCL2; Cohort Studies; Contrast Media; Eplerenone; Female; Humans; Magnetic Resonance Imaging; Male; Matrix Metalloproteinases; Middle Aged; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Spironolactone; Time Factors; Ventricular Function, Left; Ventricular Remodeling | 2010 |
The L-, N-, and T-type triple calcium channel blocker benidipine acts as an antagonist of mineralocorticoid receptor, a member of nuclear receptor family.
Topics: Aldosterone; Binding Sites; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, N-Type; Calcium Channels, T-Type; Cell Line; Dihydropyridines; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Models, Molecular; Molecular Conformation; Mutation; Pyridines; Receptors, Mineralocorticoid; Spironolactone; Stereoisomerism | 2010 |
Sensitivity of NOS-dependent vascular relaxation pathway to mineralocorticoid receptor blockade in caveolin-1-deficient mice.
Topics: Acetylcholine; Aldosterone; Animals; Caveolin 1; Eplerenone; Male; Mice; Mice, Knockout; Mineralocorticoid Receptor Antagonists; Models, Animal; Muscle Relaxation; Muscle, Smooth, Vascular; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Phenylephrine; Receptors, Mineralocorticoid; Signal Transduction; Sodium Chloride, Dietary; Spironolactone; Vasoconstriction; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents | 2010 |
Aldosterone-receptor antagonism as a potential therapeutic option for atrial fibrillation.
Topics: Atrial Fibrillation; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone | 2010 |
Aldosterone receptor inhibition alters the viscoelastic biomechanical behavior of the aortic wall.
Topics: Aldosterone; Animals; Aorta; Biomechanical Phenomena; Blood Pressure; Disease Progression; Elasticity; Eplerenone; Hyperlipidemias; Male; Mineralocorticoid Receptor Antagonists; Rabbits; Spironolactone; Viscosity | 2010 |
Stereochemical requirements for the mineralocorticoid receptor antagonist activity of dihydropyridines.
Topics: Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Crystallography, X-Ray; Dihydropyridines; Eplerenone; Genes, Reporter; Humans; Luciferases; Mineralocorticoid Receptor Antagonists; Models, Molecular; Protein Binding; Rats; Receptors, Mineralocorticoid; Spironolactone; Stereoisomerism; Structure-Activity Relationship | 2010 |
The effects of the selective mineralocorticoid receptor antagonist eplerenone on hepatic fibrosis induced by bile duct ligation in rat.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aldehydes; Animals; Bile Ducts; Deoxyguanosine; Eplerenone; Gene Expression Regulation; Hydroxyproline; Immunohistochemistry; Ligation; Lipid Peroxidation; Liver Cirrhosis; Male; Mineralocorticoid Receptor Antagonists; Oxidative Stress; Rats; Rats, Wistar; RNA, Messenger; Spironolactone | 2010 |
Effect of eplerenone on endothelial progenitor cells and oxidative stress in ischemic hindlimb.
Topics: Angiopoietin-1; Angiopoietin-2; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Endothelial Cells; Eplerenone; Hindlimb; Immediate-Early Proteins; Ischemia; Male; Mineralocorticoid Receptor Antagonists; Monocytes; NADPH Oxidases; Nitric Oxide Synthase Type III; Oxidative Stress; Protein Serine-Threonine Kinases; Rats; Rats, Wistar; Spironolactone; Stem Cells; Tetrazoles; Valine; Valsartan; Vascular Endothelial Growth Factors | 2010 |
Reduction of fibrosis-related arrhythmias by chronic renin-angiotensin-aldosterone system inhibitors in an aged mouse model.
Topics: Age Factors; Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Arrhythmias, Cardiac; Blood Pressure; Cardiac Pacing, Artificial; Cell Communication; Cellular Senescence; Connexin 43; Disease Models, Animal; Echocardiography, Doppler; Electrocardiography; Epicardial Mapping; Eplerenone; Female; Fibrosis; Heart Conduction System; Heart Diseases; Losartan; Mice; Mice, Inbred C57BL; Mineralocorticoid Receptor Antagonists; Myocardium; Renin-Angiotensin System; Spironolactone; Ventricular Function, Left; Ventricular Function, Right | 2010 |
Eplerenone in chronic renal disease: the EVALUATE trial.
Topics: Adult; Aged; Aged, 80 and over; Chronic Disease; Clinical Trials as Topic; Eplerenone; Female; Humans; Hyperkalemia; Hypertension; Kidney Diseases; Male; Middle Aged; Spironolactone; Young Adult | 2010 |
Mineralocorticoid receptor activation contributes to salt-induced hypertension and renal injury in prepubertal Dahl salt-sensitive rats.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Antihypertensive Agents; Antioxidants; Blood Pressure; Cyclic N-Oxides; Deoxyguanosine; Eplerenone; Hydralazine; Hypertension; Kidney; Male; Mineralocorticoid Receptor Antagonists; Rats; Rats, Inbred Dahl; Receptors, Mineralocorticoid; Renal Insufficiency; Sodium Chloride, Dietary; Spin Labels; Spironolactone | 2010 |
Effects of mineralocorticoid and angiotensin II receptor blockers on proteinuria and glomerular podocyte protein expression in a model of minimal change nephrotic syndrome.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Disease Models, Animal; Eplerenone; Fluorescent Antibody Technique; Intracellular Signaling Peptides and Proteins; Losartan; Male; Membrane Proteins; Mineralocorticoid Receptor Antagonists; Nephrosis, Lipoid; Podocytes; Proteinuria; Puromycin Aminonucleoside; Rats; Rats, Sprague-Dawley; Sialoglycoproteins; Spironolactone; Time Factors | 2010 |
Aldosterone and mineralocorticoid receptor antagonists modulate elastin and collagen deposition in human skin.
Topics: Adult; Aldosterone; Biopsy; Cells, Cultured; Cicatrix; Collagen Type I; Elasticity; Elastin; Eplerenone; Extracellular Matrix; Female; Fibroblasts; Gene Expression; Humans; Keloid; Mineralocorticoid Receptor Antagonists; Organ Culture Techniques; Receptor, IGF Type 1; RNA, Messenger; Skin; Spironolactone; Up-Regulation | 2010 |
Eplerenone suppresses salt-induced vascular endothelial growth factor expression in the kidney.
Topics: Animals; Blood Pressure; Eplerenone; Gene Expression Regulation; Kidney; Male; Mineralocorticoid Receptor Antagonists; Rats; Rats, Inbred Dahl; Spironolactone; Vascular Endothelial Growth Factor A | 2010 |
Reduction of endothelial tight junction proteins is related to cerebral aneurysm formation in rats.
Topics: Animals; Base Sequence; Brain; Cells, Cultured; Chemokine CCL2; DNA Primers; Endothelial Cells; Eplerenone; Female; Humans; Intracranial Aneurysm; Macrophages; Matrix Metalloproteinase 9; Membrane Proteins; Occludin; Phosphoproteins; Rats; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spironolactone; Tight Junctions; Zonula Occludens-1 Protein | 2010 |
Blockade of mineralocorticoid receptors improves salt-induced left-ventricular systolic dysfunction through attenuation of enhanced sympathetic drive in mice with pressure overload.
Topics: Animals; Brain; Epithelial Sodium Channels; Eplerenone; Hypertension; Male; Mice; Mice, Inbred ICR; Mineralocorticoid Receptor Antagonists; Receptors, Mineralocorticoid; Sodium Chloride, Dietary; Spironolactone; Sympathetic Nervous System; Systole; Ventricular Dysfunction, Left | 2010 |
Differential actions of eplerenone and spironolactone on the protective effect of testosterone against cardiomyocyte apoptosis in vitro.
Topics: Animals; Apoptosis; Blotting, Western; Cell Line; Cell Survival; DNA Fragmentation; Drug Synergism; Eplerenone; Mineralocorticoid Receptor Antagonists; Myocytes, Cardiac; Rats; Spironolactone; Testosterone | 2010 |
Interference between eplerenone and digoxin in fluorescence polarization immunoassay, microparticle enzyme immunoassay, and affinity column-mediated immunoassay.
Topics: Anti-Arrhythmia Agents; Antibodies; Cross Reactions; Digoxin; Eplerenone; Fluorescence Polarization Immunoassay; Humans; Immunoassay; In Vitro Techniques; Mineralocorticoid Receptor Antagonists; Spironolactone | 2010 |
Increased renal alpha-epithelial sodium channel (ENAC) protein and increased ENAC activity in normal pregnancy.
Topics: Amiloride; Animals; Epithelial Sodium Channel Blockers; Epithelial Sodium Channels; Eplerenone; Female; Immunoblotting; Kidney; Mineralocorticoid Receptor Antagonists; Mineralocorticoids; Natriuresis; Plasma Volume; Pregnancy; Proteomics; Rats; Rats, Sprague-Dawley; Sodium; Sodium Channel Blockers; Spironolactone; Up-Regulation | 2010 |
Effect of ramipril alone compared to ramipril with eplerenone on diabetic nephropathy in streptozocin-induced diabetic rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Creatinine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Drug Therapy, Combination; Eplerenone; Glomerular Mesangium; Hypertrophy; Kidney Glomerulus; Male; Mineralocorticoid Receptor Antagonists; Proteinuria; Ramipril; Random Allocation; Rats; Rats, Wistar; Severity of Illness Index; Spironolactone | 2010 |
Disparate effects of eplerenone, amlodipine and telmisartan on podocyte injury in aldosterone-infused rats.
Topics: Albuminuria; Aldosterone; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Apoptosis; Benzimidazoles; Benzoates; Blotting, Western; Calcium Channel Blockers; Eplerenone; Immunoenzyme Techniques; Kidney Glomerulus; Male; Membrane Proteins; Mineralocorticoid Receptor Antagonists; Podocytes; Proteinuria; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spironolactone; Telmisartan | 2011 |
Aldosterone and angiogenesis.
Topics: Aldosterone; Animals; Dogs; Eplerenone; Mineralocorticoid Receptor Antagonists; Neovascularization, Physiologic; Rats; Rats, Wistar; Spironolactone | 2010 |
Effects of selective mineralocorticoid receptor antagonism on atrial ion currents and early ionic tachycardia-induced electrical remodelling in rabbits.
Topics: Animals; Atrial Fibrillation; Calcium Channels, L-Type; Cardiac Pacing, Artificial; Disease Models, Animal; Electric Conductivity; Eplerenone; Female; Heart Atria; Heart Conduction System; Ion Channel Gating; Mineralocorticoid Receptor Antagonists; Potassium Channels; Rabbits; Spironolactone; Tachycardia | 2010 |
Stereoselective construction of a steroid 5α,7α-oxymethylene derivative and its use in the synthesis of eplerenone.
Topics: Eplerenone; Molecular Conformation; Spironolactone; Stereoisomerism | 2011 |
Acid retention during kidney failure induces endothelin and aldosterone production which lead to progressive GFR decline, a situation ameliorated by alkali diet.
Topics: Acid-Base Equilibrium; Acidosis; Administration, Oral; Aldosterone; Animals; Bicarbonates; Calcium Gluconate; Dietary Supplements; Disease Models, Animal; Endothelin A Receptor Antagonists; Endothelin-1; Eplerenone; Female; Glomerular Filtration Rate; Kidney; Male; Microdialysis; Mineralocorticoid Receptor Antagonists; Nephrectomy; Phenylpropionates; Pyrimidines; Rats; Rats, Wistar; Receptor, Endothelin A; Renal Insufficiency; Spironolactone; Time Factors | 2010 |
Impairment of endothelial progenitor cell function and vascularization capacity by aldosterone in mice and humans.
Topics: Aldosterone; Animals; Cells, Cultured; Cyclic AMP-Dependent Protein Kinases; Endothelial Cells; Endothelium, Vascular; Eplerenone; Female; Humans; Hyperaldosteronism; Male; Mice; Middle Aged; Mineralocorticoid Receptor Antagonists; Reactive Oxygen Species; Receptors, Mineralocorticoid; Spironolactone; Stem Cells; Vasodilation | 2011 |
Aldosterone antagonists--last man standing?
Topics: Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Implantable; Eplerenone; Heart Failure; Hospitalization; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone | 2011 |
Successful blood pressure control with additive administration of eplerenone, an aldosterone receptor blocker, in a patient with bilateral renovascular hypertension treated with angioplasty.
Topics: Adult; Angioplasty; Eplerenone; Female; Humans; Hypertension, Renovascular; Mineralocorticoid Receptor Antagonists; Remission Induction; Spironolactone | 2010 |
11β-hydroxysteroid dehydrogenase type 2 deficiency accelerates atherogenesis and causes proinflammatory changes in the endothelium in apoe-/- mice.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Amiloride; Animals; Aorta; Apolipoproteins E; Atherosclerosis; Cell Line; Endothelium, Vascular; Eplerenone; Gene Expression Regulation, Enzymologic; Inflammation; Male; Mice; Mice, Knockout; Mineralocorticoid Receptor Antagonists; Sodium Channel Blockers; Spironolactone | 2011 |
Effects of eplerenone on nephrotic syndrome in a patient with renovascular hypertension.
Topics: Amlodipine; Antihypertensive Agents; Dihydropyridines; Eplerenone; Humans; Hypertension, Renovascular; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Nephrotic Syndrome; Proteinuria; Radiography; Spironolactone; Treatment Outcome | 2011 |
Timing of defibrillator implant after acute myocardial infarction: what's new?
Topics: Death, Sudden, Cardiac; Defibrillators, Implantable; Eplerenone; Health Knowledge, Attitudes, Practice; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Practice Guidelines as Topic; Risk Factors; Spironolactone; Time Factors; Treatment Outcome | 2011 |
Aldosterone/Mineralocorticoid receptor stimulation induces cellular senescence in the kidney.
Topics: Acetylglucosaminidase; Aldosterone; Animals; Blood Pressure; Blotting, Western; Cells, Cultured; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p21; Eplerenone; Humans; Hydralazine; Hypertension; Kidney; Male; Mineralocorticoid Receptor Antagonists; Rats; Rats, Sprague-Dawley; Receptors, Mineralocorticoid; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Sirtuin 1; Spironolactone; Tumor Suppressor Protein p53 | 2011 |
Aldosterone-receptor antagonists in heart failure: insights after EMPHASIS-HF.
Topics: Eplerenone; Heart Failure, Systolic; Humans; Mineralocorticoid Receptor Antagonists; Patient Selection; Randomized Controlled Trials as Topic; Research Design; Severity of Illness Index; Spironolactone; Treatment Outcome; Ventricular Remodeling | 2011 |
Treatment considerations with aldosterone receptor antagonists.
Topics: Dose-Response Relationship, Drug; Eplerenone; Homeostasis; Humans; Hyperkalemia; Hypertension; Kidney; Magnesium; Mineralocorticoid Receptor Antagonists; Spironolactone; Treatment Outcome | 2011 |
[Aldosterone blocker in heart failure: life prolonging even in mild symptoms].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Early Termination of Clinical Trials; Eplerenone; Germany; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Spironolactone; Survival Rate; United States | 2010 |
Effects of mineralocorticoid receptor blockade on glucocorticoid-induced renal injury in adrenalectomized rats.
Topics: Adrenalectomy; Animals; Base Sequence; Dexamethasone; DNA Primers; Eplerenone; Gene Expression; Glucocorticoids; Hydrocortisone; Hypertension; Kidney; Male; Mineralocorticoid Receptor Antagonists; Rats; Rats, Inbred WKY; Receptors, Mineralocorticoid; RNA, Messenger; Spironolactone | 2011 |
Role of mineralocorticoid receptor on atrial structural remodeling and inducibility of atrial fibrillation in hypertensive rats.
Topics: Animals; Atrial Fibrillation; Cardiomegaly; Eplerenone; Fibrosis; Heart Atria; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Myocardium; Oxidative Stress; rac1 GTP-Binding Protein; Rats; Rats, Inbred Dahl; Receptors, Mineralocorticoid; Sodium Chloride, Dietary; Spironolactone | 2011 |
Eplerenone suppresses aldosterone/ salt-induced expression of NOX-4.
Topics: Acetophenones; Aldosterone; Animals; Blood Pressure; Blotting, Western; Body Weight; Dinoprost; Eplerenone; Male; NADPH Oxidase 4; NADPH Oxidases; Nitric Oxide; Protein Subunits; Proteinuria; Rats; Rats, Inbred Dahl; Sodium; Sodium Chloride, Dietary; Spironolactone; Systole; Urinalysis | 2011 |
Eplerenone for gitelman syndrome in pregnancy.
Topics: Eplerenone; Female; Gitelman Syndrome; Humans; Live Birth; Mineralocorticoid Receptor Antagonists; Mutation; Pregnancy; Pregnancy Complications; Receptors, Drug; Solute Carrier Family 12, Member 3; Spironolactone; Symporters; Treatment Outcome; Young Adult | 2011 |
SM-368229, a novel selective and potent non-steroidal mineralocorticoid receptor antagonist with strong urinary Na+ excretion activity.
Topics: Animals; Area Under Curve; Benzoxazines; Chlorocebus aethiops; COS Cells; Drug Evaluation, Preclinical; Eplerenone; Estrus; Female; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Potassium; Prostate; Rats; Rats, Sprague-Dawley; Receptors, Glucocorticoid; Receptors, Mineralocorticoid; Seminal Vesicles; Sodium; Spironolactone; Sulfonamides | 2011 |
Impact of diabetes mellitus on outcomes in patients with acute myocardial infarction and systolic heart failure.
Topics: Aged; Diabetic Angiopathies; Eplerenone; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Propensity Score; Randomized Controlled Trials as Topic; Recurrence; Spironolactone; Treatment Outcome | 2011 |
Efficacy of eplerenone added to renin-angiotensin blockade in elderly hypertensive patients: the Jichi-Eplerenone Treatment (JET) study.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Eplerenone; Female; Hemostasis; Humans; Hypertension; Japan; Male; Peptide Fragments; Procollagen; Renin; Renin-Angiotensin System; Spironolactone; Time Factors; Treatment Outcome | 2011 |
Effect of eplerenone on hypertension-associated renal damage in rats: potential role of peroxisome proliferator activated receptor gamma (PPAR-γ).
Topics: Animals; Blood Pressure; Connective Tissue Growth Factor; Cytokines; Down-Regulation; Eplerenone; Gene Expression; Hypertension; Kidney Cortex; Kidney Diseases; Male; Mineralocorticoid Receptor Antagonists; PPAR gamma; Protein-Lysine 6-Oxidase; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptors, Mineralocorticoid; Signal Transduction; Smad2 Protein; Spironolactone; Up-Regulation | 2011 |
Eplerenone in mild heart failure.
Topics: Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Stroke Volume | 2011 |
Eplerenone in mild heart failure.
Topics: Aldosterone; Cardiovascular Diseases; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Sodium, Dietary; Spironolactone; Stroke Volume | 2011 |
Eplerenone in mild heart failure.
Topics: Blood Pressure; Cardiovascular Diseases; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Regression Analysis; Spironolactone | 2011 |
Eplerenone in mild heart failure.
Topics: Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone | 2011 |
Angiotensin II and aldosterone-induced neuronal damage in neurons through an astrocyte-dependent mechanism.
Topics: Aldosterone; Angiotensin II; Animals; Astrocytes; Cells, Cultured; DNA Damage; Eplerenone; Ganglia, Spinal; Mice; Mice, Inbred C57BL; Receptor, Angiotensin, Type 1; Receptors, Mineralocorticoid; Spironolactone; Tetrazoles; Valine; Valsartan | 2011 |
Eplerenone potentiates protective effects of amlodipine against cardiovascular injury in salt-sensitive hypertensive rats.
Topics: Aldosterone; Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Carotid Arteries; Drug Therapy, Combination; Endothelium, Vascular; Eplerenone; Heart; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Myocardium; Nitric Oxide Synthase Type III; Oxidative Stress; Proto-Oncogene Proteins c-akt; Rats; Rats, Inbred Dahl; Receptor, Angiotensin, Type 1; Sodium Chloride, Dietary; Spironolactone; Superoxides; Treatment Outcome | 2011 |
Mineralocorticoid receptor activation: a major contributor to salt-induced renal injury and hypertension in young rats.
Topics: Acute Kidney Injury; Aldosterone; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Eplerenone; Hypertension; Imidazoles; Immunohistochemistry; Kidney; Male; Radioimmunoassay; Rats; Rats, Sprague-Dawley; Receptors, Mineralocorticoid; Reverse Transcriptase Polymerase Chain Reaction; Sodium Chloride; Spironolactone; Tetrazoles | 2011 |
[The EMPHASIS-HF study].
Topics: Aldosterone; Biomarkers; Canrenone; Cause of Death; Double-Blind Method; Early Termination of Clinical Trials; Eplerenone; Female; Heart Failure; Hospitalization; Humans; Hyperkalemia; Male; Mineralocorticoid Receptor Antagonists; Models, Cardiovascular; Molecular Structure; Multicenter Studies as Topic; Myocardial Infarction; Patient Selection; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Research Design; Risk; Spironolactone | 2011 |
Eplerenone, amlodipine and experimental hypertension: one plus one equals three.
Topics: Amlodipine; Animals; Antihypertensive Agents; Eplerenone; Heart; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Spironolactone | 2011 |
Effects of aldosterone and related steroids on LPS-induced increased expression of inducible NOS in rat aortic smooth muscle cells.
Topics: Aldosterone; Animals; Aorta, Thoracic; Cells, Cultured; Eplerenone; Lipopolysaccharides; Male; Mifepristone; Muscle, Smooth, Vascular; Nitric Oxide Synthase Type II; Rats; Rats, Sprague-Dawley; Spironolactone; Steroids | 2011 |
Protective effects of eplerenone on podocyte injury in adriamycin nephropathy rats.
Topics: Animals; Cytokines; Down-Regulation; Doxorubicin; Eplerenone; Kidney Diseases; Kidney Glomerulus; Male; Mineralocorticoid Receptor Antagonists; Podocytes; Protective Agents; Proteinuria; Rats; Rats, Sprague-Dawley; Spironolactone | 2011 |
Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease.
Topics: Acute Kidney Injury; Aged; Alabama; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biomarkers; Blood Pressure; Chi-Square Distribution; Chronic Disease; Creatinine; Diuretics; Drug Resistance; Drug Therapy, Combination; Eplerenone; Female; Glomerular Filtration Rate; Humans; Hyperkalemia; Hypertension; Kidney; Kidney Diseases; Logistic Models; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Potassium; Retrospective Studies; Risk Assessment; Risk Factors; Spironolactone; Time Factors; Treatment Outcome | 2012 |
Glucocorticoid and mineralocorticoid receptors regulate paracellular permeability in a primary cultured gill epithelium.
Topics: Aldosterone; Animals; Cell Membrane Permeability; Cells, Cultured; Desoxycorticosterone; Dexamethasone; Electric Impedance; Epithelial Cells; Epithelium; Eplerenone; Fish Proteins; Gene Expression Regulation; Gills; Hydrocortisone; Mifepristone; Mineralocorticoid Receptor Antagonists; Oncorhynchus mykiss; Receptors, Glucocorticoid; Receptors, Mineralocorticoid; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spironolactone; Tight Junctions | 2011 |
The long-term antiproteinuric effect of eplerenone, a selective aldosterone blocker, in patients with non-diabetic chronic kidney disease.
Topics: Adult; Aged; Blood Pressure; Diabetic Nephropathies; Eplerenone; Female; Glomerular Filtration Rate; Humans; Kidney Failure, Chronic; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Multivariate Analysis; Proteinuria; Spironolactone; Time Factors | 2012 |
Osteopontin deficiency protects against aldosterone-induced inflammation, oxidative stress, and interstitial fibrosis in the kidney.
Topics: Albuminuria; Aldosterone; Animals; Blood Pressure; Eplerenone; Fibrosis; Inflammation; Kidney; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mineralocorticoid Receptor Antagonists; Osteopontin; Oxidative Stress; Sodium Chloride, Dietary; Spironolactone | 2011 |
Dehydroepiandrosterone-induced phosphorylation and translocation of FoxO1 depend on the mineralocorticoid receptor.
Topics: Animals; Blotting, Western; Cells, Cultured; CHO Cells; Cricetinae; Cricetulus; Dehydroepiandrosterone; Dose-Response Relationship, Drug; Endothelial Cells; Eplerenone; Fibroblasts; Forkhead Box Protein O1; Forkhead Transcription Factors; Humans; Microscopy, Confocal; Mineralocorticoid Receptor Antagonists; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Phosphorylation; Protein Transport; Rats; Receptors, Mineralocorticoid; RNA Interference; Spironolactone; Time Factors | 2011 |
Eplerenone, an aldosterone antagonist, reduces hospitalization and death in heart failure patients with NYHA class II and an ejection fraction of less than 30%.
Topics: Eplerenone; Heart Failure; Hospitalization; Humans; Mineralocorticoid Receptor Antagonists; Randomized Controlled Trials as Topic; Severity of Illness Index; Spironolactone; Stroke Volume | 2011 |
Adipocyte-derived factors regulate vascular smooth muscle cells through mineralocorticoid and glucocorticoid receptors.
Topics: 3T3-L1 Cells; Adipocytes; Aldosterone; Angiotensin II; Animals; Blotting, Western; Cells, Cultured; Corticosterone; Culture Media, Conditioned; Eplerenone; Fadrozole; Fibronectins; Hormone Antagonists; Mice; Mice, Inbred C57BL; Mifepristone; Mineralocorticoid Receptor Antagonists; Mitogen-Activated Protein Kinases; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Phosphorylation; Proliferating Cell Nuclear Antigen; Proto-Oncogene Proteins c-bcl-2; Receptor, Angiotensin, Type 1; Receptors, Glucocorticoid; Receptors, Mineralocorticoid; Spironolactone | 2011 |
Delineating the receptor mechanisms underlying the rapid vascular contractile effects of aldosterone and estradiol.
Topics: Aldosterone; Animals; Cells, Cultured; Eplerenone; Estradiol; Estrogen Receptor alpha; Muscle Contraction; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Myosin Light Chains; Phosphorylation; Rats; Rats, Inbred WKY; Receptors, G-Protein-Coupled; Receptors, Mineralocorticoid; Signal Transduction; Spironolactone; Tamoxifen; Vasoconstriction | 2011 |
The effect of treatment on monocyte and lymphocyte cytokine release in patients with aldosteronoma.
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Adenoma; Adult; Aldosterone; Blood Pressure; Cytokines; Eplerenone; Female; Humans; Lymphocytes; Mineralocorticoid Receptor Antagonists; Monocytes; Spironolactone | 2012 |
The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities.
Topics: Angiotensin II Type 1 Receptor Blockers; Aortic Valve Stenosis; Benzimidazoles; Biphenyl Compounds; Cardiac Catheterization; Cardiovascular Diseases; Clinical Trials as Topic; Endpoint Determination; Eplerenone; Heart Failure; Hospitalization; Humans; Matched-Pair Analysis; Mineralocorticoid Receptor Antagonists; Proportional Hazards Models; Risk Factors; Spironolactone; Tetrazoles | 2012 |
The selective mineralocorticoid receptor antagonist eplerenone is protective in mild anti-GBM glomeru-lonephritis.
Topics: Albuminuria; Animals; Anti-Glomerular Basement Membrane Disease; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cytokines; Eplerenone; Immunoglobulin G; Kidney Glomerulus; Lymph Nodes; Male; Mice; Mineralocorticoid Receptor Antagonists; Rabbits; Spironolactone; Spleen | 2011 |
Chronic antagonism of the mineralocorticoid receptor ameliorates hypertension and end organ damage in a rodent model of salt-sensitive hypertension.
Topics: Aldosterone; Animals; Blood Pressure; Chronic Disease; Creatinine; Disease Models, Animal; Disease Progression; Electrolytes; Eplerenone; Heart Rate; Hypertension, Renal; Kidney; Male; Mineralocorticoid Receptor Antagonists; Organ Size; Rats; Rats, Inbred Dahl; Receptors, Mineralocorticoid; Sodium Chloride, Dietary; Spironolactone | 2011 |
Protective effects of mineralocorticoid receptor blockade against neuropathy in experimental diabetic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blotting, Western; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Eplerenone; Male; Mineralocorticoid Receptor Antagonists; NF-kappa B; Peripheral Nerves; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; Receptors, Mineralocorticoid; RNA, Messenger; Spironolactone; Tetrazoles | 2012 |
What is the role of aldosterone excess in resistant hypertension and how should it be investigated and treated?
Topics: Aldosterone; Eplerenone; Female; Humans; Hyperaldosteronism; Hyperkalemia; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Practice Guidelines as Topic; Spironolactone | 2011 |
[Pharmacological sheet: eplerenone (Inspra), orally].
Topics: Cardiovascular Diseases; Drug Interactions; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Spironolactone | 2011 |
Effect of eplerenone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric chronic hemodialysis patients - a pilot study.
Topics: Aged; Anuria; Blood Pressure; Eplerenone; Female; Humans; Hypertension; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Oliguria; Pilot Projects; Prospective Studies; Renal Dialysis; Renin-Angiotensin System; Spironolactone; Treatment Outcome | 2011 |
Eplerenone prevents salt-induced vascular stiffness in Zucker diabetic fatty rats: a preliminary report.
Topics: Animals; Diabetes Mellitus, Type 2; Eplerenone; Male; Rats; Rats, Zucker; Sodium Chloride, Dietary; Spironolactone; Vascular Resistance; Vascular Stiffness | 2011 |
Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival St
Topics: Aged; Clinical Trials as Topic; Diuresis; Eplerenone; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Potassium; Spironolactone | 2011 |
The month after a novel tale on eplerenone, but with a different ending.
Topics: Diuresis; Eplerenone; Female; Heart Failure; Humans; Male; Mineralocorticoid Receptor Antagonists; Potassium; Spironolactone | 2011 |
A sensitive and specific HPLC-MS/MS analysis and preliminary pharmacokinetic characterization of isoforskolin in beagle dogs.
Topics: Animals; Chromatography, High Pressure Liquid; Colforsin; Dogs; Drug Stability; Eplerenone; Female; Linear Models; Liquid-Liquid Extraction; Male; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Spironolactone; Tandem Mass Spectrometry | 2011 |
Mineralocorticoid receptor antagonists for heart failure.
Topics: Aldosterone; Animals; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone | 2011 |
Aldosterone does not contribute to renal p21 expression during the development of angiotensin II-induced hypertension in mice.
Topics: Actins; Aldosterone; Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Cellular Senescence; Eplerenone; Genes, p16; Genes, p53; Hydralazine; Hypertension; Imidazoles; Kidney; Mice; Mice, Inbred C57BL; p21-Activated Kinases; Sirtuin 1; Sodium Chloride; Spironolactone; Tetrazoles | 2012 |
Eplerenone use in primary aldosteronism during pregnancy.
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Adenoma; Adult; Eplerenone; Female; Follow-Up Studies; Humans; Hyperaldosteronism; Mineralocorticoid Receptor Antagonists; Pregnancy; Pregnancy Complications; Spironolactone; Treatment Outcome | 2012 |
Aldosterone induces vascular insulin resistance by increasing insulin-like growth factor-1 receptor and hybrid receptor.
Topics: Aldosterone; Animals; Aorta, Thoracic; Blood Pressure; Cells, Cultured; Chimera; Eplerenone; Glucose; Hypertrophy; Insulin; Insulin Resistance; Male; Models, Animal; Muscle, Smooth, Vascular; Oxidative Stress; Rats; Rats, Sprague-Dawley; Receptor, IGF Type 1; Receptor, Insulin; Spironolactone; Up-Regulation | 2012 |
Role of mineralocorticoid receptor/Rho/Rho-kinase pathway in obesity-related renal injury.
Topics: Animals; Chemokine CCL2; Diet, Fat-Restricted; Diet, High-Fat; Eplerenone; Gene Expression Regulation; Immunohistochemistry; Kidney; Male; Mice; Mice, Inbred C57BL; Mineralocorticoid Receptor Antagonists; Obesity; Oxidative Stress; rho-Associated Kinases; Signal Transduction; Spironolactone; Tumor Necrosis Factor-alpha | 2012 |
Aldosterone inhibits endothelial morphogenesis and angiogenesis through the downregulation of vascular endothelial growth factor receptor-2 expression subsequent to peroxisome proliferator-activated receptor gamma.
Topics: Aldosterone; Angiogenesis Inhibitors; Animals; Collagen; Down-Regulation; Drug Combinations; Endothelium; Eplerenone; Human Umbilical Vein Endothelial Cells; Humans; Laminin; Male; Mice; Mice, Inbred C57BL; Mineralocorticoid Receptor Antagonists; Morphogenesis; Neovascularization, Physiologic; PPAR gamma; Proteoglycans; Spironolactone; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Eplerenone improved hypokalemia in a patient with Gitelman's syndrome.
Topics: Base Sequence; DNA Mutational Analysis; Eplerenone; Female; Gitelman Syndrome; Humans; Hypokalemia; Middle Aged; Mineralocorticoid Receptor Antagonists; Mutation, Missense; Potassium; Receptors, Drug; Solute Carrier Family 12, Member 3; Spironolactone; Symporters; Treatment Outcome | 2012 |
Activation of mineralocorticoid receptors in the rostral ventrolateral medulla is involved in hypertensive mechanisms in stroke-prone spontaneously hypertensive rats.
Topics: Aldosterone; Animals; Blood Pressure; Eplerenone; Hypertension; Male; Medulla Oblongata; Microinjections; Mineralocorticoid Receptor Antagonists; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptors, Mineralocorticoid; Spironolactone; Stroke; Sympathetic Nervous System | 2012 |
Antiapolipoprotein A-1 IgG chronotropic effects require nongenomic action of aldosterone on L-type calcium channels.
Topics: Aldosterone; Animals; Animals, Newborn; Apolipoprotein A-I; Calcium Channels, L-Type; Cells, Cultured; Dactinomycin; Electrophysiology; Eplerenone; Immunoglobulin G; Myocytes, Cardiac; Oxidation-Reduction; Oxygen; Phosphatidylinositol 3-Kinases; Rats; Rats, Wistar; Receptors, Mineralocorticoid; Spironolactone; Time Factors | 2012 |
Contribution of glucocorticoid-mineralocorticoid receptor pathway on the obesity-related adipocyte dysfunction.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; 3T3-L1 Cells; Adipocytes; Adipokines; Animals; Body Mass Index; Eplerenone; Glucocorticoids; Humans; Male; Metabolic Networks and Pathways; Mice; Mice, Mutant Strains; Mifepristone; Mineralocorticoid Receptor Antagonists; Obesity; Receptors, Glucocorticoid; Receptors, Mineralocorticoid; RNA, Small Interfering; Spironolactone | 2012 |
Genes implicated in insulin resistance are down-regulated in primary aldosteronism patients.
Topics: Adipocytes; Adiponectin; Adult; Aged; Aldosterone; Carrier Proteins; Cells, Cultured; Down-Regulation; Eplerenone; Female; Gene Expression; Humans; Hyperaldosteronism; Insulin Resistance; Intra-Abdominal Fat; Intracellular Signaling Peptides and Proteins; Lipid Metabolism; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Perilipin-1; Phosphoenolpyruvate Carboxykinase (GTP); Phosphoproteins; Potassium; PPAR gamma; Spironolactone | 2012 |
Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.
Topics: Androgen Receptor Antagonists; Androgens; Androstenes; Androstenols; Anilides; Benzamides; Binding, Competitive; Cell Line, Tumor; Drug Interactions; Eplerenone; Humans; Male; Metribolone; Nitriles; Phenylthiohydantoin; Prednisolone; Prostatic Neoplasms; Receptors, Androgen; Spironolactone; Tosyl Compounds | 2012 |
Angiotensin II- and salt-induced kidney injury through Rac1-mediated mineralocorticoid receptor activation.
Topics: Acute Kidney Injury; Adrenalectomy; Aldosterone; Analysis of Variance; Angiotensin II; Animals; Blotting, Western; Disease Models, Animal; Eplerenone; Immunohistochemistry; Male; Mice; Mice, Inbred Strains; rac1 GTP-Binding Protein; Random Allocation; Real-Time Polymerase Chain Reaction; Receptors, Mineralocorticoid; Signal Transduction; Sodium Chloride, Dietary; Spironolactone; Statistics, Nonparametric | 2012 |
Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Eplerenone; Heart; Heart Failure; Hospitalization; Humans; Kidney; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Randomized Controlled Trials as Topic; Spironolactone; Stroke Volume; Ventricular Dysfunction, Left | 2012 |
Spironolactone, but not eplerenone, impairs glucose tolerance in a rat model of metabolic syndrome.
Topics: Animals; Area Under Curve; Blood Glucose; Eplerenone; Glucose; Glucose Intolerance; Metabolic Syndrome; Mineralocorticoid Receptor Antagonists; Potassium; Rats; Sodium; Spironolactone | 2012 |
Low-dose spironolactone prevents apoptosis repressor with caspase recruitment domain degradation during myocardial infarction.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Caspase 2; Caspase 3; Caspase 9; Cell Line; Dose-Response Relationship, Drug; Enzyme Activation; Eplerenone; Immunoblotting; In Vitro Techniques; Male; Mineralocorticoid Receptor Antagonists; Muscle Proteins; Myocardial Infarction; Proteolysis; Rats; Rats, Sprague-Dawley; Receptors, Mineralocorticoid; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Spironolactone | 2012 |
Permanent muscular sodium overload and persistent muscle edema in Duchenne muscular dystrophy: a possible contributor of progressive muscle degeneration.
Topics: Adolescent; Child; Disease Progression; Edema; Eplerenone; Female; Follow-Up Studies; Humans; Male; Muscle Strength; Muscular Dystrophy, Duchenne; Pilot Projects; Prospective Studies; Sodium; Spironolactone; Young Adult | 2012 |
Aldosterone inhibits antifibrotic factors in mouse hypertensive heart.
Topics: Aldosterone; Animals; Animals, Newborn; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Blood Pressure; Blotting, Western; Bone Morphogenetic Protein 4; Cells, Cultured; Cytochrome P-450 CYP11B2; Eplerenone; Female; Fibrosis; Galectin 3; Gene Expression; Hyperaldosteronism; Hypertension; Male; Mice; Mice, Transgenic; Mineralocorticoid Receptor Antagonists; Myocardium; Natriuretic Peptide, Brain; Organ Size; Renin; Reverse Transcriptase Polymerase Chain Reaction; Spironolactone | 2012 |
Eplerenone inhibits aldosterone-induced renal expression of cyclooxygenase.
Topics: Acetophenones; Aldosterone; Animals; Blood Pressure; Blotting, Western; Cyclooxygenase 1; Cyclooxygenase 2; Dinoprostone; Eplerenone; Epoprostenol; Heart Rate; Immunohistochemistry; Kidney; Male; Membrane Proteins; Rats; Rats, Inbred Dahl; Spironolactone; Systole; Vasoconstrictor Agents | 2012 |
A diastereoselective synthesis of 7α-nitromethyl steroid derivative and its use for an efficient synthesis of eplerenone.
Topics: Canrenone; Crystallography, X-Ray; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Molecular Structure; Spironolactone; Stereoisomerism | 2012 |
Positive effect of eplerenone treatment on endothelial progenitor cells in patients with chronic heart failure.
Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Endothelial Cells; Eplerenone; Exercise; Heart Failure; Humans; Male; Middle Aged; Spironolactone; Stem Cells; Ultrasonography; Young Adult | 2012 |
Rationale for treating oedema in Duchenne muscular dystrophy with eplerenone.
Topics: Adult; Animals; Diaphragm; Edema; Eplerenone; Female; Forearm; Humans; In Vitro Techniques; Leg; Magnetic Resonance Imaging; Membrane Potentials; Mineralocorticoid Receptor Antagonists; Muscle Strength; Muscular Dystrophy, Duchenne; Rats; Rats, Wistar; Spironolactone; Young Adult | 2012 |
Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy.
Topics: Adult; Aldosterone; Animals; Central Serous Chorioretinopathy; Choroid; Corticosterone; Eplerenone; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Rats; Receptors, Mineralocorticoid; Retina; Signal Transduction; Small-Conductance Calcium-Activated Potassium Channels; Spironolactone; Treatment Outcome; Vasodilation; Vasodilator Agents; Visual Acuity | 2012 |
Usefulness of matrix metalloproteinase-9 plasma levels to identify patients with preserved left ventricular systolic function after acute myocardial infarction who could benefit from eplerenone.
Topics: Aged; Biomarkers; Enzyme-Linked Immunosorbent Assay; Eplerenone; Female; Humans; Male; Matrix Metalloproteinase 9; Middle Aged; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Prognosis; Proportional Hazards Models; Prospective Studies; ROC Curve; Spironolactone; Statistics, Nonparametric; Systole; Ventricular Function, Left | 2012 |
Eplerenone, an aldosterone blocker, is more effective in reducing blood pressure in patients with, than without, metabolic syndrome.
Topics: Aged; Albuminuria; Antihypertensive Agents; Blood Pressure; Eplerenone; Female; Humans; Male; Metabolic Syndrome; Middle Aged; Mineralocorticoid Receptor Antagonists; Natriuretic Peptide, Brain; Peptide Fragments; Prospective Studies; Spironolactone | 2012 |
Stress induced hippocampal mineralocorticoid and estrogen receptor β gene expression and long-term potentiation in male adult rats is sensitive to early-life stress experience.
Topics: Age Factors; Animals; Azacitidine; Corticosterone; Cyclofenil; Decitabine; Dentate Gyrus; DNA Methylation; DNA Modification Methylases; Eplerenone; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Gene Expression; Hippocampus; Long-Term Potentiation; Male; Maternal Deprivation; Mineralocorticoid Receptor Antagonists; Promoter Regions, Genetic; Rats; Rats, Wistar; Receptors, Androgen; Receptors, Glucocorticoid; Receptors, Mineralocorticoid; Spironolactone; Stress, Psychological; Testosterone; Up-Regulation | 2013 |
The 2012 ESC Guidelines on Heart Failure.
Topics: Benzazepines; Cardiac Resynchronization Therapy; Cardiotonic Agents; Eplerenone; Europe; Heart Failure; Humans; Infusions, Intravenous; Iron; Ivabradine; Life Style; Mineralocorticoid Receptor Antagonists; Practice Guidelines as Topic; Societies, Medical; Spironolactone | 2012 |
Recent developments in the management of heart failure.
Topics: Algorithms; Benzazepines; Cyclic Nucleotide-Gated Cation Channels; Eplerenone; Heart Failure; Humans; Ivabradine; Mineralocorticoid Receptor Antagonists; Natriuretic Peptide, Brain; Patient Care Team; Peptide Fragments; Spironolactone; Ventricular Dysfunction, Left | 2012 |
Effect of low dose mineralocorticoid receptor antagonist eplerenone on glucose and lipid metabolism in healthy adult males.
Topics: Adolescent; Adult; Blood Glucose; Blood Pressure; Cholesterol; Eplerenone; Glucose; Humans; Insulin; Insulin Resistance; Lipid Metabolism; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Postprandial Period; Prospective Studies; Receptors, Mineralocorticoid; Regression Analysis; Spironolactone; Young Adult | 2013 |
Ethics and eplerenone.
Topics: Clinical Trials as Topic; Cost-Benefit Analysis; Drug Costs; Eplerenone; Ethics Committees, Research; Ethics, Research; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Periodicals as Topic; Placebos; Research Personnel; Severity of Illness Index; Spironolactone; Therapeutic Equipoise; Treatment Outcome; United States; United States Food and Drug Administration | 2013 |
Mineralocorticoid receptor blocker eplerenone reduces pain behaviors in vivo and decreases excitability in small-diameter sensory neurons from local inflamed dorsal root ganglia in vitro.
Topics: Animals; Behavior, Animal; Eplerenone; Ganglia, Spinal; Inflammation; Male; Mineralocorticoid Receptor Antagonists; Pain; Pain Measurement; Primary Cell Culture; Rats; Rats, Sprague-Dawley; Sensory Receptor Cells; Spironolactone | 2012 |
Back pain and the mineralocorticoid receptor: is there a connection?
Topics: Animals; Eplerenone; Ganglia, Spinal; Male; Mineralocorticoid Receptor Antagonists; Pain; Sensory Receptor Cells; Spironolactone | 2012 |
Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizations.
Topics: Aged; Eplerenone; Follow-Up Studies; Heart Failure, Systolic; Hospitalization; Humans; Incidence; Linear Models; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Regression Analysis; Risk Factors; Spironolactone; Time Factors | 2012 |
A therapeutic opportunity that needs to be optimized.
Topics: Antihypertensive Agents; Aortic Valve Stenosis; Asymptomatic Diseases; Atrial Fibrillation; Eplerenone; Heart Ventricles; Humans; Hypertension; Spironolactone | 2012 |
Global systolic load, left ventricular hypertrophy, and atrial fibrillation.
Topics: Antihypertensive Agents; Aortic Valve Stenosis; Asymptomatic Diseases; Atrial Fibrillation; Eplerenone; Humans; Hypertension; Spironolactone | 2012 |
[Is eplerenone nephrotoxic?].
Topics: Aged; Controlled Clinical Trials as Topic; Creatinine; Dose-Response Relationship, Drug; Eplerenone; Female; Glomerular Filtration Rate; Heart Failure; Humans; Kidney Failure, Chronic; Mineralocorticoid Receptor Antagonists; Spironolactone; Ventricular Dysfunction, Left | 2012 |
Mineralocorticoid receptor antagonists and renal involvement in primary aldosteronism: opening of a new era.
Topics: Eplerenone; Female; Humans; Hyperaldosteronism; Kidney; Male; Spironolactone | 2013 |
Mineralocorticoid receptors/epithelial Na(+) channels in the choroid plexus are involved in hypertensive mechanisms in stroke-prone spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Choroid Plexus; Disease Models, Animal; Epithelial Sodium Channels; Eplerenone; Hypertension; Immediate-Early Proteins; Male; Mineralocorticoid Receptor Antagonists; Protein Serine-Threonine Kinases; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptors, Mineralocorticoid; Risk Factors; Signal Transduction; Sodium; Sodium Chloride, Dietary; Spironolactone; Stroke | 2013 |
3-Pyridyl substituted aliphatic cycles as CYP11B2 inhibitors: aromaticity abolishment of the core significantly increased selectivity over CYP1A2.
Topics: Algorithms; Androstadienes; Aromatase Inhibitors; Catalytic Domain; Cytochrome P-450 CYP11B2; Cytochrome P-450 CYP1A2 Inhibitors; Drug Design; Enalapril; Eplerenone; Fadrozole; Humans; Inhibitory Concentration 50; Models, Chemical; Models, Molecular; Molecular Conformation; Spironolactone; Structure-Activity Relationship; Temperature | 2012 |
Mineralocorticoid receptor blockade inhibits accelerated atherosclerosis induced by a low sodium diet in apolipoprotein E-deficient mice.
Topics: Aldosterone; Animals; Aorta; Apolipoproteins E; Atherosclerosis; Biomarkers; Diet, Sodium-Restricted; Eplerenone; Humans; Inflammation; Macrophages, Peritoneal; Mice; Mineralocorticoid Receptor Antagonists; Receptors, Mineralocorticoid; Renin; Renin-Angiotensin System; Spironolactone | 2014 |
Eplerenone reduced lesion size in early but not advanced atherosclerosis in apolipoprotein E-deficient mice.
Topics: Animals; Aorta, Thoracic; Aortic Diseases; Apolipoproteins E; Atherosclerosis; Cytochrome P-450 CYP11B2; Cytokines; Disease Models, Animal; Disease Progression; Eplerenone; Inflammation Mediators; Lipids; Macrophages, Peritoneal; Male; Mice; Mice, Knockout; Mineralocorticoid Receptor Antagonists; Plaque, Atherosclerotic; Receptors, Mineralocorticoid; RNA, Messenger; Spironolactone | 2012 |
Prostate effect in dogs with the aldosterone receptor blocker eplerenone.
Topics: Animals; Atrophy; Dihydrotestosterone; Dogs; Eplerenone; Finasteride; Histocytochemistry; Male; Mineralocorticoid Receptor Antagonists; Organ Size; Prostate; Protein Binding; Receptors, Androgen; Spironolactone | 2013 |
Determinants of blood pressure reduction by eplerenone in uncontrolled hypertension.
Topics: Adult; Blood Pressure; Eplerenone; Female; Humans; Hypertension; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Spironolactone; Treatment Outcome | 2013 |
Aldosterone-specific activation of cardiomyocyte mineralocorticoid receptor in vivo.
Topics: Aldosterone; Animals; Connective Tissue Growth Factor; Eplerenone; Mice; Mice, Transgenic; Mineralocorticoid Receptor Antagonists; Myocytes, Cardiac; Receptors, Mineralocorticoid; Spironolactone; Transcriptome | 2013 |
Myeloid mineralocorticoid receptor during experimental ischemic stroke: effects of model and sex.
Topics: Animals; Brain Ischemia; Disease Models, Animal; Eplerenone; Female; Gene Expression Profiling; Immunohistochemistry; Infarction, Middle Cerebral Artery; Male; Mice; Mice, Knockout; Mineralocorticoid Receptor Antagonists; Receptors, Mineralocorticoid; Spironolactone; Stroke | 2012 |
Effect of eplerenone on maintenance of sinus rhythm after catheter ablation in patients with long-standing persistent atrial fibrillation.
Topics: Atrial Fibrillation; Biomarkers; Catheter Ablation; Chi-Square Distribution; Combined Modality Therapy; Electrocardiography, Ambulatory; Eplerenone; Female; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Proportional Hazards Models; Retrospective Studies; Risk Factors; Spironolactone; Treatment Outcome | 2013 |
Aldosterone is synthesized in and activates bulbospinal neurons through mineralocorticoid receptors and ENaCs in the RVLM.
Topics: Aldosterone; Amiloride; Animals; Aromatase Inhibitors; Calcium; Diuretics; Epithelial Sodium Channels; Eplerenone; Excitatory Postsynaptic Potentials; Fadrozole; Magnesium; Medulla Oblongata; Membrane Potentials; Neurons; Patch-Clamp Techniques; Rats; Rats, Wistar; Receptors, Mineralocorticoid; Spinal Cord; Spironolactone; Tissue Fixation | 2013 |
The mineralocorticoid receptor antagonist eplerenone reduces renal interstitial fibrosis after long-term cyclosporine treatment in rat: antagonizing cyclosporine nephrotoxicity.
Topics: Animals; Cyclosporine; Drug Interactions; Eplerenone; Fibrosis; Immunosuppressive Agents; Kidney; Longitudinal Studies; Male; Mineralocorticoid Receptor Antagonists; Nephritis, Interstitial; Rats; Rats, Sprague-Dawley; Spironolactone; Treatment Outcome | 2013 |
Rho kinase pathway is likely responsible for the profibrotic actions of aldosterone in renal epithelial cells via inducing epithelial-mesenchymal transition and extracellular matrix excretion.
Topics: Actins; Aldosterone; Amides; Cadherins; Cell Line; Collagen Type I; Collagen Type III; Epithelial Cells; Epithelial-Mesenchymal Transition; Eplerenone; Extracellular Matrix; Gene Expression Regulation; Humans; Kidney; Mineralocorticoid Receptor Antagonists; Protein Kinase Inhibitors; Pyridines; Receptors, Mineralocorticoid; rho-Associated Kinases; RNA, Messenger; Signal Transduction; Spironolactone | 2013 |
Blood pressure variability activates cardiac mineralocorticoid receptor and induces cardiac remodeling in hypertensive rats.
Topics: Active Transport, Cell Nucleus; Aldosterone; Animals; Blood Pressure; Cardiomegaly; Cell Nucleus; Eplerenone; Humans; Hydrocortisone; Hypertension; Macrophages; Mineralocorticoid Receptor Antagonists; Muscle Proteins; Myocarditis; Myocardium; p21-Activated Kinases; Phosphorylation; Rats; Rats, Inbred SHR; Receptors, Mineralocorticoid; Spironolactone; Ventricular Remodeling | 2013 |
Central mineralocorticoid receptors and the role of angiotensin II and glutamate in the paraventricular nucleus of rats with angiotensin II-induced hypertension.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Disease Models, Animal; Eplerenone; Glutamic Acid; Heart Rate; Hypertension; Infusions, Intravenous; Infusions, Intraventricular; Kynurenic Acid; Male; Mineralocorticoid Receptor Antagonists; Paraventricular Hypothalamic Nucleus; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptors, Glutamate; Receptors, Mineralocorticoid; Signal Transduction; Spironolactone; Tetrazoles | 2013 |
The effects of aldosterone on diet-induced fatty liver formation in male C57BL/6 mice: comparison of adrenalectomy and mineralocorticoid receptor blocker.
Topics: Adrenalectomy; Aldosterone; Animals; Blood Glucose; Blood Pressure; Cells, Cultured; Cholesterol; Diet, High-Fat; Disease Models, Animal; Eplerenone; Fatty Liver; Hepatocytes; Insulin; Insulin Resistance; Lipoproteins, VLDL; Liver; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Mineralocorticoid Receptor Antagonists; Oleic Acid; Spironolactone; Triglycerides; Weight Gain | 2013 |
Eplerenone promotes alternative activation in human monocyte-derived macrophages.
Topics: Adolescent; Adult; Aldosterone; Arginase; Cells, Cultured; Eplerenone; Female; Gene Expression Regulation; Humans; Lectins, C-Type; Macrophages; Male; Mannose Receptor; Mannose-Binding Lectins; Mineralocorticoid Receptor Antagonists; Nitric Oxide; Nitric Oxide Synthase Type II; Reactive Oxygen Species; Receptors, Cell Surface; Spironolactone; Young Adult | 2013 |
Endothelial mineralocorticoid receptor activation mediates endothelial dysfunction in diet-induced obesity.
Topics: Adipose Tissue; Aldosterone; Animals; Antioxidants; Aorta; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Cytochrome P-450 Enzyme System; Diet, High-Fat; Endothelium, Vascular; Eplerenone; Glutathione Peroxidase; Glutathione Peroxidase GPX1; Hyperglycemia; Inflammation; Intramolecular Oxidoreductases; Male; Mice; Mice, Inbred C57BL; Mineralocorticoid Receptor Antagonists; Obesity; Oxidative Stress; Receptors, Mineralocorticoid; Spironolactone; Superoxide Dismutase; Superoxide Dismutase-1; Up-Regulation | 2013 |
Renin angiotensin antagonists normalize aberrant activation of epithelial sodium channels in sodium-sensitive hypertension.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Down-Regulation; Epithelial Sodium Channels; Eplerenone; Hypertension; Imidazoles; Male; Mice; Mice, Inbred C57BL; Mineralocorticoid Receptor Antagonists; Perindopril; Renin; Sodium; Sodium Chloride, Dietary; Spironolactone; Tetrazoles | 2012 |
Mineralocorticoid receptor agonists induce mouse aortic aneurysm formation and rupture in the presence of high salt.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta; Aortic Aneurysm, Abdominal; Aortic Aneurysm, Thoracic; Aortic Rupture; Apoptosis; Blood Pressure; Desoxycorticosterone; Disease Models, Animal; Elastin; Enalapril; Eplerenone; Losartan; Male; Mice; Mice, Inbred C57BL; Mineralocorticoid Receptor Antagonists; Muscle, Smooth, Vascular; Oxidative Stress; Receptors, Mineralocorticoid; Sodium Chloride, Dietary; Spironolactone; Time Factors | 2013 |
Mineralocorticoid receptor throughout the vessel: a key to vascular dysfunction in obesity.
Topics: Animals; Diet, High-Fat; Endothelium, Vascular; Eplerenone; Male; Mineralocorticoid Receptor Antagonists; Obesity; Receptors, Mineralocorticoid; Spironolactone | 2013 |
Protective effects of selective mineralocorticoid receptor antagonist against aortic aneurysm progression in a novel murine model.
Topics: Animals; Aortic Aneurysm; Blood Pressure; Chemokine CCL2; Disease Models, Animal; Disease Progression; Eplerenone; Gene Expression; Interleukin-6; Macrophages; Male; Mice; Mice, Inbred C57BL; Mineralocorticoid Receptor Antagonists; Spironolactone; Tumor Necrosis Factor-alpha; Vasculitis | 2013 |
Echocardiographic effects of eplerenone and aldosterone in hypertensive rats.
Topics: Aldosterone; Animals; Echocardiography; Eplerenone; Hypertension; Male; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Spironolactone | 2013 |
Eplerenone: another drug to add to the mix?
Topics: Eplerenone; Female; Heart Failure; Hospitalization; Humans; Hyperkalemia; Male; Mineralocorticoid Receptor Antagonists; Renal Insufficiency, Chronic; Spironolactone | 2013 |
Systematic approach: an evidence management strategy for better decision-making.
Topics: Decision Making; Eplerenone; Evidence-Based Medicine; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Reproducibility of Results; Spironolactone; Survival Rate; Ventricular Dysfunction, Left | 2013 |
Aldosterone signaling through transient receptor potential melastatin 7 cation channel (TRPM7) and its α-kinase domain.
Topics: Adenosine Triphosphate; Aldosterone; Annexin A1; Binding Sites; Boron Compounds; Calpain; Eplerenone; Gene Expression Regulation; HEK293 Cells; Humans; Ion Transport; Magnesium; NADPH Oxidases; Phosphorylation; Protein Binding; Protein Kinases; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Reactive Oxygen Species; Signal Transduction; Spectrin; Spironolactone; TRPM Cation Channels | 2013 |
Role of brain corticosterone and aldosterone in central angiotensin II-induced hypertension.
Topics: Aldosterone; Angiotensin II; Animals; Blood Pressure; Brain; Corticosterone; Cytochrome P-450 CYP11B2; Dose-Response Relationship, Drug; Eplerenone; Fadrozole; Heart Rate; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptors, Mineralocorticoid; Spironolactone | 2013 |
Eplerenone and chronic heart failure. No comparison with spironolactone.
Topics: Chronic Disease; Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Hyperkalemia; Mineralocorticoid Receptor Antagonists; Spironolactone | 2013 |
Patients' interest overlooked.
Topics: Chronic Disease; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone | 2013 |
[Effect of RAAS antagonist on the expression of gap junction cx43 in myocardium of spontaneously hypertensive rat].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Benzoates; Connexin 43; Eplerenone; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Myocardium; Ramipril; Rats; Rats, Inbred SHR; Rats, Wistar; Renin-Angiotensin System; Spironolactone; Telmisartan | 2013 |
A cornerstone of heart failure treatment is not effective in experimental right ventricular failure.
Topics: Animals; Disease Models, Animal; Drug Therapy, Combination; Eplerenone; Heart Failure; Losartan; Male; Random Allocation; Rats; Rats, Wistar; Spironolactone; Treatment Outcome; Ventricular Dysfunction, Right | 2013 |
Eplerenone enhances cardioprotective effects of standard heart failure therapy through matricellular proteins in hypertensive heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Drug Therapy, Combination; Eplerenone; Heart; Heart Failure; Hypertension; Hypertrophy, Left Ventricular; Male; Matrix Metalloproteinases; Mineralocorticoid Receptor Antagonists; Myocardium; Random Allocation; Rats; Rats, Inbred SHR; Spironolactone | 2013 |
Eplerenone ameliorates the phenotypes of metabolic syndrome with NASH in liver-specific SREBP-1c Tg mice fed high-fat and high-fructose diet.
Topics: Animals; Cells, Cultured; Diet, High-Fat; Dietary Carbohydrates; Eplerenone; Fatty Liver; Fructose; Liver; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mineralocorticoid Receptor Antagonists; Non-alcoholic Fatty Liver Disease; Phenotype; Rats; Rats, Wistar; Spironolactone; Sterol Regulatory Element Binding Protein 1 | 2013 |
Anatomical location and redistribution of G protein-coupled estrogen receptor-1 during the estrus cycle in mouse kidney and specific binding to estrogens but not aldosterone.
Topics: Aldosterone; Animals; Eplerenone; Estradiol; Estrus; Female; Gene Expression Regulation; Guanosine 5'-O-(3-Thiotriphosphate); HEK293 Cells; Humans; Kidney Tubules, Distal; Loop of Henle; Low Density Lipoprotein Receptor-Related Protein-2; Mice; Mineralocorticoid Receptor Antagonists; Protein Binding; Receptors, Estrogen; Receptors, G-Protein-Coupled; Receptors, Mineralocorticoid; Reproduction; Spironolactone | 2014 |
[REMINDER Study: myocardial infarct without heart failure: does eplerenone have an advantage?].
Topics: Double-Blind Method; Early Medical Intervention; Eplerenone; Germany; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Multicenter Studies as Topic; Myocardial Infarction; Prognosis; Randomized Controlled Trials as Topic; Spironolactone; Survival Rate | 2013 |
Eplerenone attenuated cardiac steatosis, apoptosis and diastolic dysfunction in experimental type-II diabetes.
Topics: Animals; Apoptosis; Cardiomegaly; Cell Line; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Diastole; Disease Models, Animal; Eplerenone; Fatty Acids; Fibrosis; Glucose; Hyperlipidemias; Lipid Metabolism; Male; Mineralocorticoid Receptor Antagonists; Mitochondria, Heart; Myocardium; Myocytes, Cardiac; Rats; Rats, Zucker; Spironolactone; Time Factors; Ventricular Dysfunction; Ventricular Function; Ventricular Remodeling | 2013 |
Eplerenone-mediated aldosterone blockade prevents renal fibrosis by reducing renal inflammation, interstitial cell proliferation and oxidative stress.
Topics: Animals; Cell Proliferation; Disease Models, Animal; Eplerenone; Fibrosis; Inflammation; Male; Mineralocorticoid Receptor Antagonists; Nephritis, Interstitial; Oxidative Stress; Random Allocation; Rats; Rats, Wistar; Spironolactone | 2013 |
Effects of eplerenone on P-wave signal-averaged electrocardiogram in hypertensive patients with coronary artery disease.
Topics: Aged; Coronary Artery Disease; Electrocardiography; Eplerenone; Female; Humans; Hypertension; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Spironolactone; Treatment Outcome | 2014 |
Eplerenone mimics features of the alternative activation in macrophages obtained from patients with heart failure and healthy volunteers.
Topics: Aged; Aldosterone; Arginase; Cell Survival; Drug Interactions; Eplerenone; Female; Gene Expression Regulation; Healthy Volunteers; Heart Failure; Humans; Interleukin-4; Lectins, C-Type; Macrophage Activation; Macrophages; Male; Mannose Receptor; Mannose-Binding Lectins; Middle Aged; Mineralocorticoid Receptor Antagonists; Nitric Oxide; Nitric Oxide Synthase Type II; Phenotype; Reactive Oxygen Species; Receptors, Cell Surface; Receptors, Mineralocorticoid; Spironolactone; Superoxide Dismutase | 2014 |
Aldosterone antagonists in systolic heart failure.
Topics: Chronic Disease; Eplerenone; Evidence-Based Medicine; Heart Failure, Systolic; Humans; Hyperkalemia; Mineralocorticoid Receptor Antagonists; Spironolactone | 2014 |
Cost effectiveness of eplerenone in patients with chronic heart failure.
Topics: Age Factors; Aged; Australia; Chronic Disease; Cost-Benefit Analysis; Eplerenone; Female; Heart Failure, Systolic; Humans; Male; Markov Chains; Middle Aged; Mineralocorticoid Receptor Antagonists; Models, Economic; Quality-Adjusted Life Years; Racial Groups; Sex Factors; Spironolactone | 2014 |
Eplerenone-mediated regression of electrical activation delays and myocardial fibrosis in heart failure.
Topics: Action Potentials; Animals; Anti-Inflammatory Agents; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Cardiovascular Agents; Disease Models, Animal; Dogs; Eplerenone; Fibrosis; Heart Failure; Hypertrophy, Left Ventricular; Inflammation Mediators; Interleukin-6; Male; Mineralocorticoid Receptor Antagonists; Myocardium; Spironolactone; Time Factors; Tumor Necrosis Factor-alpha; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2014 |
Effects of eplerenone on the activation of matrix metalloproteinase-2 stimulated by high glucose and interleukin-1β in human cardiac fibroblasts.
Topics: Cell Line; Culture Media; Enzyme Activation; Eplerenone; Fibroblasts; Gelatinases; Gene Expression; Glucose; Humans; Interleukin-1beta; Mannitol; Matrix Metalloproteinase 2; Myocardium; Osmolar Concentration; RNA, Messenger; Spironolactone | 2014 |
Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury.
Topics: Animals; Autoradiography; Cardiomegaly; Disease Models, Animal; Eplerenone; Heart Failure; Kidney Diseases; Male; Mineralocorticoid Receptor Antagonists; Naphthyridines; Natriuretic Peptide, Brain; Peptide Fragments; Rats; Rats, Sprague-Dawley; Rats, Wistar; Spironolactone; Tissue Distribution | 2014 |
The velocity of home blood pressure reduction in response to low-dose eplerenone combined with other antihypertensive drugs determined by exponential decay function analysis.
Topics: Adult; Aged; Aged, 80 and over; Aldosterone; Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Drug Therapy, Combination; Eplerenone; Female; Humans; Hypertension; Male; Middle Aged; Spironolactone; Treatment Outcome | 2014 |
Heart failure with systolic dysfunction complicating acute myocardial infarction - differential outcomes but similar eplerenone efficacy by ST-segment or non-ST-segment elevation: A post hoc substudy of the EPHESUS trial.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Cause of Death; Comorbidity; Coronary Thrombosis; Disease Progression; Electrocardiography; Eplerenone; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Revascularization; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Retrospective Studies; Spironolactone; Treatment Outcome | 2014 |
Significance of AT1 receptor independent activation of mineralocorticoid receptor in murine diabetic cardiomyopathy.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Eplerenone; Male; Mice; Mice, Knockout; Mineralocorticoid Receptor Antagonists; Receptor, Angiotensin, Type 1; Receptors, Mineralocorticoid; Spironolactone; Ventricular Dysfunction, Left | 2014 |
The use of eplerenone in therapy-resistant chronic central serous chorioretinopathy.
Topics: Administration, Oral; Adult; Central Serous Chorioretinopathy; Chronic Disease; Eplerenone; Female; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Receptors, Mineralocorticoid; Spironolactone; Subretinal Fluid; Tomography, Optical Coherence; Treatment Outcome; Visual Acuity | 2014 |
Mineralocorticoid receptor function in bone metabolism and its role in glucocorticoid-induced osteopenia.
Topics: Animals; Bone and Bones; Bone Diseases, Metabolic; Eplerenone; Glucocorticoids; Mice; Mice, Inbred Strains; Mineralocorticoid Receptor Antagonists; Osteocytes; Osteogenesis; Prednisone; Receptors, Mineralocorticoid; Spironolactone | 2014 |
Evaluating the efficacy of mineralocorticoid receptor antagonism in patients with STEMI without heart failure.
Topics: Eplerenone; Female; Humans; Male; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Spironolactone | 2014 |
Blocking the mineralocorticoid receptor improves effectiveness of steroid treatment for low back pain in rats.
Topics: Androstadienes; Animals; Disease Models, Animal; Eplerenone; Fluticasone; Ganglia, Spinal; Inflammation; Low Back Pain; Methylprednisolone; Mineralocorticoid Receptor Antagonists; Rats; Rats, Sprague-Dawley; Receptors, Mineralocorticoid; Spironolactone | 2014 |
Preconditioning actions of aldosterone through p38 signaling modulation in isolated rat hearts.
Topics: Aldosterone; Animals; Eplerenone; Heart; Ischemic Preconditioning, Myocardial; Male; Myocardial Reperfusion Injury; Myocardium; p38 Mitogen-Activated Protein Kinases; Perfusion; Rats; Rats, Wistar; Signal Transduction; Spironolactone | 2014 |
Aldosterone sensitizes connecting tubule glomerular feedback via the aldosterone receptor GPR30.
Topics: Aldosterone; Amiloride; Animals; Arterioles; Cycloheximide; Dactinomycin; Epithelial Sodium Channels; Eplerenone; Feedback; Kidney Tubules; Male; Rabbits; Receptors, G-Protein-Coupled; Receptors, Mineralocorticoid; Spironolactone | 2014 |
Atrial natriuretic peptide locally counteracts the deleterious effects of cardiomyocyte mineralocorticoid receptor activation.
Topics: Animals; Atrial Natriuretic Factor; Blotting, Western; Cardiomyopathy, Dilated; Connective Tissue Growth Factor; Disease Models, Animal; DNA; Eplerenone; Gene Expression Regulation; HEK293 Cells; Humans; Immunohistochemistry; Mice; Mice, Knockout; Microscopy, Confocal; Mineralocorticoid Receptor Antagonists; Myocytes, Cardiac; Receptors, Mineralocorticoid; Reverse Transcriptase Polymerase Chain Reaction; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Signal Transduction; Spironolactone; Ventricular Remodeling | 2014 |
Eplerenone reduces arterial thrombosis in diabetic rats.
Topics: Animals; Carotid Arteries; Diabetes Mellitus, Experimental; Eplerenone; Hemostasis; Interleukins; Male; Rats, Wistar; Regional Blood Flow; Spironolactone; Thrombosis; Vascular Patency | 2015 |
Cardiac macrophages and apoptosis after myocardial infarction: effects of central MR blockade.
Topics: Aldosterone; Animals; Apoptosis; Caspase 3; Disease Models, Animal; Eplerenone; Macrophages; Male; Myocardial Infarction; Rats, Wistar; Receptors, Mineralocorticoid; Spironolactone; Ventricular Remodeling | 2014 |
Adrenal gland inclusions in patients treated with aldosterone antagonists (Spironolactone/Eplerenone): incidence, morphology, and ultrastructural findings.
Topics: Adrenal Glands; Adrenalectomy; Adult; Aged; Eplerenone; Female; Humans; Hyperaldosteronism; Hypertension; Incidence; Inclusion Bodies; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Retrospective Studies; Spironolactone | 2014 |
Effectiveness of aldosterone antagonists for preventing atrial fibrillation after cardiac surgery in patients with systolic heart failure: a retrospective study.
Topics: Aged; Atrial Fibrillation; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Chi-Square Distribution; Coronary Artery Bypass; Eplerenone; Female; Greece; Heart Failure, Systolic; Heart Valves; Humans; Incidence; Logistic Models; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Multivariate Analysis; Odds Ratio; Retrospective Studies; Risk Factors; Spironolactone; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function, Left | 2015 |
The influence of ionizing radiation, temperature, and light on eplerenone in the solid state.
Topics: Chromatography, High Pressure Liquid; Drug Stability; Eplerenone; Light; Radiation, Ionizing; Spironolactone; Sterilization; Temperature | 2014 |
Developing a list of high-alert medications for patients with chronic diseases.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Amiodarone; Analgesics, Opioid; Anti-Arrhythmia Agents; Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Cytostatic Agents; Digoxin; Dronedarone; Drug-Related Side Effects and Adverse Reactions; Eplerenone; Humans; Hypoglycemic Agents; Immunosuppressive Agents; Insulin; Methotrexate; Mineralocorticoid Receptor Antagonists; Platelet Aggregation Inhibitors; Sodium Potassium Chloride Symporter Inhibitors; Spironolactone | 2014 |
Non-genomic effects of spironolactone and eplerenone in cardiomyocytes of neonatal Wistar rats: do they evoke cardioprotective pathways?
Topics: Aldosterone; Animals; Calcium; Cell Proliferation; Cyclic AMP; Cyclic GMP; Eplerenone; Female; Male; MAP Kinase Signaling System; Mineralocorticoid Receptor Antagonists; Myocytes, Cardiac; Protein Kinase C; Rats; Rats, Wistar; Signal Transduction; Spironolactone | 2015 |
Inhibition of local aldosterone by eplerenone reduces renal structural damage in a novel model of chronic cyclosporine A nephrotoxicity.
Topics: Adrenalectomy; Aldosterone; Animals; Chronic Disease; Cyclosporine; Cytochrome P-450 CYP11B2; Disease Models, Animal; Electrolytes; Eplerenone; Fibrosis; Kidney; Kidney Diseases; Male; Potassium; Rats, Sprague-Dawley; RNA, Messenger; Sodium; Spironolactone | 2015 |
Oxidative DNA damage in kidneys and heart of hypertensive mice is prevented by blocking angiotensin II and aldosterone receptors.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cyclic N-Oxides; Deoxyguanosine; DNA Damage; DNA Repair; Enzyme Activation; Eplerenone; Guanosine; Heart; Hypertension; Kidney; Male; Mice; Mice, Inbred C57BL; Mineralocorticoid Receptor Antagonists; NF-E2-Related Factor 2; NF-kappa B; Oxidative Stress; Reactive Oxygen Species; Renin-Angiotensin System; Spin Labels; Spironolactone; Tetrazoles | 2014 |
Prevention of cardiomyopathy in Duchenne muscular dystrophy.
Topics: Cardiomyopathies; Eplerenone; Humans; Male; Mineralocorticoid Receptor Antagonists; Muscular Dystrophy, Duchenne; Spironolactone | 2015 |
[High doses of aldosterone antagonist is a condition of sufficient blood pressure control in bilateral adrenal hyperplasia].
Topics: Adrenal Glands; Aged; Eplerenone; Humans; Hyperplasia; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Spironolactone | 2015 |
Beneficial effects of mineralocorticoid receptor blockade in experimental non-alcoholic steatohepatitis.
Topics: Animals; Biomarkers; Disease Models, Animal; Eplerenone; Liver; Liver Cirrhosis; Male; Mice; Mice, Inbred C57BL; Mineralocorticoid Receptor Antagonists; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Receptors, Mineralocorticoid; Spironolactone | 2015 |
Regulation of myogenic tone and structure of parenchymal arterioles by hypertension and the mineralocorticoid receptor.
Topics: Animals; Antihypertensive Agents; Arterioles; Calcium; Calcium Channel Blockers; Calcium Channels, L-Type; Cerebrovascular Circulation; Cerebrum; Compliance; Eplerenone; Hydralazine; Hydrochlorothiazide; Hypertension; Middle Cerebral Artery; Mineralocorticoid Receptor Antagonists; Muscle Tonus; Muscle, Smooth, Vascular; Nifedipine; Organ Size; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptors, Mineralocorticoid; Reserpine; Spironolactone; Vascular Remodeling; Vascular Stiffness | 2015 |
DSR-71167, a novel mineralocorticoid receptor antagonist with carbonic anhydrase inhibitory activity, separates urinary sodium excretion and serum potassium elevation in rats.
Topics: Animals; Antihypertensive Agents; Benzamides; Carbonic Anhydrase Inhibitors; Chlorocebus aethiops; COS Cells; Eplerenone; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Potassium; Rats, Inbred Dahl; Rats, Sprague-Dawley; Receptors, Androgen; Receptors, Glucocorticoid; Receptors, Mineralocorticoid; Receptors, Progesterone; Risk Assessment; Sodium; Spironolactone; Sulfonamides; Transcriptional Activation | 2015 |
Oral eplerenone for treatment of chronic central serous chorioretinopathy: a case series.
Topics: Administration, Oral; Adult; Aged; Central Serous Chorioretinopathy; Choroid; Chronic Disease; Eplerenone; Female; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Retrospective Studies; Spironolactone; Subretinal Fluid; Tomography, Optical Coherence; Visual Acuity | 2015 |
[Treatment of diffuse retinal pigment epitheliopathies by antialdosterones or by photodynamic therapy].
Topics: Central Serous Chorioretinopathy; Eplerenone; Follow-Up Studies; Humans; Mineralocorticoid Receptor Antagonists; Photochemotherapy; Pigment Epithelium of Eye; Retinal Diseases; Retrospective Studies; Spironolactone; Tomography, Optical Coherence | 2015 |
Crosstalk between peroxisome proliferator-activated receptor-γ and mineralcorticoid receptor in TNF-α activated renal tubular cell.
Topics: Anilides; Anti-Inflammatory Agents; Cell Line; Drug Synergism; Eplerenone; Humans; Intercellular Adhesion Molecule-1; Interleukin-6; Kidney Tubules, Proximal; Mineralocorticoid Receptor Antagonists; NF-kappa B; Pioglitazone; PPAR gamma; Receptors, Mineralocorticoid; Spironolactone; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2015 |
Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist.
Topics: Administration, Oral; Adrenalectomy; Aldosterone; Animals; Antihypertensive Agents; Binding, Competitive; Blood Pressure; Desoxycorticosterone Acetate; Disease Models, Animal; Dose-Response Relationship, Drug; Eplerenone; Female; HEK293 Cells; Humans; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Potassium; Protein Binding; Pyrroles; Rabbits; Radioligand Assay; Rats, Inbred WKY; Rats, Sprague-Dawley; Receptors, Mineralocorticoid; Sodium; Spironolactone; Sulfones; Transcriptional Activation; Transfection; Urological Agents; Water-Electrolyte Balance | 2015 |
Effects of Add-on Therapy Consisting of a Selective Mineralocorticoid Receptor Blocker on Arterial Stiffness in Patients with Uncontrolled Hypertension.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Eplerenone; Female; Humans; Hypertension; Male; Receptors, Mineralocorticoid; Retrospective Studies; Spironolactone; Treatment Outcome; Vascular Stiffness | 2015 |
Cooperative Role of Mineralocorticoid Receptor and Caveolin-1 in Regulating the Vascular Response to Low Nitric Oxide-High Angiotensin II-Induced Cardiovascular Injury.
Topics: Angiotensin II; Animals; Aorta; Blood Pressure; Cardiovascular System; Caveolin 1; Cyclic GMP; Eplerenone; Heart Injuries; Male; Mice; Mineralocorticoid Receptor Antagonists; Models, Molecular; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nucleic Acid Conformation; Receptors, Mineralocorticoid; Renin-Angiotensin System; Signal Transduction; Spironolactone; Vasoconstriction; Vasodilation | 2015 |
Angiotensin and mineralocorticoid receptor antagonism attenuates cardiac oxidative stress in angiotensin II-infused rats.
Topics: Adrenal Glands; Aldehydes; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Blood Pressure; Disease Models, Animal; Drug Therapy, Combination; Eplerenone; Heart Diseases; Hypertension; Lipid Peroxidation; Losartan; Male; Mineralocorticoid Receptor Antagonists; Myocardium; Oxidative Stress; Rats, Sprague-Dawley; Renin-Angiotensin System; Signal Transduction; Spironolactone; Time Factors; Tyrosine | 2015 |
[Cardiovascular drugs in aged and multimorbid patients].
Topics: Aged; Aged, 80 and over; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Comorbidity; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Eplerenone; Female; Guideline Adherence; Heart Failure; Humans; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Pacemaker, Artificial; Risk Factors; Spironolactone | 2015 |
CENTRAL SEROUS CHORIORETINOPATHY TREATED WITH MINERALOCORTICOID ANTAGONISTS: A ONE-YEAR PILOT STUDY.
Topics: Adult; Aged; Central Serous Chorioretinopathy; Eplerenone; Female; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Multimodal Imaging; Pilot Projects; Retrospective Studies; Spironolactone; Subretinal Fluid; Visual Acuity | 2016 |
Successful Treatment with an Antihypertensive Drug Regimen Including Eplerenone in a Patient with Malignant Phase Hypertension with Renal Failure.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Calcium Channel Blockers; Creatinine; Drug Therapy, Combination; Eplerenone; Heart Failure; Humans; Hypertension, Malignant; Male; Nifedipine; Nitroglycerin; Obesity; Renal Insufficiency; Spironolactone; Tetrazoles; Treatment Outcome; Vasodilator Agents | 2015 |
Rac1-Mediated Activation of Mineralocorticoid Receptor in Pressure Overload-Induced Cardiac Injury.
Topics: Animals; Disease Models, Animal; Eplerenone; Heart Failure; Male; Mice; Mice, Inbred C57BL; Mineralocorticoid Receptor Antagonists; Myocytes, Cardiac; Neuropeptides; Oxidative Stress; rac1 GTP-Binding Protein; Receptors, Mineralocorticoid; Signal Transduction; Spironolactone; Ventricular Pressure; Ventricular Remodeling | 2016 |
Role of brain aldosterone and mineralocorticoid receptors in aldosterone-salt hypertension in rats.
Topics: Aldosterone; Animals; Arterial Pressure; Corticosterone; Cytochrome P-450 CYP11B2; Drinking Behavior; Eplerenone; Fadrozole; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Neurons; Paraventricular Hypothalamic Nucleus; Rats; Rats, Wistar; Receptors, Mineralocorticoid; RNA, Messenger; Sodium Chloride; Spironolactone; Subfornical Organ; Supraoptic Nucleus | 2016 |
Eplerenone in patients with chronic recurring central serous chorioretinopathy.
Topics: Aged; Central Serous Chorioretinopathy; Chronic Disease; Eplerenone; Female; Fluorescein Angiography; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Photochemotherapy; Recurrence; Retrospective Studies; Spironolactone; Tomography, Optical Coherence; Visual Acuity | 2016 |
Eplerenone improves carotid intima-media thickness (IMT) in patients with primary aldosteronism.
Topics: Adrenalectomy; Adult; Aged; Aldosterone; Atherosclerosis; Biomarkers; Carotid Intima-Media Thickness; Drug Monitoring; Eplerenone; Female; Follow-Up Studies; Humans; Hyperaldosteronism; Hypertension; Hypokalemia; Japan; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Potassium; Reproducibility of Results; Risk; Spironolactone | 2016 |
Ceramide Production Mediates Aldosterone-Induced Human Umbilical Vein Endothelial Cell (HUVEC) Damages.
Topics: Aldosterone; Ceramides; Eplerenone; Gene Knockdown Techniques; Human Umbilical Vein Endothelial Cells; Humans; Lysophospholipids; Membrane Proteins; Signal Transduction; Sphingosine; Sphingosine N-Acyltransferase; Spironolactone | 2016 |
Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF study.
Topics: Aged; Aspirin; Blood Pressure; Chronic Disease; Drug Interactions; Eplerenone; Female; Glomerular Filtration Rate; Heart Failure, Systolic; Humans; Male; Mineralocorticoid Receptor Antagonists; Platelet Aggregation Inhibitors; Potassium; Proportional Hazards Models; Spironolactone; Stroke Volume | 2016 |
Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists Cause Differential Cardiac Gene Expression in Pressure Overload-induced Cardiac Hypertrophy.
Topics: Animals; Cardiomegaly; Disease Models, Animal; Eplerenone; Gene Expression; Male; Mice; Mice, Inbred C57BL; Mineralocorticoid Receptor Antagonists; Naphthyridines; Natriuretic Peptide, Brain; Spironolactone; Troponin T; Ventricular Remodeling | 2016 |
Hyperaldosteronism after decreased renal K+ excretion in KCNMB2 knockout mice.
Topics: Aldosterone; Animals; Blood Pressure; Epithelial Sodium Channels; Eplerenone; Female; Hyperaldosteronism; Kidney; Large-Conductance Calcium-Activated Potassium Channel beta Subunits; Male; Mice, Inbred C57BL; Mice, Knockout; Polyuria; Potassium; Sodium, Dietary; Solute Carrier Family 12, Member 3; Spironolactone | 2016 |
Mineralocorticoid Antagonists in the Treatment of Central Serous Chorioretinopathy: A Comparative Analysis.
Topics: Administration, Oral; Adult; Central Serous Chorioretinopathy; Dose-Response Relationship, Drug; Eplerenone; Female; Fluorescein Angiography; Follow-Up Studies; Fundus Oculi; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Retinal Ganglion Cells; Retrospective Studies; Spironolactone; Time Factors; Tomography, Optical Coherence; Treatment Outcome | 2016 |
Eplerenone restores 24-h blood pressure circadian rhythm and reduces advanced glycation end-products in rhesus macaques with spontaneous hypertensive metabolic syndrome.
Topics: Anesthesia, General; Animals; Antihypertensive Agents; Blood Pressure; Circadian Rhythm; Drug Evaluation, Preclinical; Eplerenone; Glycation End Products, Advanced; Hypertension; Macaca mulatta; Metabolic Syndrome; Mineralocorticoid Receptor Antagonists; Models, Animal; Spironolactone; Telemetry; Wakefulness | 2016 |
Biotransformation of the mineralocorticoid receptor antagonists spironolactone and canrenone by human CYP11B1 and CYP11B2: Characterization of the products and their influence on mineralocorticoid receptor transactivation.
Topics: Biotransformation; Canrenone; Cloning, Molecular; Cortodoxone; Cytochrome P-450 CYP11B2; Desoxycorticosterone; Eplerenone; Escherichia coli; Humans; Kinetics; Mineralocorticoid Receptor Antagonists; Receptors, Mineralocorticoid; Recombinant Proteins; Spironolactone; Steroid 11-beta-Hydroxylase; Transcriptional Activation | 2016 |
Clinical experience with eplerenone to treat chronic central serous chorioretinopathy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Central Serous Chorioretinopathy; Chronic Disease; Dose-Response Relationship, Drug; Eplerenone; Female; Fluorescein Angiography; Follow-Up Studies; Fundus Oculi; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Retinal Pigment Epithelium; Retrospective Studies; Spironolactone; Tomography, Optical Coherence; Treatment Outcome; Visual Acuity | 2016 |
Cost-Effectiveness of Eplerenone Compared to Usual Care in Patients With Chronic Heart Failure and NYHA Class II Symptoms, an Australian Perspective.
Topics: Australia; Chronic Disease; Cost-Benefit Analysis; Eplerenone; Heart Failure; Hospitalization; Humans; Medication Therapy Management; Mineralocorticoid Receptor Antagonists; Severity of Illness Index; Spironolactone; Survival Analysis | 2016 |
A novel role for the mineralocorticoid receptor in glucocorticoid driven vascular calcification.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Apoptosis; Corticosterone; Disease Models, Animal; Eplerenone; Flow Cytometry; Glucocorticoids; Mice; Mice, Inbred C57BL; Mifepristone; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Phosphates; Receptors, Glucocorticoid; Receptors, Mineralocorticoid; RNA, Messenger; Spironolactone; Vascular Calcification | 2016 |
Pharmacokinetic study of eplerenone in rats after long-term coadministration with buckwheat tea.
Topics: Animals; Calibration; Chromatography, High Pressure Liquid; Eplerenone; Fagopyrum; Limit of Detection; Male; Mass Spectrometry; Rats, Sprague-Dawley; Reference Standards; Reproducibility of Results; Solutions; Spironolactone; Teas, Herbal; Time Factors | 2016 |
[Eplerenone treatment in chronic central serous chorioretinopathy].
Topics: Adult; Aged; Central Serous Chorioretinopathy; Chronic Disease; Eplerenone; Female; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Retrospective Studies; Spironolactone; Treatment Outcome; Young Adult | 2016 |
A validated stability-indicating ultra performance liquid chromatography method for the determination of potential process-related impurities in eplerenone.
Topics: Chromatography, High Pressure Liquid; Drug Stability; Eplerenone; Mineralocorticoid Receptor Antagonists; Molecular Conformation; Spironolactone | 2016 |
Cost Effectiveness of Eplerenone for the Treatment of Systolic Heart Failure with Mild Symptoms in Alberta, Canada.
Topics: Aged; Aged, 80 and over; Alberta; Cost-Benefit Analysis; Drug Costs; Drug-Related Side Effects and Adverse Reactions; Eplerenone; Female; Heart Failure, Systolic; Humans; Male; Mineralocorticoid Receptor Antagonists; Quality-Adjusted Life Years; Spironolactone | 2016 |
Do Diuretics have Antinociceptive Actions: Studies of Spironolactone, Eplerenone, Furosemide and Chlorothiazide, Individually and with Oxycodone and Morphine.
Topics: Analgesics; Analgesics, Opioid; Animals; Behavior, Animal; Brain; Chlorothiazide; Disease Models, Animal; Diuretics; Drug Interactions; Drug Therapy, Combination; Eplerenone; Furosemide; Male; Morphine; Neurons; Oxycodone; Pain; Rats, Sprague-Dawley; Spironolactone; Tissue Distribution | 2017 |
SFE/SFHTA/AFCE consensus on primary aldosteronism, part 7: Medical treatment of primary aldosteronism.
Topics: Eplerenone; Female; France; Humans; Hyperaldosteronism; Hypertension; Hypokalemia; Male; Mineralocorticoid Receptor Antagonists; Spironolactone; Treatment Outcome | 2016 |
Eplerenone inhibits atrial fibrosis in mutant TGF-β1 transgenic mice.
Topics: Animals; Blotting, Western; Cells, Cultured; Coculture Techniques; Connective Tissue Growth Factor; Eplerenone; Fibroblasts; Fibronectins; Fibrosis; Gene Expression; Heart Atria; Interleukin-6; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microscopy, Fluorescence; Mineralocorticoid Receptor Antagonists; Mutation; Myocardium; Reverse Transcriptase Polymerase Chain Reaction; Spironolactone; Transforming Growth Factor beta1 | 2016 |
Parathyroid hormone, aldosterone-to-renin ratio and fibroblast growth factor-23 as determinants of nocturnal blood pressure in primary hyperparathyroidism: the eplerenone in primary hyperparathyroidism trial.
Topics: Aged; Aldosterone; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium; Circadian Rhythm; Cross-Sectional Studies; Diastole; Eplerenone; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperparathyroidism, Primary; Hypertension; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Parathyroid Hormone; Randomized Controlled Trials as Topic; Renin; Risk Factors; Sex Factors; Spironolactone; Systole | 2016 |
ARAs to the RESCUE.
Topics: Aldosterone; Eplerenone; Gynecomastia; Humans; Hyperaldosteronism; Hypertension; Hypokalemia; Meta-Analysis as Topic; Mineralocorticoid Receptor Antagonists; Spironolactone | 2016 |
The TBX1 Transcription Factor in Cardiac Remodeling After Myocardial Infarction.
Topics: Actinin; Animals; Atrial Natriuretic Factor; Blotting, Western; Eplerenone; Fibrosis; Gene Expression Regulation, Developmental; Heart; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Myocardium; Myosin Heavy Chains; Natriuretic Peptide, Brain; Rats; Real-Time Polymerase Chain Reaction; RNA, Messenger; Spironolactone; T-Box Domain Proteins; Ventricular Remodeling | 2016 |
Aldosterone Upregulates Transient Receptor Potential Melastatin 7 (TRPM7).
Topics: Aldosterone; Benzoates; Bridged Bicyclo Compounds, Heterocyclic; Eplerenone; HEK293 Cells; Humans; Immediate-Early Proteins; Protein Domains; Protein Serine-Threonine Kinases; Receptors, Mineralocorticoid; Signal Transduction; Spironolactone; TRPM Cation Channels; Up-Regulation | 2016 |
Effect of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer on bioadhesion and release rate property of eplerenone pellets.
Topics: Adhesiveness; Administration, Oral; Animals; Biological Availability; Chemistry, Pharmaceutical; Drug Implants; Drug Liberation; Eplerenone; Excipients; Kinetics; Particle Size; Polyethylene Glycols; Polyvinyls; Rabbits; Rats; Rats, Wistar; Solubility; Spectroscopy, Fourier Transform Infrared; Spironolactone | 2017 |
Mineralocorticoid Receptor Blockade Improves Insulin Sensitivity in the Rat Heart and a Possible Molecular Mechanism.
Topics: Adiponectin; Aldosterone; Animals; Animals, Newborn; Biological Transport; Eplerenone; Gene Expression Regulation; Glucose; Glucose Clamp Technique; Insulin; Insulin Resistance; Male; Mineralocorticoid Receptor Antagonists; Myocytes, Cardiac; p38 Mitogen-Activated Protein Kinases; PPAR alpha; Primary Cell Culture; Rats; Rats, Sprague-Dawley; Receptors, Mineralocorticoid; RNA, Messenger; Signal Transduction; Spironolactone | 2016 |
Aldosterone Synthase Inhibition Improves Glucose Tolerance in Zucker Diabetic Fatty (ZDF) Rats.
Topics: Adrenal Glands; Aldosterone; Animals; Blood Glucose; Body Weight; Cytochrome P-450 CYP11B2; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Evaluation, Preclinical; Eating; Eplerenone; Fadrozole; Glucose Tolerance Test; Glycated Hemoglobin; Insulin; Insulin Resistance; Insulin Secretion; Liver; Male; Mineralocorticoid Receptor Antagonists; Organ Size; Potassium; Random Allocation; Rats, Zucker; Sodium; Spironolactone; Triglycerides | 2016 |
The Clinical Value of Salivary Aldosterone in Diagnosis and Follow-Up of Primary Aldosteronism.
Topics: Adrenalectomy; Aged; Aldosterone; Case-Control Studies; Circadian Rhythm; Eplerenone; Female; Follow-Up Studies; Humans; Hyperaldosteronism; Hypertension; Male; Middle Aged; Prognosis; Prospective Studies; Retrospective Studies; Saliva; Spironolactone | 2016 |
Caveolin 1 Modulates Aldosterone-Mediated Pathways of Glucose and Lipid Homeostasis.
Topics: Adipose Tissue; Adolescent; Adult; Aged; Aldehyde Reductase; Aldosterone; Animals; Blood Glucose; Caveolin 1; Cholesterol; Dyslipidemias; Eplerenone; Female; Gene Frequency; Glucose; Homeostasis; Humans; Hypertriglyceridemia; Insulin; Insulin Resistance; Lipid Metabolism; Lipoproteins, HDL; Liver; Male; Mice; Mice, Knockout; Middle Aged; Mineralocorticoid Receptor Antagonists; NADPH Oxidase 4; Polymorphism, Single Nucleotide; Receptors, Mineralocorticoid; Resistin; Retinol-Binding Proteins, Plasma; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Spironolactone; Triglycerides; Young Adult | 2016 |
Pathophysiological aldosterone levels modify the secretory activity of cardiac progenitor cells.
Topics: Aldosterone; Animals; Cell Movement; Cell Proliferation; Cytokines; Eplerenone; Mice; Mineralocorticoid Receptor Antagonists; Myocardium; Proteome; Reproducibility of Results; Spironolactone; Stem Cells | 2017 |
Similar efficacy from specific and non-specific mineralocorticoid receptor antagonist treatment of muscular dystrophy mice.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Disease Models, Animal; Eplerenone; Gene Knockdown Techniques; Heart; Lisinopril; Male; Mice; Mice, Inbred mdx; Mineralocorticoid Receptor Antagonists; Muscle, Skeletal; Muscular Dystrophy, Animal; Myocardium; Spironolactone; Treatment Outcome; Utrophin | 2016 |
Efficacy of Eplerenone in the Management of Mineralocorticoid Excess in Men With Metastatic Castration-resistant Prostate Cancer Treated With Abiraterone Without Prednisone.
Topics: Abiraterone Acetate; Aged; Antineoplastic Combined Chemotherapy Protocols; Eplerenone; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Spironolactone; Survival Analysis; Treatment Outcome | 2017 |
Eplerenone in the management of resistant hypertension with obstructive sleep apnoea in pregnancy.
Topics: Adult; Eplerenone; Female; Humans; Mineralocorticoid Receptor Antagonists; Obesity, Morbid; Pre-Eclampsia; Pregnancy; Pregnancy Outcome; Sleep Apnea, Obstructive; Spironolactone; Ultrasonography, Prenatal | 2017 |
Eplerenone repolarizes muscle membrane through Na,K-ATPase activation by Tyr10 dephosphorylation.
Topics: Animals; Cell Line; Diaphragm; Enzyme Inhibitors; Eplerenone; Membrane Potentials; Mice; Mineralocorticoid Receptor Antagonists; Muscular Dystrophy, Duchenne; Ouabain; Phosphorylation; Proto-Oncogene Proteins c-akt; Rats; RNA, Messenger; Sodium-Potassium-Exchanging ATPase; Spironolactone; Transcription, Genetic | 2016 |
The Inhibitory Effect of Eplerenone on Cell Proliferation in the Contralateral Kidneys of Rats with Unilateral Ureteral Obstruction.
Topics: Actins; Aldosterone; Animals; Cell Proliferation; Collagen; Eplerenone; Fibrosis; Immediate-Early Proteins; Kidney; Male; MAP Kinase Signaling System; Mineralocorticoid Receptor Antagonists; Proliferating Cell Nuclear Antigen; Protein Serine-Threonine Kinases; Rats; Rats, Sprague-Dawley; Receptors, Mineralocorticoid; Spironolactone; Tumor Necrosis Factor-alpha; Up-Regulation; Ureteral Obstruction | 2017 |
Gene expression effects of glucocorticoid and mineralocorticoid receptor agonists and antagonists on normal human skeletal muscle.
Topics: Adolescent; Adult; Aldosterone; Blotting, Western; Cells, Cultured; Eplerenone; Humans; Male; Muscle, Skeletal; Muscular Dystrophy, Duchenne; Prednisolone; Receptors, Glucocorticoid; Receptors, Mineralocorticoid; Spironolactone; Young Adult | 2017 |
Emphasis on abdominal obesity as a modifier of eplerenone effect in heart failure: hypothesis-generating signals from EMPHASIS-HF.
Topics: Eplerenone; Heart Failure; Mineralocorticoid Receptor Antagonists; Obesity, Abdominal; Spironolactone | 2017 |
Eplerenone for chronic central serous chorioretinopathy-a randomized controlled prospective study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Central Serous Chorioretinopathy; Choroid; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind Method; Eplerenone; Female; Fluorescein Angiography; Follow-Up Studies; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Prospective Studies; Spironolactone; Time Factors; Tomography, Optical Coherence; Treatment Outcome; Visual Acuity; Young Adult | 2017 |
Topics: Adipose Tissue; Child; Diuretics; Edema; Elasticity; Eplerenone; Glucocorticoids; Humans; Hydrogen; Imaging, Three-Dimensional; Magnetic Resonance Imaging; Male; Muscle, Skeletal; Muscular Dystrophy, Duchenne; Pilot Projects; Pregnenediones; Sodium Radioisotopes; Spironolactone | 2017 |
The Aldosterone Receptor Antagonist Eplerenone Inhibits Isoproterenol-Induced Collagen-I and 11β-HSD1 Expression in Rat Cardiac Fibroblasts and the Left Ventricle.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adrenergic beta-Agonists; Animals; Cells, Cultured; Collagen Type I; Eplerenone; Fibroblasts; Fibrosis; Heart Ventricles; Isoproterenol; Male; Mineralocorticoid Receptor Antagonists; Rats; Rats, Inbred WKY; Spironolactone | 2017 |
Spironolactone-induced degradation of the TFIIH core complex XPB subunit suppresses NF-κB and AP-1 signalling.
Topics: Animals; Anti-Inflammatory Agents; Disease Models, Animal; DNA Helicases; DNA-Binding Proteins; Endothelial Cells; Eplerenone; Fibroblasts; HEK293 Cells; Humans; Hypertension, Pulmonary; Inflammation Mediators; Lung; Mineralocorticoid Receptor Antagonists; Mutation; NF-kappa B; Proteasome Endopeptidase Complex; Proteolysis; Pulmonary Artery; Rats, Sprague-Dawley; Retrospective Studies; RNA Polymerase II; Signal Transduction; Spironolactone; Transcription Factor AP-1; Transcription Factor TFIIH | 2018 |
Irvine-Gass Macular Edema Responding to the Combination of Oral Mineralocorticoid-Receptor Antagonist With Dexamethasone Drops.
Topics: Administration, Oral; Administration, Topical; Aged; Aged, 80 and over; Dexamethasone; Drug Therapy, Combination; Eplerenone; Female; Glucocorticoids; Humans; Macular Edema; Male; Mineralocorticoid Receptor Antagonists; Ophthalmic Solutions; Spironolactone; Tomography, Optical Coherence | 2017 |
Mineralocorticoid receptor antagonism protects the aorta from vascular smooth muscle cell proliferation and collagen deposition in a rat model of adrenal aldosterone-producing adenoma.
Topics: ACTH-Secreting Pituitary Adenoma; Aldosterone; Animals; Antihypertensive Agents; Aorta; Cell Proliferation; Collagen; Disease Models, Animal; Eplerenone; Hydralazine; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Muscle, Smooth, Vascular; Proto-Oncogene Proteins c-mdm2; Random Allocation; Rats, Sprague-Dawley; Spironolactone; Transforming Growth Factor beta; Vascular Remodeling; Vasodilator Agents | 2018 |
Eplerenone Reduces Atrial Fibrillation Burden Without Preventing Atrial Electrical Remodeling.
Topics: Animals; Atrial Fibrillation; Atrial Remodeling; Cardiac Pacing, Artificial; Eplerenone; Fibrosis; Male; Mineralocorticoid Receptor Antagonists; Sheep; Spironolactone | 2017 |
Upstream Targets to Treat Atrial Fibrillation.
Topics: Atrial Fibrillation; Atrial Remodeling; Eplerenone; Heart Atria; Humans; Spironolactone | 2017 |
Multimodal retinal imaging in central serous chorioretinopathy treated with oral eplerenone or photodynamic therapy.
Topics: Administration, Oral; Adult; Central Serous Chorioretinopathy; Choroid; Eplerenone; Female; Fluorescein Angiography; Follow-Up Studies; Fundus Oculi; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Multimodal Imaging; Photochemotherapy; Photosensitizing Agents; Prospective Studies; Retina; Spironolactone; Tomography, Optical Coherence; Visual Acuity | 2018 |
Aldosterone is involved in the pathogenesis of obesity-related glomerulopathy through activation of Wnt/β-catenin signaling in podocytes.
Topics: Aldosterone; Animals; beta Catenin; Disease Models, Animal; Down-Regulation; Eplerenone; Glomerulonephritis; Intercellular Signaling Peptides and Proteins; Intracellular Signaling Peptides and Proteins; Kidney Cortex; Male; Membrane Proteins; Mice; Mice, Inbred C57BL; Obesity; Podocytes; Sialoglycoproteins; Spironolactone; Wnt Proteins; Wnt Signaling Pathway | 2018 |
Eplerenone pretreatment protects the myocardium against ischaemia/reperfusion injury through the phosphatidylinositol 3-kinase/Akt-dependent pathway in diabetic rats.
Topics: Animals; Cardiotonic Agents; Diabetes Mellitus, Experimental; Eplerenone; Male; Myocardial Reperfusion Injury; Myocardium; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Rats; Rats, Wistar; Signal Transduction; Spironolactone | 2018 |
Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion.
Topics: Administration, Oral; Aldosterone; Animals; Benzoates; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Eplerenone; Humans; Kidney; Male; Mice, Mutant Strains; Mineralocorticoid Receptor Antagonists; Molecular Structure; Oxazines; Potassium; Rats, Sprague-Dawley; Receptors, Mineralocorticoid; Renal Insufficiency, Chronic; Sodium; Sodium, Dietary; Spironolactone | 2018 |
ENVIRONMENTALLY FRIENDLY LC/MS DETERMINATION OF EPLERENONE IN HUMAN PLASMA.
Topics: Chromatography, Liquid; Eplerenone; Humans; Liquid-Liquid Extraction; Mineralocorticoid Receptor Antagonists; Spironolactone; Tandem Mass Spectrometry | 2016 |
Mineralocorticoid receptor inhibitor for long-standing central serous chorioretinopathy.
Topics: Administration, Oral; Central Serous Chorioretinopathy; Dose-Response Relationship, Drug; Eplerenone; Female; Follow-Up Studies; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Retinal Pigment Epithelium; Spironolactone; Time Factors; Treatment Outcome | 2018 |
Effect of Eplerenone on the Glomerular Filtration Rate (GFR) in Primary Aldosteronism: Sequential Changes in the GFR During Preoperative Eplerenone Treatment to Subsequent Adrenalectomy.
Topics: Adrenalectomy; Adult; Blood Pressure; Drug Administration Schedule; Eplerenone; Female; Glomerular Filtration Rate; Humans; Hyperaldosteronism; Kidney Glomerulus; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Preoperative Care; Retrospective Studies; Spironolactone | 2018 |
The use of mineralocorticoid receptor antagonists in chronic central serous chorioretinopathy.
Topics: Adult; Aged; Central Serous Chorioretinopathy; Choroid; Chronic Disease; Eplerenone; Female; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Retina; Spironolactone; Tomography, Optical Coherence; Treatment Outcome; Vision Tests | 2016 |
Association Between Mineralocorticoid Receptor Antagonist Use and Outcome in Myocardial Infarction Patients With Heart Failure.
Topics: Aged; Aged, 80 and over; Eplerenone; Female; Follow-Up Studies; Heart Failure; Humans; Male; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Percutaneous Coronary Intervention; Registries; Retrospective Studies; Spironolactone; Stroke Volume; Survival Rate; Sweden; Time Factors; Treatment Outcome; Ventricular Function, Left | 2018 |
Mineralocorticoid receptor blockade improves arginine transport and nitric oxide generation through modulation of cationic amino acid transporter-1 in endothelial cells.
Topics: Arginine; Biological Transport; Cationic Amino Acid Transporter 1; Eplerenone; Glycosylation; Human Umbilical Vein Endothelial Cells; Humans; Mineralocorticoid Receptor Antagonists; Nitric Oxide; Phosphorylation; Protein Kinase C-alpha; Receptors, Mineralocorticoid; Signal Transduction; Spironolactone | 2018 |
Comparison of effects of aldosterone receptor antagonists spironolactone and eplerenone on cardiovascular outcomes and safety in patients with acute decompensated heart failure.
Topics: Acute Disease; Aged; Eplerenone; Female; Follow-Up Studies; Heart Failure; Humans; Male; Mineralocorticoid Receptor Antagonists; Prospective Studies; Spironolactone; Time Factors; Treatment Outcome; Ventricular Function, Left | 2019 |
Antihypertensive effect of the mineralocorticoid receptor antagonist eplerenone: a pooled analysis of patient-level data from comparative trials using regulatory-approved doses.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Clinical Trials, Phase III as Topic; Eplerenone; Female; Humans; Hypertension; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Randomized Controlled Trials as Topic; Spironolactone; Treatment Outcome | 2018 |
RAAS inhibitors directly reduce diabetes-induced renal fibrosis via growth factor inhibition.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Cell Line; Connective Tissue Growth Factor; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Epithelial Cells; Eplerenone; Fibroblasts; Fibrosis; Humans; Kidney; Losartan; Male; Mannitol; Mineralocorticoid Receptor Antagonists; Proto-Oncogene Proteins c-sis; Ramipril; Rats, Wistar; Renin-Angiotensin System; Spironolactone | 2019 |
Escaping residual albuminuria in hypertension: should we start eplerenone or reduce salt intake?
Topics: Albuminuria; Diabetes Mellitus; Eplerenone; Humans; Hypertension; Receptors, Mineralocorticoid; Sodium Chloride, Dietary; Spironolactone | 2019 |
Mineralocorticoid receptor blockade attenuates disrupted glutathione-dependent antioxidant defense and elevated endoglin in the hearts of pregnant rats exposed to testosterone.
Topics: Animals; Antioxidants; Endoglin; Eplerenone; Female; Gestational Age; Glutathione; Mineralocorticoid Receptor Antagonists; Myocardium; Pregnancy; Pregnancy Complications, Cardiovascular; Pregnancy Outcome; Rats, Wistar; Receptors, Mineralocorticoid; Spironolactone; Testosterone | 2019 |
Mineralocorticoid Receptor Antagonists Stimulate Human Hair Growth ex vivo.
Topics: Adult; Aged; Aldosterone; Eplerenone; Female; Hair; Humans; Middle Aged; Mineralocorticoid Receptor Antagonists; Receptors, Mineralocorticoid; Spironolactone | 2019 |
Mineralocorticoid receptor antagonists lead to increased adenosine bioavailability and modulate contractile cardiac parameters.
Topics: 5'-Nucleotidase; Adenosine; Adenosine Deaminase; Animals; Calcium Signaling; Eplerenone; GPI-Linked Proteins; Male; Membrane Proteins; Mineralocorticoid Receptor Antagonists; Myocardial Contraction; Myocytes, Cardiac; Rats, Wistar; Receptor, Adenosine A1; Receptor, Adenosine A3; Spironolactone; Up-Regulation | 2020 |
Eplerenone is not superior to placebo for chronic central serous chorioretinopathy.
Topics: Central Serous Chorioretinopathy; Double-Blind Method; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone | 2020 |
Crystal structure of the mineralocorticoid receptor ligand-binding domain in complex with a potent and selective nonsteroidal blocker, esaxerenone (CS-3150).
Topics: Amino Acid Sequence; Crystallography, X-Ray; Eplerenone; Humans; Ligands; Mineralocorticoid Receptor Antagonists; Models, Molecular; Protein Domains; Pyrroles; Receptors, Mineralocorticoid; Spironolactone; Substrate Specificity; Sulfones | 2020 |
Lack of efficacy of eplerenone for treatment of active central serous chorioretinopathy.
Topics: Central Serous Chorioretinopathy; Eplerenone; Fluorescein Angiography; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Tomography, Optical Coherence | 2020 |
Striatin heterozygous mice are more sensitive to aldosterone-induced injury.
Topics: Aldosterone; Animals; Blood Pressure; Calmodulin-Binding Proteins; Eplerenone; Kidney; Male; Membrane Proteins; Mice; Mice, Knockout; Mineralocorticoid Receptor Antagonists; Nerve Tissue Proteins; NG-Nitroarginine Methyl Ester; Pyrroles; Spironolactone; Sulfones | 2020 |
Eplerenone prevents an increase in serum carboxy-terminal propeptide of procollagen type I after myocardial infarction complicated by left ventricular dysfunction and/or heart failure.
Topics: Collagen Type I; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Peptide Fragments; Procollagen; Spironolactone; Ventricular Dysfunction, Left | 2020 |
Mineralocorticoid Receptor Antagonists in ESKD.
Topics: Aldosterone; Cardiovascular Diseases; Eplerenone; Humans; Kidney Failure, Chronic; Mineralocorticoid Receptor Antagonists; Spironolactone | 2020 |
Antidepressant effect in diabetes-associated depression: A novel potential of RAAS inhibition.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antidepressive Agents; Antihypertensive Agents; Behavior, Animal; Blood Pressure; Depression; Diabetes Mellitus, Experimental; Disease Models, Animal; Down-Regulation; Enalapril; Eplerenone; Male; Mineralocorticoid Receptor Antagonists; Ramipril; Rats; Rats, Wistar; Renin-Angiotensin System; Spironolactone | 2020 |
Eplerenone for treatment of chronic central serous chorioretinopathy.
Topics: Administration, Oral; Central Serous Chorioretinopathy; Chronic Disease; Eplerenone; Fluorescein Angiography; Humans; Mineralocorticoid Receptor Antagonists; Retrospective Studies; Spironolactone; Tomography, Optical Coherence; Treatment Outcome; Visual Acuity | 2021 |
Central amygdala mineralocorticoid receptors modulate alcohol self-administration.
Topics: Alcohol Drinking; Animals; Central Amygdaloid Nucleus; Central Nervous System Depressants; Dose-Response Relationship, Drug; Eplerenone; Ethanol; Female; Gene Knockdown Techniques; Male; Mineralocorticoid Receptor Antagonists; Oligonucleotides, Antisense; Rats; Rats, Long-Evans; Receptors, Mineralocorticoid; Self Administration; Spironolactone | 2020 |
Estimating the Lifetime Benefits of Treatments for Heart Failure.
Topics: Eplerenone; Heart Failure; Humans; Infant; Mineralocorticoid Receptor Antagonists; Spironolactone; Stroke Volume | 2020 |
Eplerenone for chronic central serous chorioretinopathy.
Topics: Central Serous Chorioretinopathy; Double-Blind Method; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone | 2020 |
Eplerenone for chronic central serous chorioretinopathy.
Topics: Central Serous Chorioretinopathy; Double-Blind Method; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone | 2020 |
Eplerenone for chronic central serous chorioretinopathy - Authors' reply.
Topics: Central Serous Chorioretinopathy; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone | 2020 |
New Horizons: Does Mineralocorticoid Receptor Activation by Cortisol Cause ATP Release and COVID-19 Complications?
Topics: Adenosine Triphosphate; Angiotensin-Converting Enzyme 2; Blood Coagulation Disorders; COVID-19; COVID-19 Drug Treatment; Dexamethasone; Eplerenone; Humans; Hydrocortisone; Mineralocorticoid Receptor Antagonists; Models, Biological; Paracrine Communication; Receptors, Mineralocorticoid; Receptors, Purinergic; Respiratory Distress Syndrome; SARS-CoV-2; Severity of Illness Index; Spironolactone | 2021 |
Spironolactone and Eplerenone Use at Discharge in Heart Failure Patients With Reduced Ejection Fraction at 3 Large Hospital Systems.
Topics: Eplerenone; Heart Failure; Hospitals; Humans; Mineralocorticoid Receptor Antagonists; Patient Discharge; Spironolactone; Stroke Volume; Treatment Outcome; Ventricular Dysfunction, Left | 2023 |
Reply to: 'Current perspectives on the use of eplerenone for chronic central serous chorioretinopathy'.
Topics: Central Serous Chorioretinopathy; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone | 2021 |
Impact of Insulin Treatment on the Effect of Eplerenone: Insights From the EMPHASIS-HF Trial.
Topics: Aged; Diabetes Mellitus; Eplerenone; Female; Heart Failure; Heart Failure, Systolic; Humans; Insulins; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Risk Factors; Spironolactone; Treatment Outcome | 2021 |
Cardiovascular and kidney outcomes of spironolactone or eplerenone in combination with ACEI/ARBs in patients with diabetic kidney disease.
Topics: Adolescent; Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Diabetic Nephropathies; Drug Therapy, Combination; Eplerenone; Humans; Hypertension; Kidney Diseases; Mineralocorticoid Receptor Antagonists; Retrospective Studies; Spironolactone; Treatment Outcome | 2021 |
INFLUENCE OF COMPLEX TREATMENT WITH MAGNESIUM AND POTASSIUM SALTS OF GLUCONIC ACID, EPLERENONE AND RIVAROXABAN ON DYNAMICS OF INDICATORS OF ISCHEMIA AND MYOCARDIAL REMODELING IN PATIENTS WITH CHRONIC HEART FAILURE AFTER MYOCARDIAL INFARCTION.
Topics: Eplerenone; Gluconates; Heart Failure; Humans; Magnesium; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Myocardium; Potassium; Rivaroxaban; Salts; Spironolactone | 2021 |
Aldosterone and dexamethasone activate African lungfish mineralocorticoid receptor: Increased activation after removal of the amino-terminal domain.
Topics: Aldosterone; Animals; Corticosterone; Cortodoxone; Desoxycorticosterone; Dexamethasone; Eplerenone; Fish Proteins; Fishes; Gene Expression; Hydrocortisone; Kinetics; Progesterone; Protein Domains; Protein Engineering; Receptors, Glucocorticoid; Receptors, Mineralocorticoid; Recombinant Proteins; Spironolactone; Triamcinolone | 2022 |
Effect of Mineralocorticoid Receptor Antagonists on the Prognosis of Patients with Ventricular Tachyarrhythmias.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Case-Control Studies; Eplerenone; Female; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Multivariate Analysis; Prognosis; Registries; Retrospective Studies; Spironolactone; Tachycardia, Ventricular; Young Adult | 2022 |
Prognostic value of cardiac magnetic resonance parameters and biomarkers following myocardial infarction; 10-year follow-up of the Eplerenone Remodelling in Myocardial Infarction without Heart Failure trial.
Topics: Biomarkers; Eplerenone; Follow-Up Studies; Heart Failure; Humans; Magnetic Resonance Spectroscopy; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Prognosis; Spironolactone | 2022 |
Metainflammation in COVID-19.
Topics: Aged; Angiotensin-Converting Enzyme 2; COVID-19; Dipeptidyl Peptidase 4; Eplerenone; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metformin; Obesity; Orlistat; Peptidyl-Dipeptidase A; SARS-CoV-2; Spironolactone; Thiazolidinediones | 2022 |
Real world comparison of spironolactone and eplerenone in patients with heart failure.
Topics: Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Prospective Studies; Spironolactone; Stroke Volume; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left | 2022 |
Is it time to shift our focus from treatment to prevention of heart failure with a mineralocorticoid receptor antagonist?
Topics: Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone | 2022 |
Adherence and blood pressure control in patients with primary aldosteronism.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Eplerenone; Female; Humans; Hyperaldosteronism; Hypertension; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Spironolactone | 2022 |
Timing of Statistical Benefit of Mineralocorticoid Receptor Antagonists Among Patients With Heart Failure and Post-Myocardial Infarction.
Topics: Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Spironolactone | 2022 |
[Multidisciplinary expert consensus for clinical application of mineralocorticoid receptor antagonists in China].
Topics: Consensus; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone | 2022 |
[New clinical opportunities for mineralocorticoid receptor antagonists: focus on antifibrotic effects].
Topics: Aldosterone; COVID-19 Drug Treatment; Eplerenone; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; SARS-CoV-2; Spironolactone | 2021 |
Estimation of Two Diuretics Using Fluorescent Nitrogen Doped Carbon Quantum Dots: Application to Spiked Human Plasma and Tablets.
Topics: Carbon; Diuretics; Eplerenone; Fluorescent Dyes; Humans; Nitrogen; Quantum Dots; Spectrometry, Fluorescence; Spironolactone; Tablets | 2023 |
Role of eplerenone in the threatment of cardiovascular diseases.
Topics: Cardiovascular Diseases; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Ventricular Dysfunction, Left | 2023 |
Initiation of eplerenone or spironolactone, treatment adherence, and associated outcomes in patients with new-onset heart failure with reduced ejection fraction: a nationwide cohort study.
Topics: Aged; Cohort Studies; Eplerenone; Heart Failure; Humans; Male; Spironolactone; Stroke Volume; Treatment Adherence and Compliance; Ventricular Dysfunction, Left | 2023 |